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Abstract 
The prevalence of metabolic syndrome is increasing throughout the 
world. Metabolic syndrome is the clustering of risk factors for cardiovascular 
disease and type 2 diabetes. These include obesity, hypertension, impaired 
glucose tolerance, dyslipidaemia and insulin resistance, caused by oxidative 
stress and inflammation.  
Nature has provided us with immense diversity in the form of plants and 
herbs, which contain a wide range of chemicals. Development of natural 
products as a potential treatment for metabolic syndrome requires a s uitable 
rodent model. To induce metabolic syndrome, young male Wistar rats were fed 
with a high-carbohydrate, high-fat diet for 16 weeks with corn starch serving as 
control diet. Treatments were given as interventions in the final 8 weeks only as 
a reversal protocol. These interventions included rutin (1.6 g/kg food), 
quercetin (0.8 g/kg food), oak bark extract (0.5 ml/kg food), ellagic acid (0.8 
g/kg food), coffee extract (5% in food), caffeine (0.5 g/kg food) and ʟ-carnitine 
(1.2 % in food).  
High-carbohydrate, high-fat diet induced hypertension, obesity, 
impaired glucose tolerance, dyslipidaemia, cardiovascular remodelling 
including ventricular dilatation, cardiomyocyte hypertrophy and cardiac 
fibrosis, reduced ventricular function, hepatic steatosis, hepatic inflammation 
and portal fibrosis and increased plasma markers of liver function.  
Rutin and quercetin ameliorated these cardiovascular and hepatic 
changes and attenuated impairment in glucose tolerance and hypertension 
whereas only rutin improved obesity and dyslipidaemia. Ellagitannins from oak 
bark extract and ellagic acid attenuated cardiovascular remodelling and non-
alcoholic fatty liver disease. Both ellagitannins from oak bark extract and 
ellagic acid reduced body weight and abdominal fat, however ellagic acid failed 
to reduce total body fat mass. Although coffee did not change body weight and 
abdominal fat, it improved the structure and function of the heart and the liver. 
xvi
These effects differed from caffeine, which reduced total body fat, body weight 
and abdominal fat, along with the attenuation of symptoms of metabolic 
syndrome, cardiovascular remodelling and non-alcoholic steatohepatitis. ʟ-
Carnitine, a transporter of fatty acid across mitochondrial membrane, attenuated 
the metabolic syndrome by increasing β-oxidation and decreasing lipogenesis 
in both the heart and the liver. 
In humans, fatty liver is caused by the excess consumption of diets rich 
in ethanol, animal fats, simple carbohydrates such as fructose or a combination 
of all three. An initiative was taken to mimic the combined effects of high-
carbohydrate, high-fat diet and ethanol in rats as in human fatty liver disease. 
Ethanol synergistically aggravated hepatic steatosis induced by high-
carbohydrate, high-fat diet; hepatic inflammation and fibrosis were unchanged 
compared to high-carbohydrate, high-fat fed rats. In contrast, ethanol feeding to 
high-carbohydrate, high-fat fed rats prevented cardiac fibrosis but caused 
minimal changes to cardiac function.  
These studies clearly indicate the potential present in many natural 
products. The mechanisms of action of these natural products were also 
different as some of them reduced abdominal fat, possibly due to increased 
utilisation or removal of excess fat from the body through excretion, and others 
redistributed the fat to other areas such as subcutaneous fat, coffee being the 
exception. 
Keywords 
metabolic syndrome; obesity; non-alcoholic fatty liver disease; cardiovascular 
remodelling; natural products; high-carbohydrate, high-fat diet; polyphenols; 
dyslipidaemia; hypertension; impaired glucose tolerance. 
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Chapter 1: Metabolic syndrome, cardiovascular 
remodelling and non-alcoholic fatty liver disease 
Metabolic syndrome 
Metabolic syndrome refers to the co-occurrence of hypertension, central 
obesity, dyslipidaemia, insulin resistance and impaired glucose tolerance as risk 
factors for the development of cardiovascular disease and type 2 diabetes [1]. 
These risk factors tend to cluster and thereby increase the overall risk [1]. 
Different diagnostic criteria have been provided [2-5]; with some of these 
definitions described in Table 1. 
Metabolic syndrome is common in adult populations throughout the 
world. In Australia (1999-2000), the prevalence of metabolic syndrome ranged 
between 13.4% to 30.7%, depending on the definition used to define metabolic 
syndrome [6]. In the USA (1999-2002), 34% males and females were 
diagnosed with metabolic syndrome [7]. In Russia (2000), the overall 
prevalence of metabolic syndrome was 18%-19%. This prevalence was higher 
in women (23%-26%) compared to men (13%-15%) using various definitions 
[8]. Similarly, high prevalence rates of metabolic syndrome have been reported 
in the Indian subcontinent [9]. 
The presence of metabolic syndrome is associated with the development 
of cardiovascular disease and non-alcoholic fatty liver disease. Clinical, 
epidemiological and animal studies have proved the relationship between 
metabolic syndrome, especially obesity and dyslipidaemia, and the presence of 
non-alcoholic fatty liver disease [10-12]. Studies have also shown the 
increasing risk of development of non-alcoholic fatty liver disease in the 
presence of metabolic syndrome and vice versa [13,14]. Metabolic syndrome 
and non-alcoholic fatty liver disease are also associated with cardiovascular 
remodelling, including cardiac hypertrophy, ventricular dysfunction and 
endothelial dysfunction [15,16]. 
Page 1
Cardiovascular remodelling 
Cardiovascular remodelling is a process of change in the size, shape and 
function of the heart as a physiological response to metabolic or hormonal 
changes in the body [17,18]. These physiological responses lead to the 
development of molecular and cellular changes, including hypertrophy, 
necrosis and apoptosis of the myocyte, fibroblast proliferation and fibrosis in 
the interstitium [18]. These changes results in abnormalities in myocardial 
function including impaired contractility and relaxation, diminished cardiac 
pump function, dilatation and increased sphericity of the heart.  U ltimately, 
these changes lead to systolic and diastolic cardiac dysfunction, which form the 
basis of heart failure and death [18]. 
Non-alcoholic fatty liver disease  
Non-alcoholic fatty liver disease is a clinical condition that includes a 
wide spectrum of liver complications ranging from simple steatosis to 
steatohepatitis, advanced fibrosis and cirrhosis [19,20]. The liver is a metabolic 
workhorse that performs a range of biochemical functions including 
metabolism of lipids. Hepatic steatosis develops when there is excess 
deposition of triglycerides in the hepatocytes. This pathological condition can 
develop when the total input of fatty acids is more than the total output [21]. 
Sources of fatty acids in the liver include the hepatic free fatty acid uptake from 
blood and de novo lipogenesis. The output of fatty acids from the liver can be 
through fatty acid oxidation and fatty acid export within very low-density 
lipoproteins [21]. The disturbances in hepatic input and output of lipids can 
occur in the conditions of dyslipidaemia, obesity and insulin resistance [10,19]. 
Steatosis is characterized by excess fat storage and it can progress to 
steatohepatitis and finally leads to cirrhosis and structural and functional 
abnormalities of the liver. Some patients only develop steatosis whereas others 
develop steatohepatitis and fibrosis. 
Page 2
T
ab
le
 1
. V
ar
io
u
s 
de
fi
n
it
io
n
s 
of
 m
et
ab
ol
ic
 s
yn
dr
om
e 
[1
] 
 
W
H
O
 (
19
98
) 
E
G
IR
 (
19
99
) 
N
C
E
P
 A
T
P
 I
II
 (
20
05
 
re
vi
si
on
) 
ID
F
 (
20
05
) 
Co
m
pu
ls
or
y 
In
su
li
n 
re
si
st
an
ce
 
H
yp
er
in
su
li
na
em
ia
 
N
on
e 
C
en
tr
al
 o
be
si
ty
 
Re
qu
ire
m
en
ts 
In
su
li
n 
re
si
st
an
ce
 o
r 
di
ab
et
es
, p
lu
s 
an
y 
tw
o 
of
 th
e 
fi
ve
 c
ri
te
ri
a 
H
yp
er
in
su
li
na
em
ia
, p
lu
s 
an
y 
tw
o 
of
 th
e 
fo
ur
 c
ri
te
ri
a 
A
ny
 th
re
e 
of
 th
e 
fi
ve
 
cr
ite
ri
a 
C
en
tr
al
 o
be
si
ty
, p
lu
s 
an
y 
tw
o 
of
 th
e 
fo
ur
 c
ri
te
ri
a 
Ce
nt
ra
l o
be
sit
y 
W
ai
st
:h
ip
 r
at
io
 (
>0
.9
0 
in
 m
al
es
, 
>
0.
85
 in
 f
em
al
es
) 
or
 B
M
I 
>
30
 k
g/
m
2  
W
ai
st
 c
ir
cu
m
fe
re
nc
e 
(≥
94
 c
m
 
in
 m
al
es
, ≥
80
 c
m
 in
 f
em
al
es
) 
W
ai
st
 c
ir
cu
m
fe
re
nc
e 
(>
40
 
in
ch
es
 in
 m
al
es
, >
35
 
in
ch
es
 in
 f
em
al
es
) 
W
ai
st
 c
ir
cu
m
fe
re
nc
e 
(≥
94
 c
m
 
in
 m
al
es
, ≥
80
 c
m
 in
 f
em
al
es
) 
H
yp
er
gl
yc
ae
m
ia
 
Im
pa
ir
ed
 g
lu
co
se
 to
le
ra
nc
e,
 
im
pa
ir
ed
 f
as
tin
g 
gl
uc
os
e,
 ty
pe
 2
 
di
ab
et
es
 o
r 
ot
he
r 
ev
id
en
ce
 o
f 
in
su
lin
 
re
si
st
an
ce
 
H
yp
er
in
su
li
na
em
ia
 r
eq
ui
re
d 
(P
la
sm
a 
in
su
lin
 >
75
th
 
pe
rc
en
til
e)
 
Fa
st
in
g 
gl
uc
os
e 
≥1
00
 
m
g/
dl
 
Fa
st
in
g 
gl
uc
os
e 
≥1
00
 m
g/
dl
 
D
ys
lip
id
ae
m
ia
 
(T
ri
gl
yc
er
id
es
) 
T
ri
gl
yc
er
id
es
 ≥
15
0 
m
g/
dl
 o
r 
H
D
L
-
ch
ol
es
te
ro
l (
<
35
 m
g/
dl
 in
 m
al
es
, 
<
39
 m
g/
dl
 in
 f
em
al
es
) 
T
ri
gl
yc
er
id
es
 ≥
17
7 
m
g/
dl
 o
r 
H
D
L
-c
ho
le
st
er
ol
 (
<
39
 m
g/
dl
) 
T
ri
gl
yc
er
id
es
 ≥
15
0 
m
g/
dl
 
T
ri
gl
yc
er
id
es
 ≥
15
0 
m
g/
dl
 
D
ys
lip
id
ae
m
ia
 
(C
ho
le
ste
ro
l) 
H
D
L
-c
ho
le
st
er
ol
 (
<
40
 
m
g/
dl
 in
 m
al
es
, <
50
 m
g/
dl
 
in
 f
em
al
es
) 
H
D
L
-c
ho
le
st
er
ol
 (
<
40
 m
g/
dl
 
in
 m
al
es
, <
50
 m
g/
dl
 in
 
fe
m
al
es
) 
H
yp
er
te
ns
io
n 
≥1
40
/9
0 
m
m
H
g 
≥1
40
/9
0 
m
m
H
g 
>
13
0/
85
 m
m
H
g 
>
13
0/
85
 m
m
H
g 
O
th
er
 c
rit
er
ia
 
M
ic
ro
al
bu
m
in
ur
ia
 (
U
ri
na
ry
 a
lb
um
in
 
ex
cr
et
io
n 
of
 2
0 
μg
/m
in
 o
r 
al
bu
m
in
-
to
-c
re
at
in
in
e 
ra
tio
 o
f 
30
 m
g/
g)
 
 
 
 
Ab
br
ev
ia
tio
ns
 u
se
d:
 W
H
O
, W
or
ld
 H
ea
lth
 O
rg
an
is
at
io
n;
 E
G
IR
, E
ur
op
ea
n 
G
ro
up
 f
or
 th
e 
St
ud
y 
of
 I
ns
ul
in
 R
es
is
ta
nc
e;
 N
CE
P 
AT
P 
III
, N
at
io
na
l 
C
ho
le
st
er
ol
 E
du
ca
tio
n 
Pr
og
ra
m
 A
du
lt
 T
re
at
m
en
t P
an
el
 I
II
; I
D
F,
 I
nt
er
na
tio
na
l D
ia
be
te
s 
Fe
de
ra
ti
on
.
Page 3
Oxidative stress 
Oxidative stress is the cellular damage caused by an imbalance between 
the reactive oxygen or nitrogen species and the antioxidant system in the body. 
Reactive oxygen and nitrogen species are highly reactive, short-lived 
derivatives of oxygen or nitrogen, produced in all biological systems [22]. Due 
to the high reactivity of these chemical species, they react with surrounding 
molecules at or near the site of formation. Some of these species include the 
superoxide radical (O2
•−), the hydroxyl radical (•OH), hydrogen peroxide 
(H2O2), nitric oxide (NO) and the peroxynitrite radical (ONOO
•). These 
molecules play important roles in many physiological conditions including 
vascular reactivity [22]. Oxidative stress has been linked to the presence of 
obesity and metabolic syndrome [23,24]. It has now been proposed that the 
changes in metabolic syndrome are initiated by oxidative stress [25]. In 
metabolic syndrome, oxidative stress is responsible for the primary myocardial 
insult leading to cardiovascular remodelling [26,27]. Earlier studies have 
already shown that oxidative stress can lead to cardiac stiffness and fibrosis 
[28,29]. Similarly, oxidative stress may initiate the development of non-
alcoholic steatohepatitis [30].  
Inflammation 
Inflammation is part of the non-specific immune response that occurs in 
reaction to any injury to the tissues. In some pathological conditions, the 
inflammatory process becomes chronic after initial activation subsequently 
leading to the development of long-term conditions such as obesity [31,32]. 
Initially, a link between obesity and inflammation was established through the 
expression of tumor necrosis factor-α (TNF-α) and this was further strengthen 
by the increased plasma concentrations of proinflammatory markers including 
cytokines and acute phase proteins such as C-reactive protein (CRP) in obese 
subjects [33-35]. CRP is now considered an independent risk factor for the 
development of cardiovascular disease [36]. Many inflammatory markers 
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present in the plasma of obese individuals originate from adipose tissue [34]. 
Thus, obesity is now defined as the state of chronic low-grade inflammation, 
which is initiated by the morphological changes in the adipose tissue [37]. 
Some of the proinflammatory cytokines from adipose tissue interfere with the 
signalling pathway for insulin. This ultimately leads to insulin resistance [38-
42]. Adipocytes also secrete certain hormones (adipokines) in response to the 
increased fat deposition. These adipokines, including adiponectin, leptin and 
resistin, modulate metabolism in the body including food intake and energy 
expenditure [43]. Liver is the other tissue that is affected by excess adipose 
tissue and proinflammatory cytokines produced by adipose tissue. Chronic 
activation of nuclear factor-κB (NF-κB) by cytokines leads to the development 
of insulin resistance in liver [44,45]. The development of hepatic steatosis and 
non-alcoholic fatty liver disease in presence of insulin resistance has been 
established [46-49]. 
Conclusion 
Metabolic syndrome is a combination of various risk factors for the 
development of cardiovascular disease and non-alcoholic fatty liver disease. 
These risk factors are responsible for the development of oxidative stress and 
inflammation in organs including the heart and liver. Oxidative damage and 
inflammation initiate the complications associated with the symptoms of 
metabolic syndrome, cardiovascular disease and non-alcoholic fatty liver 
disease. Thus, in this study, oxidative stress and inflammation have been 
targeted with antioxidants and anti-inflammatory agents for the treatment of 
metabolic syndrome and related disorders.  
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Abstract 
Natural products have been used for medicinal purposes for 
millennia. Ayurveda and Chinese medicine systems are based on us e of 
natural products from herbs and plant parts. One of the major classes of 
compounds found in the nature is polyphenol. Polyphenols are the plant 
secondary metabolites synthesized from shikimate pathway-derived 
products, with more than one phenolic ring without any nitrogen-based 
functional group. These polyphenols have been categorized into different 
classes including flavonoids. Metabolic syndrome, being the clustering of 
the risk factors for the development of cardiovascular disease and type 2 
diabetes, is increasing in its prevalence throughout the world. This review 
has described the potential benefits associated with the dietary 
supplementation of polyphenols, in particular the wine polyphenols, 
resveratrol, rutin and quercetin, ellagtiannins and ellagic acid, catechins, and 
curcumin against the symptoms of metabolic syndrome. To characterize the 
effects of polyphenols, most studies have used biochemical methods, cell 
cultures, or animal models with few clinical trials in humans with metabolic 
syndrome or its components. Further clinical trials are required to confirm 
the effects in humans with multiple symptoms of metabolic syndrome. Also, 
the synergistic effects of these polyphenols should be considered with 
standard drug treatment of hypertension, diabetes, and obesity.  
Keywords – Obesity, Resveratrol, Quercetin, Curcumin, Catechins.  
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Polyphenols: definition and classification 
Polyphenols are compounds that are widely distributed in nature. 
The history of polyphenols goes back to the archaic period in Ancient 
Greece (800-500 BC) where they were called ‘vegetable tannins’ for use in 
the processing of leather (Quideau et al., 2011).  Polyphenols can be defined 
as the plant secondary metabolites that are derived exclusively from the 
shikimate-derived phenylpropanoid and/or the polyketide pathway(s), 
featuring more than one phenolic ring and being devoid of any nitrogen-
based functional group in their most basic structural expressions (Quideau et 
al., 2011). Thus, procyanidins, gallotannins, ellagitannins, flavonoids, 
flavanoids, lignans, ellagic acid, and curcumin are included as polyphenols. 
Polyphenols can be categorized into different classes including 
flavonoids, phenolic acids (e.g. chlorogenic acid), lignans (e.g. seco-
isolariciresinol), and stilbenes (e.g. resveratrol and pterostilbene). 
Flavonoids can further be classified as flavanols, flavanones (e.g. naringenin 
and hesperetin), flavonols (e.g. quercetin), anthocyanins (e.g. malvidin), 
isoflavones (e.g. genistein and daidzein), and chalcones (e.g. phloridzin) 
(Cook & Samman, 1996; Kim et al., 2004). Flavanols include monomers 
(e.g. catechins and epicatechins) and polymers (condensed and hydrolysable 
tannins; e.g. ellagitannins) (Figure 1).  
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 Figure 1: Classification of polyphenols 
Biosynthesis of polyphenols: The shikimate pathway 
Polyphenols are synthesized through shikimate-derived 
phenylpropanoid pathway or polyketide pathway. This pathway is used by 
plants and microorganisms for the biosynthesis of aromatic amino acids 
such as phenylalanine, tyrosine, and tryptophan (Herrmann, 1995b; 
Herrmann & Weaver, 1999). The seven steps of the shikimate pathway lead 
to the formation of chorismate which is the precursor of the three aromatic 
amino acids and several other aromatic compounds of primary metabolism 
(Figure 2). The intermediates of the shikimate pathway can also lead to the 
formation of many secondary metabolites including chlorogenic acid 
(Herrmann, 1995b; Herrmann, 1995a; Herrmann & Weaver, 1999). In 
addition, the three aromatic amino acids are precursors for many plant 
secondary metabolites including indole-3-acetic acid, indole glucosinolates, 
s 
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ephedrine, taxine, lunarine, morphine, and dhurrin (Radwanski & Last, 
1995; Celenza, 2001). Synthesis of polyphenols from chorismate-derived 
metabolites has been extensively reviewed (Dewick, 1998; Knaggs, 1999). 
  
Figure 2: Shikimate pathway for biosynthesis of chorismate 
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Metabolic syndrome 
Metabolic syndrome has become one of the major public health 
challenges worldwide (Lakka et al., 2002; Cameron et al., 2004; Day, 2007; 
Scholze et al., 2010). It refers to the clustering of insulin resistance, 
hypertension, central obesity, impaired glucose tolerance, and dyslipidemia 
(Chew et al., 2006) as risk factors for cardiovascular disease (Isomaa et al., 
2001; Lakka et al., 2002), type 2 diabetes (Grundy, 2004), and nonalcoholic 
fatty liver disease (Abdelmalek & Diehl, 2007). Prevalence of metabolic 
syndrome is increasing throughout the world. In Australian population, the 
prevalence of metabolic syndrome ranged between 13.4% to 30.7%, 
depending on the definition used to define metabolic syndrome (Cameron et 
al., 2007). This prevalence was 34% in males and females in the USA 
(Ford, 2005). In Russia, the overall prevalence of metabolic syndrome was 
approximately 18%-19% using various definitions (Sidorenkov et al., 2010). 
Similarly, high prevalence rates of metabolic syndrome have been reported 
in the Indian subcontinent and European countries such as Germany, Italy, 
and Spain (Ramaraj & Chellappa, 2008; Scholze et al., 2010). This high 
prevalence of metabolic syndrome throughout the world makes the finding 
of interventions that can reduce the risk to health an important exercise. 
This review will focus on t he potentials of polyphenols as 
nutraceuticals to improve the clinical conditions of metabolic syndrome. 
Nutraceuticals are defined as alternative/complementary medicines derived 
from nutritional sources, such as plants; the study of their therapeutic 
possibilities is termed nutrapharmacology. Plants and microorganisms 
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produce non-nutritive products including polyphenols for many purposes, 
one example being the production of flavonoids as protection against fungal 
infection (Grayer & Harborne, 1994; Harborne, 1999; Galeotti et al., 2008; 
Iwashina et al., 2010; Hichri et al., 2011). The relatively easy availability of 
polyphenols from herbs and plants increases their use in traditional medical 
systems and decreases their cost. As examples, both Ayurveda, the 
traditional medical system practiced in India (Mishra et al., 2001), and 
traditional Chinese medicine (Kam & Liew, 2002) have used natural 
products containing polyphenols in the prevention and treatment of disease. 
There has been a push to combine anecdotal evidence with modern science 
to indicate the usefulness of natural products, including polyphenols, for 
therapeutic use outside these traditional systems. 
Wine: rich source of polyphenols 
Consumption of wine with food is a typical feature of the 
Mediterranean diet (Ursini & Sevanian, 2002). The low incidence of 
cardiovascular disease in France, despite high dietary intake of saturated fat, 
has been described as the French Paradox, and attributed to moderate 
regular red wine intake (Renaud & de Lorgeril, 1992). Wine contains many 
polyphenols including phenolic acids, stilbenes, flavonoids, and tannins 
with the antioxidant capacity of red wine being greater than white wine 
(Tubaro et al., 1999; Waterhouse, 2002). Most of the polyphenols in wine 
come from grapes whereas tannins are extracted into the wine during 
maturation in oak barrels (Waterhouse, 2002). Red wine contains about 20 
times more polyphenols than white wine, in particular flavonoids (e.g., 
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quercetin, catechin, and epicatechin) and stilbenes (e.g., resveratrol) (Soleas 
et al., 1997; Parks & Booyse, 2002; Waterhouse, 2002). However, white 
wine can also protect the heart from damage caused by ischemia-reperfusion 
injury by improving post-ischemic ventricular function and reducing 
myocardial infarction (Cui et al., 2002). Red wine reduced body weight gain 
as well as adipocyte size in rats fed with normal diet (Monteiro et al., 2009) 
and reduced epididymal fat content along with reduction in body weight in 
high-fat diet-fed rats (Vadillo et al., 2006). In humans, red wine reduced 
total and LDL cholesterol and increased HDL cholesterol more than white 
wine; triglycerides were minimally affected with both wines (van Velden et 
al., 2002). Plasma total antioxidant status was increased with red wine while 
it was decreased with white wine (van Velden et al., 2002). These responses 
to red wine can be attributed to polyphenols, including phenolic acids, 
resveratrol, hydrolysable tannins, flavonols, and anthocyanins (Waterhouse, 
2002).  
Resveratrol 
Resveratrol (Figure 3A) is extracted into the wine from the grape 
skin where it is synthesized as a response to fungal infection (Kroon et al., 
2010). Red wine (0.1-14.3 mg/L) contains more resveratrol than white wine 
(0.002-0.1 mg/L) (Romero-Pérez et al., 1996; Baur & Sinclair, 2006). The 
physiological and biochemical responses of resveratrol in animal models, 
tissues, and cells have been extensively reviewed (Brown et al., 2009; 
Kroon et al., 2010; Mullin, 2011).  
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Both in vivo and in vitro studies have confirmed the effects of 
resveratrol in the components of metabolic syndrome (Kroon et al., 2010). 
Resveratrol induced apoptosis and inhibited cell differentiation in 3T3-L1 
preadipocytes by up-regulating expression of Sirt1 and inhibition of Akt 
(Rayalam et al., 2008; Chen et al., 2011a; Chen et al., 2011b). Short-term 
incubation of freshly isolated rat hepatocytes with 25 μM resveratrol for 30 
minutes decreased incorporation of acetate into triglycerides (Gnoni & 
Paglialonga, 2009). Resveratrol (10 mg/kg/day) improved dyslipidemia, 
hyperinsulinemia, and hypertension in obese Zucker rats (Rivera et al., 
2009). Resveratrol failed to inhibit the increase in body weight and body fat 
of high-fat diet-fed mice or rats (Baur et al., 2006; Rivera et al., 2009; 
Rocha et al., 2009; Tauriainen et al., 2011). In another study, resveratrol 
reduced body weight as well as body fat (Lagouge et al., 2006). However, 
resveratrol inhibited the development of hepatic steatosis and hepatocyte 
ballooning in high-fat diet-fed mice (Tauriainen et al., 2011). Pre-treatment 
with resveratrol (30 mg/kg/day for 1 week) in streptozotocin (STZ)-induced 
diabetic rats inhibited apoptosis in pancreatic β-cells along with the 
reduction in blood glucose concentrations and increase in serum insulin 
concentrations (Ku et al., 2012). Resveratrol (1 mg/kg/day for 32 da ys) 
lowered systolic blood pressure and cardiac fibrosis, attenuated 
inflammation in the left ventricle, and improved ventricular and vascular 
function in deoxycorticosterone acetate-salt hypertensive rats (Chan et al., 
2011). Similarly, resveratrol (10 mg/kg/day) treatment reduced systolic 
blood pressure and cardiac hypertrophy in fructose-fed rats (Miatello et al., 
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2005). These changes were accompanied by an increased expression of 
eNOS in mesenteric vascular bed and heart (Miatello et al., 2005).  
Daily 10 mg resveratrol was given for 3 months in a double-blind, 
placebo-controlled, randomized study, to patients with a history of 
myocardial infarction. Blood pressures and plasma concentrations of C-
reactive protein, glycosylated haemoglobin, TNF-α, total cholesterol, 
triglyceride, and HDL-cholesterol were unchanged. Resveratrol increased 
flow-mediated dilation of the brachial artery and improved left ventricular 
function (increases in ejection fraction and E/A ratio) (Magyar et al., 2012). 
In older adults with impaired glucose tolerance, resveratrol treatment for 4 
weeks (1, 1.5, and 2 g/day) did not change fasting glucose concentrations, 
but peak post-meal glucose and 3-hour glucose area under the curve were 
lowered. Furthermore, insulin sensitivity (using the Matsuda index) was 
improved following treatment with resveratrol treatment, although body 
weight, percent body fat, blood pressure, fasting lipid profile, plasma high 
sensitivity C-reactive protein and adiponectin concentrations were 
unchanged (Crandall et al., 2012). In obese humans, resveratrol (150 
mg/day) treatment for 30 da ys decreased hepatic lipid content, plasma 
inflammation markers, glucose, and triglycerides, and alanine-
aminotransferase activity; also, systolic blood pressure was lowered and 
HOMA index improved after resveratrol treatment (Timmers et al., 2011). 
The responses to resveratrol have been widely studied in animal tissues in 
vivo and in vitro, but there is minimal large-scale evidence on chronic 
responses to resveratrol from human studies in conditions such as obesity 
(Chachay et al., 2011). 
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 Figure 3: Polyphenols found in wine. (A) Resveratrol, (B) Ellagic acid, (C) 
Quercetin, and (D) Rutin 
Ellagitannins and ellagic acid 
Ellagitannins become constituents of red wine during its maturation 
in oak barrels (Saucier et al., 2006; García-Estévez et al., 2010). Different 
species of oak are used in the wine-making industry including American oak 
(Quercus alba) and European oak (Quercus petraea and Quercus robur). 
Ellagitannins are complex polyphenolic compounds found in oak as 
monomers or oligomers (Karonen et al., 2010; Yoshida et al., 2010). The 
major ellagitannins found in oak are vescalagin, castalagin, roburin and 
grandinin. Related ellagitannins are found in pomegranates, chestnuts, 
raspberries, strawberries, blackberries, and walnuts (Cerdá et al., 2005; 
Seeram et al., 2006; Coates et al., 2007; Bakkalbaşi et al., 2009). 
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Chemically, ellagitannins are hydrolysable tannins, which upon h ydrolysis 
release ellagic acid. Ellagic acid (Figure 3B) is a polyphenol found in nuts 
as well as fruits such as raspberries, pomegranates, grapes, and 
blackcurrants (Talcott & Lee, 2002; Mari Kannan & Darlin Quine, 2012). 
The potential therapeutic role of the ellagitannins in red wine has been 
neglected, even though the presence of these polyphenols in wine and other 
dietary constituents has been known for a long time. 
Ellagitannins from pomegranate juice attenuated isoproterenol-
induced cardiac necrosis in rats (Jadeja et al., 2010) and angiotensin-
induced hypertension, glucosuria and proteinuria in STZ-induced diabetic 
rats (Mohan et al., 2010). Pomegranate fruit extract containing punicalagin 
as the major ellagitannin improved vascular endothelial function without 
affecting the plasma lipid profile in obese Zucker rats (Seeram et al., 2004; 
de Nigris et al., 2007). In elderly hypertensive subjects, pomegranate juice 
consumption for 2 weeks reduced systolic blood pressure along with serum 
angiotensin converting enzyme activity (Aviram & Dornfeld, 2001). In type 
2 diabetic subjects, concentrated pomegranate juice consumption (40 g/day) 
for 9 w eeks reduced serum total cholesterol and LDL cholesterol 
(Esmaillzadeh et al., 2004). In our recent study, we have shown that the 
ellagitannins from European oak (Quercus petraea) attenuated 
cardiovascular remodeling and nonalcoholic fatty liver, accompanied by 
reduction in systolic blood pressure, abdominal fat deposition, blood lipid 
concentrations, and improvements in glucose tolerance in high-
carbohydrate, high-fat diet-fed rats, probably due to anti-oxidative and anti-
inflammatory activities of ellagitannins (Panchal & Brown, 2011). Also, 
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ellagitannins from oak attenuated cardiovascular remodeling and lowered 
systolic  bl ood pressure in Spontaneously Hypertensive Rats (Panchal & 
Brown, 2011). These studies have used rich but complex sources of 
ellagitannins including oak wood extract and pomegranate juice; studies 
with purified compound are justified. 
Studies with purified ellagic acid in animals and humans with 
metabolic syndrome are limited (Larrosa et al., 2010). Ellagic acid induced 
cardioprotection against isoproterenol-induced myocardial infarction 
(Kannan & Quine, 2011) and also showed anti-proliferative effects in 
cancerous cell lines (Losso et al., 2004). Ellagic acid protected liver cells in 
vitro and in vivo in rat models of hepatic damage (Girish et al., 2009; 
Hwang et al., 2010). In high-carbohydrate, high-fat diet-fed rats, ellagic acid 
reduced body weight, abdominal fat content, basal blood glucose 
concentrations, plasma triglycerides, plasma total cholesterol, and plasma 
nonesterified fatty acid concentrations. In these rats, ellagic acid also 
improved the structure and function of the heart and the liver (Panchal et al., 
2012b). 
Flavonoids 
Flavonoids are naturally occurring low molecular weight 
polyphenolic compounds widely distributed in fruits and vegetables (Park et 
al., 2008). More than 6000 flavonoids have been identified to date (Egert et 
al., 2010). Anticancer, antimicrobial, antiviral, anti-inflammatory, 
immunomodulatory, and antithrombotic activities have been claimed for 
flavonoids (Havsteen, 1983; Kim et al., 2004). Some flavonoids have shown 
Page 24
promising results in metabolic syndrome (Hu et al., 2009; Mulvihill et al., 
2009). Effects of major flavonoids present in the diet have been described 
here. 
Quercetin 
Quercetin (3,3′,4′,5,7-pentahydroxy flavone; Figure 3C) is a major 
flavonoid found in plants and plant products (Galisteo et al., 2004), 
including red onions, apples, berries, citrus fruits, tea, and red wine (Ruiz et 
al., 2009; Egert et al., 2010). Quercetin has improved most aspects of the 
metabolic syndrome in experimental studies, but the doses/concentrations 
have differed markedly. Quercetin and its metabolites inhibited neutrophil-
mediated modification of LDL in vitro through the inhibition of 
myeloperoxidase (Loke et al., 2008). Quercetin protected human 
hepatocytes from ethanol-induced oxidative stress by activating Nrf2-
mediated heme oxygenase-1 (Yao et al., 2007). Quercetin reduced systolic 
blood pressure in hypertensive human patients as well as in animal models 
of hypertension (Egert et al., 2009; Perez-Vizcaino et al., 2009). Quercetin 
(0.5% in diet) reduced systolic blood pressure of high-fat, high-sucrose diet-
fed rats after 4 weeks of treatment, possibly due to increased NO 
bioavailability through increased NOS activity (Yamamoto & Oue, 2006). 
Quercetin dilated isolated rat vascular smooth muscle, possibly by inhibiting 
protein kinase C (Duarte et al., 1993). Quercetin (0.8% diet) increased the 
energy expenditure in high fat diet-fed mice without affecting the body 
weight and body composition (Stewart et al., 2008). Quercetin (0.05 
mg/kg/day) reduced serum triglyceride and cholesterol concentrations in 
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high-fat diet-fed rabbits after 12 w eeks of treatment, whereas it did not 
affect the serum concentrations of triglyceride and cholesterol after 4 weeks 
of treatment (Juźwiak et al., 2005). Quercetin (10 mg/kg/day) reduced body 
weight in obese Zucker rats without changing the average daily food intake 
(Rivera et al., 2008). It also reduced plasma levels of triglycerides, free fatty 
acids, total cholesterol, and insulin in obese rats whereas adiponectin 
concentrations in plasma were increased. In this study, quercetin increased 
eNOS expression while decreasing iNOS expression in visceral adipose 
tissue of obese Zucker rats (Rivera et al., 2008). In mice fed with a diet rich 
in fat, cholesterol, and sucrose, quercetin reduced visceral and liver fat 
accumulation and improved hyperglycemia, hyperinsulinemia, 
dyslipidemia, and plasma concentrations of adiponectin and TNF-α. 
Quercetin also reduced oxidative stress in these mice (Kobori et al., 2011). 
In Spontaneously Hypertensive Rats, quercetin supplementation (1.5 g/kg in 
food) did not change blood pressure or left ventricular dimensions, 
ventricular functions, vascular morphology, vascular resistance, and 
conductance vessel reactivity (Carlstrom et al., 2007). In high-carbohydrate, 
high-fat diet-fed rats, quercetin (~50 mg/kg/day) attenuated hypertension, 
impairment in glucose tolerance, and central obesity without reducing body 
weight (Panchal et al., 2012a). These changes were accompanied by the 
improvements in structure and function of the heart and the liver (Panchal et 
al., 2012a). 
In a double-blind, randomized, placebo-controlled, crossover trial in 
obese subjects, quercetin supplementation (150 mg/day for 6 weeks) did not 
change body weight, waist circumference, fat mass, fat-free mass, serum 
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concentrations of total cholesterol, triacylglycerols, or glucose, although a 
decreased systolic blood pressure was observed (Egert et al., 2010). 
Quercetin did not change serum concentrations of hs-CRP whereas serum 
concentrations of hs-TNF-α were decreased (Egert et al., 2010). Quercetin 
supplementation (730 mg/day for 28 d ays) reduced systolic and diastolic 
blood pressure in a randomized, double-blind, placebo-controlled, crossover 
study in hypertensive subjects (Edwards et al., 2007). 
Rutin 
Rutin (Figure 3D) is found abundantly in onions (200-300 mg/kg), 
apples (0.17% of dry weight), tea (10.18% in dry weight), and red wine (4-5 
mg/L) (López et al., 2001; Makris & Rossiter, 2001; Slimestad et al., 2007; 
Atanassova & Bagdassarian, 2009). Rutin (1 mg/ml of medium) suppressed 
the differentiation of adiopocytes in pre-adipocyte 3T3-L1 cell lines (Choi 
et al., 2006). Rutin (50 mg/kg/day) decreased serum glucose and lipid 
concentrations in STZ-induced type I diabetic rats (Fernandes et al., 2010). 
In these diabetic rats, rutin decreased the serum activities of liver enzymes 
(alanine transaminase (ALT), aspartate transaminase (AST), and lactate 
dehydrogenase) (Fernandes et al., 2010). Similarly, serum concentrations of 
insulin, total cholesterol, free fatty acid, and triglyceride were decreased 
with rutin treatment in STZ-diabetic rats (Fernandes et al., 2010). Reduction 
in concentrations of total cholesterol may result from inhibition of HMG-
CoA reductase (Fernandes et al., 2010). In STZ-induced diabetic rats, rutin 
(100 and 300 mg/kg/day) inhibited the decrease in left ventricular function 
measured as fractional shortening and ejection fraction (Krishna et al., 
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2005). High fat diet-fed C57BL/6 mice showed reduction in body weight 
and total cholesterol in blood with rutin treatment (25 and 50 mg/kg/day) 
whereas the treatment did not affect the triglyceride concentrations in blood 
(Choi et al., 2006). Rutin (10 and 100 mg/kg/day) reduced concentrations of 
total cholesterol and LDL cholesterol along with plasma activities of AST 
and ALT in hypercholesterolemic rats after 4 weeks (Ziaee et al., 2009). In 
rats fed a h igh-carbohydrate, high-fat diet, we have shown that rutin 
attenuated hepatic steatosis, cardiovascular remodeling, obesity, 
hypertension, dyslipidemia, hyperinsulinemia, and impaired glucose 
tolerance (Panchal et al., 2011). 
In a randomized controlled implementation trial in diabetic patients, 
rutin supplementation (500 mg/day) reduced blood pressure, body weight, 
and serum LDL cholesterol and increased serum HDL cholesterol but did 
not affect serum triglycerides (Sattanathan et al., 2010). Withdrawal of rutin 
supplementation reversed these changes (Sattanathan et al., 2010). 
Anthocyanins 
Anthocyanins are water-soluble natural pigments responsible for 
red-blue or purple colors in fruits and vegetables (He & Giusti, 2010). 
Cyanidin (Figure 4A), delphinidin (Figure 4B), malvidin (Figure 4C), 
pelargonidin, peonidin, and petunidin are the major dietary anthocyanins 
(Lamy et al., 2006). Major dietary sources include fruits and vegetables 
such as berries (blueberry, bilberry, and chokeberry), purple carrot, black 
currant, red radish, purple maize, red cabbage, and purple sweet potato (He 
& Giusti, 2010; Tsuda, 2012). 
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 Figure 4: Anthocyanins found in fruits and vegetables. (A) Cyanidin, (B) 
Delphinidin, and (C) Malvidin 
Epidemiological studies have shown that increased consumption of 
diets rich in anthocyanins reduced the risk of developing cardiovascular 
diseases (Wallace, 2011). Our studies have shown that purple carrot juice 
(5% of the diet) reduced abdominal obesity, systolic blood pressure, plasma 
lipids, hepatic steatosis, cardiac fibrosis, and inflammation along with 
improved glucose tolerance in high-carbohydrate, high-fat diet-fed rats 
(Poudyal et al., 2010). Chokeberry fruit juice (5, 10, a nd 20 m l/kg body 
weight) for 30 da ys reduced total cholesterol, LDL cholesterol, and 
triglycerides in 4% cholesterol diet-fed rats (Valcheva-Kuzmanova et al., 
2007). Chokeberries (100 and 200 m g/kg/day) also reduced visceral 
adiposity, blood glucose, serum triglycerides, total cholesterol, and LDL 
cholesterol in fructose-fed rats (Qin & Anderson, 2011). In the same study, 
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anthocyanin supplementation increased plasma adiponectin levels, inhibited 
the plasma levels of pro-inflammatory cytokines such as TNF-α and IL-6, 
down-regulated adipogenic markers (Gsk3β, Fabp4, Fas, and Lpl) mRNA 
expression, and up-regulated important intermediates of the insulin 
signalling cascade (Irs1, Irs2, Pi3k, Glut1, Glut4, and Gys1) (Qin & 
Anderson, 2011). In diabetes induced by high-fructose diet and 
simultaneous single injection of STZ (20 mg/kg), dietary supplementation 
with chokeberry fruit extract (0.2%; ~400mg/g of anthocyanin glycosides in 
the extract) decreased antioxidant status of vital organs, total plasma 
cholesterol, and blood glucose concentrations (Jurgoński et al., 2008). In 
Zucker rats fed a h igh-fat diet, supplementation with 2% dietary blueberry 
or 1% whole tart cherry powder reduced plasma triglycerides, fasting 
insulin, HOMA-IR, and abdominal fat mass and increased adipose and 
skeletal muscle PPAR-α and PPAR-γ activity along with reductions in TNF-
α, IL-6, and NF-κB in the plasma and the adipose tissue, and improved 
glucose tolerance (Seymour et al., 2009; Seymour et al., 2011). At the same 
dosage after 90 days, tart cherries reduced fasting blood glucose, 
hyperlipidemia, hyperinsulinemia, and fatty liver with increased hepatic 
PPAR-α expression in salt-sensitive Dahl rats (Seymour et al., 2008). 
Anthocyanins from black soybean seed coats (cyanidin-3-glucoside, 
delphinidin-3-glucoside, and petunidin-3-glucoside; 10-100 μg/mL) 
inhibited TNF-α-mediated VCAM-1 expression in human umbilical vein 
endothelial cells (Nizamutdinova et al., 2009). In the same cell line, 
delphinidin inhibited oxidised LDL-induced cell viability loss primarily by 
up-regulating proteins involved in inhibiting apoptosis including Bcl-2 and 
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Bax proteins (Chen et al., 2010). These results suggest that the responses to 
anthocyanins supplementation may be mediated by its anti-inflammatory 
and antiapoptotic properties and up-regulation of the insulin-signalling 
cascade. 
Anthocyanins have direct protective effects on the heart. Hearts from 
male Wistar rats fed on a diet based on a nthocyanins containing maize 
kernels for 8 weeks were more resistant to regional ischemia and 
reperfusion insult induced in an isolated heart preparation (Toufektsian et 
al., 2008). This diet also reduced the infarct size in coronary occlusion and 
reperfusion model (Toufektsian et al., 2008). Anthocyanin extract from 
black rice (5 g/kg diet) lowered body weight gain, serum triglyceride, raised 
hepatic CPT-1 expression, and inhibited platelet hyperactivity suggested by 
decreased thromboxane A2, the thrombogenic ratio of thromboxane A₂ and 
prostacyclin, serum calmodulin, and soluble P-selectin expression in high-
fat diet-fed rats (Yang et al., 2011).  
Human studies concur with the therapeutic responses produced in 
animal models to dietary anthocyanins. In patients with metabolic 
syndrome, chokeberries extract (3 x 100 mg/day) for two months decreased 
both systolic and diastolic blood pressure, endothelin-1, total cholesterol, 
LDL cholesterol, triglycerides, TBARS, catalase activity, and induced 
superoxide dismutase activity (Broncel et al., 2010). In 
hypercholesterolemic patients, 320 mg/day of purified anthocyanins isolated 
from bilberries and blackcurrants increased brachial artery flow-mediated 
dilation, cGMP, and HDL cholesterol concentrations and decreased the 
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serum soluble vascular adhesion molecule-1 and LDL cholesterol 
concentrations (Zhu et al., 2011). Anthocyanins also improved endothelial 
function in these patients as well as in isolated rat aortic rings; these effects 
were abolished by nitric oxide-cGMP inhibitors suggesting the role of nitric 
oxide-cGMP signalling pathway in anthocyanins-mediated vasodilation 
(Zhu et al., 2011) 
Tea polyphenols: Catechins 
Tea is one of the most widely consumed beverages in the world. It is 
consumed in the form of green tea, oolong tea, or black tea. Green tea is 
prepared by drying the leaves of the plant Camellia sinensis using steam. 
This process prevents the oxidation of tea polyphenols by inactivating the 
enzymes in the leaves. Black tea is prepared by crushing the tea leaves to 
promote enzymatic oxidation which leads to condensation of tea 
polyphenols resulting in polymers (Chacko et al., 2010). Green tea mainly 
contains catechins (Figure 5A-D), along with flavanols and polymeric 
flavonoids (Balentine et al., 1997; Lakenbrink et al., 2000). 
Epigallocatechin gallate is the major catechin found in green tea. Black tea 
mainly contains oligomeric and polymeric polyphenols such as thearubigin 
and theaflavins (Balentine et al., 1997; Lakenbrink et al., 2000) 
Catechins are flavonoids often found as the gallate derivatives, 
usually catechin gallate (CG), epigallocatechin (EGC), epigallocatechin 
gallate (EGCG), epicatechin gallate (ECG), and epicatechin (EC). Tea is 
one of the major sources of catechins (Cabrera et al., 2006); other sources 
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include wine, grape skins, grape seeds, and cacao beans (Yilmaz & Toledo, 
2004; Auger et al., 2005). 
 
Figure 5: Catechins found in tea 
CG, EGC, EGCG, and ECG prevented the differentiation of 
preadipocytes to adipocytes (Furuyashiki et al., 2004). Administration of 
0.5% tea catechins in drinking water to rats for 3 weeks reduced liver lipid 
content, serum total cholesterol concentration, and body weight in normal 
diet-fed rats, indicating that tea catechins can control lipid metabolism in 
obese as well as non-obese rodents (Ito et al., 2008). Tea catechins showed 
increased excretion of carbohydrates, proteins, and lipids in the feces 
suggesting the reduction in digestibility of these macromolecules 
accompanied by the reduction in the body weight gain (Unno et al., 2009). 
Tea catechins (1% of the diet) also showed body fat reduction along with 
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reduction in liver triglyceride content in rats after 23 days of feeding (Ikeda 
et al., 2005).  
EGCG reduced body weight, blood glucose, and plasma insulin 
concentrations and improved insulin sensitivity in high-fat diet-fed mice 
(Sae-Tan et al., 2011). EGCG also reduced plasma ALT activity, hepatic 
steatosis, and liver weight in these mice (Sae-Tan et al., 2011). In high-fat 
diet-fed mice, tea catechins reduced body weight gain, abdominal fat 
deposition, liver triglycerides, and plasma concentrations of insulin, leptin, 
and total cholesterol (Murase et al., 2002). The anti-obesity effect of EGCG 
may involve mediating the balance between energy intake and energy 
expenditure (Moon et al., 2007). In a pressure overload rat model induced 
by abdominal aortic constriction, EGCG inhibited cardiac hypertrophy and 
cardiac fibrosis with improved ventricular function without changing 
systolic blood pressure (Hao et al., 2007). In stroke-prone Spontaneously 
Hypertensive Rats, green tea polyphenols reduced blood pressure and 
increased aortic expression of catalase (Negishi et al., 2004). This study 
confirms the antioxidant effect of green tea polyphenols in reducing blood 
pressure. 
The reported responses to catechins from tea have shown health 
benefits in humans (Higdon & Frei, 2003; Cabrera et al., 2006; Feng, 2006; 
Hsu et al., 2011; Yang et al., 2012). In overweight human subjects, 
supplementation of green tea extract containing catechins reduced body 
weight, body mass index, total body fat mass, total body lean mass, systolic 
blood pressure, and blood glucose concentrations (Yang et al., 2012). In the 
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Ohsaki National Health Insurance Cohort Study, green tea consumption 
reduced cardiovascular mortality (Kuriyama et al., 2006). In a meta-analysis 
study, it was concluded that green tea consumption lowered serum total 
cholesterol and LDL cholesterol concentrations (Zheng et al., 2011). In a 
prospective cohort study, it was concluded that the consumption of green tea 
substantially decreased serum concentrations of total cholesterol, LDL 
cholesterol, VLDL cholesterol, and triglycerides whereas increased serum 
HDL cholesterol concentration was found (Imai & Nakachi, 1995). An 
inverse association was found between green tea consumption and serum 
activity of AST (Imai & Nakachi, 1995). Results from this cross-sectional 
study indicated that the consumption of green tea might prevent 
cardiovascular and liver diseases.  
Turmeric polyphenol: Curcumin 
Turmeric (Curcuma longa) is an Indian spice used as a dry powder 
in food preparations all over the world. Turmeric has been used as a 
medicine in Ayurveda, traditional Chinese medicine, and in traditional 
household treatments. Curcumin (Figure 6) is the principal ingredient found 
in turmeric (Kiuchi et al., 1993; Goel et al., 2008b). Responses to curcumin 
have been extensively reviewed (Aggarwal et al., 2007; Anand et al., 2008; 
Goel et al., 2008a; Aggarwal & Harikumar, 2009; Aggarwal & Sung, 2009).  
 
Figure 6: Structure of curcumin 
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Curcumin decreased the symptoms of metabolic syndrome in rodent 
models. In high-fat diet-fed rats, curcumin (80 mg/kg/day) reduced fasting 
plasma concentrations of glucose, insulin, total cholesterol, triglycerides, 
LDL cholesterol, free fatty acids, and TNF-α whereas it increased plasma 
HDL cholesterol concentrations after 60 days in a prevention protocol; these 
changes were accompanied by improved insulin sensitivity and glucose 
tolerance (El-Moselhy et al., 2011). High-fat diet-fed mice (treated with 4 g 
curcumin/kg diet for 2 days/week for 28 weeks) showed reduction in body 
weight, epididymal fat content, total body fat content, fasting plasma insulin 
concentrations, and improved tolerance to glucose, pyruvate, and insulin 
with inhibition of hepatic steatosis and infiltration of macrophages in 
adipose tissue and liver (Shao et al., 2012). Similar results were found with 
curcumin (3% in food) in ob/ob mice (Weisberg et al., 2008). Curcumin 
inhibited adipokine-induced adipogenesis in 3T3-L1 adipocytes and 
preadipocyte differentiation (Ejaz et al., 2009). Curcumin treatment (500 
mg/kg/day) suppressed body weight gain, reduced total body fat, prevented 
hepatic steatosis, and lowered serum total cholesterol in high-fat diet-fed 
mice (Ejaz et al., 2009). Curcumin treatment (100 mg/kg/day) lowered 
blood pressure in L-NG-nitroarginine methyl ester-hypertensive rats 
(Hlavačková et al., 2011). Curcumin (50 mg/kg/day) improved ventricular 
dimensions and functions in salt-sensitive Dahl rats and in surgically-
induced myocardial infarction in rats by attenuating cardiac hypertrophy and 
fibrosis (Morimoto et al., 2008). Blood pressure in these rats was unaltered 
with curcumin treatment (Morimoto et al., 2008). Similar cardioprotective 
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roles of curcumin have been reviewed previously (Wongcharoen & 
Phrommintikul, 2009; Alappat & Awad, 2010).  
A phase I clinical trial showed that 8 g /day curcumin orally for 3 
months had no s ide-effects or toxicity in subjects (Cheng et al., 2001). In 
healthy individuals, administration of curcumin (500 mg/day) decreased 
serum lipid peroxides and total cholesterol concentration while increasing 
serum HDL cholesterol concentrations (Soni & Kuttan, 1992). Similarly, 
curcumin (10 mg twice a day, for 30 days) reduced serum LDL cholesterol 
and increased serum HDL cholesterol in atheroscelerosis patients (Ramírez-
Boscá et al., 2000).  
Dosage and chronic intake of polyphenols 
In vivo studies with polyphenols have shown that these compounds 
can be effective in treating the symptoms of metabolic syndrome. Although 
the doses of polyphenols used in animal studies have been effective, the 
doses cannot be directly applied to the humans due to various differences 
between rodents and human. There are various conversion equations that 
can be used to transform the animal doses to the human doses. Some of 
these are scaling equation based on metabolic rate difference between 
animals and humans (Bachmann et al., 1996) and a conversion based on 
body surface area (Reagan-Shaw et al., 2008). Also, the length of protocol 
in animal is very short and varies from one study to the other study. 
Similarly, the life span of animals used in the studies (for example, 27-30 
months for a rat) is much shorter than the human life span (65-70 years on 
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an average). Thus, a relative period has to be considered in humans to see a 
consistent response with the polyphenols. 
Toxicity 
Hazards, safety, and risks related to polyphenol consumption have 
previously been considered (Schilter et al., 2003; Mennen et al., 2005; 
Lambert et al., 2007; Martin & Appel, 2010). Most studies with polyphenols 
or natural products have focussed on characterizing their beneficial effects 
in various disease conditions and the toxicity related to polyphenols has 
been overlooked (Mennen et al., 2005). Repeated oral doses of pomegranate 
husk extract (6% punicalagin-containing diet) to the rats for 37 days did not 
show any toxic effects (Cerdá et al., 2003). In another long-term study, 
toxicity and carcinogenicity of quercetin were tested in male and female 
rats. Quercetin (0, 1000, 10,000, or 40,000 ppm) was given in the diet for 2 
years at doses from ~40 to 1900 mg/kg/day. High dose groups showed 
reduction in body weight gain compared to controls during the 2nd year of 
the study. After 2 years, quercetin showed carcinogenic activity in the 
kidney of the male rat without inducing tumors at other sites (Dunnick & 
Hailey, 1992). Similarly, tea catechins (EGCG) have shown pro-oxidant 
activities in different studies (Yang et al., 2000; Hong et al., 2002; 
Weisburg et al., 2004; Hou et al., 2005). Another study reported the 
reduction in rat hepatocyte viability with EGCG (Galati et al., 2006).  
The use of polyphenols can be questioned, considering the 
differences between various cancers and other pathological conditions 
including cardiovascular disease, hypertension, and diabetes. To reduce cell 
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growth in cancer, compounds will cause toxicity to the cells whereas in 
metabolic diseases such as diabetes, cell growth needs to be maintained and 
its function should be improved. Thus, theoretically, anything that is active 
in cancer may not be effective in metabolic diseases; unless highly different 
doses are used. Thus, the toxicity of polyphenols in cancer can be used 
though application of higher doses whereas the potential benefits of 
polyphenols could be utilized by using a relatively lower but 
pharmacologically active dose.  
Conclusion 
Natural products are abundant in phytochemicals some of which 
belong to the class of polyphenols. These polyphenols are synthesized by 
the plants through shikimate pathway. Some of the polyphenols found in 
wine and tea have been studied for their pharmacological activities in vitro, 
in vivo in animal models of metabolic syndrome, and in humans. Red wine 
consists of a range of polyphenols including resveratrol, ellagitannins, 
quercetin and anthocyanins. These phytochemicals are effective in 
attenuating the symptoms of metabolic syndrome and associated 
complications. Similarly, tea catechins and curcumin from turmeric have 
been effective against the symptoms of metabolic syndrome. Some of the 
polyphenols such as ellagic acid have been studied to lesser extent for their 
activity against metabolic syndrome. With the effectiveness shown by 
polyphenols in metabolic syndrome, it can be proposed that these 
phytochemicals, either in extract form or purified form, can be used as a 
complimentary medicine in treatment of metabolic syndrome, 
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cardiovascular disease, type 2 diabetes, and non-alcoholic fatty liver 
disease. 
Although most of the polyphenols have shown therapeutic effects in 
metabolic syndrome in animal models, there have been limited numbers of 
human trials to justify the data. Also, the subjects in the human trials were 
considered for limited parameters related to metabolic syndrome in a 
particular trial. Thus, the responses to polyphenols need to be explored in 
subjects with wide range of symptoms of metabolic syndrome. Also, the 
literature on the combinatorial effects of polyphenols with standard drugs in 
various symptoms of metabolic syndrome is missing. If not used alone, 
these phytochemicals may enhance the effectiveness of standard drugs in 
attenuating the symptoms of metabolic syndrome. 
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Spices used in Indian cooking have a long history of use as medicines to prevent and treat diseases. Many studies have 
confirmed that spices can be useful medicines, but the major challenge is now to provide scientific evidence and plausible 
mechanisms for their therapeutic responses. This review focuses on the therapeutic potential of Indian spices to treat 
multiple symptoms of the metabolic syndrome such as insulin resistance, diabetes, obesity, altered lipid profile and 
hypertension. The metabolic syndrome is prevalent and has become an important financial burden to the healthcare system 
in both developed and developing countries. Inflammation and oxidative stress have been proposed as initiators of the 
metabolic syndrome, especially of insulin resistance. Natural products with anti-inflammatory and anti-oxidant properties 
are found in spices. Adequate doses of these compounds may be effective in treating the metabolic syndrome. Testing these 
potential treatments requires adequate animal models, usually rodents, so the limitations of these models are important. 
Furthermore, this review highlights the need for adequate legislation and regulation to ensure the safety and success of 
evidence-based functional foods and nutraceuticals. 
Keywords: Spices, Diabetes, Cardiovascular disease, Metabolic syndrome, Inflammation, Oxidative stress, 
Nutraceuticals, Food safety 
 
Introduction 
Dietary choice remains the basis for maintaining a 
healthy lifestyle and well-being, especially relating to 
cardiovascular disease (CVD), despite remarkable 
advances in medicine and pharmaceutical drug 
development1,2. Besides food being a lifestyle choice, 
age-old anecdotal reports from many cultures strongly 
suggest a role for diet as well as Indian spices in both 
preventive and therapeutic medicine3,4. However, the 
major challenge in the use of spices as preventive and 
therapeutic medicines is in demonstrating their health 
benefits by scientific means, comparable with the 
standards applied for pharmaceutical agents3. Further, 
unlike pharmaceutical agents which are administered 
in predetermined doses as pure and concentrated 
preparations, spices are consumed in combinations 
and in unmeasured and variable quantities in different 
cultural settings. Therefore, the major challenge is to 
provide scientific evidence to define these benefits as 
well as plausible mechanisms by which these products 
are effective in a disease setting. 
Around 60% of the world’s population depends on 
herbal medicine, a broad term including spices, for 
primary healthcare5. Spices are pungent or aromatic 
substances from dried seeds, fruits, roots, bark or 
leaves used as additives to flavour, colour or preserve 
food; the differences with dried herbs used for 
flavouring is somewhat arbitrary. In India, many of 
these spices are part of everyday cooking and 
significant quantities may be consumed in a single 
meal. It is estimated that an adult in India can 
consume 80-200 mg/day of curcumin, the bioactive 
component of turmeric3. Some Indians have been 
reported to consume up to 50 g of garlic in a week3,6. 
These data suggest a realistic possibility to achieve 
therapeutic doses of the active ingredients in spices by 
dietary consumption alone. However, for many 
patients, treatment with functional foods or 
nutraceuticals with enhanced concentrations of the 
active ingredients of the spices may be necessary. 
There is a widespread research effort in India to 
define the potential health benefits of herbal 
medicines, including spices, and identify the active 
ingredients, especially compounds with anti-oxidant 
and anti-inflammatory properties4,5. 
______________ 
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This review investigates the potential of commonly 
used spices in India for treatment for the symptoms of 
metabolic syndrome in humans. To do this, we will 
define the metabolic syndrome and the likely 
mechanisms for the symptoms, discuss the choice of 
an appropriate rodent model for preclinical studies 
and present the available evidence for individual 
products. Two other important issues will then be 
presented: evaluation of the quality of the evidence as 
well as testing the safety and efficacy of these 
products. 
 
Metabolic syndrome and its significance 
The spices used in Indian cooking have potential 
for use in the treatment of the metabolic syndrome, a 
central preliminary pathological indication in the 
development of cardiovascular diseases, causing 
major public health challenges worldwide7-9 and 
especially in the Indian sub-continent10. Metabolic 
syndrome refers to the clustering of several 
cardiovascular and metabolic risk factors, including 
dyslipidaemia, hyperglycaemia and increased blood 
pressure, where abdominal obesity and insulin 
resistance represent core parameters of this 
cluster7,8,11. There are several definitions of the 
metabolic syndrome (Table 1), of which the first 
functioning definition was provided by the World 
Health Organization (WHO), emphasising insulin 
resistance and hyperglycaemia as key symptoms with 
additional associated metabolic symptoms. More 
recently, the US National Cholesterol Education 
Program Adult Treatment Panel III, International 
Diabetes Federation and the American Heart 
Association and National Heart, Lung, and Blood 
 
Table 1—Diagnostic criteria and definitions for the metabolic syndrome provided by major agencies around the world 
 
Clinical 
measure 
WHO* (1998) EGIR^ (1999) AACE
%
 
(2003) ATP III 
#(2004) IDF** (2005) AHA/NHLBI
^^
 
(2005) 
       
Insulin 
resistance 
Impaired glucose 
tolerance (IGT), 
impaired fasting glucose 
(IFG) or insulin 
resistance (IR) plus any 2 
of the following: 
Plasma insulin 
> 75th 
percentile plus 
any 2 of the 
following: 
Impaired 
glucose 
tolerance, 
impaired 
fasting 
glucose plus 
any of the 
following: 
NONE 
Any 3 of the following 5 features: 
     
Dyslipidaemia 
Triglycerides (TG): 
≥ 1.695 mmol/L and 
high-density lipoprotein 
cholesterol (HDL-C)  
≤  0.9 mmol/L (male),  
≤ 1.0 mmol/L (female) 
TG ≥ 2.0 
mmol/L and/or 
HDL-C 
< 1.0 mmol/L 
or treated for 
dyslipidaemia 
TG ≥ 1.69 
mmol/L and 
HDL-C 
< 1.03 
mmol/L 
TG ≥ 1.695 
mmol/L HDL-C 
< 40 mg/dL 
(male), <  50 
mg/dL (female) 
TG ≥ 1.7 mmol/L 
or on TG Rx, 
HDL-C  < 1.03 
mmol/L or on 
HDL-C Rx 
TG ≥ 1.69 mmol/L 
or on TG Rx, HDL-C 
< 1.03 mmol/L or on 
HDL-C Rx 
       
Blood 
pressure ≥ 140/90 mm Hg 
≥ 140/90 mm 
Hg 
≥ 130/85 
mm Hg ≥ 130/85 mm Hg ≥ 130/85 mm Hg ≥ 130/85 mm Hg 
       
Plasma 
glucose ≥ 7.0 mmol/l (Fasting) 
≥ 6.1 mmol/l 
(Fasting) 
IGT or IFG 
(but not 
diabetes) 
> 5.6 mmol/L 
≥ 5.6 mmol/L 
(includes 
diabetes) 
≥ 5.6 mmol/L or on 
hypoglycemic 
 
       
Central 
obesity 
Waist: hip ratio > 0.90 
(male); > 0.85 (female), 
and/or body mass index 
> 30 kg/m2 
Waist 
circumference 
≥ 94 cm (male), 
≥ 80 cm 
(female) 
BMI ≥ 25 
kg/m2 
Waist 
circumference 
≥ 102 cm 
(male), ≥ 88 cm 
(female) 
Waist 
circumference  
> 94 cm 
Waist circumference 
≥ 102 cm 
       
Other 
Urinary albumin 
excretion ratio ≥ 20 
mg/min or 
albumin:creatinine ratio 
≥ 30 mg/g 
     
       
*World Health Organization22, ^The European Group for the Study of Insulin Resistance23, %American Association of Clinical 
Endocrinologists24, #The US National Cholesterol Education Program Adult Treatment Panel III25, **International Diabetes Federation26,
^^American Heart Association and National Heart, Lung, and Blood Institute12; Rx, medication; BMI, body mass index. 
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Institute have suggested that at least three of the 
following conditions must be met for a diagnosis of 
metabolic syndrome, although threshold values may 
differ: abdominal obesity, elevated triglyceride 
concentrations, reduced HDL-cholesterol concen-
trations, elevated blood pressure or fasting glucose 
concentrations12 (Table 1). 
The metabolic syndrome is common in adult 
populations throughout the world. In Australian 
adults, its prevalence ranges between 13.4 and 30.7%, 
depending on the definition used13,14. In the USA, its 
overall percentage in adults was 22.8% for men and 
22.6% for women15. In the Japanese population, 51% 
of male and 53% of female subjects met the WHO 
criteria for the metabolic syndrome, whereas 45% of 
male and 38% of female subjects met the US National 
Cholesterol Education Program Adult Treatment 
Panel III criteria for the metabolic syndrome16. In 
Finland, metabolic syndrome was present in 38.8% of 
men and 22.2% of women17. 
This situation appears to be similar in the Indian 
sub-continent with recent data suggesting about one-
fourth to one-third of the adult Indian population 
suffer from the metabolic syndrome18,19. Some 
communities such as the Punjabi Bhatia community in 
north India are more prone to be obese with type II 
diabetes and the symptoms of metabolic 
syndrome18,19. The prevalence of metabolic syndrome 
in the Sri Lankan population is high with 35% and 
51% in males and females, respectively18,19. In adults 
aged 25 years and older from an urban population in 
Karachi (Pakistan), the prevalence of metabolic 
syndrome was 34.8 and 49%, according to the 
International Diabetes Federation and US National 
Cholesterol Education Program Adult Treatment 
Panel III definitions, respectively20. The overall 
prevalence in Pakistan has been reported as 18-46%, 
comparable to other South Asian countries19,21. 
Comparable data from Bangladesh and Nepal are not 
available, but the prevalence would be expected to be 
similar. Intrauterine and early postnatal under-
nutrition has been suggested as an important cause of 
the relatively high incidence of cardiovascular disease 
and metabolic syndrome in Indian populations10. 
Thus, the metabolic syndrome provides many 
challenges to governments and healthcare providers 
from birth to death. 
 
Aetiology of metabolic syndrome 
The aetiology of metabolic syndrome involves 
many complex biochemical pathways. Different 
mechanisms linking the symptoms of metabolic 
syndrome have been postulated, all possibly 
hampering normal cardiovascular function. Increased 
levels of reactive oxygen species (ROS), non-
esterified fatty acids, oxidized LDL and lipotoxicity 
may be related to insulin resistance27. Adipose tissue 
releases numerous bioactive mediators, including pro-
inflammatory cytokines that not only influence body 
weight homeostasis, but also induce changes in 
cardiovascular structure and function, glucose 
metabolism, blood pressure, lipid metabolism, 
coagulation and inflammation, leading to endothelial 
dysfunction and atherosclerosis27,28. 
 
Inflammation has been proposed as the critical 
process initiating the symptoms of metabolic 
syndrome29. The pro-inflammatory state of obesity 
and metabolic syndrome is probably initiated by an 
excessive caloric intake in a high carbohydrate/high 
fat diet29,30. Increased oxidative stress in the adipose 
tissues of obese subjects is closely linked to enhanced 
inflammatory signals, adipokine dysregulation and 
insulin resistance31-33. Redox regulation of 
inflammatory signalling occurs at several levels, 
including direct effects of oxidants, modulation by 
antioxidants, alterations in the redox equilibrium (for 
example, ratio of reduced: oxidized glutathione and 
thioredoxin) and activation of oxidant- and redox-
sensitive transcription cofactors such as NF-κB and 
AP-134,35. 
 
Activation of the NF-κB pathway has been linked 
to a range of inflammatory disorders, including 
atherosclerosis, myocardial infarction and diabetes; 
this pathway can be interrupted by phytochemicals 
derived from the spices36. The pro-inflammatory/pro-
oxidant state induces insulin resistance, leading to the 
clinical and biochemical symptoms of metabolic 
syndrome27,32. This resistance to insulin action 
promotes inflammation through an increase in free 
fatty acid concentrations and hinders the anti-
inflammatory effects of insulin29,30. Both human and 
animal studies have shown that diets rich in 
carbohydrates and saturated fats contribute to insulin 
resistance, metabolic defects, excess body weight, 
lipid abnormalities, increased reactive oxygen/ 
nitrogen species, decreased anti-oxidant defences and 
the development of pre-diabetic or diabetic state27. 
The contributions towards this metabolic dysfunction 
from insulin signalling, oxidative stress and 
inflammation (Figure 1) have been difficult to 
separate27. 
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Fig. 1—Metabolic changes in obesity. Hyperglycaemia, 
hyperlipidaemia and elevated inflammatory cytokines are found in 
obese and diabetic conditions, which elevate both metabolic and 
inflammatory stress. Mitochondrial dysfunction, polyol pathway, 
hexosamine pathway, AGE pathway, and pro-oxidative genes 
such as iNOS and NADPH oxidases are associated with ROS 
generation and result in oxidative stress. Such stresses combine to 
activate PKCs and NF-κB signalling pathways, which cause 
insulin resistance by attenuating the insulin signalling pathway. 
Abbreviations used: TNF-α, tumour necrosis factor-α; IL6, 
interleukin 6; MCP, Monocyte chemoattractant protein; NFκB, 
nuclear factor kappa B; IR, insulin receptor; IRS, insulin receptor 
substrate; PKC, protein kinase C; AGE, advanced glycation end-
products; iNOS, inducible nitric oxide synthase; NADPH, 
nicotinamide adenine dinucleotide phosphate; ROS, reactive 
oxygen species; Akt, thymoma viral proto-oncogene designated as 
protein kinase B (PKB). Figure adapted from33 
 
Table 2—Rodent models of the metabolic syndrome 
Spontaneously diabetic rodents 
Otsuka Long-Evans Tokushima  
fatty rats (OLETF)43,44 
Mild obesity, postprandial hyperglycaemia, insulin resistance, hyperinsulinaemia, 
hyperplasia with fibrosis followed by atrophy of the pancreatic islet, diabetic 
nephropathy, left ventricular fibrosis, endothelial dysfunction, hyperlipidemia  
Goto-Kakizaki rats45 Non-obese, hyperglycaemia, hyperinsulinaemia, insulin resistance, endothelial 
dysfunction  
Zucker diabetic fatty rats46,47 Non-functional leptin receptors, obese, dyslipidaemia, hyperinsulinaemia, insulin 
resistance, hyperleptinaemia, moderately elevated blood pressure 
The JCR: LA-Cp rat48,49 Obese, insulin resistance, hyperinsulinaemia, impairment of endothelium-dependent 
vascular relaxation 
Spontaneously hypertensive rat50 Insulin resistance, hypertension, cardiac hypertrophy, endothelial dysfunction  
ob/ob mouse51 Obesity, hyperglycaemia, impaired glucose tolerance, dyslipidaemia 
db/db mouse52 Hyperinsulinaemia, insulin resistance, hyperglycaemia, polyuria, glycosuria 
  
Genetically engineered diabetic mice 
Insulin receptor-deficient mouse (IR-/-)53 Fatty acid infiltration in the liver, increased ketone bodies production, hyperglycaemia, 
hyperinsulinaemia, increased serum triglycerides, death within a week 
GLUT4 deficient mouse (GLUT4-/-)54 Retarded growth, decreased longevity, cardiac hypertrophy, post-prandial 
hyperinsulinaemia, insulin resistance 
IRS-1 deficient mice (IRS-1-/-)55 Highly reduced intrauterine growth, impaired glucose tolerance, decreased insulin/IGF-
1-stimulated glucose uptake 
  
Artificially-induced diabetic rodents 
Fructose-fed rats56,57 Hyperinsulinaemia, impaired glucose tolerance, insulin resistance, hypertension, 
hypertriglyceridaemia, cardiac fibrosis, endothelial dysfunction 
Sucrose-fed rats58 Insulin resistance, dyslipidaemia, obesity 
High fat-diet model59,60 Obesity, dyslipidaemia, insulin resistance, hyperinsulinaemia, hyperglycaemia, impaired 
glucose tolerance, endothelial dysfunction, hypertension, hyperleptinaemia 
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Rodent models of metabolic syndrome 
Rat and mouse models of human diseases such as 
obesity, diabetes and cardiovascular diseases have 
been widely used to investigate the progression of 
disease symptoms (Table 2)37-39. Understanding the 
influence of diet as a cause of the symptoms of 
metabolic syndrome requires adequate animal models 
with the symptoms relevant to human pathology, such 
as diet-induced obesity, diabetic and cardiovascular 
symptoms, to test proposed treatment options and 
dietary interventions. The most-used rat models of the 
complications of diabetes are induced by either 
streptozotocin40 or a high fructose diet41,42. However, 
streptozotocin induces type I diabetes and a high 
fructose diet does not induce abdominal obesity42. 
Thus, results from these models may be relevant only 
to a small proportion of diabetic patients. 
Diets including a significant component of animal-
derived fats, such as lard or beef tallow, or plant oils 
such as corn or safflower oil may cause diabetes and 
obesity as well as cardiovascular changes39. Obesity 
and diabetes increase the risk of cardiovascular 
disease and its associated metabolic risk factors, 
probably by the releasing bioactive mediators from 
adipose tissue initiated by an excessive caloric intake 
in a high carbohydrate/high fat diet27,29,30. Thus, 
administering a high carbohydrate/high fat diet should 
induce the range of symptoms of metabolic syndrome 
rather than streptozotocin- or fructose-induced 
diabetes. These dietary interventions should serve as a 
more relevant model to investigate possible 
therapeutic interventions for the complications of 
metabolic syndrome. 
 
Health benefits of Indian spices: what is the 
evidence? 
The contribution of oxidative stress and 
inflammation in initiating the symptoms of metabolic 
syndrome is now well-known. Suitable therapeutic 
interventions targeting these oxidative and inflame-
matory processes may be effective in preventing and 
treating the metabolic syndrome.  Several reviews 
have discussed the use of herbal medicines, including 
spices, in the treatment of the symptoms of metabolic 
syndrome such as diabetes4,61, insulin resistance62, 
hypertension and other cardiovascular diseases63, and 
inflammation64. This section deals with the possible 
therapeutic benefits of the spices in the treatment of 
the symptoms of metabolic syndrome, in particular 
because of their anti-oxidant or anti-inflammatory 
effects. 
Cardamon or Elaichi (Elettaria cardamomum) 
Cardamon, a perennial herb indigenous to the 
Indian subcontinent, contains a wide variety of 
compounds, including α-terpineol, myrcene, subinene, 
limonene, cineol, α-phellandrene, menthone, α and  
β-pinene65, cis/trans-linalol oxides, trans-nerolidol66, 
β-sitostenone, γ-sitosterol, phytol, eugenyl acetate67, 
bisabolene, borneol, citronellol, p-cymene, geraniol, 
geranyl acetate, stigmasterol and terpinene68. In vitro 
studies showed that cardamon inhibited platelet 
aggregation, when induced with agents such as ADP, 
epinephrine, collagen and calcium ionophore A 
2318769. Cardamon reduced blood pressure in rats, 
probably by acting through cholinergic and calcium 
antagonist mechanisms70. 
 
Cinnamon or Dalchini (Cinnamomum verum) 
Cinnamon is a small evergreen tree, approximately 
10-15 m tall, native to Sri Lanka and Southern India71. 
Its bark has been widely used as a spice and 
flavouring agent for centuries. Cinnamon has been 
suggested to have many pharmacological properties, 
including antioxidant activity and antimicrobial 
effects72,73. The major active components of aqueous 
cinnamon extract appear to be doubly-linked 
procyanidin type-A polymers74, cinnamaldehyde and 
esters such as ethyl cinnamate (Figure 2). 
 
 
Fig. 2—Bioactive constituents in cinnamon 
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Pre-clinical and clinical data show that cinnamon 
attenuated the progression of type II diabetes75,76. 
Cinnamon (8% w/w in diet) prevented sucrose-
induced increases in blood pressure in spontaneously 
hypertensive rats77 and a cinnamon extract 
(300 mg/kg/day) decreased insulin resistance in 
fructose-fed diabetic rats, partly by enhancing insulin 
signalling and partly by activating the NO pathway in 
skeletal muscle78. An aqueous extract of cinnamon 
bark improved insulin resistance and prevented lipid 
abnormalities in fructose-fed rats79. In cholesterol-fed 
rats, cinnamate (0.1 g/100 g diet) inhibited hepatic 
HMGCoA reductase activity and suppressed lipid 
peroxidation in the liver80. Cinnamaldehyde (5-20 
mg/kg/day) decreased plasma glucose, glycosylated 
haemoglobin, cholesterol and triglyceride concen-
trations, while increasing plasma insulin and HDL-
cholesterol concentrations as well as hepatic glycogen 
in streptozotocin-induced diabetic rats81. Similar 
decreases were reported when poorly-controlled type 
2 diabetic patients were given 1-6 g/day cinnamon for 
40 days75. 
A related species, cassia cinnamon (C. aromaticum) 
also known as Chinese cinnamon, reduced fasting 
blood glucose concentrations, improved plasma lipid 
profiles in diabetic humans and reduced glucose and 
insulin responses in oral glucose tolerance 
testing75,82,83. In subjects diagnosed with the metabolic 
syndrome, an aqueous extract of Chinese cinnamon 
standardised to doubly-linked polyphenol type-A 
polymers as the bioactive component (500 mg/day) 
reduced systolic blood pressure, fasting blood 
glucose concentrations and also attenuated whole 
body fat deposition to body weight ratio84. The pre-
clinical and clinical evidence for therapeutic 
usefulness of both common and cassia cinnamon has 
been reviewed71. 
 
Coriander or Dhania (Coriandrum sativum) 
Coriandrum sativum is a well-known herb, native 
to Europe and Western Asia, used as fresh and dried 
fruit and leaves to flavour meals and as an ingredient 
in curry powder (http://www.botanical.com/botanical/ 
mgmh/c/corian99.html). It is generally used in 
gastrointestinal complaints such as anorexia, 
dyspepsia, flatulence, diarrhoea, griping pain and 
vomiting85. The stems and leaves contain caffeic, 
chlorogenic, ferulic and gallic acids86. The seeds were 
effective as an antidiabetic agent administered as 
6.25% in food in streptozotocin-diabetic mice87, and 
as a hypolipidaemic agent as 10% in food in rats fed 
15% coconut oil and 2% cholesterol88. Continuous 
intravenous infusion of the crude aqueous extract of 
coriander (40 and 100 mg/kg) induced dose-
dependent diuresis, natriuresis, kaliuresis, increased 
chloride excretion and increased glomerular 
filtration rate in anaesthetized Wistar rats89. Alcoholic 
extract of coriander (200 mg/kg) decreased fasting 
serum glucose concentration and increased insulin 
release from pancreatic β-cells in streptozotocin-
induced diabetic rats90. Oral intake of fruit powder 
(8% w/w of food) in cholesterol-fed rats decreased 
plasma total cholesterol, LDL-cholesterol and total 
lipid concentrations, while increasing the HDL-
cholesterol91. 
 
Cumin seeds or Jeera (Cuminum cyminum) 
Cumin seeds are a common dietary spice consumed 
in fairly large quantities in India. They are widely 
used in Ayurvedic medicine for treatment of 
dyspepsia, diarrhoea and jaundice80. Cuminaldehyde 
is suggested as the active ingredient in cumin seeds 
(Figure 3)92. An aqueous extract of cumin seeds 
prevented the accumulation of advanced glycation 
end-products due to fructose-mediated in vitro 
glycation of eye lens soluble proteins92. 
Hypoglycaemic effects of cumin seeds were also 
observed in normal rabbits93. Dietary cumin showed 
marked hypoglycaemic responses in streptozotocin-
diabetic rats by reducing blood and urinary glucose 
concentrations94. An aqueous extract of seeds lowered 
blood glucose and plasma and tissue lipid 
concentrations in alloxan-induced diabetic rats80. 
 
Curry plant/leaves or Kadipatta (Murraya 
koenigii) 
Curry leaves are used as a culinary spice and also 
as a traditional medicine. Several carbazole alkaloids 
were reported in the plant95. Recently, a 35 kDa 
antioxidant protein PII, purified from leaf powder, 
inhibited lipid peroxidation and lipoxygenase activity 
in vitro in human erythrocyte ghosts and also 
effectively scavenged ROS96. The leaf extract supple-
mentation (80 mg/kg) decreased blood cholesterol and 
glucose concentrations in diabetic ob/ob mice with 
 
 
Fig. 3—Cuminaldehyde, an active ingredient of cumin 
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reduction in body weight97. Extracts of leaves showed 
hypoglycaemic effect in both normal and alloxan-
induced diabetic dogs and rabbits98. In alloxan-
induced mild and streptozotocin-induced moderately 
diabetic rats, feeding of 15% curry leaf powder diet 
reduced blood glucose concentrations by 21.4% and 
8.2% respectively99. In normal rats, 10% leaf 
administration in food increased hepatic glycogen 
concentration and glycogenesis by increased activity 
of glycogen synthetase, and decreased glycogenolysis 
and gluconeogenesis by decreased activity of glycogen 
phosphorylase and gluconeogenic enzymes100. Curry 
leaf supplementation lowered lipid peroxidation and 
also modulated the hepatic function to near normal 
level in rats fed with a high-fat diet101. Supple-
mentation with 10% curry leaves in high fat-fed 
young male albino rats reduced total serum 
cholesterol, LDL and VLDL concentrations, increased 
HDL concentration, lowered release of lipoproteins 
into the circulation and increased the lecithin 
cholesterol acyltransferase (LCAT) activity102. 
 
Fenugreek or Methi (Trigonella foenum) 
Fenugreek, a strongly scented annual herb, is 
recommended for the treatment of rheumatism in 
traditional medicine. Saponins, glycoside-D and 
trigofoenoside-A are major components in the 
seeds103, while alkaloids, cardiac glycosides and 
phenols are found in the leaf extract104. The steroidal 
saponins present in the seeds as parent compounds for 
physiological steroid production could influence the 
local inflammatory response105,106. Galactomannan, a 
guar gum comprising approx. 50% of the seed weight 
is postulated as another active ingredient in fenugreek 
seeds107. In high sucrose-fed rats, galactomannan 
feeding reduced appetite, body weight gain, glycemic 
response, plasma insulin concentrations and plasma 
triglycerides and total cholesterol concentrations108. In 
human studies, galactomannan reduced post-prandial 
blood glucose concentrations109,110 and improved 
insulin sensitivity in both non-diabetic111 and diabetic 
subjects112. Feeding guar-galactomannan fibre 
reduced both total and LDL cholesterol concen-
trations in healthy and type 2 diabetic subjects113. 
 
Garlic or Lahsun (Allium sativum) 
Garlic has been used as both an important dietary 
constituent and a medicine in different cultures 
around the world. A broad range of therapeutic 
responses to garlic has been reported, including 
decreases in blood pressure, blood lipid and glucose 
concentrations and the risk of atherosclerosis as well 
as antimicrobial, anticancer and hepatoprotective 
effects114-116. The responses with garlic have been 
attributed to its sulphur-containing antioxidants 
(Figure 4). Allicin (diallyl thiosulphinate) is the major 
bioactive thiosulphinate compound found in garlic 
homogenate and is liberated from alliin by the 
enzyme alliinase when garlic is crushed or bruised117. 
Other important sulphur-containing compounds 
include allyl methyl thiosulphonate, 1-propenyl allyl 
thiosulphonate and γ-L-glutamyl-S-allyl-L-cysteine117. 
In vitro animal and human tissue studies showed 
that garlic inhibited angiotensin II responses, possibly 
by inhibition of angiotensin converting enzyme to 
promote vasodilation118-120. In animal studies, dose-
dependent antioxidant and organ-protective effects of 
raw garlic homogenate (125, 250 and 500 mg/kg 
doses) have been observed in various organs such as 
heart, liver and kidneys121,122. An aqueous extract of 
garlic neutralised free radicals and reduced oxidative 
damage in rabbit liver homogenates123. Furthermore, 
an aged garlic extract inhibited the development of 
thickened, lipid-filled lesions by approximately 50% 
in preformed neointimas produced following injury of 
the right carotid artery in cholesterol-fed rabbits, in 
addition to reducing the surface area of the thoracic 
aorta covered by fatty streaks (64% decrease)114. Two 
meta-analyses have demonstrated that garlic 
preparations reduced blood pressure in hypertensive 
 
 
Fig. 4—Bioactive constituents in garlic 
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patients124,125, although an earlier review concluded 
that the reported effects were too small to be clinically 
meaningful126. 
 
Ginger or Sonth (Zingiber officinale) 
The therapeutic potential of ginger is recognised in 
a wide range of unrelated disease states including 
stomach aches, diarrhoea, nausea, asthma, respiratory 
disorders, toothache, gingivitis and arthritis127,128. 
Recent research has focussed on elucidating the anti-
inflammatory properties of ginger. As with most 
herbal preparations, ginger extracts are complex with 
more than 400 chemical compounds already isolated 
and identified129. A subfraction containing the 
structurally related compounds gingerols, shogaols 
and paradols is likely to account for the anti-
inflammatory properties of ginger (Figure 5)129. The 
anti-inflammatory effect of ginger was attributed to its 
ability to inhibit cycloxygenase-2 (COX-2) and 5-
lipoxygenase (5-LOX), the enzymes critical in 
prostaglandin and leukotriene synthesis, respect-
tively129. Ginger lowered blood pressure through both 
stimulation of muscarinic receptors and blockade of 
calcium channels128,130. 
 
Malabar tamarind or Imli (Garcinia cambogia) 
Fruits of G. cambogia are commonly known as 
gambooge or brindleberries. The active ingredient is 
hydroxycitric acid (Figure 6), a potent inhibitor of 
adenosine triphosphate (ATP) citrate lyase131. ATP 
citrate lyase is critical in catalyzing the cleavage of 
citrate to oxaloacetate and acetyl-coenzyme A. 
Inhibition of ATP citrate lyase can reduce the 
availability of acetyl-coenzyme A units for fatty acid 
synthesis and lipogenesis, thus modulating fat 
metabolism131. In human studies, oral intake of 
hydroxycitrate increased fat oxidation, when 
supplemented with moderate intensity exercise132. In 
animal studies, oral intake of G. cambogia extract 
effectively attenuated body weight gain, visceral fat 
accumulation, blood and hepatic lipid concentrations 
and plasma insulin and leptin concentrations in obese 
mice fed a high fat diet133. The extract ameliorated 
diet-induced obesity by modulating multiple genes 
associated with adipogenesis, such as aP2, SREBP1c, 
PPARγ2, and C/EBPα in the visceral fat tissue133. The 
calcium-potassium salt known as HCA-SX or Super 
citrimax, a derivative of hydroxycitric acid, reduced 
food intake and body weight gain in obese Zucker rats 
and also attenuated the increased inflammation, 
oxidative stress and insulin resistance in untreated 
Zucker rats134. In a human study, treatment with 
HCA-SX for 8 weeks decreased body weight and 
BMI by 5.4% and 5.2%, respectively135. 
 
Turmeric or Haldi (Curcuma longa) 
Turmeric is a perennial herb, yielding a rhizome 
widely used as a culinary ingredient. Both Ayurvedic 
and traditional Chinese medicines have used turmeric 
for the treatment of inflammatory and digestive 
disorders. Research has focussed the antioxidant, 
hepatoprotective, anti-inflammatory, anticarcinogenic 
and anti-microbial properties of turmeric, in addition 
to its use in cardiovascular disease and 
gastrointestinal disorders136. Curcuminoids constitute 
5% of the turmeric rhizome and are suggested as the 
active ingredients, showing both antioxidant and anti-
inflammatory effects. Both turmeric extract and 
curcumin (Figure 7), one of the major curcuminoids, 
have been widely examined for possible therapeutic 
effects in the symptoms of metabolic syndrome. 
In in vitro studies, turmeric prevented protein 
glycosylation and lipid peroxidation induced by high 
 
 
Fig. 5—Bioactive compounds in ginger; shogaols are formed  
upon drying. 
 
 
 
Fig. 6—Hydroxycitric acid, the active principle of Malabar 
tamarind 
 
 
Fig. 7—Curcumin, the major bioactive ingredient of turmeric. 
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glucose concentrations137. Curcumin showed anti-
differentiation effects, possibly through AMPKα-
PPAR-γ in 3T3-L1 adipocytes138. It also inhibited 
NFκB-mediated cytokine expression in adipocytes139. 
In this study, curcumin inhibited TNF-α, IL-1β, IL-6 
and COX-2 gene expression at an IC50 of 2 µM and 
also showed a reduction in secreted IL-6 and PGE2 at 
IC50 ~20 µM in adipocytes139. Dietary curcumin 
improved inflammation and diabetes associated with 
obesity140. In high-fat fed obese and leptin-deficient 
ob/ob mice, curcumin reduced macrophage 
infiltration of white adipose tissue, increased adipose 
tissue adiponectin production and decreased hepatic 
NF-κB activity, hepatomegaly and other markers of 
hepatic inflammation140. Curcumin and other 
curcuminoids prevented lipid accumulation in the 
liver and epididymal adipose tissues in high fat-fed 
Sprague-Dawley rats, possibly by altering fatty acid 
metabolism141. 
An extract of turmeric decreased LDL oxidation 
and lowered oxidation of erythrocyte and liver 
membranes in rabbits on a high saturated fat and 
cholesterol diet142. Interestingly, curcumin did not 
show any hypoglycaemic activity in streptozotocin-
induced diabetic rats61, suggesting it may have a 
therapeutic potential in type II but not type I diabetes. 
Early studies showed anti-thrombotic responses by 
curcumin in normal mice, possibly by suppressing 
thromboxane-2 production143. In humans, a longer-
term study with 30 healthy subjects given turmeric 
extract equivalent to 20 mg curcumin for 60 days also 
showed decreased peroxidation of both HDL and 
LDL cholesterol144. The biological activity of 
curcumin in humans has been extensively reviewed, 
although evidence on the symptoms of metabolic 
syndrome is limited145. 
 
Black mustard or Rai (Brassica nigra), black 
pepper or Kali Mirchi (Piper nigrum) and nutmeg 
or Jaiphal (Myristica fragrans) 
Black mustard, black pepper and nutmeg are some 
of the other spices sparingly examined for possible 
therapeutic effects in the symptoms of metabolic 
syndrome in experimental diseased animals. Mustard 
showed hypoglycaemic effect in rats in a study to test 
its effect on the enzymes of carbohydrate 
metabolism61,100. The mucilage (soluble fibre) of 
mustard at 5%, 10% and 15% in the food improved 
post-prandial glucose concentrations and insulinaemia 
in normal rats61. 
Black pepper supplementation (0.25 or 0.5 g/kg 
body weight) in high fat-fed rats lowered concen-
trations of thiobarbituric acid reactive substances and 
conjugated dienes, maintained superoxide dismutase, 
catalase, glutathione peroxidase and glutathione-S-
transferase concentrations and reduced glutathione 
concentrations in the liver, heart, kidney, intestine and 
aorta compared to control rats146. Black peppers also 
showed potential in obesity by increasing thermo-
genesis and fat oxidation147. 
An in vitro study suggests that meso-dihydro-
guaiaretic acid isolated from the nutmeg plant may act 
as an enhancing agent in intracellular insulin 
signalling, possibly through the inhibition of PTP1B 
activity148. An extract of nutmeg seeds prevented lipid 
abnormalities and atherosclerosis in hypercholestero-
laemic rabbits149,150. 
 
Health benefits of Indian spices: how strong is the 
evidence? 
The quality of evidence for health benefits can be 
categorised into different levels. As an example, the 
evidence for cinnamon bark has been reported under 
the following levels71: A: very strong scientific 
evidence from systematic reviews or meta-analysis; 
B1: strong scientific evidence from one or more 
randomised controlled trials; B2: good scientific 
evidence from one or more randomised controlled 
trials of limited size or methodology; C: fair scientific 
evidence from one or more cohort studies or outcome 
studies or case control studies; D: weak scientific 
evidence from case series; E: indirect evidence from 
case reports or expert opinion or laboratory studies; 
and F: historical or traditional evidence. 
This provides an evaluation on each study and 
possible clinical indication; for example, the 
randomised clinical trials of 60-79 patients using 
cinnamon for diabetes75,82 have been both classified as 
level B1, a smaller clinical trial of 25 patients151 is 
classified as level B2, while a case report of a chronic 
carrier of Salmonella enteritidis showing improve-
ment after consumption of cinnamon bark is classified 
as level E71. A thorough evaluation of all evidence for 
therapeutic effectiveness of spices in the metabolic 
syndrome is not possible for this review. However, 
the evidence for individual spices would appear to be 
level B for cinnamon to lower blood glucose 
concentrations or insulin resistance, for turmeric to 
improve the lipid profile, for hydroxycitrate from 
tamarind to reduce obesity and for garlic to reduce 
blood pressure. 
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Similarly, the potential of therapeutic interventions 
to harm the patient can be categorised into levels as 
follows71: 1a: very strong scientific evidence from 
systematic reviews or randomised clinical trials; 1b: 
strong scientific evidence from outcome studies, 
cohort studies or case control studies; 1c: good 
scientific evidence from one or more case series; 2: 
fair scientific evidence from case reports; 3: in vitro 
scientific evidence from studies on animals, insects, 
micro-organisms or cell cultures; 4: indirect evidence 
based on scientific theory or expert opinion; and 5: no 
available evidence. 
In general, spices are generally recognised as safe 
(GRAS) by the United States Food and Drug 
Administration, when used in therapeutic doses. Some 
studies have reported minor adverse effects, usually 
gastrointestinal complaints with spices used as 
therapeutic agents. 
The development of more active nutraceuticals and 
purified products from herbal medicines raises the 
controversial issues of patents and protection of 
intellectual property152. This issue is very relevant to 
India, as shown by the discussions on the Traditional 
Knowledge Digital Library (http://www.tkdl.res.in/ 
tkdl/langdefault/common/home.asp?GL=Eng), a sear-
chable database of more than 230,000 formulations 
taken from ancient texts on Indian systems of 
medicine - Ayurveda, Unani, Siddha and Yoga - in 
Hindi, Sanskrit, Arabic, Persian and Urdu153. Since 
spices are a part of herbal medicines, these issues 
become relevant to this review. 
 
Safety and toxicity 
Herbal medicines, including spices, have the 
potential to produce adverse effects, especially when 
used in concentrated forms. Further, these products 
may interact with other herbal products as well as 
drugs154. Although spices are regularly consumed in 
the diet by many populations, their use as 
nutraceuticals in a concentrated form needs further 
investigation for efficacy and toxicity. Nutraceuticals 
may tend to show fewer adverse effects compared to 
prescription drugs or herbal remedies, but the lack of 
documentation does not necessarily mean they are 
safe. Other safety issues include variability in biologic 
potency in different crops, contamination and use of 
the incorrect plant species155. In addition, it is 
extremely difficult to guard against consumer fraud in 
this unregulated industry. Very limited regulation can 
lead to problems including unreliable herb quality, the 
marketing of secret formulas with unsubstantiated 
claims, the proliferation of unqualified practitioners 
and the possibility of deliberate adulteration of the 
product. Even with the ban imposed on claims that a 
food can cure a disease in the United States, European 
Union and Australia, consumers are still being lured 
into buying the products by "marketing strategies"156. 
Stronger regulation of this industry is essential to 
ensure that the same high standards of preparation, 
quality control and management are enforced as with 
conventional pharmaceutical products. Stricter 
regulations will bring modern scientific techniques 
and intellectual rigour to traditional herbal medicine. 
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Rodents are widely used to mimic human diseases to improve understanding of the causes and progression of disease symptoms
and to test potential therapeutic interventions. Chronic diseases such as obesity, diabetes and hypertension, together known as
the metabolic syndrome, are causing increasing morbidity and mortality. To control these diseases, research in rodent models that
closely mimic the changes in humans is essential. This review will examine the adequacy of the many rodent models of metabolic
syndrome to mimic the causes and progression of the disease in humans. The primary criterion will be whether a rodent model
initiates all of the signs, especially obesity, diabetes, hypertension and dysfunction of the heart, blood vessels, liver and kidney,
primarily by diet since these are the diet-induced signs in humans with metabolic syndrome. We conclude that the model that
comes closest to fulfilling this criterion is the high carbohydrate, high fat-fed male rodent.
1. Introduction
Hypertension, diabetes and obesity are common but not
independent in humans and the combination is referred
to as metabolic syndrome [1, 2]. While the definition
of the syndrome may help understanding causes and
prognosis, there are continuing arguments on the clinical
usefulness of defining the syndrome in humans. Human
metabolic syndrome is accepted as a consequence of dietary
imbalance rather than a genetically programmed disease.
This syndrome includes central obesity, insulin resistance,
elevated blood pressure, impaired glucose tolerance and
dyslipidaemia [1, 2]; these are accepted risk factors that
increase the incidence of cardiovascular disease and type 2
diabetes [3–5]. Metabolic syndrome is also associated with
an increased risk of nonalcoholic fatty liver disease and
kidney dysfunction [6, 7]. Similarly, there is solid evidence
for correlations between metabolic syndrome and functional
changes in the lungs, dementia and cancers of the breast,
pancreas and bladder (Figure 1) [8–12]. Lifestyle and diet
modulate metabolic syndrome [4, 13] and this induces
pathophysiological changes throughout the body. Hence it is
important to study the progression and treatment strategies
for metabolic syndrome.
The number of adults with metabolic syndrome is
substantial and the prevalence is increasing throughout the
world [14]. The gender ratio was similar in the USA [15],
Singapore and Australia showed increased rates in females
[16, 17], while Japan showed increased rates in males [18].
In 2002, the prevalence of metabolic syndrome in the USA
was 24% and 23.4% in males and females, respectively
[19]. In 2005 and 2006, this prevalence had increased to
34% in both males and females [15, 20]. In the Australian
population, 18.8% of males and 25.4% of females fulfilled
the requirements for diagnosis with metabolic syndrome
in 2000 [17]. In a Japanese study, 45% of males and 38%
of females were diagnosed with metabolic syndrome [18].
Similar prevalence rates of metabolic syndrome have been
reported in the Indian subcontinent [21].
The widespread occurrence of metabolic syndrome in
humans means that there is an urgent need to study
relevant causes and progression of the signs. These studies
require viable animal models that adequately mimic all
the aspects of the human disease, developing all major
signs of metabolic syndrome, especially obesity, diabetes,
dyslipidaemia, hypertension and possibly fatty liver disease
and kidney dysfunction. Rodents have been used for many
years as models of human disease, especially hypertension,
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Figure 1: Metabolic syndrome and associated complications.
diabetes and obesity [22–25]. This review will examine
whether the existing rodent models for components of
metabolic syndrome mimic the range of changes in humans
and are therefore suitable to evaluate potential treatments for
human metabolic syndrome.
2. Genetic Models of Obesity and
Type 2 Diabetes
Genetic models of obesity and diabetes include db/db mice,
ob/ob mice, Zucker diabetic fatty rats and Otsuka Long-Evans
Tokushima Fatty rats, while Goto-Kakizaki rats are diabetic
but nonobese. These models are useful in evaluating specific
molecular mechanisms that may be involved in development
of obesity in rodents, but the metabolic syndrome in humans
is not a monogenetic disorder. Therefore, the relevant
questions are whether these genetic changes mimic those
observed in humans and whether these models show the
range of signs that characterise the metabolic syndrome.
As an example, several of these models have mutations in
the leptin gene or receptor (Figure 2), yet similar mutations
are a very rare recessive genetic disorder in humans with
only 4 mutations in 15 people reported up until 2009 [26].
Further, although cholecystokinin is important as a satiation
signal [27], there are only a few reports of CCK-1 receptor
mutations, as found in the Otsuka Long-Evans Tokushima
fatty rats, inducing obesity in humans [28, 29].
3. ob/ob (C57BL/6J-ob/ob) Mice
This was one of the first genetic models used for the study of
diabetes [30]. These mice inherited a monogenetic autoso-
mal recessive mutation in the leptin gene on chromosome
6 [31, 32] and developed obesity, hyperinsulinaemia and
hyperglycaemia after 4 weeks of age [33]. They showed an
increased body weight compared to their lean littermates at
all ages [33, 34]. The presence of impaired glucose tolerance
was found after 12 weeks of age [35]. These mice developed
left ventricular hypertrophy with decreased cardiac function
at 24 weeks of age [36], cardiac fibrosis after 20 weeks of
age [37] and hepatic steatosis and inflammation at 12 weeks
of age [38, 39]. Unlike humans with metabolic syndrome,
these mice showed reduced blood pressure [34] and did not
develop dyslipidaemia even after the age of 36 weeks [35].
4. db/db (C57BL/KsJ-db/db) Mice
These mice have inherited an autosomal recessive mutation
in the leptin receptor gene present on chromosome 4 [40]
leading to higher body weights than their lean littermates
after 6 weeks of age [41]. Fasting blood glucose concen-
trations were higher after 8 weeks of age and these mice
showed increased plasma concentrations of triglycerides,
total cholesterol and nonesterified fatty acids along with
reduced HDL/LDL cholesterol ratio after 13 weeks of age
[42]. Hyperinsulinaemia and impaired glucose tolerance
were observed after 12 weeks of age [41, 43]. In the heart,
both infiltration with inflammatory cells and fibrosis were
present after 12 weeks of age, although blood pressure was
unchanged [41]. These mice showed vascular endothelial
dysfunction at 12 weeks of age [41] and developed hepatic
steatosis after 20 weeks of age [44]. db/db mice failed to show
hepatic inflammation and fibrosis [45].
5. Zucker Diabetic Fatty Rats (fa/fa)
Diabetic Zucker fatty rats (ZDF), a model of early onset
obesity, have a mutation in the leptin receptor gene [46].
ZDF rats became hyperglycaemic after 13–15 weeks of
age [47] with hyperinsulinaemia and hypertriglyceridaemia
after 12–14 weeks of age along with diastolic and systolic
dysfunction [48]. Serum cholesterol concentrations were
slightly increased in ZDF rats compared to lean Zucker rats
at 10 weeks of age whereas the serum concentration of
cholesterol was ∼2.5 times higher compared to lean Zucker
rats at 20 weeks of age [49]. These rats also developed
endothelial dysfunction after 12 weeks of age [50]. ZDF rats
showed only moderate increases in systolic blood pressure by
15 weeks of age [51]. Albuminuria was present at the age
of 31 weeks [52] with thickening of basal membrane and
glomerular fibrosis after 47 weeks [52]. Increased hepatic
triglyceride deposition was observed after 20 weeks of age
in ZDF rats [53]. ZDF rats also showed increased serum
markers of inflammation such as TNF-α and IL-1β after 26
weeks of age [54].
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Figure 2: Mechanism of the actions of leptin including the effects of leptin deficiency or leptin receptor deficiency.
6. Otsuka Long-Evans Tokushima Fatty Rats
Otsuka Long-Evans Tokushima Fatty (OLETF) rats have
been used as a rat model of human diabetes and obesity
[55]. Pancreatic acini cells in OLETF rats were insensitive to
the actions of cholecystokinin (CCK), which controls food
intake [56], due to the absence of CCK-1 receptors [57]. Male
and female OLETF rats were similar in body weight to lean
Long-Evans Tokushima rats at the time of weaning but they
became 30–40% heavier than age-matched lean Long-Evans
Tokushima Otsuka rats after 20 weeks [58]. Due to the lack
of CCK-1 receptors, the average meal size and overall food
intake were higher in OLETF rats [57]. OLETF rats presented
with high blood glucose concentrations after 18 weeks of
age but they showed impaired glucose tolerance starting at
24 weeks of age [58]. Plasma triglyceride concentrations
in OLETF rats started increasing from 8 weeks of age but
cholesterol concentrations were only slightly higher even
after 40 weeks of age [58]. After week 40 of age, OLETF rats
showed diffuse glomerulosclerosis [58]. Hearts from OLETF
rats showed cardiac hypertrophy with left ventricular systolic
and diastolic dysfunction [59]. OLETF rats showed higher
blood pressure compared to lean Long-Evans Tokushima
Otsuka rats after 14 weeks of age [60]. After 34 weeks of age,
OLETF rats showed 5 times higher triglyceride deposition in
liver compared to the lean Long-Evans Tokushima Otsuka
rats [61].
7. Goto-Kakizaki Rats
Goto-Kakizaki (GK) rats are nonobese and spontaneously
diabetic [62]. The occurrence of diabetes in these rats is an
interaction of several events including presence of suscep-
tibility loci for some diabetic traits, gestational impairment
inducing decreased β-cell neogenesis and proliferation and
loss of β-cell differentiation [63]. These inbred rats were
hyperglycaemic after 4 weeks of age with impaired glucose
tolerance but they were lighter than the age-matched Wistar
rats [64]. These rats developed cardiac hypertrophy and
decreased systolic function at 20 weeks of age [65]. There was
no change in blood pressure even after 14 months of age [66].
Plasma and liver lipid concentrations were higher in Goto-
Kakizaki rats after 8 weeks of age compared to age-matched
Wistar rats [67]. Goto-Kakizaki rats had higher urinary
excretion of albumin and decreased creatinine clearance after
14 months of age along with increases in glomerular volume,
basement membrane thickness and kidney weight [66].
These genetic models consistently develop obesity and
non-insulin-dependent diabetes, but metabolic syndrome is
a much broader constellation of pathophysiological changes,
especially including hypertension. Thus, these rodent mod-
els, although used in obesity research, replicate neither the
causes nor the changes that occur in human metabolic
syndrome (summarised in Table 1).
8. Genetically Engineered Diabetic Mice
In recent years, genetically engineered mice models, either
transgenic or knockout, have been developed to study the
normal and abnormal effects of a particular protein or
a set of proteins. Different proteins, signalling molecules
and hormones, important in development of diabetes and
obesity, can be removed by changes in the genome of the
mice. Some of the important proteins that have been deleted
from the mice for obesity and diabetes research include
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Table 1: Different rodent models with the signs of metabolic syndrome.
Rodent
model
Age (weeks)
Signs of metabolic syndrome shown by rodents
References
Obesity Hypertension Dyslipidaemia
Cardiovascular
dysfunction
Impaired
glucose
tolerance
Fatty liver
Kidney
dysfunction
ob/ob
mice
4  × × × × × U
[33–39]12  × × ×   U
24  × ×    U
db/db
mice
6  × × × × × U
[41–44]12-13  ×    × U
20  ×     U
ZDF rat
12–15     × × ×
[47–53]20     ×  ×
31–47     ×  
OLETF
rats
8 × ×  × × × ×
[58–61]
14 ×   × × × ×
20    × × × ×
24    ×  × ×
34    ×   ×
40    ×   
60–66       
Goto-
Kakizaki
rats
4 × × × ×  × ×
[64–67]
8 × ×  ×   ×
20 × ×     ×
60 × ×     
This table represents the signs of metabolic syndrome at different ages. The symbols  and × indicate the presence and absence of these signs of metabolic
syndrome at that age, respectively, whereas U indicates unavailability of the data. The table indicates that age is an important parameter since some of the
signs are developed in very young rodents whereas others take much longer to develop.
insulin receptor, GLUT4, IRS-1 and IRS-2. Insulin receptor-
null mice do not survive for more than 72 hours as they
develop severe ketoacidosis [68] with hyperglycaemia and
hyperinsulinaemia [69]. Thus they cannot be used in long-
term studies as adults. Further, the insulin receptor knockout
mice are unlikely to mimic human conditions as this receptor
loss is very rare in humans [68, 70]. Other models lacking
GLUT4, IRS-1 and IRS-2 may give useful information about
the roles of each protein [71–75], but they do not mimic the
cause of human metabolic syndrome.
9. Chemically Induced Rodent Models
of Diabetes
Alloxan and streptozotocin are structural analogues of
glucose that enter pancreatic beta cells via the GLUT2
transporter [86]. Single injections of alloxan or strepto-
zotocin induce selective necrosis of pancreatic β cells in
rats, mice and rabbits [86–91] as a model of type 1
diabetes. Chemically induced diabetic rodents show fatty
liver and inflammation [92] along with decreased ventricular
contractility and function [93]. In contrast to patients with
metabolic syndrome, alloxan- and streptozotocin-induced
diabetic rats are hypoinsulinaemic [94], do not gain weight
and are usually hypotensive. Thus, chemically induced type 1
diabetic rodents do not show the diverse characteristics of
the metabolic syndrome and therefore they are not a suitable
model for this syndrome in humans.
Type 2 diabetes may be induced by low-dose streptozo-
tocin given neonatally, for example, at a dose of 70 mg/kg
on day 5 of life, producing moderate hyperglycaemia in
adult rats with decreased HDL-cholesterol concentrations
but no other lipid abnormalities or oxidative enzyme changes
[95]. Insulin resistance and an approximate doubling of
plasma C-reactive peptide and TNF-α were produced in 14-
week-old rats treated on day 2 of life with streptozotocin
(90 mg/kg) [96]. However, these changes following neonatal
streptozotocin are insufficient to define the signs of the
metabolic syndrome. A better option may be treatment with
low-dose streptozotocin in a nutritional model of type 2
diabetes induced by an increased energy diet. In 8-week-
old rats, the combination of streptozotocin (25 mg/kg) and
a high-fructose, high-fat diet for 6 weeks increased plasma
glucose, insulin and triglyceride concentrations, decreased
left ventricular contractile function and reduced myocardial
metabolic efficiency [97]. A similar protocol with a high-
energy diet for 5 weeks followed by streptozotocin admin-
istration (40 mg/kg) produced metabolic abnormalities with
insulin resistance that could be decreased by administration
Page 86
Journal of Biomedicine and Biotechnology 5
Table 2: Effects of some treatment strategies on rodent models of metabolic syndrome.
Rodent model Interventions
Reversal or prevention of signs of metabolic
syndrome and associated complications
Signs of metabolic syndrome
not affected by drug treatment
ob/ob mice
Temocapril (ACE
inhibitor) and
olmesartan (AT1
receptor blocker) [37]
Reduced blood pressure and ventricular fibrosis
No change in body weight and
blood glucose concentrations
Resveratrol [76]
Reduced blood glucose, plasma insulin,
adiponectin concentrations, improved glucose
tolerance
No change in body weight and
blood lipid concentrations
db/db mice
Aliskiren (renin
inhibitor) [41]
Reduced blood pressure, cardiac fibrosis,
macrophage infiltration in heart and coronary
remodelling, improved endothelial function and
glucose tolerance, increased pancreatic insulin
content and beta cell mass, reduced pancreatic
fibrosis
No change in body weight,
visceral fat and liver weight
ZDF rats
Sitagliptin (DPP-4
inhibitor) [54]
Reduced body weight and blood pressure,
reduced blood glucose, plasma triglyceride,
plasma insulin and serum inflammatory markers,
reduced pancreatic fibrosis and inflammation
No change in total cholesterol
concentration
OLETF rats
Rosiglitazone (PPARγ
agonist) [77]
Reduced blood glucose, plasma insulin and
serum inflammatory markers
No change in body weight
GK rats
Levosimendan (calcium
sensitiser) [78]
Reduced cardiac fibrosis and cardiac hypertrophy,
improved ventricular function
No change in blood pressure
Hesperidin [67]
Reduced serum insulin and blood glucose, serum
triglyceride, serum total cholesterol
concentrations, increased serum HDL-cholesterol
and adiponectin concentrations
—
Alloxan
Cucurbita pepo peel
extract [79]
Reduced blood glucose, plasma total cholesterol,
HDL-cholesterol, triglycerides, LDL-cholesterol
and VLDL-cholesterol, increased plasma insulin
concentrations
—
Streptozotocin Quercetin [80]
Increase in body weight, reduced serum glucose
concentrations and increased plasma insulin
concentrations, pancreatic beta cell protection
—
Fructose-induced
metabolic
syndrome
Lipoic acid [81]
Reduced blood pressure, blood glucose and
plasma insulin concentrations, improved renal
function
—
Sucrose-induced
metabolic
syndrome
Hippophae rhamnoides
(sea buckthorn) seed
extract [82]
Reduced blood pressure, reduced plasma
concentrations of triglycerides, total cholesterol
and free fatty acids, increased plasma
HDL-cholesterol concentrations
No change in body weight,
blood glucose and plasma
insulin concentrations
High fat-induced
metabolic
syndrome
Enalapril (ACE
inhibitor) [83]
Reduced body weight, epididymal fat pads and
plasma insulin concentrations, increased plasma
leptin and cholesterol concentrations, improved
vascular relaxation
No change in blood glucose,
plasma triglyceride and plasma
free fatty acids concentrations,
glucose tolerance
High fructose,
high fat-induced
metabolic
syndrome
Purple carrot juice [84]
Reduced body weight gain, improved glucose
tolerance, reduced plasma triglycerides, total
cholesterol, free fatty acids concentrations,
reduced plasma inflammatory marker, improved
ventricular function, reduced cardiac fibrosis and
stiffness, reduced blood pressure, improved
vascular relaxation, attenuation of fatty liver
—
High sucrose,
high fat-induced
metabolic
syndrome
Piperine [85]
Reduced body weight, reduced abdominal fat
pads
No change in blood glucose,
plasma triglyceride, plasma
total cholesterol and free fatty
acid concentrations
ACE - Angiotensin converting enzyme, AT - Angiotensin, ZDF - Zucker diabetic fatty, DPP-4 - dipeptidyl peptidase-4, OLETF - Otsuka Long-Evans Tokushima
Fatty, PPAR - peroxisome proliferator-activated receptor, GK - Goto-Kakizaki.
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of chitooligosaccharides for 8 weeks [98]. While these models
may be suitable for studies in type 2 diabetes [99], the key
signs of hypertension and obesity necessary for the metabolic
syndrome were not reported.
10. Diet-Induced Metabolic Syndrome
Diet plays an important role in growth and development as
a source of nutrition, but the composition of the diet decides
its nutritional status. The modern diet, especially in Western
countries, is rich in carbohydrates such as fructose and
sucrose as well as saturated fat. This increased calorific intake
has been associated with many diet-induced complications
including metabolic syndrome, cardiovascular diseases and
nonalcoholic fatty liver disease [100, 101]. Combinations
of carbohydrate and fat-rich dietary components have been
used in rodents to mimic these signs and symptoms of
human metabolic syndrome.
11. Fructose-Induced Metabolic Syndrome
Fructose has become an important and pervasive ingredient
in Western diets [102, 103]. The world average per capita
daily fructose intake increased by 16% between 1986 and
2007 [103]. Together with the increase in consumption
of fructose in the diet over the last fifty years, there has
been a proportionate increase in the incidence of obesity
[104]. The main sources of fructose in the diet are sucrose,
high-fructose corn syrup, fruits and honey. Unlike glucose,
high-fructose feeding to rodents induced the development
of symptoms of metabolic syndrome including high blood
pressure, insulin resistance, impaired glucose tolerance and
dyslipidemia [102, 105]. Fructose feeding induced ventricu-
lar dilatation, ventricular hypertrophy, decreased ventricular
contractile function, infiltration of inflammatory cells in
heart and hepatic steatosis [106, 107]. In the liver, fructose
feeding induced both microvesicular and macrovesicular
steatosis with periportal fibrosis and lobular inflammation
[108]. Fructose has been reported to induce obesity [109]
but this was not confirmed [106]. Fructose feeding in
rats caused renal tubular injury, collagen deposition in
interstitium and increased macrophage infiltration along
with proliferation and hyperplasia of renal proximal tubules
[110] as well as leptin resistance without changes in body
weight and adiposity [111]. Increases in plasma uric acid
and plasma triglyceride concentrations have been reported
without changes in plasma cholesterol concentrations [112,
113].
Fructose, unlike glucose, did not elicit insulin secretion
from pancreatic β-cells, possibly due to the absence of the
fructose transporter (GLUT5) on pancreatic β-cells [104].
Fructose also lacks the ability to stimulate the secretion of
leptin [104] whereas it has the ability to activate de novo
lipogenesis in the liver (Figure 3) [114]. During metabolism,
fructose bypasses the rate-limiting step, the reaction catal-
ysed by phosphofructokinase, leading to uncontrolled supply
of carbon skeleton for lipogenesis in liver [115].
12. Sucrose-Induced Metabolic Syndrome
Sucrose is a dietary source of fructose [103], thus sucrose
feeding has been used to mimic human metabolic syndrome
in animal models. Similar to fructose, sucrose feeding has
shown variable results, especially with obesity [116, 117]. As
with fructose, sucrose induced lipogenesis in rats along with
increased plasma concentrations of insulin, leptin, triglyc-
erides, glucose and free fatty acids, and impaired glucose
tolerance [118, 119]. Sucrose feeding in rats led to an insulin-
resistant state with no change in fasting plasma insulin
and glucose concentrations, but higher postprandial plasma
concentrations of insulin and glucose [117]. Sucrose feeding
increased systolic blood pressure in rats with increased left
ventricular mass but without cardiac fibrosis [120] and
caused development of hepatic steatosis [121]. No changes
were seen in kidneys of rats fed with high-sucrose diet [122].
13. High Fat-Induced Metabolic Syndrome
High-fat diets have been used to model obesity, dyslipi-
daemia and insulin resistance in rodents for many decades.
The complications developed by high-fat diets resemble the
human metabolic syndrome and these complications may
extend to cardiac hypertrophy, cardiac fibrosis, myocardial
necrosis and hepatic steatosis [123–126]. High-fat diet
feeding in mice increased systolic blood pressure and induced
endothelial dysfunction [126]. High-fat diet-fed mice also
showed albuminuria, increased glomerular tuft area, mesan-
gial expansion, renal lipid accumulation, collagen deposition
in glomeruli and increased infiltration of macrophages in
renal medulla [127]. Different types of high-fat diets have
been used with fat fractions ranging between 20% and 60%
energy as fat as either animal-derived fats, such as lard or
beef tallow, or plant oils such as olive or coconut oil [125].
Long-term feeding of rats (60% of energy) and mice (35% fat
wt/wt) with high-fat diet increased body weight compared to
standard chow-fed controls [128, 129]. Although the increase
in body weight was significant after as little as 2 weeks, the
diet-induced phenotype became apparent after more than 4
weeks of high-fat diet feeding [128]. Long-term feeding with
both animal and plant fat-enriched diets eventually led to
moderate hyperglycaemia and impaired glucose tolerance in
most rat and mouse strains [130, 131].
Lard, coconut oil and olive oil (42% of energy con-
tent) increased body weight, deposition of liver triglyc-
erides, plasma triglyceride and free fatty acid concentrations
and plasma insulin concentrations and decreased plasma
adiponectin concentrations [125]. Lard and olive oil but
not coconut oil decreased insulin sensitivity [125]. Lard,
coconut oil and olive oil caused hepatic steatosis with no
signs of inflammation and fibrosis in any of the groups
[125]. Beef tallow when used as fat source (40% of energy)
increased plasma insulin and leptin concentrations with
increased plasma lipid concentrations and hepatic steatosis
[132]. Although high-fat diet induces most of the symptoms
of human metabolic syndrome in rodents, it does not
resemble the diet causing metabolic syndrome and associated
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Figure 3: Metabolism of fructose.
complications, as the human diet is more complex than a
high-fat diet.
14. High Carbohydrate-, High Fat-Induced
Metabolic Syndrome
A diet high in carbohydrates together with fat, either of
animal or plant origin, mimics the human diet more closely.
This combined diet should induce metabolic syndrome in
rodents (Figure 4). Different combinations and amounts of
carbohydrates and fats have been used in different studies
[133–136]. The common carbohydrates used are fructose
and sucrose whereas the source of fat varies in different
studies.
Different combinations of sucrose and fat have been
used to induce signs of metabolic syndrome. Sucrose content
varied between 10% and 30% whereas fat content in
this diet group varied between 20% and 40% [137–139].
Rodents fed on high-sucrose, high-fat diet had increased
body weight, abdominal fat deposition, hyperinsulinaemia,
hyperglycaemia and hyperleptinaemia [137, 138]. Sucrose
and fat in combination also caused hepatic steatosis and
increased hepatic lipogenic enzymes [139].
Fructose and fat have been used in combination to induce
metabolic syndrome. The fructose content varies between
10% and 60%, either in the diet or drinking water or both,
whereas the fat content varies between 20% and 60% [133,
140–143]. Fructose and fat feeding increased body weight
and the plasma concentrations of triglycerides, cholesterol,
free fatty acids and leptin [133, 140]. The combination
of fructose and fat also caused hyperinsulinaemia, insulin
resistance, impaired glucose tolerance, increased abdominal
fat deposition, hepatic steatosis and inflammation [133,
140]. The rats fed with the high-fructose, high-fat diet
showed cardiac hypertrophy, increased ventricular stiffness,
ventricular dilatation, cardiac inflammation and fibrosis,
hypertension, decreased cardiac function and endothelial
dysfunction along with mild renal damage and increased
pancreatic islet mass [133].
Since high-carbohydrate, high-fat diet-fed rodents
develop all the complications present in human metabolic
syndrome and the diet is similar to human diets (sometimes
called a “cafeteria diet”), this model is probably the
best model to study the human metabolic syndrome.
Pharmaceutical and nutraceutical preparations can be tested
for treatment of diet-induced human metabolic syndrome
in this high-carbohydrate, high-fat diet-fed model.
15. Obesity-Resistant Rat Strain
The interaction of genes with the diet is crucial for the
induction of obesity in rodents and humans as shown by
the studies with diet-induced obese (DIO) and diet-resistant
(DR) rats [144, 145]. DR rats, even when fed with high-
fat diet, did not produce the signs of metabolic syndrome,
whereas DIO rats clearly showed those signs [144, 145].
The signs shown by DIO rats and not shown by DR rats
included increases in body weight and body fat, impairment
of glucose tolerance, dyslipidaemia, hyperinsulinaemia and
hyperleptinaemia [144, 145]. However, these signs are similar
to many control rats and mice fed standard rodent food that
are sedentary, obese and develop impaired glucose tolerance,
described as “metabolically morbid” [146].
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Figure 4: High-carbohydrate, high-fat diet-induced metabolic syndrome.
16. Fatty Liver Disease
Nonalcoholic steatohepatitis is now recognized as a compli-
cation of metabolic syndrome [147]. The most important
model of nonalcoholic steatohepatitis is the methionine-
and choline-deficient diet-fed rat. This special diet produced
hepatic steatosis and fibrosis, increased hepatic triglycerides,
increased serum activities of transaminases and alkaline
phosphatase and increased serum concentrations of total
bilirubin [148, 149]. Methionine- and choline-deficient diet-
fed rats showed extreme reduction in body weight and
liver weight along with decreased serum triglyceride and
total protein concentrations [148, 149]. Although these rats
develop nonalcoholic steatohepatitis, they do not show the
other signs of metabolic syndrome.
17. High-Fat Diet-Fed Spontaneously
Hypertensive Rats
Spontaneously hypertensive rats (SHRs) are the most widely
used genetic model of human hypertension [22]. High-fat
feeding to SHRs led to an increased body weight compared
to SHRs fed on normal chow diet [150]. High-fat-fed SHRs
also showed renal inflammation and albuminuria but did not
show changes in plasma concentrations of total cholesterol,
triglycerides and insulin, although plasma concentrations of
free fatty acids were higher in high-fat-fed SHRs compared
to normal diet-fed SHRs [150]. There was no change in
systolic blood pressure with high-fat feeding in SHRs [151].
High-fat-fed SHRs also showed impaired glucose tolerance
[152]. Although high-fat-fed SHRs show some symptoms
of metabolic syndrome, they have genetically induced rather
than diet-induced hypertension. Since human hypertension
is not monogenetic, this model should not be considered
appropriate as a model of the metabolic syndrome.
18. Nile Grass Rats
Apart from laboratory animals, wild rodents have been
tested for the development of diabetes and obesity with
laboratory diets. The Nile rat (African grass rat; Arvican-
this niloticus) and sand rat (Psammomys obesus) are two
examples. These rats do not develop diabetes in the wild,
but diabetes was induced when these rats were kept under
laboratory conditions on chow diet [153]. These rats show
hyperglycaemia and dyslipidaemia after 1 year of age [154].
They also develop liver steatosis, abdominal fat deposition,
hypertension and hyperinsulinaemia [153, 154]. These rats
show promise for metabolic syndrome research, even though
these signs develop when fed on normal diet rather than the
high-carbohydrate, high-fat diet in humans. This is similar
to the concept of metabolically morbid rodents fed a normal
diet [146].
19. Useful Treatment Strategies in
Metabolic Syndrome Research
These rodent models have been used to characterize
responses to many interventions. Success has been variable
but some treatments have attenuated most of the signs
Page 90
Journal of Biomedicine and Biotechnology 9
of the metabolic syndrome. These treatment strategies
clearly indicate that it is possible to inhibit the progression
of metabolic syndrome and associated complications and
maybe to reverse them. Some of the responses to treatments
in different rodent models have been described in Table 2.
20. Conclusion
Pharmaceutical and nutraceutical preparations are required
to decrease morbidity and mortality in chronic diseases
such as metabolic syndrome. These preparations need to
be tested for efficacy in an appropriate rodent model.
Thus, different animal models have been developed for this
purpose. While many rodent models display some of the
signs of the metabolic syndrome, few models can adequately
mimic the range of signs that characterise this syndrome
in humans. In particular, the presence of inflammation has
often not been tested or defined. Further, many models rely
on genetic changes to induce symptoms even though the
human disease is usually diet induced. It is our opinion
that chronic consumption of a high-carbohydrate, high-fat
diet by normal rodents provides an adequate rodent model
to mimic the human metabolic syndrome and for testing
potential therapeutic interventions.
Conflict of Interests
The authors declare no conflict of interests.
Acknowledgments
The authors’ own studies were supported by grants from
the National Health and Medical Research Council of
Australia, The Prince Charles Hospital Foundation and Dr
Red Nutraceuticals, Mt Nebo, Queensland, Australia.
References
[1] R. K. Simmons, K. G. M. M. Alberti, E. A. M. Gale et al., “The
metabolic syndrome: useful concept or clinical tool? Report
of a WHO expert consultation,” Diabetologia, vol. 53, no. 4,
pp. 600–605, 2010.
[2] B. Bauduceau, E. Vachey, H. Mayaudon et al., “Should we
have more definitions of metabolic syndrome or simply take
waist measurement?” Diabetes and Metabolism, vol. 33, no. 5,
pp. 333–339, 2007.
[3] B. Isomaa, P. Almgren, T. Tuomi et al., “Cardiovascular
morbidity and mortality associated with the metabolic
syndrome,” Diabetes Care, vol. 24, no. 4, pp. 683–689, 2001.
[4] H. M. Lakka, D. E. Laaksonen, T. A. Lakka et al., “The
metabolic syndrome and total and cardiovascular disease
mortality in middle-aged men,” Journal of the American
Medical Association, vol. 288, no. 21, pp. 2709–2716, 2002.
[5] P. Aschner, “Metabolic syndrome as a risk factor for diabetes,”
Expert Review of Cardiovascular Therapy, vol. 8, no. 3, pp.
407–412, 2010.
[6] E. Vanni, E. Bugianesi, A. Kotronen, S. de Minicis, H.
Yki-Ja¨rvinen, and G. Svegliati-Baroni, “From the metabolic
syndrome to NAFLD or vice versa?” Digestive and Liver
Disease, vol. 42, no. 5, pp. 320–330, 2010.
[7] N. Palanisamy, P. Viswanathan, M. K. Ravichandran, and C.
V. Anuradha, “Renoprotective and blood pressure-lowering
effect of dietary soy protein via protein kinase C βII
inhibition in a rat model of metabolic syndrome,” Canadian
Journal of Physiology and Pharmacology, vol. 88, no. 1, pp.
28–37, 2010.
[8] D. J. Foster, P. Ravikumar, D. J. Bellotto, R. H. Unger, and
C. C. W. Hsia, “Fatty diabetic lung: altered alveolar structure
and surfactant protein expression,” American Journal of
Physiology, vol. 298, no. 3, pp. L392–L403, 2010.
[9] T. Bjørge, A. Lukanova, H. Jonsson et al., “Metabolic
syndrome and breast cancer in the Me-Can (metabolic syn-
drome and cancer) project,” Cancer Epidemiology Biomarkers
and Prevention, vol. 19, no. 7, pp. 1737–1745, 2010.
[10] D. Johansen, T. Stocks, H. Jonsson et al., “Metabolic factors
and the risk of pancreatic cancer: a prospective analysis of
almost 580,000 men and women in the metabolic syndrome
and cancer project,” Cancer Epidemiology Biomarkers and
Prevention, vol. 19, no. 9, pp. 2307–2317, 2010.
[11] C. Ha¨ggstro¨m, T. Stocks, K. Rapp et al., “Metabolic syndrome
and risk of bladder cancer: prospective cohort study in
the metabolic syndrome and cancer project (Me-Can),”
International Journal of Cancer. In press.
[12] P. Forti, N. Pisacane, E. Rietti et al., “Metabolic syndrome
and risk of dementia in older adults,” Journal of the American
Geriatrics Society, vol. 58, no. 3, pp. 487–492, 2010.
[13] K. Esposito, A. Ceriello, and D. Giugliano, “Diet and
the metabolic syndrome,” Metabolic Syndrome and Related
Disorders, vol. 5, no. 4, pp. 291–295, 2007.
[14] P. Zimmet, D. Magliano, Y. Matsuzawa, G. Alberti, and
J. Shaw, “The metabolic syndrome: a global public health
problem and a new definition,” Journal of Atherosclerosis and
Thrombosis, vol. 12, no. 6, pp. 295–300, 2005.
[15] R. B. Ervin, “Prevalence of metabolic syndrome among
adults 20 years of age and over, by sex, age, race and ethnicity,
and body mass index: United States, 2003–2006,” National
Health Statistics Reports, no. 13, pp. 1–7, 2009.
[16] H. M. Termizy and M. Mafauzy, “Metabolic syndrome and
its characteristics among obese patients attending an obesity
clinic,” Singapore Medical Journal, vol. 50, no. 4, pp. 390–394,
2009.
[17] A. J. Cameron, D. J. Magliano, P. Z. Zimmet, T. Welborn,
and J. E. Shaw, “The metabolic syndrome in Australia:
prevalence using four definitions,” Diabetes Research and
Clinical Practice, vol. 77, no. 3, pp. 471–478, 2007.
[18] H. Sone, N. Yamada, H. Yamashita, S. Katayama, and Y.
Akanuma, “Prevalence and incidence of diabetic microan-
giopathy in Japan,” Nippon Rinsho, vol. 63, supplement 6, pp.
18–22, 2005.
[19] E. S. Ford, W. H. Giles, and W. H. Dietz, “Prevalence of
the metabolic syndrome among US adults: findings from the
Third National Health and Nutrition Examination Survey,”
Journal of the American Medical Association, vol. 287, no. 3,
pp. 356–359, 2002.
[20] E. S. Ford, “Prevalence of the metabolic syndrome defined
by the international diabetes federation among adults in the
U.S,” Diabetes Care, vol. 28, no. 11, pp. 2745–2749, 2005.
[21] R. Ramaraj and P. Chellappa, “Cardiovascular risk in South
Asians,” Postgraduate Medical Journal, vol. 84, no. 996, pp.
518–523, 2008.
[22] S. A. Doggrell and L. Brown, “Rat models of hypertension,
cardiac hypertrophy and failure,” Cardiovascular Research,
vol. 39, no. 1, pp. 89–105, 1998.
Page 91
10 Journal of Biomedicine and Biotechnology
[23] D. Chen and M. W. Wang, “Development and application
of rodent models for type 2 diabetes,” Diabetes, Obesity and
Metabolism, vol. 7, no. 4, pp. 307–317, 2005.
[24] J. Speakman, C. Hambly, S. Mitchell, and E. Kro´l, “Animal
models of obesity,” Obesity Reviews, vol. 8, no. 1, pp. 55–61,
2007.
[25] J. Ai, N. Wang, M. Yang, Z. M. Du, Y. C. Zhang, and
B. F. Yang, “Development of Wistar rat model of insulin
resistance,” World Journal of Gastroenterology, vol. 11, no. 24,
pp. 3675–3679, 2005.
[26] I. Mazen, M. El-Gammal, M. Abdel-Hamid, and K. Amr,
“A novel homozygous missense mutation of the leptin gene
(N103K) in an obese Egyptian patient,” Molecular Genetics
and Metabolism, vol. 97, no. 4, pp. 305–308, 2009.
[27] S. C. Woods and D. A. D’Alessio, “Central control of body
weight and appetite,” Journal of Clinical Endocrinology and
Metabolism, vol. 93, no. 11, supplement 1, pp. s37–s50, 2008.
[28] K. Miyasaka, S. Takiguchi, and A. Funakoshi, “Cholecys-
tokinin 1(A) receptor polymorphisms,” Current Topics in
Medicinal Chemistry, vol. 7, no. 12, pp. 1205–1210, 2007.
[29] S. Marchal-Victorion, N. Vionnet, C. Escrieut et al., “Genetic,
pharmacological and functional analysis of cholecystokinin-
1 and cholecystokinin-2 receptor polymorphism in type 2
diabetes and obese patients,” Pharmacogenetics, vol. 12, no.
1, pp. 23–30, 2002.
[30] M. Enser, “Clearing-factor lipase in obese hyperglycaemic
mice (ob-ob),” Biochemical Journal, vol. 129, no. 2, pp. 447–
453, 1972.
[31] J. M. Friedman, R. L. Leibel, D. S. Siegel, J. Walsh, and N.
Bahary, “Molecular mapping of the mouse ob mutation,”
Genomics, vol. 11, no. 4, pp. 1054–1062, 1991.
[32] Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, and
J. M. Friedman, “Positional cloning of the mouse obese gene
and its human homologue,” Nature, vol. 372, no. 6505, pp.
425–432, 1994.
[33] P. U. Dubuc, “The development of obesity, hyperinsulinemia,
and hyperglycemia in ob/ob mice,” Metabolism, vol. 25, no.
12, pp. 1567–1574, 1976.
[34] A. L. Mark, R. A. Shaffer, M. L. G. Correia, D. A. Morgan, C.
D. Sigmund, and W. G. Haynes, “Contrasting blood pressure
effects of obesity in leptin-deficient ob/ob mice and agouti
yellow obese mice,” Journal of Hypertension, vol. 17, no. 12,
pp. 1949–1953, 1999.
[35] A. van den Bergh, A. Vanderper, P. Vangheluwe et al.,
“Dyslipidaemia in type II diabetic mice does not aggravate
contractile impairment but increases ventricular stiffness,”
Cardiovascular Research, vol. 77, no. 2, pp. 371–379, 2008.
[36] P. Dobrzyn, A. Dobrzyn, M. Miyazaki, and J. M. Ntambi,
“Loss of stearoyl-CoA desaturase 1 rescues cardiac function
in obese leptin-deficient mice,” Journal of Lipid Research, vol.
51, no. 8, pp. 2202–2210, 2010.
[37] A. K. M. T. Zaman, S. Fujii, D. Goto et al., “Salutary effects
of attenuation of angiotensin II on coronary perivascular
fibrosis associated with insulin resistance and obesity,”
Journal of Molecular and Cellular Cardiology, vol. 37, no. 2,
pp. 525–535, 2004.
[38] H. J. Park, D. A. DiNatale, M.-Y. Chung et al., “Green tea
extract attenuates hepatic steatosis by decreasing adipose
lipogenesis and enhancing hepatic antioxidant defenses in
ob/ob mice,” Journal of Nutritional Biochemistry. In press.
[39] A. E. Bigorgne, L. Bouchet-Delbos, S. Naveau et al., “Obesity-
induced lymphocyte hyperresponsiveness to chemokines: a
new mechanism of fatty liver inflammation in obese mice,”
Gastroenterology, vol. 134, no. 5, pp. 1459–1469, 2008.
[40] H. Chen, O. Charlat, L. A. Tartaglia et al., “Evidence that the
diabetes gene encodes the leptin receptor: identification of a
mutation in the leptin receptor gene in db/db mice,” Cell, vol.
84, no. 3, pp. 491–495, 1996.
[41] Y. F. Dong, L. Liu, K. Kataoka et al., “Aliskiren prevents
cardiovascular complications and pancreatic injury in a
mouse model of obesity and type 2 diabetes,” Diabetologia,
vol. 53, no. 1, pp. 180–191, 2010.
[42] S. Ae Park, M. S. Choi, S. Y. Cho et al., “Genistein and
daidzein modulate hepatic glucose and lipid regulating
enzyme activities in C57BL/KsJ-db/db mice,” Life Sciences,
vol. 79, no. 12, pp. 1207–1213, 2006.
[43] M. S. Winzell, E. M. Wulff, G. S. Olsen, P. Sauerberg, C. F.
Gotfredsen, and B. Ahre´n, “Improved insulin sensitivity and
islet function after PPARδ activation in diabetic db/db mice,”
European Journal of Pharmacology, vol. 626, no. 2-3, pp. 297–
305, 2010.
[44] F. Ge, S. Zhou, C. Hu, H. Lobdell IV, and P. D. Berk, “Insulin-
and leptin-regulated fatty acid uptake plays a key causal role
in hepatic steatosis in mice with intact leptin signaling but
not in ob/ob or db/db mice,” American Journal of Physiology,
vol. 299, no. 4, pp. G855–G866, 2010.
[45] A. Sahai, P. Malladi, X. Pan et al., “Obese and diabetic db/db
mice develop marked liver fibrosis in a model of nonalcoholic
steatohepatitis: role of short-form leptin receptors and
osteopontin,” American Journal of Physiology, vol. 287, no. 5,
pp. G1035–G1043, 2004.
[46] A. Scarda, C. Franzin, G. Milan et al., “Increased adipogenic
conversion of muscle satellite cells in obese Zucker rats,”
International Journal of Obesity, vol. 34, no. 8, pp. 1319–1327,
2010.
[47] M. Mizuno, T. Sada, M. Kato, and H. Koike, “Renoprotective
effects of blockade of angiotensin II AT1 receptors in an
animal model of type 2 diabetes,” Hypertension Research, vol.
25, no. 2, pp. 271–278, 2002.
[48] C. E. van den Brom, M. C. Huisman, R. Vlasblom et al.,
“Altered myocardial substrate metabolism is associated with
myocardial dysfunction in early diabetic cardiomyopathy in
rats: studies using positron emission tomography,” Cardio-
vascular Diabetology, vol. 8, article 39, 2009.
[49] J. D. Sparks, T. L. Phung, M. Bolognino et al., “Lipoprotein
alterations in 10- and 20-week-old Zucker diabetic fatty
rats: Hyperinsulinemic versus insulinopenic hyperglycemia,”
Metabolism, vol. 47, no. 11, pp. 1315–1324, 1998.
[50] S. Serpillon, B. C. Floyd, R. S. Gupte et al., “Superoxide pro-
duction by NAD(P)H oxidase and mitochondria is increased
in genetically obese and hyperglycemic rat heart and aorta
before the development of cardiac dysfunction. The role
of glucose-6-phosphate dehydrogenase-derived NADPH,”
American Journal of Physiology, vol. 297, no. 1, pp. H153–
H162, 2009.
[51] Y. Suzaki, Y. Ozawa, and H. Kobori, “Intrarenal oxidative
stress and augmented angiotensinogen are precedent to renal
injury in zucker diabetic fatty rats,” International Journal of
Biological Sciences, vol. 3, no. 1, pp. 40–46, 2007.
[52] S. Scha¨fer, H. L. Schmidts, M. Bleich, A. E. Busch, and
W. Linz, “Nephroprotection in Zucker diabetic fatty rats by
vasopeptidase inhibition is partly bradykinin B2 receptor
dependent,” British Journal of Pharmacology, vol. 143, no. 1,
pp. 27–32, 2004.
[53] K. Z. Y. Xu, C. Zhu, M. S. Kim, J. Yamahara, and Y. Li,
“Pomegranate flower ameliorates fatty liver in an animal
model of type 2 diabetes and obesity,” Journal of Ethnophar-
macology, vol. 123, no. 2, pp. 280–287, 2009.
Page 92
Journal of Biomedicine and Biotechnology 11
[54] L. Ferreira, E. Teixeira-de-Lemos, F. Pinto et al., “Effects
of sitagliptin treatment on dysmetabolism, inflammation,
and oxidative stress in an animal model of type 2 diabetes
(ZDF rat),” Mediators of Inflammation, vol. 2010, Article ID
592760, 2010.
[55] K. Shima, M. Zhu, and A. Mizuno, “Pathoetiology and
prevention of NIDDM lessons from the OLETF rat,” Journal
of Medical Investigation, vol. 46, no. 3-4, pp. 121–129, 1999.
[56] J. Antin, J. Gibbs, J. Holt, R. C. Young, and G. P. Smith,
“Cholecystokinin elicits the complete behavioral sequence
of satiety in rats,” Journal of Comparative and Physiological
Psychology, vol. 89, no. 7, pp. 784–790, 1975.
[57] T. H. Moran and S. Bi, “Hyperphagia and obesity in OLETF
rats lacking CCK-1 receptors,” Philosophical Transactions of
the Royal Society B: Biological Sciences, vol. 361, no. 1471, pp.
1211–1218, 2006.
[58] K. Kawano, T. Hirashima, S. Mori, and T. Natori, “OLETF
(Otsuka Long-Evans Tokushima fatty) rat: a new NIDDM
rat strain,” Diabetes Research and Clinical Practice, vol. 24,
supplement, pp. S317–S320, 1994.
[59] I. Karakikes, M. Kim, L. Hadri et al., “Gene remodeling in
type 2 diabetic cardiomyopathy and its phenotypic rescue
with SERCA2a,” PLoS ONE, vol. 4, no. 7, article e6474, 2009.
[60] K. Yagi, S. Kim, H. Wanibuchi, T. Yamashita, Y. Yamamura,
and H. Iwao, “Characteristics of diabetes, blood pressure,
and cardiac and renal complications in Otsuka Long-Evans
Tokushima Fatty rats,” Hypertension, vol. 29, no. 3, pp. 728–
735, 1997.
[61] M. Shimizu, S. Tanabe, F. Morimatsu et al., “Consumption
of pork-liver protein hydrolysate reduces body fat in Otsuka
Long-Evans Tokushima Fatty rats by suppressing hepatic
lipogenesis,” Bioscience, Biotechnology and Biochemistry, vol.
70, no. 1, pp. 112–118, 2006.
[62] K. Yasuda, W. Nishikawa, N. Iwanaka et al., “Abnormality in
fibre type distribution of soleus and plantaris muscles in non-
obese diabetic Goto-Kakizaki rats,” Clinical and Experimental
Pharmacology and Physiology, vol. 29, no. 11, pp. 1001–1008,
2002.
[63] B. Portha, G. Lacraz, A. Chavey et al., “Islet structure and
function in the GK rat,” Advances in Experimental Medicine
and Biology, vol. 654, pp. 479–500, 2010.
[64] S. Gupte, N. Labinskyy, R. Gupte, A. Csiszar, Z. Ungvari,
and J. G. Edwards, “Role of NAD(P)H oxidase in superoxide
generation and endothelial dysfunction in Goto-Kakizaki
(GK) rats as a model of nonobese NIDDM,” PLoS ONE, vol.
5, no. 7, article e11800, 2010.
[65] M. Louhelainen, E. Vahtola, H. Forsten et al., “Oral lev-
osimendan prevents postinfarct heart failure and cardiac
remodeling in diabetic Goto-Kakizaki rats,” Journal of Hyper-
tension, vol. 27, no. 10, pp. 2094–2107, 2009.
[66] B. F. Schrijvers, A. S. de Vriese, J. van de Voorde, R. Rasch,
N. H. Lameire, and A. Flyvbjerg, “Long-term renal changes
in the Goto-Kakizaki rat, a model of lean type 2 diabetes,”
Nephrology Dialysis Transplantation, vol. 19, no. 5, pp. 1092–
1097, 2004.
[67] S. Akiyama, S. I. Katsumata, K. Suzuki, Y. Nakaya, Y. Ishimi,
and M. Uehara, “Hypoglycemic and hypolipidemic effects of
hesperidin and cyclodextrin-clathrated hesperetin in Goto-
Kakizaki rats with type 2 diabetes,” Bioscience, Biotechnology
and Biochemistry, vol. 73, no. 12, pp. 2779–2782, 2009.
[68] J. C. Bru¨ning, M. D. Michael, J. N. Winnay et al., “A muscle-
specific insulin receptor knockout exhibits features of the
metabolic syndrome of NIDDM without altering glucose
tolerance,” Molecular Cell, vol. 2, no. 5, pp. 559–569, 1998.
[69] M. Jackerott, A. Baudry, B. Lamothe, D. Bucchini, J. Jami, and
R. L. Joshi, “Endocrine pancreas in insulin receptor-deficient
mouse pups,” Diabetes, vol. 50, no. 1, pp. S146–S149, 2001.
[70] T. Kitamura, C. R. Kahn, and D. Accili, “Insulin receptor
knockout mice,” Annual Review of Physiology, vol. 65, pp.
313–332, 2003.
[71] A. Shirakami, T. Toyonaga, K. Tsuruzoe et al., “Heterozygous
knockout of the IRS-1 gene in mice enhances obesity-linked
insulin resistance: a possible model for the development of
type 2 diabetes,” Journal of Endocrinology, vol. 174, no. 2, pp.
309–319, 2002.
[72] A. M. Valverde, C. R. Kahn, and M. Benito, “Insulin
signaling in insulin receptor substrate (IRS)-1-deficient
brown adipocytes: requirement of IRS-1 for lipid synthesis,”
Diabetes, vol. 48, no. 11, pp. 2122–2131, 1999.
[73] A. E. Stenbit, T. S. Tsao, J. Li et al., “GLUT4 heterozygous
knockout mice develop muscle insulin resistance and dia-
betes,” Nature Medicine, vol. 3, no. 10, pp. 1096–1101, 1997.
[74] T. S. Tsao, A. E. Stenbit, J. Li et al., “Muscle-specific trans-
genic complementation of GLUT4-deficient mice: effects
on glucose but not lipid metabolism,” Journal of Clinical
Investigation, vol. 100, no. 3, pp. 671–677, 1997.
[75] M. Gorselink, M. R. Drost, K. F. J. de Brouwer et al.,
“Increased muscle fatigability in GLUT-4-deficient mice,”
American Journal of Physiology, vol. 282, no. 2, pp. E348–
E354, 2002.
[76] S. Sharma, C. S. Mishra, S. Arumugam et al., “Antidiabetic
activity of resveratrol, a known SIRT1 activator in a genetic
model for type-2 diabetes,” Phytotherapy Research, vol. 25,
no. 1, pp. 67–73, 2011.
[77] J. W. Lee, I. S. Nam-Goong, J. G. Kim et al., “Effects
of rosiglitazone on inflammation in Otsuka Long-Evans
Tokushima Fatty rats,” Korean Diabetes Journal, vol. 34, no.
3, pp. 191–199, 2010.
[78] M. Louhelainen, E. Vahtola, H. Forsten et al., “Oral lev-
osimendan prevents postinfarct heart failure and cardiac
remodeling in diabetic Goto-Kakizaki rats,” Journal of Hyper-
tension, vol. 27, no. 10, pp. 2094–2107, 2009.
[79] Y. Dixit and A. Kar, “Protective role of three vegetable peels in
alloxan induced diabetes mellitus in male mice,” Plant Foods
for Human Nutrition, vol. 65, no. 3, pp. 284–289, 2010.
[80] O. Coskun, M. Kanter, A. Korkmaz, and S. Oter,
“Quercetin, a flavonoid antioxidant, prevents and protects
streptozotocin-induced oxidative stress and β-cell damage in
rat pancreas,” Pharmacological Research, vol. 51, no. 2, pp.
117–123, 2005.
[81] V. Thirunavukkarasu, A. T. Anitha Nandhini, and C. V. Anu-
radha, “Lipoic acid attenuates hypertension and improves
insulin sensitivity, kallikrein activity and nitrite levels in high
fructose-fed rats,” Journal of Comparative Physiology B, vol.
174, no. 8, pp. 587–592, 2004.
[82] X. Pang, J. Zhao, W. Zhang et al., “Antihypertensive effect
of total flavones extracted from seed residues of Hippophae
rhamnoides L. in sucrose-fed rats,” Journal of Ethnopharma-
cology, vol. 117, no. 2, pp. 325–331, 2008.
[83] E. P. Davidson, L. J. Coppey, B. Dake, and M. A. Yorek, “Effect
of treatment of Sprague Dawley rats with AVE7688, enalapril,
or candoxatril on diet-induced obesity,” Journal of Obesity,
vol. 2011, Article ID 686952, 9 pages, 2011.
[84] H. Poudyal, S. Panchal, and L. Brown, “Comparison of
purple carrot juice and β-carotene in a high-carbohydrate,
high-fat diet-fed rat model of the metabolic syndrome,”
British Journal of Nutrition, vol. 104, no. 9, pp. 1322–1332,
2010.
Page 93
12 Journal of Biomedicine and Biotechnology
[85] Y. Okumura, M. Narukawa, and T. Watanabe, “Adiposity
suppression effect in mice due to black pepper and its main
pungent component, piperine,” Bioscience, Biotechnology and
Biochemistry, vol. 74, no. 8, pp. 1545–1549, 2010.
[86] S. Lenzen, “The mechanisms of alloxan- and streptozotocin-
induced diabetes,” Diabetologia, vol. 51, no. 2, pp. 216–226,
2008.
[87] T. Szkudelski, “The mechanism of alloxan and streptozotocin
action in B cells of the rat pancreas,” Physiological Research,
vol. 50, no. 6, pp. 537–546, 2001.
[88] C. T. Spadella, O. A. X. Suarez, A. N. Lucchesi, and A. J. M.
Cataneo, “Pancreas transplantation prevents morphologic
and ultrastructural changes in pulmonary parenchyma of
alloxan-induced diabetic rats,” Transplantation Proceedings,
vol. 42, no. 6, pp. 2092–2096, 2010.
[89] F. Akar, M. B. Pektas, C. Tufan et al., “Resveratrol shows
vasoprotective effect reducing oxidative stress without affect-
ing metabolic disturbances in insulin-dependent diabetes of
rabbits,” Cardiovascular Drugs and Therapy. In press.
[90] Y.-C. Weng, H.-L. Chiu, Y.-C. Lin, T.-C. Chi, Y.-H. Kuo,
and M.-J. Su, “Antihyperglycemic effect of a caffeamide
derivative, KS370G, in normal and diabetic mice,” Journal of
Agricultural and Food Chemistry, vol. 58, no. 18, pp. 10033–
10038, 2010.
[91] N. Yamabe, K. S. Kang, and B. T. Zhu, “Beneficial effect of
17β-estradiol on hyperglycemia and islet β-cell functions in
a streptozotocin-induced diabetic rat model,” Toxicology and
Applied Pharmacology, vol. 249, no. 1, pp. 76–85, 2010.
[92] M. Zafar, S. N. Naqvi, M. Ahmed, and Z. A. Kaimkhani,
“Altered liver morphology and enzymes in streptozotocin
induced diabetic rats,” International Journal of Morphology,
vol. 27, no. 3, pp. 719–725, 2009.
[93] T. Radovits, S. Korkmaz, S. Loganathan et al., “Comparative
investigation of the left ventricular pressure-volume relation-
ship in rat models of type 1 and type 2 diabetes mellitus,”
American Journal of Physiology, vol. 297, no. 1, pp. H125–
H133, 2009.
[94] R. Dheer and P. Bhatnagar, “A study of the antidiabetic activ-
ity of Barleria prionitis Linn,” Indian Journal of Pharmacology,
vol. 42, no. 2, pp. 70–73, 2010.
[95] Y. K. Sinzato, P. H. O. Lima, K. E. de Campos, A. C. I. Kiss,
M. V. C. Rudge, and D. C. Damascene, “Neonatally-induced
diabetes: lipid profile outcomes and oxidative stress status in
adult rats,” Revista da Associacao Medica Brasileira, vol. 55,
no. 4, pp. 384–388, 2009.
[96] A. K. Sharma and B. P. Srinivasan, “Triple verses glimepiride
plus metformin therapy on cardiovascular risk biomarkers
and diabetic cardiomyopathy in insulin resistance type 2
diabetes mellitus rats,” European Journal of Pharmaceutical
Sciences, vol. 38, no. 5, pp. 433–444, 2009.
[97] S. L. Me´nard, E. Croteau, O. Sarrhini et al., “Abnormal
in vivo myocardial energy substrate uptake in diet-induced
type 2 diabetic cardiomyopathy in rats,” American Journal of
Physiology, vol. 298, no. 5, pp. E1049–E1057, 2010.
[98] C. Ju, W. Yue, Z. Yang et al., “Antidiabetic effect and mecha-
nism of chitooligosaccharides,” Biological and Pharmaceutical
Bulletin, vol. 33, no. 9, pp. 1511–1516, 2010.
[99] K. Srinivasan, B. Viswanad, L. Asrat, C. L. Kaul, and P.
Ramarao, “Combination of high-fat diet-fed and low-dose
streptozotocin-treated rat: a model for type 2 diabetes and
pharmacological screening,” Pharmacological Research, vol.
52, no. 4, pp. 313–320, 2005.
[100] F. Massiera, P. Barbry, P. Guesnet et al., “A Western-like fat
diet is sufficient to induce a gradual enhancement in fat mass
over generations,” Journal of Lipid Research, vol. 51, no. 8, pp.
2352–2361, 2010.
[101] J. S. Lim, M. Mietus-Snyder, A. Valente, J. M. Schwarz,
and R. H. Lustig, “The role of fructose in the pathogenesis
of NAFLD and the metabolic syndrome,” Nature Reviews
Gastroenterology and Hepatology, vol. 7, no. 5, pp. 251–264,
2010.
[102] K. A. Leˆ and L. Tappy, “Metabolic effects of fructose,” Current
Opinion in Clinical Nutrition and Metabolic Care, vol. 9, no.
4, pp. 469–475, 2006.
[103] L. Tappy and K. A. Le, “Metabolic effects of fructose and the
worldwide increase in obesity,” Physiological Reviews, vol. 90,
no. 1, pp. 23–46, 2010.
[104] G. A. Bray, S. J. Nielsen, and B. M. Popkin, “Consumption of
high-fructose corn syrup in beverages may play a role in the
epidemic of obesity,” American Journal of Clinical Nutrition,
vol. 79, no. 4, pp. 537–543, 2004.
[105] L. T. Tran, V. G. Yuen, and J. H. McNeill, “The fructose-
fed rat: a review on the mechanisms of fructose-induced
insulin resistance and hypertension,” Molecular and Cellular
Biochemistry, vol. 332, no. 1-2, pp. 145–159, 2009.
[106] J. Patel, A. Iyer, and L. Brown, “Evaluation of the chronic
complications of diabetes in a high fructose diet in rats,”
Indian Journal of Biochemistry and Biophysics, vol. 46, no. 1,
pp. 66–72, 2009.
[107] K. C. Chang, J. T. Liang, C. D. Tseng et al., “Aminoguanidine
prevents fructose-induced deterioration in left ventricular-
arterial coupling in Wistar rats,” British Journal of Pharma-
cology, vol. 151, no. 3, pp. 341–346, 2007.
[108] T. Kawasaki, K. Igarashi, T. Koeda et al., “Rats fed fructose-
enriched diets have characteristics of nonalcoholic hepatic
steatosis,” Journal of Nutrition, vol. 139, no. 11, pp. 2067–
2071, 2009.
[109] M. E. Bocarsly, E. S. Powell, N. M. Avena, and B. G. Hoebel,
“High-fructose corn syrup causes characteristics of obesity in
rats: increased body weight, body fat and triglyceride levels,”
Pharmacology Biochemistry and Behavior, vol. 97, no. 1, pp.
101–106, 2010.
[110] T. Nakayama, T. Kosugi, M. Gersch et al., “Dietary fructose
causes tubulointerstitial injury in the normal rat kidney,”
American Journal of Physiology, vol. 298, no. 3, pp. F712–
F720, 2010.
[111] A. Shapiro, W. Mu, C. Roncal, K. Y. Cheng, R. J. Johnson, and
P. J. Scarpace, “Fructose-induced leptin resistance exacer-
bates weight gain in response to subsequent high-fat feeding,”
American Journal of Physiology, vol. 295, no. 5, pp. R1370–
R1375, 2008.
[112] T. Nakagawa, K. R. Tuttle, R. A. Short, and R. J. Johnson,
“Hypothesis: fructose-induced hyperuricemia as a causal
mechanism for the epidemic of the metabolic syndrome,”
Nature clinical practice. Nephrology, vol. 1, no. 2, pp. 80–86,
2005.
[113] R. Miatello, M. Va´zquez, N. Renna, M. Cruzado, A. P.
Zumino, and N. Risler, “Chronic administration of resvera-
trol prevents biochemical cardiovascular changes in fructose-
fed rats,” American Journal of Hypertension, vol. 18, no. 6, pp.
864–870, 2005.
[114] H. Basciano, L. Federico, and K. Adeli, “Fructose, insulin
resistance, and metabolic dyslipidemia,” Nutrition and
Metabolism, vol. 2, no. 5, 2005.
Page 94
Journal of Biomedicine and Biotechnology 13
[115] A. C. Rutledge and K. Adeli, “Fructose and the metabolic
syndrome: pathophysiology and molecular mechanisms,”
Nutrition Reviews, vol. 65, no. 6, pp. S13–S23, 2007.
[116] R. B. Kanarek, J. R. Aprille, E. Hirsch, L. Gualtiere, and C.
A. Brown, “Sucrose-induced obesity: effect of diet on obesity
and brown adipose tissue,” American Journal of Physiology,
vol. 253, no. 1, pp. R158–R166, 1987.
[117] M. Santure´, M. Pitre, A. Marette et al., “Induction of insulin
resistance by high-sucrose feeding does not raise mean
arterial blood pressure but impairs haemodynamic responses
to insulin in rats,” British Journal of Pharmacology, vol. 137,
no. 2, pp. 185–196, 2002.
[118] M. S. Coelho, K. L. Lopes, R. D. A. Freitas et al., “High
sucrose intake in rats is associated with increased ACE2 and
angiotensin-(1–7) levels in the adipose tissue,” Regulatory
Peptides, vol. 162, no. 1–3, pp. 61–67, 2010.
[119] Y. B. Lombardo, S. Drago, A. Chicco et al., “Long-term
administration of a sucrose-rich diet to normal rats: Rela-
tionship between metabolic and hormonal profiles and mor-
phological changes in the endocrine pancreas,” Metabolism,
vol. 45, no. 12, pp. 1527–1532, 1996.
[120] N. Sharma, I. C. Okere, B. R. Barrows et al., “High-sugar diets
increase cardiac dysfunction and mortality in hypertension
compared to low-carbohydrate or high-starch diets,” Journal
of Hypertension, vol. 26, no. 7, pp. 1402–1410, 2008.
[121] W. Huang, A. Metlakunta, N. Dedousis et al., “Depletion of
liver kupffer cells prevents the development of diet-induced
hepatic steatosis and insulin resistance,” Diabetes, vol. 59, no.
2, pp. 347–357, 2010.
[122] P. Andrews, P. A. Karadaghi, S. Memon et al., “No effect of
high sucrose diets on the kidneys of Wister Kyoto (WKY)
rats,” Geriatric Nephrology and Urology, vol. 2, no. 1, pp. 35–
42, 1992.
[123] S. C. Woods, R. J. Seeley, P. A. Rushing, D. D’Alessio, and P.
Tso, “A controlled high-fat diet induces an obese syndrome
in rats,” Journal of Nutrition, vol. 133, no. 4, pp. 1081–1087,
2003.
[124] M. B. Aguila and C. A. Mandarim-de-Lacerda, “Heart and
blood pressure adaptations in Wistar rats fed with different
high-fat diets for 18 months,” Nutrition, vol. 19, no. 4, pp.
347–352, 2003.
[125] R. Buettner, K. G. Parhofer, M. Woenckhaus et al., “Defining
high-fat-diet rat models: metabolic and molecular effects of
different fat types,” Journal of Molecular Endocrinology, vol.
36, no. 3, pp. 485–501, 2006.
[126] R. Kobayasi, E. H. Akamine, A. P. Davel, M. A. M. Rodrigues,
C. R. O. Carvalho, and L. V. Rossoni, “Oxidative stress and
inflammatory mediators contribute to endothelial dysfunc-
tion in high-fat diet-induced obesity in mice,” Journal of
Hypertension, vol. 28, no. 10, pp. 2111–2119, 2010.
[127] N. Deji, S. Kume, S. I. Araki et al., “Structural and functional
changes in the kidneys of high-fat diet-induced obese mice,”
American Journal of Physiology, vol. 296, no. 1, pp. F118–
F126, 2009.
[128] L. N. Sutherland, L. C. Capozzi, N. J. Turchinsky, R. C. Bell,
and D. C. Wright, “Time course of high-fat diet-induced
reductions in adipose tissue mitochondrial proteins: poten-
tial mechanisms and the relationship to glucose intolerance,”
American Journal of Physiology, vol. 295, no. 5, pp. E1076–
E1083, 2008.
[129] F. Lei, X. N. Zhang, W. Wang et al., “Evidence of anti-
obesity effects of the pomegranate leaf extract in high-fat diet
induced obese mice,” International Journal of Obesity, vol. 31,
no. 6, pp. 1023–1029, 2007.
[130] K. L. Sweazea, M. Lekic, and B. R. Walker, “Comparison
of mechanisms involved in impaired vascular reactivity
between high sucrose and high fat diets in rats,” Nutrition &
Metabolism, vol. 7, article 48, 2010.
[131] S. M. Kim, C. W. Rico, S. C. Lee, and M. Y. Kang,
“Modulatory effect of rice bran and phytic acid on glucose
metabolism in high fat-fed C57BL/6N mice,” Journal of
Clinical Biochemistry and Nutrition, vol. 47, no. 1, pp. 12–17,
2010.
[132] C. L. Hsu, C. H. Wu, S. L. Huang, and G. C. Yen, “Phenolic
compounds rutin and o-coumaric acid ameliorate obesity
induced by high-fat diet in rats,” Journal of Agricultural and
Food Chemistry, vol. 57, no. 2, pp. 425–431, 2009.
[133] S. Panchal, H. Poudyal, A. Iyer et al., “High carbohydrate-
high fat diet-induced metabolic syndrome and cardiovascu-
lar remodeling in rats,” Journal of Cardiovascular Pharmacol-
ogy. In Press.
[134] A. Lomba, F. I. Milagro, D. F. Garcia-Diaz, A. Marti, J.
Campion, and J. A. Martinez, “Obesity induced by a pair-
fed high fat sucrose diet: methylation and expression pattern
of genes related to energy homeostasis,” Lipids in Health and
Disease, vol. 9, article 60, 2010.
[135] M.-R. Chun, Y. J. Lee, K.-H. Kim et al., “Differential effects of
high-carbohydrate and high-fat diet composition on muscle
insulin resistance in rats,” Journal of Korean Medical Science,
vol. 25, no. 7, pp. 1053–1059, 2010.
[136] R. Kohli, M. Kirby, S. A. Xanthakos et al., “High-fructose,
medium chain trans fat diet induces liver fibrosis and elevates
plasma coenzyme Q9 in a novel murine model of obesity and
nonalcoholic steatohepatitis,” Hepatology, vol. 52, no. 3, pp.
934–944, 2010.
[137] T. Murase, T. Mizuno, T. Omachi et al., “Dietary diacyl-
glycerol suppresses high fat and high sucrose diet-induced
body fat accumulation in C57BL/6J mice,” Journal of Lipid
Research, vol. 42, no. 3, pp. 372–378, 2001.
[138] P. I. Parekh, A. E. Petro, J. M. Tiller, M. N. Feinglos, and R.
S. Surwit, “Reversal of diet-induced obesity and diabetes in
C57BL/6J mice,” Metabolism, vol. 47, no. 9, pp. 1089–1096,
1998.
[139] A. Sato, H. Kawano, T. Notsu et al., “Antiobesity effect of
eicosapentaenoic acid in high-fat/high-sucrose diet-induced
obesity: importance of hepatic lipogenesis,” Diabetes, vol. 59,
no. 10, pp. 2495–2504, 2010.
[140] T. Wada, H. Kenmochi, Y. Miyashita et al., “Spironolactone
improves glucose and lipid metabolism by ameliorating hep-
atic steatosis and inflammation and suppressing enhanced
gluconeogenesis induced by high-fat and high-fructose diet,”
Endocrinology, vol. 151, no. 5, pp. 2040–2049, 2010.
[141] L. N. Axelsen, J. B. Lademann, J. S. Petersen et al., “Cardiac
and metabolic changes in long-term high fructose-fat fed
rats with severe obesity and extensive intramyocardial lipid
accumulation,” American Journal of Physiology, vol. 298, no.
6, pp. R1560–R1570, 2010.
[142] S. L. Me´nard, E. Croteau, O. Sarrhini et al., “Abnormal
in vivo myocardial energy substrate uptake in diet-induced
type 2 diabetic cardiomyopathy in rats,” American Journal of
Physiology, vol. 298, no. 5, pp. E1049–E1057, 2010.
[143] K. Couturier, C. Batandier, M. Awada et al., “Cinnamon
improves insulin sensitivity and alters the body composition
in an animal model of the metabolic syndrome,” Archives
of Biochemistry and Biophysics, vol. 501, no. 1, pp. 158–161,
2010.
Page 95
14 Journal of Biomedicine and Biotechnology
[144] A. N. Madsen, G. Hansen, S. J. Paulsen et al., “Long-term
characterization of the diet-induced obese and diet-resistant
rat model: a polygenetic rat model mimicking the human
obesity syndrome,” Journal of Endocrinology, vol. 206, no. 3,
pp. 287–296, 2010.
[145] B. E. Levin, A. A. Dunn-Meynell, B. Balkan, and R. E. Keesey,
“Selective breeding for diet-induced obesity and resistance
in Sprague-Dawley rats,” American Journal of Physiology, vol.
273, no. 2, pp. R725–R730, 1997.
[146] B. Martin, S. Ji, S. Maudsley, and M. P. Mattson, “”Control”
laboratory rodents are metabolically morbid: why it matters,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 107, no. 14, pp. 6127–6133, 2010.
[147] A. M. Zivkovic, J. B. German, and A. J. Sanyal, “Comparative
review of diets for the metabolic syndrome: implications for
nonalcoholic fatty liver disease,” American Journal of Clinical
Nutrition, vol. 86, no. 2, pp. 285–300, 2007.
[148] S. Kajikawa, K. Imada, T. Takeuchi et al., “Eicosapentaenoic
acid attenuates progression of hepatic fibrosis with inhibition
of reactive oxygen species production in rats fed methionine-
and choline-deficient diet,” Digestive Diseases and Sciences. In
press.
[149] H. Nakagami, M. K. Osako, F. Nakagami et al., “Prevention
and regression of non-alcoholic steatohepatitis (NASH) in
a rat model by metabosartan, telmisartan,” International
Journal of Molecular Medicine, vol. 26, no. 4, pp. 477–481,
2010.
[150] S. Chung, C. W. Park, S. J. Shin et al., “Tempol or candesartan
prevents high-fat diet-induced hypertension and renal dam-
age in spontaneously hypertensive rats,” Nephrology Dialysis
Transplantation, vol. 25, no. 2, pp. 389–399, 2010.
[151] S. F. Knight, J. Yuan, S. Roy, and J. D. Imig, “Simvastatin
and tempol protect against endothelial dysfunction and renal
injury in a model of obesity and hypertension,” American
Journal of Physiology, vol. 298, no. 1, pp. F86–F94, 2010.
[152] S. J. Shin, J. H. Lim, S. Chung et al., “Peroxisome proliferator-
activated receptor-α activator fenofibrate prevents high-fat
diet-induced renal lipotoxicity in spontaneously hyperten-
sive rats,” Hypertension Research, vol. 32, no. 10, pp. 835–845,
2009.
[153] F. Chaabo, A. Pronczuk, E. Maslova, and K. Hayes, “Nutri-
tional correlates and dynamics of diabetes in the Nile
rat (Arvicanthis niloticus): a novel model for diet-induced
type 2 diabetes and the metabolic syndrome,” Nutrition &
Metabolism, vol. 7, article 29, 2010.
[154] K. Noda, M. I. Melhorn, S. Zandi et al., “An animal model
of spontaneous metabolic syndrome: nile grass rat,” FASEB
Journal, vol. 24, no. 7, pp. 2443–2453, 2010.
Page 96
ORIGINAL ARTICLE
High-carbohydrate, High-fat Diet–induced Metabolic
Syndrome and Cardiovascular Remodeling in Rats
Sunil K. Panchal, MSc,* Hemant Poudyal, MBiotech,† Abishek Iyer, MMolBiol,† Reeza Nazer, BSc,†
Md.Ashraful Alam, MSc,† Vishal Diwan, MPharm,† Kathleen Kauter, PhD,* Conrad Sernia, PhD,†
Fiona Campbell, PhD,‡ Leigh Ward, PhD,§ Glenda Gobe, PhD,¶ Andrew Fenning, PhD,k
and Lindsay Brown, PhD*†
Abstract: The prevalence of metabolic syndrome including central
obesity, insulin resistance, impaired glucose tolerance, hypertension,
and dyslipidemia is increasing. Development of adequate therapy for
metabolic syndrome requires an animal model that mimics the human
disease state. Therefore, we have characterized the metabolic, car-
diovascular, hepatic, renal, and pancreatic changes in male Wistar rats
(8–9 weeks old) fed on a high-carbohydrate, high-fat diet including
condensed milk (39.5%), beef tallow (20%), and fructose (17.5%)
together with 25% fructose in drinking water; control rats were fed
a cornstarch diet. During 16 weeks on this diet, rats showed pro-
gressive increases in body weight, energy intake, abdominal fat
deposition, and abdominal circumference along with impaired glu-
cose tolerance, dyslipidemia, hyperinsulinemia, and increased plasma
leptin and malondialdehyde concentrations. Cardiovascular signs
included increased systolic blood pressure and endothelial dys-
function together with inflammation, fibrosis, hypertrophy, increased
stiffness, and delayed repolarization in the left ventricle of the heart.
The liver showed increased wet weight, fat deposition, inflammation,
and fibrosis with increased plasma activity of liver enzymes. The
kidneys showed inflammation and fibrosis, whereas the pancreas
showed increased islet size. In comparison with other models of
diabetes and obesity, this diet-induced model more closely mimics the
changes observed in human metabolic syndrome.
Key Words: metabolic syndrome, obesity, cardiovascular disease,
hypertension, dyslipidemia, high-carbohydrate, high-fat diet
(J Cardiovasc PharmacolTM 2011;57:611–624)
INTRODUCTION
Cardiovascular disease and type 2 diabetes remain
major public health challenges.1 Metabolic syndrome as the
clustering of risk factors for cardiovascular disease and type 2
diabetes increases cardiovascular mortality.2–5 These risk
factors include central obesity, elevated blood pressure,
impaired glucose tolerance, insulin resistance, and dyslipide-
mia.6,7 The initiation of symptoms of metabolic syndrome
has been linked to high-carbohydrate, high-fat diet–induced
oxidative stress.8 Oxidative stress along with chronic low-
grade inflammation, induced by sugars and lipids,9 may
initiate changes in cardiovascular structure and function such
as endothelial dysfunction, cardiac hypertrophy, cardiac
fibrosis, and ventricular contractile dysfunction.10–13
Understanding the causes and progression of metabolic
syndrome leading to cardiovascular disease is the foundation
for the development of better pharmacological interventions
for metabolic syndrome and cardiovascular disease. Appro-
priate animal models, mimicking the human pathogenesis of
metabolic syndrome leading to cardiovascular disease, are
therefore necessary to investigate the causes and progression
of disease and potential pharmacological interventions.14,15
There are several spontaneous (genetic) rodent models of
metabolic syndrome with cardiovascular complications,
including Zucker diabetic fatty rats,16,17 Goto-Kakizaki rats,18
spontaneously hypertensive rats,19 and Otsuka Long Evans
Tokushima fatty rats.20 The most commonly used nongenetic
rodent models of diabetes are those induced by death of
pancreatic b cells by streptozotocin or alloxan.21 Although
these models may provide useful information on the causes
and treatment of some aspects of metabolic syndrome, they are
unlikely to be relevant to the diet-induced human metabolic
syndrome.22
Rats fed on high-carbohydrate diets, for example, with
sucrose23 or fructose,24 developed hypertension, dyslipidemia,
and impaired glucose tolerance, but failed to develop central
obesity while the structural and functional changes in the
cardiovascular system were not addressed. In contrast, high-fat
diets in rats induced marked central obesity and dyslipide-
mia,25 but human diets causing metabolic syndrome are much
more complex than a high-fat diet. Thus, a combination of
high carbohydrate with high fat in the diet may be more
relevant to mimic the diet responsible for human metabolic
syndrome and cardiovascular complications as a basis to
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investigate potential interventions. High-carbohydrate, high-fat
diets (HCHF) in rats induced the symptoms of metabolic
syndrome such as hypertension, dyslipidemia, impaired glucose
tolerance, excess fat deposition, increased proinflammatory
markers, and decreased antioxidant defenses.8,26,27 Although
these studies have defined the biochemical changes, the
structural and functional changes in the cardiovascular system,
liver, kidneys, and pancreas are yet to be thoroughly addressed.
Therefore, the aim of this study was to define the structural and
functional changes in heart, thoracic aorta, liver, kidneys, and
pancreas in presence of metabolic syndrome.
This study has characterized structural changes in the
heart by echocardiography and histopathology, while heart
function was assessed in vivo using echocardiography and ex
vivo in isolated perfused hearts. Single-cell microelectrode
studies were performed on isolated left ventricular papillary
muscles to quantify the changes in electrical conductance.
Isolated thoracic aortic rings were used to measure vascular
reactivity. Histological and biochemical parameters were
assessed to define structural and functional changes in the
liver, kidneys, and pancreas.
MATERIALS AND METHODS
Diet-induced Metabolic Syndrome in Rats
All experimental protocols were approved by The
University of Queensland Animal Experimentation Ethics
Committee, under the guidelines of the National Health and
Medical Research Council of Australia. Male Wistar rats (8–9
weeks old, weighing 331 6 6 g, n = 77) were obtained from
The University of Queensland Biological Resources facility.
The rats were randomly divided into 3 experimental groups
and were fed with chow diet (n = 21), cornstarch diet (CS;
n = 21) or HCHF diet (n = 35). Thirteen rats from HCHF group
were euthanized after 8 weeks of feeding to assess the
progression of pathophysiological changes and the remaining
rats continued with the HCHF diet for a further 8 weeks; total
feeding time was 16 weeks. The CS group was fed for
16 weeks. The CS diet contained 570 g of cornstarch, 155 g of
powdered rat food (Specialty Feeds, Glen Forest, Western
Australia, Australia; all nutritional parameters of this diet meet
or exceed the National Research Council, Canada, guidelines
for rats and mice), 25 g of Hubble, Mendel, and Wakeman salt
mixture,28 and 250 g of water per kilogram of diet. HCHF diet
consisted of 175 g of fructose, 395 g of sweetened condensed
milk, 200 g of beef tallow, 155 g of powdered rat food, 25 g of
Hubble, Mendel and Wakeman salt mixture, and 50 g of water
per kilogram of diet. In addition, the drinking water for the
HCHF group was supplemented with 25% fructose. Chow-fed
rats were fed powdered rat food (Specialty Feeds; all
nutritional parameters of this diet meet or exceed the National
Research Council, Canada, guidelines for rats and mice). Rats
were given ad libitum access to food and water and were
individually housed in a temperature-controlled 12-hour light–
dark conditions. Energy intake was calculated from the
following values in kilojoules per gram: fructose, 15.40; CS,
15.94; condensed milk, 13.80; beef tallow, 37.70; and
powdered rat food, 13.80. The energy densities of the CS
diet and the HCHF diet were 11.23 kJ/g and 17.83 kJ/g of
food, respectively, and an additional 3.85 kJ/mL in the
drinking water for the HCHF diet–fed rats.
Physiological Parameters
Body weight and food and water intakes were measured
daily. Oral glucose tolerance tests were performed every fourth
week after determining overnight fasting blood glucose
concentrations in tail vein blood using Medisense Precision
Q.I.D. glucose meters (Abbott Laboratories, Bedford, MA).
For overnight fasting, rats were deprived of all types of diets
for 12 hours. Fructose-supplemented drinking water in HCHF
groups was replaced with normal drinking water for the
overnight food deprivation period. Rats were given a glucose
load of 2 g/(kg body weight) as 40% glucose solution via oral
gavage, and blood glucose concentrations were measured
again 30, 60, 90, and 120 minutes after oral glucose
administration. Abdominal circumference and body length
(nose to anus) were measured every fourth week using
a standard measuring tape under light anesthesia with Zoletil
[tiletamine 10 mg/kg, zolazepam 10 mg/kg, intraperitoneal
(IP); Virbac, Peakhurst, New South Wales, Australia]. Body
mass index (BMI) was calculated as body weight (in
grams)/[body length (in centimeters)]2.29 Feed efficiency
was calculated as [mean body weight gain (in grams)/daily
energy intake (in kilojoules)].29 Rectal temperature was
measured using a digital thermometer lubricated with a smear
of Xylocaine jelly (lidocaine; AstraZeneca Pty Ltd, New South
Wales, Australia).
Body Composition Measurements
Dual-energy X-ray absorptiometric (DXA) measure-
ments were performed on the rats after 8 and 16 weeks of
feeding (2 days before rats were euthanized for pathophys-
iological assessments) using a Norland XR36 DXA instrument
(Norland Corp, Fort Atkinson, WI). DXA scans were analyzed
using the manufacturer’s recommended software for use in
laboratory animals (Small Subject Analysis Software, version
2.5.3/1.3.1; Norland Corp) as previously described.30 The
precision error of lean mass for replicate measurements, with
repositioning, was 3.2%.
Experimental Protocol
Ten rats from each group were used for isolated
Langendorff preparations and vascular reactivity studies,
and 3 rats per group were taken exclusively for histopatho-
logical analysis. Eight chow-fed rats, 8 rats from the CS group,
and 9 rats from the HCHF group (all 16 weeks) were used for
single-cell microelectrode studies. For terminal experiments,
rats were euthanized with Lethabarb (pentobarbitone sodium,
100 mg/kg, IP; Virbac). After euthanasia, heparin (200 IU;
Sigma-Aldrich Australia, Sydney, New South Wales, Aus-
tralia) was injected through the right femoral vein. The
abdomen was then opened and blood (;6 mL) was withdrawn
from the abdominal aorta and collected into heparinized tubes.
One milliliter of blood was stored at 4C, and the remaining
blood was centrifuged at 5,000g for 15 minutes to obtain
plasma. Plasma was stored at 220C for further character-
ization. Hearts were removed from rats for isolated
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Langendorff preparation, and thoracic aorta was used for
vascular reactivity studies as described below. Liver, kidney,
and fat pads were removed from these rats and weighed. After
perfusion studies, right ventricles from the hearts were
removed and weighed, whereas the left ventricle (LV) was
weighed with septum. Weights of these organs were
normalized relative to the tibial length at the time of removal
(expressed as tissue weight in milligram per millimeter tibial
length). Heart, liver, kidney, and pancreas from the rats used
for histopathological analysis were removed and fixed in
appropriate solutions.
Cardiovascular Structure and Function
Systolic blood pressure of rats was measured every
fourth week under light sedation with Zoletil (tiletamine
10 mg/kg, zolazepam 10 mg/kg, IP), using an MLT1010
Piezo-Electric Pulse Transducer (ADInstruments, Sydney,
New South Wales, Australia) and inflatable tail-cuff connected
to an MLT844 Physiological Pressure Transducer (ADInstru-
ments) and PowerLab data acquisition unit (ADInstruments).
Echocardiographic examination (Phillips iE33, 12-MHz
transducer) was performed as previously described31 in all rats
after 8 and 16 weeks of feeding. Briefly, rats were anesthetized
using Zoletil (tiletamine 25 mg/kg and zolazepam 25 mg/kg,
IP) and Ilium Xylazil (xylazine 15 mg/kg, IP; Troy
Laboratories, Smithfield, New South Wales, Australia) and
positioned in dorsal recumbency. Electrodes attached to the
skin overlying the elbows and right stifle facilitated the
simultaneous recording of a lead II electrocardiogram (ECG).
A short-axis view of the LV at the level of the papillary
muscles was obtained and used to direct acquisition of M-
mode images of the LV for measurement of interventricular
septum in diastole, diastolic posterior wall thickness
(LVPWd), internal systolic dimensions, and end-diastolic
dimension (LVIDd). Measurements were taken in accordance
with the guidelines of the American Society of Echocardiog-
raphy using the leading-edge method.32 For these parameters,
diastole was defined by the beginning of the QRS complex on
the simultaneously recorded ECG and systole identified as the
nadir of systolic anterior wall motion independent of the ECG
complex.
Pulsed-wave Doppler velocity profiles of mitral inflow
were obtained from the left apical 4-chamber view for
measurement of early (EM) and late (AM) mitral inflow
velocity, mitral inflow E-wave deceleration time, and time
from mitral valve closure to opening. A pulsed-wave Doppler
velocity profile of the ascending aorta was obtained from
a suprasternal view for measurement of ejection time and the
diameter of the ascending and descending aorta at the point of
transition to the transverse aorta.
Derived indices of LV systolic function (fractional
shortening and ejection fraction) were calculated using well-
established formulas.31 Left ventricular mass was estimated
using the standard cube equation as modified by Litwin et al33:
Left ventricular mass (in grams) = [1.04 (IVSDd + LVIDd +
LVPWd)32 (LVIDd)3]3 0.8 + 0.14, where 1.04 is the specific
gravity of muscle, IVSDd is interventricular septum diameter
in diastole (in centimeters), LVIDd is left ventricular internal
diameter in diastole (in centimeters), and LVPWd is left
ventricular posterior wall thickness in diastole (in centi-
meters). Multiplication factor of 0.8 and the addition factor of
0.14 are constants similar to those used in the anatomically
validated Devereux correction for American Society for
Echocardiography dimensions in humans, which allow more
accurate prediction of LV mass in rats.33
The isolated Langendorff heart preparation was used to
assess left ventricular function of the rats in all the groups as in
previous studies.34–36 Hearts isolated from euthanized rats
were perfused with modified Krebs–Henseleit bicarbonate
buffer, containing (in millimolar): NaCl, 119.1; KCl, 4.75;
MgSO4, 1.19; KH2PO4, 1.19; NaHCO3, 25.0; glucose, 11.0;
and CaCl2, 2.16. Buffer was bubbled with 95% O2–5% CO2
and maintained at 35C. Isovolumetric ventricular function
was measured by inserting a latex balloon catheter into the LV
connected to a Capto SP844 MLT844 physiological pressure
transducer and Chart software on a Maclab system (ADInstru-
ments). All left ventricular end-diastolic pressure values were
measured during pacing of the heart at 250 beats per minute
using an electrical stimulator. End-diastolic pressures were
obtained from 0 up to 30 mmHg for calculation of diastolic
stiffness constant (k, dimensionless) as described in previous
studies.34–36
Microelectrode studies were performed on isolated left
ventricular papillary muscles quickly dissected in cold Tyrode
physiological salt solution (in millimolar: NaCl, 136.9; KCl,
5.4; MgCl2H2O, 1.0; NaH2PO42H2O, 0.4; NaHCO3, 22.6;
CaCl22H2O, 1.8; glucose, 5.5; ascorbic acid, 0.3; and
ethylenediaminetetraacetic acid, 0.05) bubbled with 95%
O2–5% CO2. Action potential duration (APD) at 20%, 50%,
and 90% of repolarization, action potential amplitude, resting
membrane potential, and force of contraction were measured
as in previous studies.35,36
Thoracic aortic rings (4 mm in length) were suspended
in an organ bath filled with Tyrode physiological salt solution
bubbled with 95% O2–5% CO2 and maintained at 35C and
allowed to stabilize at a resting tension of 10 mN.35,36
Cumulative concentration–response curves (contraction) were
obtained for norepinephrine (Sigma-Aldrich Australia), and
cumulative concentration–response curves (relaxation) were
obtained for acetylcholine (Sigma-Aldrich Australia) and
sodium nitroprusside (Sigma-Aldrich Australia) after sub-
maximal (70%) contraction to norepinephrine.35,36
Hearts were processed by 2 different procedures for
histopathological studies. For picrosirius red staining, hearts
were initially fixed for 3 days in Telly fixative (85 mL of 70%
ethanol, 5 mL of glacial acetic acid, and 10 mL of 40%
formaldehyde) and then transferred into modified Bouin fluid
(85 mL of saturated picric acid, 5 mL of glacial acetic acid, and
10 mL of 40% formaldehyde) for 2 days. The samples were then
dehydrated and embedded in paraffin wax. Collagen deposition
in the LV was observed after staining with picrosirius red
(magnification340) and analyzed by laser confocal microscopy
(Zeiss LSM 510 upright Confocal Microscope).35 Color
intensity was quantified using NIH-imageJ software (National
Institutes of Health, Bethesda, MD) to determine the extent of
collagen deposition in selected tissue sections. Results are
presented as mean 6 standard error of the mean (SEM) of the
area of view. For other staining, hearts were fixed in 10% neutral
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buffered formalin for 3 days. The samples were then dehydrated
and embedded in paraffin wax. Thin sections (5 mm) of LV were
cut and stained with hematoxylin and eosin to study infiltration
of inflammatory cells and with toluidine blue to study mast cells.
After staining, pictures were taken with a Zeiss Microscope
(magnification 340).
Oxidative Stress Markers
Erythrocyte Reactive Oxygen Species Production
Heparinized blood stored at 4C was used 2 days after
withdrawal to measure the production of reactive oxygen
species by erythrocytes using a fluorometric assay based on the
oxidation of the fluorochrome 2#,7#-dichloroflourescein-
diacetate (DCFH-DA; Sigma-Aldrich Australia).37 Plasma
was removed from blood by washing with 1:9 phosphate-
buffered saline, followed by centrifugation at 1500g for 5
minutes. The supernatant was removed, and the packed
erythrocytes were diluted with phosphate-buffered saline to
a final content of 1% erythrocytes. Aliquots of 50 mL of this
erythrocyte suspension were added to a microtitre plate
followed immediately by 50 mL of 100 mM DCFH-DA. The
rate at which DCFH-DA was oxidized by intracellular reactive
oxygen species to 2#,7#-dichlorofluorescein was determined
fluorometrically by reading the microtitre plate with a SPEC-
TRAMax M2 spectrofluorometer set at Ex484/Em535. Fluo-
rescence was measured at 0, 30, 60, 120, and 180 minutes. The
data were expressed in arbitrary fluorescence units.
Plasma Marker of Oxidative Stress
Plasma concentrations of malondialdehyde were deter-
mined by high-performance liquid chromatography (Shimadzu,
Kyoto, Japan).38
Metabolic Parameters and Plasma
Inflammatory Marker
Activities of aspartate transaminase (AST), alanine
transaminase (ALT), alkaline phosphatase (ALP), lactate
dehydrogenase (LDH), and creatine kinase and concentrations
of total cholesterol, triglycerides, nonesterified fatty acids
(NEFA), uric acid, creatinine, urea, total bilirubin, albumin:-
globulin ratio, sodium (Na+), potassium (K+), calcium (Ca2+),
and chloride (Cl2) in plasma were measured. Plasma
enzymatic activities and analyte concentrations were de-
termined using kits and controls supplied by Olympus using an
Olympus analyzer (AU 400; Tokyo, Japan): LDH, Olympus
OSR6127 kinetic UV test; ALT, Olympus OSR6107 kinetic
UV test; AST, Olympus OSR6109 kinetic UV test; total
plasma cholesterol, Olympus OSR6516 enzymatic color test;
plasma triglycerides, Olympus OSR6133 enzymatic color test;
urea, Olympus OSR6134 kinetic UV test; uric acid, Olympus
OSR6098 enzymatic color test; albumin, Olympus OSR 6101
photometric color test; and total bilirubin, Olympus OSR 6111
photometric color test. Globulin was calculated as total protein2
albumin; NEFA were determined using a commercial kit
(Wako, Osaka, Japan). Plasma C-reactive protein (CRP)
concentrations were estimated using commercial kits (Kamiya
Biomedical, Thousand Oaks, CA) according to manufacturer-
provided standards and protocols using a Cobas-Mira
automated analyzer (Roche Diagnostics, Basel, Switzerland).
Plasma insulin (Laboratory Diagnostics, Kurnell, New South
Wales, Australia) and leptin and corticosterone (both Quantum
Scientific, Murarrie, Queensland, Australia) were measured
using commercial kits according to manufacturer-provided
standards and protocols using Titertek Multiskan MCC/340
spectrophotometer (Flow Laboratories, Irvine, Scotland).
Structural Changes in Liver, Kidney,
and Pancreas
Liver, kidneys, and pancreas were fixed with 10%
neutral buffered formalin for 3 days. These tissue samples
were dehydrated and then embedded in paraffin wax. Thin
sections (5 mm) of these tissues were cut and stained with
hematoxylin and eosin for determining inflammatory cell
infiltration and for determining the fat vacuoles in liver. Liver
sections were also stained with Milligan’s stain to determine
collagen deposition and with oil red ‘‘O’’ to determine fat
droplets.
Fixed kidney tissues were embedded in paraffin, and
4 mm sections were cut onto glass slides. Routine histological
stains used were hematoxylin and eosin for general histology
and Masson’s trichrome for assessment of collagen deposition.
For quantification of collagen, Masson’s trichrome–stained
slides were visualized using a Nikon Eclipse 50i microscope
(Kanagawa, Japan) fitted with a DSFi1 camera, and images
were captured directly digitally (magnification 3200). NIS
Elements software was used for morphometrical analysis. All
color parameters were kept constant for each section. The NIS
Elements software automatically calculates the area of blue-
stained color in each of the areas selected, which were all
284,023 mm2. For each kidney section, 10 randomly placed
fields in the cortex were analyzed separately. Positive areas
around large vessels were removed digitally from the
morphometric assessment. Results are presented as mean 6
SEM of the Masson’s trichrome-positive percentage of the area
of view.
Pancreatic sections were stained with aldehyde fuchsin
staining after pretreatment with potassium permanganate
(0.5%) and hematoxylin and eosin staining to determine
infiltration of inflammatory cells. After staining, tissues were
mounted and pictures were taken with a Zeiss Microscope
(magnification 340 for hematoxylin and eosin and 320 for
aldehyde fuchsin, oil red ‘‘O,’’ and Milligan’s stain). Islet area
was quantified using NIH-imageJ software (National Institutes
of Health). Results are presented as mean 6 SEM of the area
of view. The a and b cells in 12 islets were counted in each rat
using NIH-imageJ software. Numbers of these cells are
presented as mean 6 SEM per islet.
Statistical Analysis
All data are presented as mean 6 SEM. Differences
between the groups were determined by 1-way analysis of
variance. Statistically significant variables were treated with
Neumann–Keuls post hoc test to compare all the groups of
animals. All statistical analyses were performed using
GraphPad Prism version 5 for Windows (San Diego, CA).
P value of ,0.05 was considered as statistically significant.
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RESULTS
Food Intake, Water Intake, Body Weight, and
Compositional Changes
Although mean daily food and water intakes were
reduced (Table 1), HCHF diet–fed rats showed higher body
weight (Fig. 1A), mean daily energy intake, and feed
efficiency (Table 1) compared with CS diet–fed rats after
16 weeks. Abdominal circumference (Fig. 1B), nose to anus
length, and BMI (Table 1) were greater for HCHF diet–fed rats
than for the CS diet–fed rats after 16 weeks. Abdominal fat
fads (Table 1) were unchanged and doubled after 8 and
16 weeks, respectively, in HCHF diet–fed rats compared with
CS diet–fed rats. Whole-body fat mass (Fig. 1C) was increased
by 126% 6 7% in HCHF diet–fed rats compared with CS
diet–fed rats after 16 weeks, whereas the whole-body lean
mass (Fig. 1D) was increased by only 11.6%6 0.6% in HCHF
diet–fed rats. Rectal temperature was unchanged between the
groups (Table 1). Values from age-matched rats fed standard
rat chow showed values intermediate between CS diet– and
HCHF diet–fed rats with a greater increase in total and lean
body mass (Table 1, Fig. 1).
Cardiovascular Structure and Function
Echocardiographic assessment of HCHF diet–fed rats
showed ventricular dilation (increased left ventricular end-
diastolic dimensions), increased systolic volume, and increased
estimated left ventricular mass. However, indices of left
ventricular function, mainly fractional shortening and ejection
fraction, were decreased in HCHF diet–fed rats when compared
with CS diet– or chow-fed rats after 16 weeks (Table 2).
Many inflammatory cells were observed in the LV of
HCHF diet–fed rats, whereas the number of inflammatory
cells in LV of CS diet– or chow-fed rats was very low (Fig. 2).
Increased numbers of mast cells were found in the LV of
HCHF diet–fed rats with an increased number of degranulated
mast cells (Fig. 2). Both perivascular and interstitial collagen
contents in LV were increased in HCHF diet–fed rats
compared with CS diet– or chow-fed rats (Fig. 2). HCHF
diet–fed rats also showed hypertrophy of cardiomyocytes
(Fig. 2). The isolated Langendorff heart preparation showed
increased diastolic stiffness in HCHF diet–fed rats at both
8 and 16 weeks compared with CS diet– or chow-fed rats
(Table 2). Systolic blood pressure in HCHF diet–fed rats was
increased at all measurement times up to 16 weeks compared
with CS diet–fed or chow-fed rats (Table 2).
Single-cell microelectrode studies in isolated left
ventricular papillary muscles of HCHF diet–fed rat hearts
showed an increased APD at 50% and 90% of repolarization
when compared with CS diet– or chow-fed rat hearts (Table 3).
The resting membrane potential was decreased in HCHF diet–
fed rats when compared with CS diet (Table 3) with the action
potential amplitude and force of contraction being unaffected
(Table 3).
Thoracic aorta isolated from HCHF diet– or chow-fed
rats showed reduced acetylcholine-induced vascular relaxation
compared with thoracic aorta from CS diet–fed rats,
suggesting endothelial dysfunction with HCHF diet or chow
feeding (Fig. 3A). The responses to norepinephrine and
sodium nitroprusside were decreased in HCHF diet–fed rats
compared with CS diet– or chow-fed rats, suggesting smooth
muscle dysfunction (Figs. 3B, C).
Oxidative Stress and Plasma
Inflammatory Marker
In HCHF diet–fed rats, the production of reactive
oxygen species by erythrocytes over 180 minutes was almost
double that of the CS diet– or chow-fed rats (Fig. 4A). Plasma
malondialdehyde concentrations were increased in HCHF
diet–fed rats in comparison with CS diet– or chow-fed rats
(Table 4). Plasma concentrations of CRP were higher with
HCHF diet after 16 weeks compared with CS diet– or chow-
fed rats (Table 4).
Metabolic Changes
Fasting blood glucose concentrations were not different
between the 2 groups after 8 weeks and 16 weeks of feeding
(Table 4). After glucose loading, blood glucose concentrations
in CS diet– or chow-fed rats decreased rapidly and returned to
fasting glucose concentrations 2 hours after glucose loading.
In HCHF (16 weeks) diet–fed rats, blood glucose concen-
trations were higher than the fasting blood glucose concen-
tration after 2 hours of glucose loading (Fig. 4B). Plasma
concentrations of insulin were unchanged with HCHF diet
after 8 weeks but increased after 16 weeks in comparison with
CS diet– or chow-fed rats (Table 4). Plasma leptin concen-
trations were increased with HCHF diet compared with CS
diet or chow feeding as early as 8 weeks. There was no
TABLE 1. Physiological Parameters in Chow-fed (16 Weeks), CS (16 Weeks), HCHF (8 Weeks), and HCHF (16 Weeks) Groups
Variables Chow-fed (16 wk) CS (16 wk) HCHF (8 wk) HCHF (16 wk)
Food intake, g/d 27.9 6 0.6b 31.9 6 0.6a 19.8 6 0.5c 20.9 6 0.3c
Water intake, mL/d 45.5 6 1.7a 31.8 6 0.5b 17.9 6 0.6c 18.3 6 0.3c
Energy intake, kJ/d 385 6 8b 364 6 9b 425 6 11a 443 6 7a
Feed efficiency, g/kJ 0.64 6 0.04a 0.21 6 0.02c 0.23 6 0.02c 0.40 6 0.02b
Nose to anus length, cm 26.7 6 0.7a 24.1 6 0.2c 24.9 6 0.3b 25.7 6 0.2ab
BMI, g/cm2 0.79 6 0.01a 0.66 6 0.01c 0.69 6 0.01b 0.78 6 0.01a
Abdominal fat pads, mg/mm 464 6 34b 395 6 30b 501 6 46b 799 6 57a
Rectal temperature, C 38.6 6 0.2 38.7 6 0.1 38.4 6 0.2 38.7 6 0.1
All data are presented as mean 6 SEM and n = 10 for each group. Mean values within a row with unlike superscript letters are significantly different (P , 0.05).
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FIGURE 1. Changes in body weight
(A), abdominal circumference (B),
whole-body fat mass (C), and
whole-body lean mass (D) in
chow-fed rats (16 weeks), CS (16
weeks), HCHF (8 weeks), and HCHF
(16 weeks) rats. Mean values with
an unlike superscript letter are
significantly different (P , 0.05).
TABLE 2. Cardiovascular Structure and Function in Chow-fed (16 Weeks), CS (16 Weeks), HCHF (8 Weeks), and HCHF
(16 Weeks) Groups
Variables Chow-fed (16 wk) CS (16 wk) HCHF (8 wk) HCHF (16 wk)
LVIDd, mm 7.01 6 0.16b 6.61 6 0.12b 6.79 6 0.10b 7.46 6 0.11a
LVIDs, mm 3.52 6 0.13c 3.31 6 0.18c 4.04 6 0.11b 4.60 6 0.09a
LVPWd, mm 2.81 6 0.16 2.69 6 0.14 2.72 6 0.13 2.85 6 0.15
Systolic volume, mL 0.08 6 0.01b 0.06 6 0.00b 0.07 6 0.00b 0.10 6 0.00a
Relative wall thickness 0.50 6 0.02 0.48 6 0.01 0.52 6 0.01 0.48 6 0.02
Ascending aorta diameter, mm 0.84 6 0.05 0.82 6 0.03 0.87 6 0.04 0.87 6 0.06
Descending aorta diameter, mm 0.73 6 0.04 0.73 6 0.05 0.78 6 0.03 0.77 6 0.05
Fractional shortening, % 56.4 6 2.0a 52.6 6 1.3a 44.9 6 2.2b 38.3 6 1.4c
Ejection fraction, % 84.1 6 2.2ab 86.9 6 1.6a 79.7 6 0.7b 72.1 6 1.3c
Ejection time, ms 90.7 6 2.3 91.1 6 1.9 92.9 6 2.9 87.9 6 2.6
Deceleration time, ms 53.6 6 2.2 52.1 6 2.0 47.7 6 1.5 55.5 6 2.9
EM, m/s 0.68 6 0.02 0.69 6 0.03 0.69 6 0.03 0.69 6 0.02
AM, m/s 0.41 6 0.03 0.38 6 0.03 0.47 6 0.03 0.44 6 0.03
MCMO, ms 113 6 3 114 6 4 111 6 3 114 6 4
Estimated LV mass, g 0.71 6 0.04c 0.67 6 0.02c 0.82 6 0.03b 0.97 6 0.04a
LV + septum wet weight, mg/mm 21.3 6 0.9 18.9 6 0.9 19.4 6 0.7 21.8 6 1.2
Right ventricular wet weight, mg/mm 4.59 6 0.30 4.14 6 0.27 4.49 6 0.29 4.48 6 0.37
Interstitial LV fibrosis, % surface area 5.2 6 0.9c 4.8 6 0.5c 14.6 6 1.4b 19.9 6 1.2a
Perivascular LV fibrosis, % surface area 20.7 6 3.6b 21.2 6 1.6b 31.2 6 2.6a 35.3 6 3.0a
LV diastolic stiffness constant, k 24.6 6 1.8b 20.8 6 1.4b 26.3 6 2.2b 27.7 6 1.4a
Systolic blood pressure, mmHg 125 6 7b 120 6 4b 144 6 4a 153 6 5a
All data are presented as mean 6 SEM and n = 10 for each group. Mean values within a row with unlike superscript letters are significantly different (P , 0.05). LVIDs, left
ventricular internal systolic dimension; MCMO, time from mitral valve closure to opening; ms, milliseconds.
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difference in plasma leptin concentrations between HCHF diet
groups fed for 8 and 16 weeks (Table 4). Plasma corticosterone
concentrations were unchanged between the groups (Table 4).
Plasma concentrations of triglycerides, total cholesterol, and
NEFAwere higher in HCHF diet–fed group compared with CS
diet–fed group (Table 4). Plasma concentrations of uric acid
were higher in HCHF diet–fed rats compared with CS diet– or
chow-fed rats, whereas no change was observed in the plasma
FIGURE 2. Inflammation and fibrosis in the heart. Picrosirius red staining of left ventricular perivascular and interstitial collagen
deposition (340) in chow-fed rats (16 weeks) (A, E), CS (16 weeks) (B, F), HCHF (8 weeks) (C, G), HCHF (16 weeks) (D, H);
perivascular fibrosis is marked as ‘‘pf,’’ interstitial fibrosis is marked as ‘‘if’’ and hypertrophied cardiomyocytes are marked as ‘‘hy.’’
Hematoxylin and eosin staining of LV of the heart (340) showing infiltration of inflammatory cells (‘‘in’’ represents inflammatory cells)
as dark spots surrounding the myocytes; chow-fed rats (16 weeks) (I), CS (16 weeks) (J), HCHF (8 weeks) (K), HCHF (16 weeks) (L).
Toluidine blue staining (340) of LV showing presence of mast cells in chow-fed rats (16 weeks) (M), CS (16 weeks) (N), HCHF
(8 weeks) (O), HCHF (16 weeks) (P); mast cells are marked as ‘‘mc’’ and degranulated mast cells are marked as ‘‘dmc.’’
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albumin:globulin ratio between the groups and plasma
concentrations of bilirubin were lowered in chow-fed rats
(Table 4).
Hepatic Structure and Function
Livers from HCHF diet– and chow-fed rats were higher
in wet weight compared with CS diet–fed rats (Table 5). In the
liver as in the LV, HCHF diet–fed rats showed increased
infiltration of inflammatory cells and increased deposition of
collagen around the blood vessels compared with CS diet– or
chow-fed rats (Fig. 5). HCHF diet–fed rats showed deposition
of fat droplets in liver, which were rarely visible in livers from
CS diet–fed rats (Fig. 5). Also, the size of fat vacuoles was
larger in HCHF diet–fed rats (Fig. 5). Similarly, HCHF diet
resulted in increased plasma activity of AST, ALT, ALP, and
LDH compared with CS diet–fed rats, although plasma AST
was higher in chow-fed rats (Table 5).
Renal and Pancreatic Structure and Function
HCHF diet– and chow-fed rats showed increased wet
weight of kidneys in comparison with CS diet–fed rats (Table 5).
There were no anomalies in the kidneys of the CS diet–fed rats.
The Masson’s trichrome-positive tissue in these sections was
2.27% 6 0.64%. Kidney sections from HCHF diet–fed rats
showed glomerular and tubular damage, including lysis of the
glomerular tuft that was seen in more than 50% of the glomeruli,
and tubular lesions consisted of hyaline and/or vacuolar
degeneration and single-cell necrosis. There was also increased
Masson’s trichrome-positive tissue (10.13%6 2.76%), mainly
in an expanded interstitial space and in the tubular and
glomerular basement membranes (Fig. 6). There were no
changes in the plasma concentrations of creatinine, Na+, and
Cl2 between the 2 groups, but plasma K+ concentrations were
increased and urea concentrations were decreased in HCHF
diet–fed rats compared with CS diet– or chow-fed rats (Table 5).
Pancreas from HCHF diet–fed rats showed an increased
number of inflammatory cells (Fig. 7) with increased size of
islets of Langerhans (15.3% 6 1.5% area) compared with CS
diet– or chow-fed rats (6.2% 6 1.4% area) (Fig. 7). Numbers
of a and b cells were also increased in HCHF diet–fed rats
compared with CS diet–fed rats (CS: 16.9 6 0.5 and 72.3 6
2.8 per islet; HCHF: 39.3 6 1.2 and 124.7 6 7.2 per islet,
respectively).
DISCUSSION
Long-term metabolic syndrome leads to multiorgan
dysfunction, especially cardiovascular disease, a major cause
of mortality in modern society.3,4,39 Metabolic syndrome also
damages the structure and function of liver, kidneys, and
TABLE 3. Single-cell Microelectrode Studies on Left Ventricular Papillary Muscles Isolated from Chow-fed (16 Weeks), CS (16
Weeks), and HCHF (16 Weeks) Groups
Variables Chow-fed (16 wk) CS (16 wk) HCHF (16 wk)
Resting membrane potential, mV 269.1 6 2.5ab 273.0 6 2.7b 262.4 6 1.9a
Action potential amplitude, mV 72.4 6 5.5 69.5 6 4.4 63.4 6 2.6
APD at 20% repolarization, ms 10.9 6 0.9b 15.0 6 1.2a 15.7 6 0.8a
APD at 50% repolarization, ms 19.5 6 1.4b 23.9 6 1.9b 28.9 6 1.7a
APD at 90% repolarization, ms 45.7 6 3.2b 55.5 6 4.0b 80.9 6 8.5a
Force of contraction, mN 2.4 6 0.4 4.2 6 1.2 2.9 6 0.8
All data are presented as mean 6 SEM and n = 8 for chow-fed and CS group and n = 9 for HCHF group. Mean values within a row with unlike superscript letters are significantly
different (P , 0.05); ms, milliseconds.
FIGURE 3. Thoracic aortic responses to various drugs. Thoracic aortic preparations developing acetylcholine-induced relaxation
(A), norepinephrine-induced contraction (B), and sodium nitroprusside–induced relaxation (C). Mean values with an unlike
superscript letter are significantly different (P , 0.05).
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pancreas.40 A suitable animal model is required that mimics all
these symptoms of human metabolic syndrome to test
potential pharmacological interventions to reverse organ
dysfunction. The primary focus of this study was to
characterize organ damage with this HCHF diet, especially
to the heart and vascular system, liver, kidneys, and pancreas.
CS was used as control diet in this study. CS is
a slowly digestible glycemic carbohydrate41 and served as
a control for the HCHF diet in this study where the key
carbohydrate is fructose. Unlike fructose, CS does not increase
blood glucose concentrations, systolic blood pressure,
abdominal fat deposition, plasma insulin, or plasma lipid
concentrations.42,43 CS diet is the appropriate control diet for
the HCHF diet because the only differences are the
replacement of the carbohydrates (CS replacing fructose and
condensed milk) and addition of the high fat as beef tallow in
the HCHF diet. Rats fed a standard chow for 16 weeks showed
evidence of ‘‘metabolic morbidity,’’44 showing that standard
chow is not an appropriate control in our model of obesity-
induced changes.
In this model, fat and sugars present in the diet provided
more energy than required by the animals. This excess energy
is stored in the adipocyte and led to hypertrophy and
hyperplasia of adipocytes.45,46 Thus, HCHF diet–fed rats
displayed increased body weight, feed efficiency, BMI,
abdominal fat deposition, and abdominal circumference.
HCHF diet–fed rats also showed increased plasma leptin
concentrations as early as 8 weeks. Increases in leptin
concentrations have been linked with high-fat feeding, leading
to increased body weight gain, energy intake, and increased
adiposity.47 Fructose and fat feeding induced dyslipidemia in
laboratory animals,48 which was also found in our model.
Dyslipidemia in these rats was characterized by the increase in
plasma concentrations of triglycerides, total cholesterol, and
NEFA. Decreased rates of glucose clearance from the blood
was also observed with HCHF diet feeding, clearly indicating
impaired glucose tolerance.
Oxidative stress is associated with obesity and metabolic
syndrome10,49 and initiates the changes occurring in the
metabolic syndrome.8 One of the hallmarks of metabolic
syndrome is oxidative stress–induced primary myocardial
insult resulting in cardiovascular remodeling.50,51 Previous
studies have ascertained the direct relationship between
increased reactive oxygen species production, diastolic
stiffness, and cardiac fibrosis.36,52 Overproduction of reactive
oxygen species seems to be the first and key event in the
activation of signaling pathways including extracellular signal-
regulated kinase (ERK)1/2, c-Jun amino terminal kinase 1/2,
thymoma viral proto-oncogene (AKT; designated as protein
kinase B), nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB), and Smad, leading to cardiac
hypertrophy, inflammation, and fibrosis.53–55 Other effects of
increased reactive oxygen species production on the cardio-
vascular system included alteration of ion channel flux and
membrane ion pump function in a biologically significant
manner in heart muscle56 and the vascular smooth muscle.57
Reactive oxygen species targeted L-type calcium channels on
the sarcolemma and suppressed the Ca2+ current.58 Reactive
oxygen species increased the cytosolic Ca2+ concentration
through mobilization of intracellular Ca2+ stores and/or
through the influx of extracellular Ca2+.57,59,60 Both direct
modulation of Ca2+ channels by reactive oxygen species and
reactive oxygen species–dependent increases in vascular
intracellular Ca2+ primarily via extracellular Ca2+ influx have
been conclusively demonstrated.57,61 The metabolic syndrome
diet seems to result in a less negative resting membrane
potential in rat papillary muscles relating to changes in
Na+/K+ATPase function or reduced cardiac cell repolarization.
Our finding of ventricular dilation, increased left
ventricular mass, and increased relative wall thickness in the
LV is consistent with subtle eccentric left ventricular
hypertrophy62 induced by HCHF diet feeding. Hypertrophied
cardiomyocytes were also observed histologically. The left
ventricular hypertrophy may have been produced in response
to systemic hypertension caused by HCHF diet feeding.62
Pressure overload may induce hypertrophy of the left
ventricular walls to compensate the stress on the walls.63,64
Consistent with these observations, HCHF diet feeding
increased left ventricular diastolic stiffness and fibrosis and
decreased function compared with the CS diet–fed rats.
Myocardial fibrosis, the major mechanism in the development
of left ventricular dysfunction, results from disproportionate
collagen deposition accompanied by reduced degradation of
extracellular matrix thus leading to increased tissue stiffness.65
HCHF diet–fed rats showed increased systolic blood pressure,
possibly due to the increased production of reactive oxygen
FIGURE 4. Changes in superoxide
production by erythrocyte (A) and
120-minute oral glucose tolerance
(B) in chow-fed rats (16 weeks), CS
(16 weeks), HCHF (8 weeks), and
HCHF (16 weeks) rats. Mean values
with an unlike superscript letter are
significantly different (P , 0.05).
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species as shown in the erythrocytes thereby reducing the
bioavailability of nitric oxide.66 HCHF diet impaired
endothelial function, defined by a decrease in acetylcholine-
induced relaxation, which also adds to the increase in blood
pressure. In obesity, adipocytes also expressed angiotensi-
nogen, leading to an angiotensin II–induced increase in blood
pressure.50
HCHF diet–fed rats showed prolonged APD at 50% and
90% of repolarization, which is consistent with the other rat
models of cardiovascular disease such as the deoxycorticos-
terone acetate salt hypertensive rats,36 spontaneously hyper-
tensive rat,67 and streptozotocin-induced diabetic rat model.68
These hypertensive and diabetic rat models induce aggressive
changes in LV structure and function with prolonged action
potentials and elevated levels of reactive oxygen species.36,68
The remodeled ventricle shows changes in Ito and Ik channel
densities and function that are thought to lengthen the action
potential and predispose the ventricle to arrhythmias.69,70 In rat
heart, the Ito current is active throughout the entire action
potential repolarization71 with the Ik inward rectifier current
driving the later phase of repolarization.72 It would seem from
these results that the HCHF diet–induced metabolic syndrome
causes changes in the later phase of repolarization and hence
might alter Ik channel function more significantly than Ito.
Although these changes are less marked than those found in
streptozotocin diabetic or deoxycorticosterone acetate-salt
hypertensive rat hearts, it is significant that the HCHF diet can
induce systemic reactive oxygen species production and
inflammation that remodels the ventricle and potentiates
arrhythmias. These findings have implications for human
patients who are obese, showing early changes in electro-
physiological remodeling of the heart, which could potentiate
later fatal arrhythmias.
HCHF diet feeding increased plasma concentrations of
malondialdehyde, the main product of polyunsaturated fatty
acid peroxidation,73 and increased time-dependent production
of reactive oxygen species in erythrocytes (Table 1). These
markers of oxidative stress were elevated as early as 8 weeks of
TABLE 4. Metabolic Parameters, Plasma Oxidative Stress, and Inflammatory Markers in Chow-fed (16 Weeks), CS (16 Weeks),
HCHF (8 Weeks), and HCHF (16 Weeks) Groups
Variables Chow-fed (16 wk) CS (16 wk) HCHF (8 wk) HCHF (16 wk)
Fasting blood glucose, mmol/L 4.1 6 0.3 3.9 6 0.2 4.1 6 0.4 4.7 6 0.3
Plasma insulin, mg/L 3.04 6 0.44b 2.28 6 0.36c 1.49 6 0.19c 4.15 6 0.34a
Plasma leptin, mg/L 6.62 6 0.80b 6.80 6 0.86b 8.65 6 0.81a 8.63 6 1.01a
Plasma corticosterone, mg/L 143 6 17 133 6 9 114 6 13 126 6 15
Plasma triglyceride, mmol/L 0.54 6 0.07b 0.42 6 0.06b 0.49 6 0.05b 0.79 6 0.09a
Plasma total cholesterol, mmol/L 1.69 6 0.09b 1.43 6 0.11b 1.48 6 0.05b 1.99 6 0.07a
Plasma NEFA, mmol/L 1.77 6 0.26b 1.15 6 0.14b 1.35 6 0.12b 3.53 6 0.21a
Plasma uric acid, mmol/L 48 6 4.3b 32.1 6 2.3c 47.6 6 1.9b 60.2 6 3.1a
Plasma total bilirubin, mmol/L 1.56 6 0.16b 2.42 6 0.09a 2.20 6 0.08a 2.30 6 0.06a
Albumin:globulin ratio 0.96 6 0.01 0.97 6 0.03 0.99 6 0.02 0.97 6 0.02
Plasma malondialdehyde, mmol/L 24.2 6 1d 26.9 6 0.7c 29.4 6 0.5b 32.1 6 1.0a
Plasma CRP concentration, mmol/L 61.2 6 6.4b 59.3 6 7.4b 58.1 6 7.4b 102.3 6 4.6a
All data are presented as mean 6 SEM and n = 10 for each group. Mean values within a row with unlike superscript letters are significantly different (P , 0.05).
TABLE 5. Hepatic and Renal Function in Chow-fed (16 Weeks), CS (16 Weeks), HCHF (8 Weeks), and HCHF (16 Weeks) Groups
Variables Chow-fed (16 wk) CS (16 wk) HCHF (8 wk) HCHF (16 wk)
Liver wet weight, mg/mm 279 6 10ab 234 6 14b 255 6 17ab 287 6 12a
Plasma ALT activity, U/L 42.4 6 0.9c 37.0 6 0.6d 50.4 6 0.5b 59.6 6 0.3a
Plasma AST activity, U/L 106.0 6 6.9a 73.2 6 5.6b 88.1 6 6.2ab 105.3 6 9.2a
Plasma ALP activity, U/L 180 6 23b 174 6 19b 219 6 16ab 251 6 21a
Plasma LDH activity, U/L 302 6 37b 204 6 23c 282 6 20b 497 6 14a
Kidney wet weight, mg/mm 53.6 6 1.0 49.8 6 1.4 50.8 6 2.3 53.9 6 1.5
Plasma creatinine, mmol/L 41.0 6 1.6b 46.6 6 1.3ab 47.6 6 2.1ab 49.4 6 2.5a
Plasma urea, mmol/L 6.05 6 0.21ab 6.45 6 0.16a 5.80 6 0.11b 2.69 6 0.11c
Plasma Na+, mmol/L 142 6 2 145 6 1 144 6 0 144 6 0
Plasma Cl2, mmol/L 100 6 2 102 6 1 101 6 1 101 6 1
Plasma K+, mmol/L 3.92 6 0.17bc 3.67 6 0.11c 4.29 6 0.14b 4.89 6 0.18a
Plasma Ca2+, mmol/L 2.17 6 0.03b 2.38 6 0.02a 2.41 6 0.02a 2.39 6 0.03a
All data are presented as mean 6 SEM and n = 10 for each group. Mean values within a row with unlike superscript letters are significantly different (P , 0.05).
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HCHF diet feeding. However, minimal symptoms of sub-
clinical inflammation were observed at 8 weeks, although
histological analysis revealed increased infiltration by in-
flammatory cells into cardiac and hepatic tissues and elevated
plasma CRP concentrations at 16 weeks. These results suggest
that oxidative stress as a result of metabolic disturbances in
HCHF diet–fed rats causes cellular insult thereby eliciting
a local inflammatory response. Increased adiposity is
associated with the activation and migration of inflammatory
cells into the adipose tissue.46 These inflammatory cells then
secrete increased amounts of inflammatory cytokines and finally
lead to low-grade chronic inflammation.46 Fructose feeding is
associated with the induction of oxidative stress74 and increased
production of proinflammatory factors such as tumor necrosis
factor a and c-Jun amino terminal kinase.75 Apart from this,
fructose induced hepatic de novo lipogenesis, leading to hepatic
steatosis,76 which is evident in this study as well.
Nonalcoholic fatty liver disease is considered as the
hepatic manifestation of metabolic syndrome.77 The increased
activities of ALT, AST, ALP, and LDH in plasma are indicative
of hepatic injury and along with inflammation, steatosis, and
fibrosis in the liver, HCHF diet–fed rats clearly show the
presence of nonalcoholic steatohepatitis. Metabolic syndrome
is a characteristic of chronic kidney disease in humans.78 The
FIGURE 5. Fat deposition, inflammation, and fibrosis in liver showing nonalcoholic steatohepatitis. Hematoxylin and eosin staining
of hepatocytes (340) showing hepatocytes with enlarged fat vacuoles (marked as ‘‘fv’’) and inflammatory cells (marked as ‘‘in’’)
(320) from chow-fed rats (16 weeks) (A, E), CS (16 weeks) (B, F), HCHF (8 weeks) (C, G), and HCHF (16 weeks) (D, H). Oil red ‘‘O’’
staining showing lipid deposition in liver (marked as ‘‘li’’); chow-fed rats (16 weeks) (I), CS (16 weeks) (J), HCHF (8 weeks) (K), and
HCHF (16 weeks) (L). Milligan’s trichrome staining of the hepatic portal regions showing collagen (marked as ‘‘pf’’) (320) in chow-
fed rats (16 weeks) (M), CS (16 weeks) (N), HCHF (8 weeks) (O), and HCHF (16 weeks) (P).
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glomerular and tubular damage and fibrosis in the kidney of
HCHF diet–fed rats shows that kidney damage has been
initiated.
Along with the moderate impairment in glucose
tolerance, HCHF diet–fed rats showed increased islet mass
and increased number of a and b cells within the islets of
Langerhans in the pancreas, suggesting hyperplasia of these
cell types. These changes were accompanied by increases in
plasma insulin concentration. This may suggest that the rats
have reduced sensitivity to insulin and to compensate for the
reduced sensitivity, islet mass and number of b cells increased
to produce and secrete more insulin. Earlier studies have
correlated increased islet mass with presence of insulin
resistance.79 Although there is increased plasma insulin
concentration with HCHF diet, there is only moderate
impairment of glucose tolerance. This indicates that the rats
are prediabetic and may progress to hyperglycemia with severe
glucose intolerance after further feeding of the HCHF diet.
CONCLUSIONS
HCHF diet feeding in rats induces metabolic syndrome
and cardiovascular remodeling, especially hypertension,
hypertrophy, ventricular fibrosis, conduction changes, and
endothelial dysfunction, along with nonalcoholic steatohepa-
titis, degeneration of renal structure, and increased mass of
islets of pancreas. The presence of all these changes in this
model makes it a viable model to test pharmacological and
other interventions for the prevention and reversal of
metabolic syndrome, cardiovascular disease, and nonalcoholic
fatty liver disease.
FIGURE 6. Masson’s trichrome staining of chow-fed (16 weeks) (A), CS (16 weeks) (B), and HCHF (16 weeks) (C–E) rat kidneys.
There were no histological anomalies in kidneys from the chow-fed (A) and CS diet–fed rats (B) and very little Masson trichrome–
positive tissue (A, B). In comparison, HCHF rat kidneys (stained with Masson trichrome) showed increased Masson trichrome–
positive tissue. The expanded interstitial space contains collagen (stained blue in the histopathology sections) and is evident
between the nephron structures (C). Lysis of the glomerular tuft (D, an example of single-cell lysis arrowed and marked as ‘‘cl’’) and
vacuolar degeneration and single-cell necrosis of tubular epithelium (E, examples arrows and marked ‘‘cn’’) demonstrate some
subtle but consistent degenerative changes in the HCHF rat kidneys (A-C: magnification, 3200; D, E: magnification, 3400).
FIGURE 7. Inflammation and increased islet size in pancreas. Hematoxylin and eosin staining (320) of pancreas showing infiltration
of inflammatory cells; chow-fed rats (16 weeks) (A), CS (16 weeks) (B), HCHF (8 weeks) (C), and HCHF (16 weeks) (D). Aldehyde
fuchsin staining (320) of pancreas showing increased size of islet; chow-fed rats (16 weeks) (E), CS (16 weeks) (F), HCHF (8 weeks)
(G), and HCHF (16 weeks) (H).
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Abstract
Metabolic syndrome (obesity, diabetes, and hypertension) increases hepatic and cardiovascular damage. This study
investigated preventive or reversal responses to rutin in high-carbohydrate, high-fat diet-fed rats as a model of metabolic
syndrome. Rats were divided into 6 groups: 2 groups were fed a corn starch-rich diet for 8 or 16 wk, 2 groups were fed a
high-carbohydrate, high-fat diet for 8 or 16 wk, and 2 groups received rutin (1.6 g/kg diet) in either diet for the last 8 wk only
of the 16-wk protocol. Metabolic changes and hepatic and cardiovascular structure and function were then evaluated in
these rats. The corn starch-rich diet contained 68% carbohydrate (mainly cornstarch) and 0.7% fat, whereas the high-
carbohydrate, high-fat diet contained 50% carbohydrate (mainly fructose) and 24% fat (mainly beef tallow) along with 25%
fructose in drinking water (total 68% carbohydrate using mean food and water intakes). The high-carbohydrate, high-fat
diet produced obesity, dyslipidemia, hypertension, impaired glucose tolerance, hepatic steatosis, infiltration of in-
flammatory cells in the liver and the heart, higher cardiac stiffness, endothelial dysfunction, and higher plasma markers of
oxidative stress with lower expression of markers for oxidative stress and apoptosis in the liver. Rutin reversed or
preventedmetabolic changes such as abdominal fat pads and glucose tolerance, reversed or prevented changes in hepatic
and cardiovascular structure and function, reversed oxidative stress and inflammation in the liver and heart, and normalized
expression of liver markers. These results suggest a non-nutritive role for rutin to attenuate chronic changes in metabolic
syndrome. J. Nutr. 141: 1062–1069, 2011.
Introduction
Polyphenolic compounds including flavonoids are widely distrib-
uted in fruits and vegetables (1,2). Flavonoids such as quercetin
and naringenin are effective in the treatment of cancer, hyperten-
sion, obesity, and dyslipidemia in both animals and humans (3–5).
Rutin (Supplemental Fig. 1A), a glycoside of quercetin (Supple-
mental Fig. 1B), is a non-nutritive component of many foods such
as onions, apples, tea, and red wine (6).
Metabolic syndrome is the constellation of central obesity,
dyslipidemia, hypertension, impaired glucose tolerance, and
insulin resistance (7). Clinical, epidemiological, and animal stud-
ies have shown the relationship between metabolic syndrome,
especially obesity and dyslipidemia, and the presence of nonal-
coholic fatty liver disease (NAFLD)6 (8–10), with metabolic
syndrome increasing the risk of development of NAFLD and vice
versa (11,12). Metabolic syndrome and NAFLD are also
associated with cardiovascular remodeling, including cardiac
hypertrophy, ventricular dysfunction, and endothelial dysfunc-
tion (13,14).
NAFLD refers to a wide spectrum of liver damage, ranging
from simple steatosis to steatohepatitis and cirrhosis (8,15).
Steatosis represents the deposition of fat in hepatocytes, whereas
steatohepatitis is the combination of steatosis with hepatic in-
flammation and fibrosis (16). Development of steatosis involves
impaired lipid metabolism in the liver (17). Insulin resistance,
hyperinsulinemia, and oxidative stress are important factors
in the development of nonalcoholic steatohepatitis (NASH)
(18,19).
Rutin has shown health-improving effects in different animal
studies. In high-fat diet-fed rats, rutin reduced the gains in body
weight, liver weight, and blood cholesterol concentrations with-
out changing blood TG concentrations (20). Rutin suppressed
adipocyte differentiation of 3T3-L1 cells (20) and suppressed
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hyperglycemia, increased plasma concentrations of insulin, and
decreased oxidative stress in streptozotocin-induced diabetic rats
(21,22). Rutin was cardioprotective in streptozotocin-induced
diabetic rats (23) and isoproterenol-induced myocardial infarc-
tion (24) and hepatoprotective in paracetamol- and carbon
tetrachloride-induced hepatotoxicity (25).
In this study, we characterized the metabolic, hepatic, and car-
diovascular responses to rutin in a rat model of high-carbohydrate,
high-fat diet-induced metabolic syndrome with obesity, mild
steatohepatitis, and cardiovascular remodeling (10). In addition,
Western blotting was used to study changes in the hepatic expres-
sion pattern of caspase-3, extracellular signal-regulated kinase
(Erk), and heat shock protein (Hsp)70.
Materials and Methods
Rats and diets
All experimental protocols were approved by The University of Queens-
land Animal Experimentation Ethics Committee under the guidelines of
the National Health and Medical Research Council of Australia. Male
Wistar rats (8–9 wk old, 332 6 7 g, n = 72) were obtained from The
University of Queensland Biological Resources facility. Rats were individ-
ually housed in a temperature-controlled room under 12-h-light/-dark
conditions and consumed ad libitum food and water.
Rats were randomly divided into 6 experimental groups (n = 12 each
group). Four groups were fed either a corn starch-rich diet (C) or a high-
carbohydrate, high-fat diet (H) for 8 wk (C8, H8) or 16 wk (C16, H16); 2
further groups, 1 fed the C diet and the other fed the H diet, were
administered rutin (1.6 g/kg food) for the last 8 wk of the 16-wk protocol
(CR, HR). The C8 and H8 groups were used to study the pathophysiology
before rutin treatment began and to determine whether rutin reversed,
prevented, or did not affect the measured variables.
The composition of the C and H diets was described in detail in our
previous study (26). The energy densities of C and H were 11.2 and 17.8
kJ/g of food, respectively, with an additional 3.85 MJ/L in the drinking
water for the H8, H16, and HR rats (26).
Physiological and metabolic variables
All the rats were monitored daily for body weight, food, and water
intakes. Abdominal circumference was measured at the end of the
feeding period using a standard measuring tape under light anesthesia
with Zoletil (tiletamine 10 mg/kg, zolazepam 10 mg/kg, i.p.; Virbac,
Peakhurst). BMI and feed efficiency were calculated as previously de-
scribed (10).
At the end of feeding period, rats were feed deprived for 12 h and oral
glucose tolerance tests were performed as described in our previous
studies (10,26,27). During feed deprivation, H rats (H8, H16, and HR)
were given drinking water without fructose supplementation. Plasma
concentrations of total cholesterol and TG were determined using kits
and controls supplied by Olympus using an Olympus analyzer (AU 400)
(10,26,27). Nonesterified fatty acids (NEFA) in plasma were determined
using a commercial kit (Wako). Plasma insulin concentrations (Labora-
tory Diagnostics) were measured using commercial kits according to
the manufacturer-provided standards and protocols using a Titertek
Multiskan MCC/340 spectrophotometer (Flow Laboratories) as in a
previous study (10).
Terminal experiments
Rats were killed with Lethabarb (pentobarbitone sodium, 100 mg/kg
i.p.; Virbac). After euthanasia, 200 IU heparin (Sigma-Aldrich Australia)
was injected through the right femoral vein. The abdomen was then
opened and blood (;6 mL) was withdrawn from the abdominal aorta
and collected into heparinized tubes. One milliliter of blood was stored
at 48C and used for erythrocyte reactive oxygen species measurements,
whereas the remaining blood was centrifuged at 5000 3 g for 15 min
to obtain plasma, which was then stored at 2208C for biochemical
analyses.
Assessment of oxidative stress variables
Erythrocyte reactive oxygen species production.Heparinized blood
stored at 48C was used to measure the production of erythrocyte reactive
oxygen species by a fluorometric assay based on the oxidation of the
fluorochrome 29,79-dichloroflourescein diacetate (Sigma-Aldrich Aus-
tralia) as described in our previous study (10).
Other plasma markers of oxidative stress. Plasma concentrations of
malondialdehyde were determined by HPLC (Shimadzu) as previously
described (28). Plasma glutathione peroxidase activity and total antiox-
idant capacity were measured using an automated spectrophotometer
(Cobas Mira) as previously described (29).
Assessment of hepatic structure and function
Histology of liver. Livers (n = 9 from each group) were isolated after
euthanasia and weighed. Liver portions were isolated (n = 3) and fixed
in 10% neutral buffered formalin for 3 d. These tissue samples were
dehydrated and then embedded in paraffin wax. Thin sections (5 mm)
of these tissues were cut and stained with hematoxylin and eosin for
determination of inflammatory cell infiltration (magnification 320)
and fat vacuoles in liver (magnification 340). Liver sections were also
stained with Milligan’s Trichrome stain to determine fibrosis (magnifica-
tion 320).
Liver enzymes in plasma. Plasma activity of alanine transaminase
(ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), lac-
tate dehydrogenase (LDH), and the concentrations of albumin, total
bilirubin, urea, and uric acid were determined using kits and controls
supplied by Olympus using an Olympus analyzer (AU 400) as previously
described (10,26,27).
Western-blot analysis. Liver samples isolated from rats (n = 3 from
each group) were stored at 2808C. Liver samples were thawed and
sonicated after adding cell lysis buffer. These samples were then ultra-
centrifuged at 100,0003 g for 30 min at 48C. Supernatants were used to
measure the protein concentration in each sample by the bicinchoninic
acid method (Thermo Scientific). The expression of Erk, Hsp70, and
caspase-3 was studied in supernatants at equal protein concentrations by
Western-blot analysis.
Assessment of cardiovascular structure and function
Systolic blood pressure measurements. The systolic blood pressure
of rats was measured at the end of feeding period under light sedation
with Zoletil by using an MLT1010 Piezo-Electric Pulse Transducer
(ADInstruments) and inflatable tail-cuff connected to a MLT844 Phys-
iological Pressure Transducer (ADInstruments) and PowerLab data ac-
quisition unit (ADInstruments).
Echocardiography. Echocardiographic examination (Phillips iE33,
12-MHz transducer) was performed to assess the cardiovascular struc-
ture and function in all the rats. The examination was performed as
previously described (10,26,27) after 8 wk for C8 and H8 and after
16 wk for the C16, CR, H16, and HR groups.
Left ventricular function. Isolated Langendorff heart preparations
(n = 9) were used to assess left ventricular function of the rats in each
group as in previous studies (10,26,27). After performing Langendorff
heart perfusion studies, the heart was separated into right ventricle and
left ventricle (with septum) for weighing.
Vascular reactivity. Thoracic aortic rings (4 mm in length; n = 9 from
each group) were suspended in an organ bath maintained at 358C and
filled with Tyrode physiological salt solution bubbled with 95% O2-5%
CO2 and allowed to stabilize at a resting tension of 10 mN. Cumulative
concentration-response curves (contraction) were obtained for noradrena-
line (Sigma-AldrichAustralia) and cumulative concentration-response curves
(relaxation) were obtained for acetylcholine (Sigma-Aldrich Australia) and
sodium nitroprusside (Sigma-Aldrich Australia) following submaximal
(70%) contraction to noradrenaline (10,26,27).
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Histology of the heart. Hearts (n = 3 from each group) were fixed in
10% neutral buffered formalin for 3 d. These tissues were used to study
collagen deposition and infiltration of inflammatory cells as previously
described (26).
Statistical analysis
All data are presented as mean 6 SEM. Results were tested for
homogenous variance using Bartlett’s test and variables that were not
normally distributed were transformed (using log 10 function) prior to
statistical analyses. C16, CR, H16, andHR groups were tested for effects
of diet, treatment, and their interactions by 2-way ANOVA. When the
interaction and/or the main effects were significant, means were
compared using Newman-Keuls multiple comparison post test. The
pairs of 8 wk and treatment groups (C8 and CR; H8 and HR) were
compared by using Student’s t test to determine whether rutin reverses,
prevents, or does not alter the signs of metabolic syndrome. Rutin
intakes in CR and HR rats were compared using Student’s t test. P ,
0.05 was considered significant. All statistical analyses were performed
using GraphPad Prism version 5 for Windows.
Results
Physiological and metabolic variables. Body weight and
energy intakes were significantly higher in H rats than in C rats
both after 8 and 16 wk. Body weight was significantly atten-
uated by rutin in HR rats without affecting energy intake (Table
1). H16 rats consumed significantly less food and water than
C16 rats. Rutin treatment significantly lowered the intake of
water in HR rats. Although there was no difference in feed
intake between the H16 and HR groups, it was significantly
higher in the HR rats than in the H8 rats. This indicates that
rutin treatment significantly increased feed intake in HR rats
without changing feed intake in CR rats (Table 1). BMI and feed
efficiency were significantly higher in H16 rats and significantly
lower in HR rats, but these variables were not different in C
and CR rats (Table 1). Abdominal circumference and abdominal
fat pads were significantly higher in H16 rats than in the C16
rats. Rutin prevented the increase in abdominal fat pads and
reversed the increase in abdominal circumference in HR rats and
also prevented the increase in abdominal circumference in CR
rats (Table 1).
Increased basal blood glucose concentrations with H feeding
were normalized by rutin treatment in HR rats (Table 1).
Although the increase in plasma concentrations of insulin was
not prevented by rutin, plasma insulin concentrations were
significantly lower in HR rats than in H16 rats (Table 1). H16
rats had impaired glucose tolerance and this impairment was
reversed by rutin treatment in HR rats (Fig. 1A). C16 and CR
rats did not differ in glucose tolerance, basal blood glucose
concentrations, or plasma insulin concentrations (Fig. 1A; Table
1). Plasma concentrations of TG, total cholesterol, and NEFA
were significantly higher in H16 rats compared with C16 rats.
Rutin treatment prevented the increase in plasma concentrations
of these lipids at 16 wk (Table 1).
Rutin intake was greater in CR (1076 5 mg/kg body weight)
than in HR (89 6 6 mg/kg body weight) rats (P ,0.05).
Oxidative stress. Erythrocytes from H16 rats produced signif-
icantly more superoxide than those from C16 rats (Fig. 1B). This
production of superoxide by erythrocytes was significantly lower
in rutin-supplemented HR rats (Fig. 1B). H16 rats had higher
plasma concentrations of malondialdehyde and lower plasma
activities of glutathione peroxidase than C16 rats. HR rats had
lower plasma concentrations ofmalondialdehyde and higher plasma
activities of glutathione peroxidase than H16 rats (Table 1). The
TABLE 1 Effects of rutin on physiological, metabolic, and oxidative stress variables in C8, C16, CR, H8, H16, and HR rats1
Variables C16 CR H16 HR
P-value
C8 H8Diet Rutin Diet 3 rutin
Physiological variables
Initial body weight, g 338 6 4 339 6 7 342 6 4 334 6 7 .0.05 .0.05 .0.05 336 6 6 338 6 8
Final body weight, g 420 6 9c 433 6 9bc 525 6 10a 456 6 12b ,0.001 ,0.001 ,0.001 378 6 8* 421 6 9#
Water intake, mL/d 32.3 6 1.6a 31.2 6 1.3a 18.6 6 0.9b 13.4 6 0.8c ,0.001 ,0.05 .0.05 34.4 6 1.5 15.3 6 1.5
Food intake, g/d 31.8 6 0.6a 30.4 6 0.5a 23.0 6 0.7b 24.4 6 0.5b ,0.001 .0.05 ,0.05 30.8 6 0.6 22.4 6 0.6#
Energy intake, kJ/d 357 6 15b 341 6 12b 481 6 14a 487 6 12a ,0.001 .0.05 .0.05 346 6 11 458 6 14
BMI, g/cm2 0.67 6 0.00b 0.69 6 0.01b 0.78 6 0.01a 0.69 6 0.01b ,0.001 ,0.001 ,0.001 0.67 6 0.01 0.65 6 0.01#
Feed efficiency, g/kJ 0.23 6 0.01b 0.28 6 0.02b 0.39 6 0.01a 0.28 6 0.02b ,0.001 .0.05 ,0.001 0.12 6 0.01* 0.18 6 0.01#
Abdominal circumference, cm 21.0 6 0.2b 19.8 6 0.2c 24.1 6 0.3a 20.3 6 0.2c ,0.001 ,0.001 ,0.001 19.2 6 0.2* 21.7 6 0.3#
Abdominal fat pads, mg/mm tibia 401 6 56b 295 6 36b 798 6 56a 466 6 77b ,0.001 ,0.001 .0.05 305 6 44 514 6 47
Metabolic variables
Basal blood glucose, mmol/L 4.0 6 0.2b 3.8 6 0.2b 5.2 6 0.3a 3.8 6 0.2b ,0.05 ,0.01 ,0.05 3.7 6 0.3 4.2 6 0.3
AUC,2 mmol/Lmin 684 6 11b 630 6 13c 764 6 10a 626 6 14c ,0.01 ,0.001 ,0.01 656 6 10 724 6 9#
Plasma insulin, pmol/L 0.39 6 0.06b 0.46 6 0.06b 0.74 6 0.06a 0.56 6 0.05b ,0.001 .0.05 ,0.05 0.48 6 0.05 0.26 6 0.04#
Plasma total cholesterol, mmol/L 1.4 6 0.1b 1.5 6 0.1b 2.0 6 0.1a 1.6 6 0.1b ,0.01 .0.05 ,0.05 1.1 6 0.1* 1.5 6 0.1
Plasma triglycerides, mmol/L 0.4 6 0.1b 0.4 6 0.1b 0.9 6 0.1a 0.6 6 0.1b ,0.01 .0.05 .0.05 0.4 6 0.1 0.5 6 0.1
Plasma NEFA, mmol/L 1.2 6 0.1b 1.2 6 0.1b 2.9 6 0.3a 1.8 6 0.2b ,0.001 ,0.01 ,0.01 1.1 6 0.1 1.4 6 0.1
Oxidative stress variables
Plasma malondialdehyde, mmol/L 27.4 6 1.2b 27.0 6 1.1b 32.2 6 1.2a 28.0 6 1.0b ,0.05 .0.05 .0.05 26.8 6 1.4 28.9 6 1.2
Plasma glutathione peroxidase activity, U/L 1340 6 60a 1372 6 43a 847 6 43b 1253 6 38a ,0.001 ,0.001 ,0.001 1361 6 40 1119 6 48#
Plasma total antioxidant capacity, mmol
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic
acid equivalents/L
1.85 6 0.02a 1.81 6 0.02ab 1.78 6 0.02b 1.87 6 0.02a .0.05 .0.05 ,0.01 1.87 6 0.02 1.80 6 0.02#
1 Values are mean 6 SEM, n = 9–12. Means without a common letter differ, * vs. CR and # vs. HR, P , 0.05.
2 AUC were calculated using the x-axis as baseline.
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total plasma antioxidant capacity of H16 rats was lower than C16
rats and this was reversed in HR rats (Table 1).
Hepatic structure and function. Compared with C16 rats
(Fig. 2B,H,N), H16 rats had a higher wet weight of liver (Table
2) with steatosis (Fig. 2E) and higher infiltration of inflamma-
tory cells (Fig. 2K) and fibrosis (Fig. 2Q) in the hepatic portal
region; these changes were attenuated in HR rats (Fig. 2F,L,R;
Table 2).
Plasma activities of ALT, AST, ALP, and LDH were signif-
icantly higher in H16 rats than in C16 rats (Table 2). Plasma
concentrations of urea were significantly lower, whereas the
plasma concentrations of total bilirubin and uric acid were
significantly higher in H16 rats compared with C16 rats (Table
2). Plasma concentrations of albumin were unchanged between
the groups (Table 2). Rutin treatment in HR rats reversed the
increase in plasma ALT activity, whereas it prevented the
increase in plasma activities of AST, ALP, and LDH (Table 2).
Rutin treatment inhibited the increase in plasma concentrations
of bilirubin in both CR and HR rats (Table 2) and also inhibited
the increase in plasma uric acid concentrations in HR rats (Table
2). The plasma urea concentrations of HR rats were significantly
higher than H16 rats but less than C16 rats (Table 2).
H16 rats had lower expression of caspase-3, Hsp70, and
Erk1/2 in liver compared with C16 rats; rutin treatment reversed
these changes in HR rats (Supplemental Fig. 2).
Cardiovascular structure and function. H rats had signif-
icantly higher systolic blood pressure as early as 8 wk (Table 3).
Left ventricular internal diameter during diastole, left ventric-
ular posterior wall thickness, and systolic volume were signif-
icantly higher and fractional shortening and ejection fraction
were significantly lower in H16 rats compared with C16 rats
(Table 3). Rutin treatment prevented increases in blood pressure
and left ventricular internal diameter during diastole, whereas it
reversed the increase in systolic volume without affecting left
ventricular posterior wall thickness during diastole (Table 3).
Rutin treatment reversed the decreases in fractional shortening
and ejection fraction in HR rats (Table 3).
Greater left ventricular masses (both estimated as well as the
actual wet weight) were observed in H16 rats than in C16 rats
and these increases were prevented by rutin treatment in HR rats
(Table 3). There were no differences in right ventricular wet
weights among the groups (Table 3). Compared with C8 and
C16 rats (Fig. 3G,H), inflammatory cells were rare in the left
ventricle of H8 rats (Fig. 3J) but more numerous in H16 rats
(Fig. 3K), whereas they were markedly lower in HR rats (Fig.
3L). These changes were accompanied by higher collagen de-
position in H16 rats (Fig. 3E) and this was reversed by rutin in
HR rats (Fig. 3F). Left ventricles of H16 rats had significantly
greater stiffness than C16 rats; rutin treatment prevented the
increase in left ventricular stiffness in HR rats (Table 3). Vascular
contraction with noradrenaline (Fig. 4A) and vascular relaxa-
tion with acetylcholine and sodium nitroprusside (Fig. 4B,C)
were significantly lower in isolated thoracic aortic rings from
H16 rats than from C16 rats. Rutin treatment in HR rats
prevented the impairment of vascular contraction and relaxation
(Fig. 4A–C).
Discussion
One of the accepted causes for developing metabolic syndrome
is the consumption of a high-carbohydrate, high-fat diet. Meta-
bolic syndrome increases the risk of cardiovascular disease.
NAFLD also increases the risk of developing cardiovascular
diseases (30), which in turn is linked with the mortality as-
sociated with metabolic syndrome and NAFLD (31–33). The
initiating factors linking these pathological conditions are
oxidative stress and inflammation (34–36). Thus, reducing over-
all oxidative stress and inflammation can be a treatment strategy
for metabolic syndrome, NAFLD, and cardiovascular disease.
We have shown that rutin is a possible treatment for diet-
induced metabolic, hepatic, and cardiovascular changes in a rat
model of diet-induced metabolic syndrome. The dose used in this
study would equal ~7 g/d in a 70-kg human based on body
weight calculations or 1.1 g/d based on body surface area
comparisons (37). The average human dietary intake of rutin is
not known, but the intake of polyphenols is probably ;1 g/d,
with two-thirds being flavonoids, including rutin (38). Although
rutin is not used for therapeutic purposes, the closely related
O-(b-hydroxyethyl)-rutosides have been used for venous insuf-
ficiency and leg edema (39) at doses of 1.5–2 g/d for up to 5 y
(40), as an i.v. dosage of 1.5 g twice daily for 3–4 wk for severe
leg ischemia (41), and for pharmacokinetic studies using up to
4 g as a single dose (42). In these studies, minimal adverse effects,
if any, were reported, including headaches, gut disturbances,
rashes, and flushing.
In this study, the H diet was used to induce metabolic
syndrome, NAFLD, and cardiovascular remodeling in rats as
previously described (10,26,27). Both the C and H diets con-
tained the same amount of carbohydrates, but the carbohydrate
components were very different in their actions. The C diet
contained cornstarch, which is a slowly digestible starch and
FIGURE 1 Effects of rutin on oral glucose tolerance (A) and sup-
eroxide production by erythrocytes (B) in C8, C16, CR, H8, H16, and
HR rats. Values are mean 6 SEM, n = 12. End-point means without a
common letter differ, * vs. CR and # vs. HR, P , 0.05. D, R, and D3R
represent effects of diet, rutin, and interaction of diet and rutin.
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does not produce the signs of metabolic syndrome (10,26,
27,43,44). However, fructose, present in the H diet together
with sucrose, produces signs of metabolic syndrome in both
humans and rats (10,45–47). Thus, cornstarch in the C diet was
replaced with fructose and sucrose in the H diet to provide a
similar intake of carbohydrate in both diet groups.
Rats fed the H diet for 16 wk showed signs of oxidative stress,
including higher plasma concentrations of malondialdehyde,
lower plasma glutathione peroxidase activity, and higher super-
oxide production by erythrocytes. Along with oxidative stress,
H-fed rats had signs of metabolic syndrome, including abdominal
obesity, impaired glucose tolerance, higher systolic blood pressure,
and dyslipidemia. Livers from these rats had steatosis, inflamma-
tion, and fibrosis, indicating the presence ofNASH, and the hearts
showed inflammation, fibrosis, and higher diastolic stiffness.
High energy-containing diets can cause steatosis or steato-
hepatitis and cardiovascular remodeling (48,49). Hyperinsuli-
nemia, higher plasma NEFA concentrations, and obesity are
additional risk factors for the development of steatohepatitis
and cardiovascular remodeling (17,50). Oxidative stress in the
liver of H-fed rats was indicated by the lower expression of
Hsp70 and impaired apoptotic process was shown by lower
expression of caspase-3. This also supports the higher wet
weight of liver in H-fed rats. Further liver findings included
higher activities of aminotransferases and ALP in plasma, higher
plasma concentrations of total bilirubin and uric acid, lower
urea concentration, and lower expression of Erk in liver.
Cardiovascular remodeling was shown by inflammation, fibro-
sis, and higher stiffness in the heart of H-fed rats.
Rutin is effective as an antioxidant and reduced oxidative
stress in plasma (21) and in the liver, kidney, and brain (6). Rutin
produced antiinflammatory effects in adjuvant-induced arthritis
in rats by inhibiting the expressions of proinflammatory cyto-
kines (51,52). In this study, rutin administered to H-fed rats
attenuated the diet-induced metabolic syndrome, NASH, and
cardiovascular abnormalities.
FIGURE 2 Effects of rutin on fat deposition, inflammation, and fibrosis in the liver of C8, C16, CR, H8, H16, and HR rats. Hematoxylin and eosin
staining of liver showing enlarged lipid vacuoles (A–F, marked as “li”) (340) and inflammatory cells (G–L, marked as “in”) (320) from C8 (A,G),
C16 (B,H ), CR (C,I ), H8 (D,J ), H16 (E,K ), and HR (F,L) rats. Milligan’s Trichrome staining of hepatic portal regions showing collagen deposition
(M–R, marked as “fi”) (320) from C8 (M), C16 (N), CR (O), H8 (P), H16 (Q), and HR (R) rats.
TABLE 2 Effects of rutin treatment on hepatic function in C8, C16, CR, H8, H16, and HR rats1
Variables C16 CR H16 HR
P-value
C8 H8Diet Rutin Diet 3 Rutin
Liver wet weight, mg/mm tibia 257 6 11b 262 6 9b 299 6 8a 266 6 7b ,0.05 .0.05 ,0.05 238 6 7 276 6 9
Plasma ALT, U/L 35 6 2c 40 6 2bc 57 6 2a 42 6 2b ,0.001 ,0.05 ,0.001 31 6 2* 51 6 2#
Plasma AST, U/L 79 6 3b 70 6 2c 105 6 3a 80 6 3b ,0.001 ,0.001 ,0.01 65 6 2 88 6 3
Plasma ALP, U/L 173 6 10c 154 6 8c 251 6 13a 209 6 11b ,0.001 ,0.05 .0.05 165 6 11 219 6 9
Plasma LDH, U/L 241 6 24b 260 6 22b 497 6 32a 308 6 25b ,0.001 ,0.01 ,0.001 219 6 22 283 6 26
Plasma albumin, g/L 28.0 6 0.5 27.9 6 0.4 28.6 6 0.3 27.6 6 0.3 .0.05 .0.05 .0.05 27.9 6 0.3 27.8 6 0.3
Plasma total bilirubin, mmol/L 2.2 6 0.1b 1.8 6 0.1c 2.5 6 0.1a 1.9 6 0.1c .0.05 ,0.001 .0.05 2.0 6 0.1 2.0 6 0.1
Plasma urea, mmol/L 5.8 6 0.2a 5.6 6 0.3a 3.2 6 0.3c 4.0 6 0.2b ,0.001 .0.05 .0.05 6.2 6 0.2 5.7 6 0.2#
Plasma uric acid, mmol/L 37 6 2b 34 6 3b 58 6 3a 43 6 3b ,0.001 ,0.01 ,0.05 32 6 2 49 6 3
1 Values are mean 6 SEM, n = 9 for each group. Means without a common letter differ, * vs. CR and # vs. HR, P , 0.05.
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Rutin lowered the lipid components in the serum of hyper-
cholesterolemic rats, probably by reducing the activity of HMG-
CoA reductase (53). In our study, rutin-treated rats had lower
plasma concentrations of total cholesterol, TG, NEFA, and
insulin. Apart from lower lipid concentrations in plasma, rutin-
treated HR rats had lower abdominal fat deposition. Because
there was no change in the energy intake with rutin treatment,
we suggest that the rutin-treated rats had higher energy
expenditure, thereby reducing the fat deposition, similar to the
effect shown by the aglycone of rutin, quercetin (54). Rutin
ameliorated NASH by attenuation of causative factors. Rutin
also upregulated the expression of caspase-3 in the liver,
suggesting higher apoptosis, probably of fat-containing hepato-
cytes, as indicated by the absence of fat vacuoles in the liver and
lower wet weight of liver. Rutin prevented the infiltration of
inflammatory cells in the liver through its antiinflammatory
activity, as shown in other studies (55,56). Liver from rutin-
treated rats also showed upregulation of Hsp70, indicating
lower oxidative stress. Rutin-treated rats probably had lower
injury and damage to hepatocytes caused by chronic H feeding,
as shown by lower aminotransferase activities in plasma and
lower plasma concentrations of total bilirubin and uric acid.
Rutin also improved cardiovascular structure and function in
H rats. The eccentric hypertrophy, inflammation, and fibrosis
caused by the H diet were prevented by rutin. Rutin-treated rats
also had lower systolic blood pressure and improved endothelial
function. High blood pressure and endothelial dysfunction have
been shown to be correlated with oxidative stress and subse-
quently reduced NO bioavailability (57–59). Rutin, by scaveng-
ing free radicals, should increase the bioavailability of NO and
thereby reduce systolic blood pressure and improve endothelial
function as shown by our results.
In conclusion, a high-carbohydrate, high-fat diet induced
symptoms of metabolic syndrome in rats, including obesity,
dyslipidemia, hypertension, and impaired glucose tolerance along
with NASH and cardiovascular remodeling. Increased markers
of oxidative stress confirmed that oxidative stress plays a role
in the development of these pathological conditions. Rutin, a
flavonoid fromplants,preventedor reversed these changes induced
by H feeding in rats. Thus, rutin was effective in attenuating
these diet-induced changes, probably by reducing oxidative
stress and inflammation in the liver and heart. Thus, rutin should
be considered as a treatment strategy for these conditions in
humans.
TABLE 3 Effects of rutin treatment on cardiovascular structure and function in C8, C16, CR, H8, H16, and HR rats1
Variables C16 CR H16 HR
P-value
C8 H8Diet Rutin Diet 3 rutin
Systolic blood pressure, mm Hg 129 6 4b 127 6 5b 151 6 3a 132 6 4b ,0.01 ,0.05 ,0.05 123 6 3 143 6 4
Left ventricular internal diameter during diastole, mm 6.6 6 0.2b 6.6 6 0.2b 7.5 6 0.2a 6.7 6 0.2b ,0.05 .0.05 .0.05 6.4 6 0.2 6.8 6 0.2
Left ventricular posterior wall thickness during diastole, mm 1.58 6 0.03c 1.53 6 0.05c 1.81 6 0.05a 1.69 6 0.04b ,0.001 ,0.05 .0.05 1.51 6 0.03 1.75 6 0.04
Systolic volume, mL 43 6 6b 59 6 6b 122 6 4a 46 6 6b ,0.001 ,0.001 ,0.001 49 6 4 71 6 4#
Relative wall thickness 0.48 6 0.01 0.51 6 0.02 0.48 6 0.01 0.49 6 0.02 .0.05 .0.05 .0.05 0.48 6 0.01 0.52 6 0.01
Fractional shortening, % 53 6 1a 49 6 2a 39 6 2b 52 6 2a ,0.01 ,0.05 ,0.001 54 6 2 46 6 2#
Ejection fraction, % 87 6 1a 82 6 2a 72 6 1b 87 6 2a ,0.01 ,0.01 ,0.001 82 6 1 78 6 1#
Time from mitral valve closure to opening, ms 114 6 3 117 6 4 114 6 3 116 6 3 .0.05 .0.05 .0.05 114 6 4 110 6 3
Estimated left ventricular mass, g 0.68 6 0.02b 0.71 6 0.02b 0.91 6 0.03a 0.73 6 0.03b ,0.001 ,0.01 ,0.001 0.63 6 0.02* 0.79 6 0.02
Left ventricle + septum wet weight,2 mg/mm tibia 19.5 6 0.8b 19.4 6 0.8b 22.8 6 0.7a 19.8 6 0.9b ,0.05 .0.05 .0.05 19.1 6 0.7 20.7 6 1.0
Right ventricular wet weight,2 mg/mm tibia 4.2 6 0.3 4.3 6 0.3 4.6 6 0.4 4.4 6 0.3 .0.05 .0.05 .0.05 4.2 6 0.4 4.5 6 0.3
Left ventricular diastolic stiffness constant2 (k) 18.1 6 0.9c 19.6 6 1.0c 28.8 6 1.2a 24.0 6 0.9b ,0.001 .0.05 ,0.01 18.3 6 0.8 25.8 6 0.9
1 Values are mean 6 SEM, n = 12 unless otherwise noted. Means without a common letter differ, * vs. CR and # vs. HR, P , 0.05.
2 n = 9.
FIGURE 3 Effects of rutin on inflammation and fibrosis in the heart of H-fed rats. Picrosirius red staining of left ventricle showing collagen
deposition (A–F, fibrosis marked as “fi” and hypertrophied cardiomyocytes as “hy”) (340) from C8 (A), C16 (B), CR (C ), H8 (D), H16 (E ), and HR
(F ) rats. Hematoxylin and eosin staining of left ventricle showing infiltration of inflammatory cells (G–L, inflammatory cells as dark spots
surrounding the myocytes marked as “in”) (340) from C8 (G), C16 (H), CR (I ), H8 (J ), H16 (K ), and HR (L) rats.
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and Metabolic Changes in Diet-Induced
Metabolic Syndrome in Rats1–3
Sunil K. Panchal,4 Hemant Poudyal,5 and Lindsay Brown4*
4Department of Biological and Physical Sciences, University of Southern Queensland, Toowoomba, Queensland, Australia; and 5School
of Biomedical Sciences, The University of Queensland, Brisbane, Queensland, Australia
Abstract
Metabolic syndrome is a risk factor for cardiovascular disease and nonalcoholic fatty liver disease (NAFLD). We
investigated the responses to the flavonol, quercetin, in male Wistar rats (8–9 wk old) divided into 4 groups. Two groups
were given either a corn starch–rich (C) or high-carbohydrate, high-fat (H) diet for 16wk; the remaining 2 groupswere given
either a C or H diet for 8 wk followed by supplementation with 0.8 g/kg quercetin in the food for the following 8 wk (CQ and
HQ, respectively). The H diet contained ;68% carbohydrates, mainly as fructose and sucrose, and ;24% fat from beef
tallow; the C diet contained;68% carbohydrates as polysaccharides and;0.7% fat. Comparedwith the C rats, the H rats
had greater body weight and abdominal obesity, dyslipidemia, higher systolic blood pressure, impaired glucose tolerance,
cardiovascular remodeling, and NAFLD. The H rats had lower protein expressions of nuclear factor (erythroid-derived 2)-
related factor-2 (Nrf2), heme oxygenase-1 (HO-1), and carnitine palmitoyltransferase 1 (CPT1) with greater expression of
NF-kB in both the heart and the liver and less expression of caspase-3 in the liver than in C rats. HQ rats had higher
expression of Nrf2, HO-1, and CPT1 and lower expression of NF-kB than H rats in both the heart and the liver. HQ rats had
less abdominal fat and lower systolic blood pressure along with attenuation of changes in structure and function of the
heart and the liver compared with H rats, although body weight and dyslipidemia did not differ between the H and HQ rats.
Thus, quercetin treatment attenuated most of the symptoms of metabolic syndrome, including abdominal obesity,
cardiovascular remodeling, and NAFLD, with the most likely mechanisms being decreases in oxidative stress and
inflammation. J. Nutr. 142: 1026–1032, 2012.
Introduction
Metabolic syndrome refers to the clustering of insulin resistance,
hypertension, central obesity, impaired glucose tolerance, and
dyslipidemia (1). Metabolic syndrome increases the risk of
cardiovascular disease, nonalcoholic fatty liver disease (NAFLD)6,
and diabetes (2–4). This increased prevalence of cardiovascular
disease and NAFLD associated with metabolic syndrome
necessitates the discovery of appropriate interventions for these
complications. One of the major causes of obesity and NAFLD
in Western society is a diet rich in both carbohydrates such as
fructose or sucrose and saturated fats from animal sources (5,6).
Excess consumption of fat and fructose in the diet leads to
disturbances in fatty acid and carbohydrate metabolism (7,8).
Excess fructose consumption also leads to increased lipid
biosynthesis, because fructose is a lipogenic carbohydrate (9).
This is accompanied by reduced fatty acid oxidation and
increased storage of fat in the visceral area. Impairment of fatty
acid metabolism in the liver leads to hepatic steatosis followed
by NAFLD (10).
Quercetin (3,39,49,5,7-pentahydroxyflavone) is an important
dietary flavonoid found in red onions, apples, berries, citrus fruits,
tea, and red wine (11). Quercetin reduced systolic blood pressure
in hypertensive human participants and in animal models of
hypertension (12–14), reduced serum TG and cholesterol con-
centrations in high-fat diet-fed rabbits after 12 wk of treatment
(15), and reduced body weight in obese Zucker rats without
changing the mean daily food intake, also reducing plasma
concentrations of TG, nonesterified fatty acids (NEFA) total
1 Supported by Dr. Red Nutraceuticals, Brisbane, Australia and the Prince
Charles Hospital Foundation, Brisbane, Australia.
2 Author disclosures: S. K. Panchal, H. Poudyal, and L. Brown, no conflicts of
interest.
3 Supplemental Figures 1 and 2 are available from the “Online Supporting
Material” link in the online posting of the article and from the same link in the
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H, high-carbohydrate, high-fat diet-fed rats; HO-1, heme oxygenase-1; HQ,
high-carbohydrate, high-fat diet-fed rats treated with quercetin; LDH, lactate
dehydrogenase; LV, left ventricle; NAFLD, nonalcoholic fatty liver disease; NEFA,
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cholesterol, and insulin (16). High-fat, high-cholesterol, and high-
sucrose diet-fed mice treated with quercetin had lower body
weight, visceral fat, blood glucose, plasma insulin, plasma total
cholesterol, plasma TG, plasma NEFA, and plasma TNFa
concentrations with higher plasma adiponectin concentrations.
These mice also had suppressed liver lipid accumulation (17). In
high-fat diet-fed mice, quercetin increased energy expenditure
and reduced plasma concentrations of inflammatory markers
without any changes in food consumption, physical activity,
body weight, or body composition (18). Recent studies have
also shown the protective effects of quercetin in thioacetamide-
and acrylonitrile-induced hepatotoxicity (19,20).
Thus, we characterized the effects of quercetin as a dietary
intervention in a diet-induced rat model of NAFLD and
cardiovascular remodeling as part of metabolic syndrome
induced in rats by feeding a high-carbohydrate, high-fat diet
for 16 wk (21). After treatment with quercetin, the structure and
function of the cardiovascular system were characterized with
echocardiography, isolated Langendorff heart preparation, vas-
cular reactivity studies, and histopathological analysis. The
structure and function of the liver were characterized with
histopathological analysis and measurement of biochemical
variables. Variables for obesity, dyslipidemia, and glucose
tolerance were also measured. The possible mechanisms in-
volved in the action of quercetin were characterized by the
expression of proteins involved in cellular metabolism and stress
regulation.
Methods
Rats, diets, and treatment with quercetin
All experimental protocols were approved by the University of Southern
Queensland Animal Ethics Committee under the guidelines of the
National Health and Medical Research Council of Australia. Male
Wistar rats (8–9 wk old, 333 6 2 g, n = 40) were obtained from The
University of Queensland Biological Resources facility. Rats were
randomly divided into 4 groups: corn starch–rich diet-fed rats (C; n =
10), corn starch–rich diet-fed rats treated with quercetin (CQ; 0.8 g/kg
food; n = 10; MP Biomedicals), high-carbohydrate, high-fat diet-fed rats
(H; n = 10), and high-carbohydrate, high-fat diet-fed rats treated with
quercetin (HQ; 0.8 g/kg food; n = 10). The compositions of the diets
were previously described in detail (21–23). C and H rats were fed with
corn starch–rich and high-carbohydrate, high-fat diets, respectively, for
16 wk. CQ and HQ rats were fed with corn starch–rich and high-
carbohydrate, high-fat diets, respectively, for the first 8 wk and the
respective diets were supplemented with quercetin (0.8 g/kg food) for a
further 8 wk. All the rats were individually housed under temperature-
controlled, 12-h-light/-dark conditions and consumed food and water ad
libitum.
Physiological and metabolic variables
All rats were monitored daily for body weight and food and water
intakes. Abdominal circumference and body length were measured every
4 wk using a standard measuring tape under light anesthesia with Zoletil
(10 mg/kg tiletamine, 10 mg/kg zolazepam, i.p.; Virbac) (21). BMI and
energy efficiency were calculated as in a previous study (21).
Oral glucose tolerance tests were performed on rats following a 12-h
food deprivation as described in a previous study (21). AUC was
calculated as in a previous study (24) and plasma concentrations of total
cholesterol, TG, and NEFA were also measured as in a previous study
(21). At the end of the protocol, abdominal fat pads (including
retroperitoneal, epididymal, and omental) were separately removed,
weighed, and expressed as mg/mm of tibial length.
Assessment of cardiovascular structure and function
Systolic blood pressure measurements. Systolic blood pressure was
measured every 4 wk under light sedation with Zoletil (10 mg/kg
tiletamine, 10 mg/kg zolazepam, i.p.; Virbac) as previously described
(21).
Echocardiography. Echocardiographic examinations (Phillips iE33,
12MHz transducer) were performed to assess cardiovascular structure
and function in all groups. The examination was performed at the end of
the protocol as previously described (21,22).
Isolated Langendorff heart preparation. Following terminal anes-
thesia and heparin injection, plasma was collected for biochemical
analyses and isolated rat hearts were perfused for measurement of left
ventricular diastolic stiffness as previously described (21).
Vascular reactivity. Thoracic aortic rings (;4 mm in length; 3–4 rings
from 10 rats/group) were used to obtain cumulative concentration-
response curves for noradrenaline (contraction), sodium nitroprusside
(relaxation), and acetylcholine (relaxation) as in a previous study (21).
Histology of the heart. Two rats from each groupwere exclusively used
for histology. Hearts were fixed, cut, and stained as previously reported
(21).
Assessment of hepatic structure and function
Histology of liver. Livers (n = 8/group) were isolated and weighed. Two
rats from each group were exclusively used for histology. Liver portions
were isolated from these rats and fixed, cut, and stained as in a previous
study (21).
Liver enzymes in plasma. Plasma activities of alanine transaminase
(ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and
lactate dehydrogenase (LDH) and the plasma concentrations of albumin,
total bilirubin, urea, and uric acid were determined as previously
described (21).
Western-blot analysis
After perfusion experiments, the heart samples were weighed and
immediately stored at 2808C for protein extraction (n = 4/group).
Similarly, the liver samples were immediately isolated after weighing the
liver (n = 4/group) and were stored at 2808C for protein extraction.
These samples were homogenized and sonicated after adding cell lysis
buffer, followed by centrifugation at 15,000 3 g for 30 min at 48C.
Supernatants were used to measure the protein concentration in each
sample by the bicinconinic acid method (Thermo Scientific). Superna-
tants in equal concentrations from each group were used in Western-blot
analyses to study the expression of carnitine palmitoyltransferase
1 (CPT1), nuclear factor (erythroid-derived 2)-related factor-2 (Nrf2),
heme oxygenase-1 (HO-1) (antibodies from Santa Cruz Biotechnology),
NF-kB, caspase-3 (antibodies from Cell Signaling Technology), and b-
actin (antibody from Sigma-Aldrich) in the liver and heart. For
quantitative analysis, the expression of proteins was normalized to the
expression of b-actin.
Statistical analysis
Values are presented as mean 6 SEM. Results were tested for variance
using Bartlett’s test and variables that were not normally distributed
were transformed (using log 10 function) prior to statistical analyses. All
the groups were tested for effects of diet, treatment, and their interaction
by 2-way ANOVA. When the interaction and/or the main effects were
significant, means were compared using the Newman-Keuls multiple
comparison post test. Mean daily quercetin intakes in CQ and HQ
groups were compared with Student’s t test. P , 0.05 was considered
significant. All statistical analyses were performed using GraphPad Prism
version 5.00 for Windows.
Results
Physiological variables. Body weight was higher in the H rats
than in the C rats at 16 wk. Although body weight was higher in
CQ than in C rats at 16 wk, it did not differ between the H and
HQ rats at 16 wk (Table 1). H rats consumed less food and
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water compared with C rats. However, total energy intake was
higher in the H rats than in the C rats. HQ rats consumed more
food and water than H rats, whereas CQ rats consumed less
water and more food compared with C rats. CQ and HQ rats
had higher energy intakes compared with C and H rats,
respectively (Table 1). Energy efficiency and BMI were higher
in the H rats than in the C rats. CQ rats had higher whereas HQ
rats had lower energy efficiency compared with C and H rats,
respectively. BMI in CQ and HQ rats did not differ from C and
H rats, respectively (Table 1). Abdominal circumference was
higher in H rats than in C rats. Abdominal circumference was
lower in HQ rats compared with H rats, whereas it did not differ
between the C and CQ rats (Table 1). Relative to body weight,
the daily intake of quercetin was greater in CQ rats (64.3 6
1.6mg/kg body weight) compared withHQ rats (48.56 1.1mg/kg
body weight) due to greater food intake (P , 0.0001).
Metabolic variables. Higher basal blood glucose concentrations
and AUC in the H rats compared with C rats were normalized in
HQ rats and there was no effect of quercetin in CQ rats on basal
blood glucose concentrations and AUC (Table 1). Plasma concen-
trations of total cholesterol, TG, and NEFA were higher in the H
rats than in C rats. CQ rats did not differ in plasma total cholesterol
concentrations from C rats, whereas plasma concentrations of TG
and NEFAwere higher in the CQ rats than in the C rats (Table 1).
H and HQ rats did not differ in plasma concentrations of total
cholesterol and NEFA, whereas plasma TG concentrations were
higher in HQ rats than in H rats (Table 1). Abdominal fat pad
weights (retroperitoneal, epididymal, and omental) were higher in
H rats compared with C rats and were normalized in HQ rats, but
lower in the CQ rats than in the C rats (Table 1).
Cardiovascular structure and function. The LV (left ventri-
cle) of the heart from H rats had more infiltration of inflamma-
tory cells (Supplemental Fig. 1C) along with hypertrophy and
more collagen deposition (Supplemental Fig. 1G) than C rats
(Supplemental Fig. 1A,E). These changes were attenuated in the
LV of the HQ rats (Supplemental Fig. 1D,H). Systolic blood
pressure was higher in H rats compared with C rats at 16 wk. It
was normalized in HQ rats, whereas it was lower in CQ rats
than in C rats (Table 2). The left ventricular internal diameter
during systole and diastole and the systolic volume were higher
in H rats than in C rats, whereas these variables were normalized
in HQ rats and did not differ between the C and CQ rats (Table
2). Left ventricular posterior wall thickness during diastole was
higher in H rats compared with C rats and it did not differ in the
CQ and HQ rats compared with the C and H rats, respectively.
Relative wall thickness did not differ between the C and H rats,
whereas it was higher in both CQ and HQ rats compared with C
and H rats, respectively (Table 2). Indicators of ventricular
function (fractional shortening, ejection fraction, and the ratio
of early mitral inflow velocity to late mitral inflow velocity) were
lower in H rats than in C rats, indicating impaired ventricular
function (Table 2). These indicators of ventricular function were
normalized with quercetin supplementation in HQ rats (Table
2). The estimated LVmass was higher in H rats compared with C
rats and did not differ between H and HQ rats, whereas it was
higher in CQ rats than in C rats. The actual LV wet weight (with
septum) did not differ between the groups. The right ventricular
wet weight did not differ between the C and H rats, was higher
in the HQ rats than in the H rats, but did not differ between the
C and CQ rats (Table 2). The left ventricular diastolic stiffness
constant was higher in H rats compared with C rats and it was
lower in HQ rats than in H rats, whereas it did not differ
between the C and CQ rats (Table 2). Vascular responses,
including noradrenaline-induced contraction and sodium nitro-
prusside- and acetylcholine-induced relaxation, were impaired
in H rats compared with C rats (Fig. 1A–C). Noradrenaline-
TABLE 1 Physiological and metabolic variables in rats fed C or H diets for 8 wk and those diets or CQ or
HQ diets for an additional 8 wk1
Variables
P value
C CQ H HQ D Q D3Q
Physiological variables
Initial body weight, g 334 6 1 332 6 1 334 6 1 331 6 2 0.71 0.07 0.71
Final body weight, g 406 6 5c 441 6 12b 499 6 9a 498 6 13a ,0.0001 0.11 0.09
Water intake, mL/d 31.4 6 1.1a 24.8 6 1.0b 19.6 6 0.8c 23.4 6 0.7b ,0.0001 0.13 ,0.0001
Food intake, g/d 30.4 6 0.7b 34.0 6 0.4a 22.1 6 0.5d 28.2 6 0.5c ,0.0001 ,0.0001 0.026
Energy intake, kJ/d 349 6 10d 382 6 6c 462 6 9b 592 6 11a ,0.0001 ,0.0001 ,0.0001
Energy efficiency, kJ/g 0.19 6 0.01c 0.28 6 0.03b 0.36 6 0.02a 0.28 6 0.02b 0.0003 0.82 0.0003
BMI, g/cm2 0.65 6 0.01b 0.66 6 0.01b 0.74 6 0.01a 0.75 6 0.01a ,0.0001 0.32 1.00
Abdominal circumference, cm 19.6 6 0.4c 19.0 6 0.4c 23.3 6 0.4a 20.9 6 0.2b ,0.0001 0.0002 0.017
Metabolic variables
Basal blood glucose, mmol/L 4.0 6 0.1b 3.9 6 0.1b 5.0 6 0.1a 4.2 6 0.2b ,0.0001 0.002 0.012
Blood glucose AUC, mmol/L  min 680 6 13b 656 6 8b 771 6 10a 641 6 24b 0.016 ,0.0001 0.001
Plasma total cholesterol, mmol/L 1.4 6 0.1b 1.4 6 0.1b 2.0 6 0.1a 1.8 6 0.1a ,0.0001 0.32 0.32
Plasma TG, mmol/L 0.4 6 0.1c 1.0 6 0.1ab 0.8 6 0.1b 1.3 6 0.2a 0.012 0.0002 0.71
Plasma NEFA, mmol/L 1.2 6 0.3b 2.9 6 0.5a 3.6 6 0.7a 3.4 6 0.7a 0.016 0.20 0.11
Retroperitoneal fat, mg/mm tibial length 213 6 9b 135 6 7c 357 6 21a 220 6 11b ,0.0001 ,0.0001 0.031
Epididymal fat, mg/mm tibial length 129 6 11b 87 6 3c 225 6 14a 141 6 4b ,0.0001 ,0.0001 0.029
Omental fat, mg/mm tibial length 93 6 6b 68 6 4c 194 6 12a 103 6 4b ,0.0001 ,0.0001 ,0.0001
Total abdominal fat, mg/mm tibial length 435 6 24b 290 6 9c 775 6 46a 465 6 14b ,0.0001 ,0.0001 0.005
1 Values are mean 6 SEM, n = 10. Means in a row with superscripts without a common letter differ, P , 0.05. C, corn starch–rich diet-fed
rats; CQ, corn starch–rich diet-fed rats treated with quercetin; D, effects of diet; D3Q, interaction between the effects of diet and
quercetin; H, high-carbohydrate, high-fat diet-fed rats; HQ, high-carbohydrate, high-fat diet-fed rats treated with quercetin; NEFA,
nonesterified fatty acids; Q, effects of quercetin.
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induced contraction and acetylcholine-induced relaxation were
normalized in HQ rats, whereas these responses did not differ
between the C and CQ rats (Fig. 1A,C). The HQ rats had a greater
sodium nitroprusside-induced relaxation response compared with
H rats, whereas CQ rats had a lower response to sodium
nitroprusside compared with C rats (Fig. 1B).
Hepatic structure and function. Liver from H rats had more
infiltration of inflammatory cells (Supplemental Fig. 2C) than C
rats (Supplemental Fig. 2A) along with presence of fat vacuoles
(Supplemental Fig. 2G) and portal fibrosis (Supplemental Fig.
2K), which were absent in the liver from C rats (Supplemental
Fig. 2E,I). The wet weight of the liver was higher in H rats than
in C rats and normalized in HQ rats, whereas it was lower in CQ
rats than in C rats (Table 3). Plasma activities of ALT, AST, ALP,
and LDH were higher in H rats compared with C rats. Plasma
activities of ALT and ALP were normalized in HQ rats, whereas
they were lower in CQ rats than in C rats. Plasma ASTand LDH
activities did not differ between C and CQ rats. Plasma AST
activities did not differ between the H and HQ rats, whereas
plasma LDH activity was normalized in HQ rats (Table 3).
Although plasma total bilirubin concentrations did not differ
between the C and H rats, they were lower in HQ rats compared
with H rats. Plasma urea and plasma uric acid concentrations
were lower and higher, respectively, in H rats than in C rats. The
HQ rats had higher plasma urea concentrations compared with
H rats, although not normalized, whereas plasma uric acid
concentrations were normalized in HQ rats (Table 3).
Expression of regulatory proteins in the liver and the
heart. In the liver from H rats, the protein expression of Nrf2,
HO-1, CPT1, and caspase-3 was lower whereas NF-kB expres-
sion was higher compared with C rats. In HQ rats, the
expression of Nrf2, CPT1, and caspase-3 in the liver was
normalized, whereas the expression of HO-1 was higher
compared with H rats. NF-kB expression in the liver was lower
in both CQ and HQ rats compared with C and H rats,
respectively. Hepatic expression of Nrf2 and CPT1 did not differ
between C and CQ rats, whereas hepatic expression of HO-
1 and caspase-3 were higher in CQ rats than in C rats. Hepatic
expression of NF-kB was lower in the CQ rats than in C rats
(Fig. 2A,C). In the heart from H rats, expression of Nrf2, HO-1,
and CPT1 was lower, whereas expression of NF-kB was higher
compared with C rats. HQ rats had higher expression of Nrf2,
HO-1, and CPT1, whereas the expression of NF-kBwas lower in
the heart compared with H rats. Cardiac expression of Nrf2,
HO-1, and CPT1 did not differ between the C and CQ rats,
whereas cardiac expression of NF-kB was lower in CQ rats than
in C rats. Caspase-3 expression in the heart did not differ
between the groups (Fig. 2B,D).
Discussion
Flavonoids are secondary plant metabolites that are useful, e.g.,
for protection of plants against fungal infection (25–27);
quercetin is one of the most common flavonoids in the human
diet. Because quercetin is abundant in plant-based products in
the diet, it is important to determine whether quercetin can
reduce human health challenges such as obesity, metabolic
syndrome, and NAFLD. Hence, we have characterized the
effects of quercetin in an appropriate animal model of diet-
induced metabolic syndrome and associated complications
(21,28). This rodent model mimics most of the complications
associated with human metabolic syndrome (21).
Obesity is a chronic condition characterized by excess fat
deposition in the abdomen, including retroperitoneal, epididy-
mal, and omental fat pads. Excess fat deposition increases
morbidity and mortality through health complications, includ-
ing oxidative stress, chronic low-grade inflammation, dyslipide-
mia, type 2 diabetes, cardiovascular disease, NAFLD, and some
cancers (29–36). In this study, we have targeted NAFLD,
obesity, and cardiovascular disease with quercetin using an
appropriate rat model of metabolic syndrome (21). Using the
same model, we showed that rutin, a glycoside of quercetin,
TABLE 2 Cardiovascular structure and function in rats fed C or H diets for 8 wk and those diets or CQ or
HQ diets for an additional 8 wk1
Variables
P value
C CQ H HQ D Q D3Q
Systolic blood pressure, mm Hg 129 6 1b 123 6 1c 145 6 1a 132 6 2b ,0.0001 0.0001 0.012
LVIDs, mm 3.38 6 0.15b 3.62 6 0.25b 4.88 6 0.14a 3.37 6 0.22b 0.003 0.003 ,0.0001
LVIDd, mm 6.64 6 0.10b 6.60 6 0.10b 7.47 6 0.09a 6.70 6 0.16b 0.0003 0.001 0.003
LVPWd, mm 1.58 6 0.02b 1.76 6 0.05ab 1.81 6 0.09a 1.85 6 0.08a 0.020 0.10 0.30
Systolic volume, mL 43 6 6b 55 6 9b 122 6 11a 44 6 9b 0.0005 0.0007 ,0.0001
Relative wall thickness 0.48 6 0.01b 0.55 6 0.02a 0.48 6 0.01b 0.56 6 0.03a 0.88 0.0006 0.88
Fractional shortening, % 53 6 1a 58 6 3a 39 6 1b 57 6 2a 0.0004 ,0.0001 0.002
Ejection fraction, % 86 6 1a 82 6 3a 72 6 1b 86 6 3a 0.032 0.032 0.0003
E:A ratio 1.88 6 0.06a 1.75 6 0.05ab 1.57 6 0.09b 1.83 6 0.07a 0.11 0.35 0.008
Estimated LV mass, g 0.68 6 0.02c 0.79 6 0.02b 0.91 6 0.03a 0.85 6 0.05ab ,0.0001 0.45 0.013
LV + septum wet weight, mg/mm
tibial length
20.3 6 0.7 21.1 6 0.7 21.8 6 1.1 21.7 6 0.7 0.21 0.67 0.59
Right ventricular wet weight, mg/mm
tibial length
4.8 6 0.2b 4.4 6 0.4b 4.5 6 0.3b 6.1 6 0.4a 0.044 0.08 0.005
LV diastolic stiffness constant (k) 19.8 6 0.8c 20.1 6 1.0c 27.5 6 1.1a 23.4 6 1.1b ,0.0001 0.07 0.038
1 Values are mean 6 SEM, n = 8–10. Means in a row with superscripts without a common letter differ, P , 0.05. C, corn starch–rich diet-
fed rats; CQ, corn starch–rich diet-fed rats treated with quercetin; D, effects of diet; D3Q, interaction between the effects of diet and
quercetin; E:A, ratio of early mitral inflow velocity to late mitral inflow velocity; H, high-carbohydrate, high-fat diet-fed rats; HQ, high-
carbohydrate, high-fat diet-fed rats treated with quercetin; LV, left ventricle; LVIDs, left ventricular internal diameter during systole; LVIDd,
left ventricular internal diameter during diastole; LVPWd, left ventricular posterior wall thickness during diastole; Q, effects of quercetin.
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reduced abdominal fat and hence NAFLD and cardiovascular
remodeling (24). Rutin reduced body weight as well as the
abdominal fat content (24), indicating that it may enhance the
utilization of fat and the lipogenic carbohydrate, fructose, or it
may inhibit further absorption and deposition of fat, or both. In
this study, quercetin did not reduce body weight, but it reduced
the abdominal fat deposition. Previously, a 10-fold higher dose
of quercetin (0.8% in food) compared with our study (0.08% in
food) increased the energy expenditure in high-fat diet-fed mice
without affecting the body weight and body composition (18).
These results suggest that quercetin may cause lipid trafficking
away from the abdomen and hence reduce the associated
complications, mainly NAFLD and cardiovascular remodeling.
Our recent study with chia seeds has demonstrated a link
between lipid trafficking away from abdomen and attenuation
of changes in the structure and function of the heart and the liver
(23). This study also showed that the lipid components in
plasma were higher with quercetin treatment consistent with the
trafficking of fat by the circulation. The lack of difference in the
body weights of quercetin-treated and untreated rats may
suggest that the abdominal fat has been moved to other fat
storage areas or has been converted to muscle mass.
Although dyslipidemia was not attenuated with quercetin,
the other symptoms of metabolic syndrome were attenuated,
including systolic blood pressure, glucose tolerance, and visceral
obesity. Quercetin abolished hepatic steatosis, prevented the
infiltration of inflammatory cells in the liver, and reduced the
portal fibrosis along with improvements in liver function. Along
with these changes were cardioprotective effects, including
reduced collagen deposition, less infiltration of inflammatory
cells, inhibition of cardiomyocyte hypertrophy, reduced ventric-
ular stiffness, lower ventricular dimensions, and a return toward
normal ventricular function.
The presence of inflammation and oxidative stress leads to
cellular injury leading to organ dysfunction (37,38). One of the
major defense systems against stress-related injury is the Nrf2
system (39). Nrf2 is the transcription factor present in inactive
forms in the cell. Once activated, Nrf2 translocates to the
nucleus and activates the antioxidant response elements (39).
This, in turn, gives rise to proteins and enzymes, such as HO-1,
which reduce the cellular stress (39). This suggests that the
activators of Nrf2 system can protect organ systems. Similarly,
the role of NF-kB has been established in the activation of
inflammation (40).
In obesity, oxidative stress and inflammation induce organ
dysfunction (31). Our results showed that the high-carbohy-
drate, high-fat diet upregulated the hepatic and cardiac expres-
sion of NF-kB, whereas the hepatic and cardiac expression of
Nrf2 was downregulated, clearly indicating the presence of
inflammation and oxidative stress in both the liver and the heart.
The hepatic and cardiac expression of NF-kB was down-
regulated by quercetin, confirming its antiinflammatory role.
Similarly, quercetin supplementation upregulated the expression
of Nrf2, resulting in activation of antioxidant response elements,
followed by upregulation of HO-1, and hence the reduction of
oxidative stress. Thus, attenuation of hepatic and cardiac
changes by quercetin could be mediated through its antioxida-
tive and antiinflammatory actions.
Quercetin also upregulated the expression of CPT1, a
regulator of fatty acid oxidation, in the liver and the heart.
This change could attenuate NAFLD, thereby leading to
attenuation of steatosis through higher fatty acid oxidation in
the liver. Caspase-3 expression was also higher in the liver, but
not in the heart, with quercetin as with rutin (24). Greater
expression of caspase-3 indicates higher levels of apoptosis,
possibly leading to the removal of steatotic cells from the liver.
These results explain the role of quercetin in the attenuation of
hepatic changes in metabolic syndrome.
In this study, 0.8 g/kg food of quercetin was used to provide a
daily dose of ~50 mg/kg body weight. This dose corresponds to
;1 g/d quercetin in a 70-kg human based on scaling equation
(41) or ;0.6 g/d based on body surface area comparisons
between rats and humans (42). Although the mean daily human
intake of quercetin is not known, the total intake of polyphenols
is ;1 g/d, with two-thirds being flavonoids, including quercetin
and rutin (43). This suggests that the dose of quercetin used in
this study is realistic in humans.
In conclusion, quercetin was effective against the symptoms
of metabolic syndrome in a diet-induced rat model. The
trafficking of fat away from the abdomen did not lower body
FIGURE 1 Noradrenaline-induced contraction (A), sodium nitroprus-
side-induced relaxation (B), and acetylcholine-induced relaxation (C) in
thoracic aortic preparations from rats fed C or H diets for 8 wk and those
diets or CQ or HQ diets for an additional 8 wk. Values are mean6 SEM,
n = 10. Means at the highest concentration without a common letter
differ, P , 0.05. C, corn starch–rich diet-fed rats; CQ, corn starch–rich
diet-fed rats treated with quercetin; D, effects of diet; D3Q, interaction
between the effects of diet and quercetin; H, high-carbohydrate, high-
fat diet-fed rats; HQ, high-carbohydrate, high-fat diet-fed rats treated
with quercetin; Q, effects of quercetin.
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weight and blood lipids, while the cardiovascular and liver
complications of metabolic syndrome were attenuated. Querce-
tin supplementation attenuated the changes in expression of
markers for oxidative stress and inflammation in the liver and
the heart such as Nrf2, HO-1, andNF-kB along with higher fatty
acid oxidation. Livers had greater expression of caspase-3, an
apoptotic marker, indicating the attenuation of steatosis. Thus,
quercetin can be considered as a nutraceutical with potential for
the treatment of metabolic syndrome; clinical trials of this
relatively safe natural compound should be undertaken.
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Supplemental Figure 1. Inflammation and fibrosis in the heart from rats fed corn starch-rich 
or high-carbohydrate, high-fat diets for 8 wk and those diets or with supplemental quercetin 
for an additional 8 wk. Hematoxylin and eosin staining of LV showing infiltration of 
inflammatory cells (A-D, inflammatory cells marked as “in”; 20) from C (A), CQ (B), H 
(C), and HQ (D) rats. Picrosirius red staining of LV showing collagen deposition and 
hypertrophy (E-H, fibrosis marked as “fi” and hypertrophied cardiomyocytes as “hy”; 40) 
from C (E), CQ (F), H (G), HQ (H) rats.  
C, corn starch-rich diet-fed rats; CQ, corn starch-rich diet-fed rats treated with quercetin; H, 
high-carbohydrate, high-fat diet-fed rats; HQ, high-carbohydrate, high-fat diet-fed rats treated 
with quercetin. 
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Supplemental Figure 2. Inflammation, fat deposition, and fibrosis in the liver from rats fed 
corn starch-rich or high-carbohydrate, high-fat diets for 8 wk and those diets or with 
supplemental quercetin for an additional 8 wk. Hematoxylin and eosin staining of the liver 
showing inflammatory cells (A-D, marked as “in”; 20) and enlarged fat vacuoles (E-H, 
marked as “fv”; 40) from C (A,E), CQ (B,F), H (C,G), and HQ (D,H) rats. Milligan’s 
trichrome staining of the liver showing collagen deposition in the hepatic portal region (I-L, 
marked as “fi”; 20) from C (I), CQ (J), H (K), and HQ (L) rats. 
C, corn starch-rich diet-fed rats; CQ, corn starch-rich diet-fed rats treated with quercetin; H, 
high-carbohydrate, high-fat diet-fed rats; HQ, high-carbohydrate, high-fat diet-fed rats treated 
with quercetin. 
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Abstract
Background Red wine contains many potentially bioac-
tive polyphenols including resveratrol, catechins, antho-
cyanins and flavonoids as well as tannins derived from oak
during maturation. This study examined the effects of a
mixture of ellagitannins from oak bark (Quercus petraea
L.) on cardiovascular, metabolic and liver changes in high-
carbohydrate, high-fat diet–fed rats and in Spontaneously
Hypertensive Rats (SHR).
Methods First, 8-week-old male Wistar rats were divided
into four groups and given either cornstarch diet, corn-
starch diet ? oak bark extract (0.5 mL/kg food), high-
carbohydrate, high-fat diet or high-carbohydrate, high-fat
diet ? oak bark extract (0.5 mL/kg food) for 16 weeks.
Oak bark extract was added to the diets for last 8 weeks of
the feeding period. Secondly, SHR aged 42 weeks fed on
standard chow diet were divided into two groups with and
without oak bark extract treatment for 12 weeks (0.5 mL/
kg food).
Results The high-carbohydrate, high-fat diet induced
signs of metabolic syndrome along with cardiovascular
remodelling and non-alcoholic steatohepatitis. Oak bark
extract attenuated the signs of metabolic syndrome in high-
carbohydrate, high-fat diet–fed rats and improved the
structure and function of the heart and the liver. SHR after
oak bark extract treatment for 12 weeks showed lower
systolic blood pressure, lower cardiac fibrosis and cardiac
stiffness and improved vascular reactivity.
Conclusions Oak bark extract containing ellagitannins
improved cardiovascular, metabolic and liver parameters in
these rat models of human disease, suggesting that part of
the benefits attributed to red wine may be produced by
these ellagitannins.
Keywords Obesity  Cardiovascular disease 
Dyslipidaemia  Ellagitannins  Hypertension
Introduction
Oak has been used in winemaking for more than two
millennia, starting in Europe during the Roman Empire. It
was later discovered that wine stored in oak barrels had
improved characteristics including better taste. The ellag-
itannins, extracted from oak barrels into the wine during
this maturation process [1, 2], are complex naturally
occurring polyphenolic compounds present as monomers
or oligomers [3, 4]. These polyphenols are hexa-
hydroxyldiphenoyl esters of carbohydrates with more than
500 naturally occurring tannins having been identified
[4, 5]. Oak is one of the major sources of ellagitannins [6]
with the European oak (Querces petraea L.) containing
vescalagin, castalagin, grandinin and roburin E as the
major ellagitannins [7]. The ellagitannins, although present
in red wine, have received little attention as potential
bioactive compounds. In contrast, the mechanisms for the
cardiovascular benefits from other polyphenols in red wine
such as resveratrol have been extensively studied [8].
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Other dietary sources of ellagitannins include pome-
granates, chestnuts, raspberries, strawberries, blackberries
and walnuts [5, 6, 9, 10]. Ellagitannins from pomegranates
have been studied for their cardioprotective effects in
laboratory animals [11]. Pomegranate juice attenuated
isoproterenol-induced cardiac necrosis [12] and reduced
angiotensin-induced hypertension, glucosuria and protein-
uria in streptozotocin-induced diabetic rats [13]. Pome-
granate fruit extract containing punicalagin as the major
ellagitannin improved vascular endothelial function with-
out affecting the plasma lipid profile in obese Zucker rats
[14, 15].
Cardiovascular disease, including hypertension, remains
a major cause of morbidity and mortality around the world
[16]. Together with obesity and insulin resistance, hyper-
tension is a key criterion for diagnosis of the metabolic
syndrome, a major risk factor for cardiovascular disease
and type 2 diabetes [17] as well as the development of non-
alcoholic fatty liver disease [18]. Rats are widely used to
mimic human disease states, especially cardiovascular and
endocrine diseases [19–22]. Signs of human metabolic
syndrome can be induced by high-carbohydrate, high-fat
feeding in male Wistar rats [20]. The Spontaneously
Hypertensive Rat (SHR) is the most common rat model of
human hypertension [19].
This study has characterised the cardioprotective and
hepatoprotective effects of oak bark extract (OBE) con-
taining ellagitannins. Studies were performed on high-
carbohydrate, high-fat diet–fed male Wistar rats (H) or the
control cornstarch diet–fed rats (C). Subgroups of H and C
rats were treated with OBE for 8 weeks (HO and CO rats,
respectively). Further, adult male SHR with stable and high
systolic blood pressure (S rats) were treated with OBE for
12 weeks (SO rats). Cardiovascular, hepatic and metabolic
parameters were studied to evaluate whether OBE was
effective in attenuating the complications observed in these
rat models of human disease.
Materials and methods
Extract preparation and characterisation
European oak bark (Querces petraea L.) was converted
into chips and extracted for 6 months at room temperature
in brandy containing 70% alcohol. OBE was filtered to
remove the solid material and de-alcoholised before being
analysed by liquid chromatography/mass spectrometry
(LC/MS) employing electrospray mass spectrometry and
ultraviolet detection. The analysis was performed on a
Micromass Quattro micro tandem quadrupole mass spec-
trometer (Waters, Manchester, UK). LC separation was
provided by a Waters liquid chromatograph (Waters,
Milford, USA), consisting of a 2,695 separation module
and 2,487 dual-wavelength ultraviolet detector. Data were
acquired by the Masslynx data system for both the MS
and ultraviolet data. For LC, a flow rate of 1 mL/min was
used with 0.1% aqueous formic acid and methanol as
solvent and injection volume of 20 lL. For UV detection,
254 and 280 nm wavelengths were used. Castalagin,1
vescalagin (see footnote 1), grandinin (see footnote 1),
roburin E (see footnote 1) and ellagic acid (MP Bio-
medicals, Seven Hills, NSW, Australia) were used as
standards in this procedure. There were 20% uncertainties
in the measurements of ellagitannins derived from the
contributions of the uncertainties in the preparation and
analysis of the standards and samples.
Rats, diets and treatment with OBE
All experimental protocols were approved by The Uni-
versity of Queensland Animal Experimentation Ethics
Committee, under the guidelines of the National Health
and Medical Research Council of Australia. Male Wistar
rats (8 weeks old, weighing 328 ± 2 g, n = 40) and male
SHR (42 weeks old, weighing 422 ± 6 g, n = 20) were
supplied by The University of Queensland Biological
Resources facility and The Prince Charles Hospital,
Brisbane, respectively.
Male Wistar rats were randomly divided into four
experimental groups and were fed with either cornstarch
diet (C; n = 10), cornstarch diet ? OBE (0.5 mL/kg food;
CO; n = 10), high-carbohydrate, high-fat diet (H; n = 10)
or high-carbohydrate, high-fat diet ? OBE (0.5 mL/kg
food; HO; n = 10) for 16 weeks. CO and HO rats were
fed with respective diets for the first 8 weeks without
OBE; OBE was supplemented in the diets of CO and HO
rats for the last 8 weeks of the protocol. Compositions of
H and C diets used in this study have been described
previously [20, 23]. Male adult SHR with high and stable
systolic blood pressure were divided into two groups of 10
rats each, one without treatment (S) and one with OBE
treatment in diet (SO; 0.5 mL/kg in food) for 12 weeks.
All SHR were fed on standard powdered chow diet
(Specialty Feeds, Glen Forest, WA, Australia). All rats
were given ad libitum access to food and water and were
individually housed in temperature-controlled 12-h light–
dark conditions. Energy intakes were calculated as
described previously [20, 23].
1 Pure castalagin, vescalagin, grandinin and roburin E for use as
standards were kindly provided by Professor Ste´phane Quideau,
European Institute of Chemistry and Biology, University of Bordeaux
I, France.
Eur J Nutr
123
Page 131
Physiological and metabolic parameters
All rats were monitored daily for body weight, food intake
and water intake. Abdominal circumference and body
length of rats were measured at the end of protocol using a
standard measuring tape under light anaesthesia with
Zoletil (tiletamine, 10 mg/kg; zolazepam, 10 mg/kg, i.p.;
Virbac, Peakhurst, NSW, Australia). Body mass index
(BMI) and feed efficiency were calculated as previously
described [20].
At the end of the protocol, rats were food-deprived for
12 h and oral glucose tolerance tests were performed as
previously described [20, 23]. Blood glucose concentra-
tions obtained from oral glucose tolerance tests were used
to calculate area under the curve (AUC). Plasma concen-
trations of total cholesterol and triglycerides were deter-
mined using kits and controls supplied by Olympus using
an Olympus analyser (AU 400, Tokyo, Japan) [20, 23].
Non-esterified fatty acids (NEFA) in plasma were deter-
mined using a commercial kit (Wako, Osaka, Japan)
[20, 23]. During terminal experiments, abdominal fat pads
were removed, weighed and normalised to tibial length at
the time of fat removal.
Assessment of cardiovascular structure and function
Systolic blood pressure measurements
Systolic blood pressure of rats was measured under light
anaesthesia with Zoletil, using an MLT1010 Piezo-Electric
Pulse Transducer (ADInstruments, Sydney, Australia), an
inflatable tail-cuff connected to a MLT844 Physiological
Pressure Transducer (ADInstruments, Sydney, Australia)
and PowerLab data acquisition unit (ADInstruments,
Sydney, Australia) [20, 23]. These measurements were
taken every fourth week for C, CO, H and HO groups
starting at initiation of feeding period and every second
week for S and SO groups starting 2 weeks before the
initiation of protocol.
Echocardiography
Echocardiographic examinations (Phillips iE33, 12 MHz
transducer) were performed to assess the cardiovascular
structure and function in all the rats at the end of protocol
as previously described [20].
Isolated Langendorff heart preparation
Rats were killed by injection with Lethabarb (pentobarbi-
tone sodium, 100 mg/kg, i.p.; Virbac, Peakhurst, NSW,
Australia), and heparin (200 IU; Sigma-Aldrich Australia,
Sydney, Australia) was injected through the right femoral
vein. The abdomen was then opened and blood (*5 mL)
was withdrawn from the abdominal aorta, collected into
heparinised tubes and centrifuged at 5,0009g for 15 min to
obtain plasma. Plasma was stored at -20 C before further
biochemical analysis. Hearts were removed and used as
isolated Langendorff heart preparations to assess left ven-
tricular function (n = 8 in each group) as previously
described [20, 23]. End-diastolic pressures were obtained
for the calculation of diastolic stiffness constant (j,
dimensionless). After performing Langendorff heart per-
fusion studies, the heart was separated into right ventricle
and left ventricle (with septum) and weighed.
Vascular reactivity
Thoracic aortic rings (*4 mm in length) from rats (n = 10
from each group) were suspended in an organ bath filled
with Tyrode physiological salt solution bubbled with 95%
O2–5% CO2, maintained at 35 C and allowed to stabilise
at a resting tension of approximately 10 mN. Cumulative
concentration–response curves (contraction) were obtained
for noradrenaline (Sigma-Aldrich Australia, Sydney,
Australia) and cumulative concentration–response curves
(relaxation) were obtained for acetylcholine (Sigma-
Aldrich Australia, Sydney, Australia) and sodium nitro-
prusside (Sigma-Aldrich Australia, Sydney, Australia)
following submaximal (70%) contraction to noradrenaline
[20, 23].
Histology of the heart
Hearts were removed from the rats (n = 2 from each
group) soon after death and were processed for histological
assessments for inflammatory cells and collagen deposition
[20].
Assessment of hepatic structure and function
Livers (n = 8 from each group) from C, CO, H and HO
rats were isolated and weighed. Liver portions were iso-
lated (n = 2 from each group) and fixed in 10% neutral
buffered formalin for three days. These tissue samples were
dehydrated and then embedded in paraffin wax. Thin sec-
tions (5 lm) of these tissues were cut and stained with
haematoxylin and eosin for the determination of inflam-
matory cell infiltration (209) and for determining the
presence of fat vacuoles (409) in the liver. Liver sections
were also stained with Milligan’s Trichrome stain to
determine portal fibrosis (209) [20, 23].
Plasma activities of alanine transaminase (ALT),
aspartate transaminase (AST), alkaline phosphatase (ALP)
and lactate dehydrogenase (LDH) and plasma concentra-
tions of albumin, total bilirubin, urea and uric acid were
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determined using kits and controls supplied by Olympus
using an Olympus analyser (AU 400, Tokyo, Japan) in C,
CO, H and HO rats [20, 23].
Oxidative stress and inflammatory markers
Plasma concentrations of malondialdehyde were determined
by high-performance liquid chromatography (Shimadzu,
Kyoto, Japan) as previously described [24]. Plasma gluta-
thione peroxidase activity was measured using an automated
spectrophotometer (Cobas Mira) as previously described
[25]. Plasma C-reactive protein concentrations were esti-
mated using commercial kits (BD Bioscience, Franklin
Lakes, NJ) according to manufacturer-provided standards
and protocols. Heart and liver samples isolated from rats
(n = 3 from each group) were stored at 280 C. These
samples were thawed and sonicated after adding cell lysis
buffer. These samples were then ultracentrifuged at
100,0009g for 30 min at 4 C. Supernatants were used to
measure the protein concentration in each sample by the bi-
cinchoninic acid method (Thermo Scientific). The expression
of Nrf2 and NF-jB was studied in these supernatants at equal
protein amounts (40 lg) by Western blot analysis.
Statistical analysis
All data are mean ± SEM. Four groups of Wistar rats (C,
CO, H and HO) were tested for homogenous variance using
Bartlett’s test, and variables that were not normally dis-
tributed were transformed (using log 10 function) prior to
statistical analyses. These four groups were tested for
effects of diet, treatment and their interactions by two-way
ANOVA. When interaction and/or the main effects were
significant, means were compared using Newman–Keuls
multiple comparison post-test. Two SHR groups (S and
SO) were compared using Student’s t test. P \ 0.05 was
considered significant. All statistical analyses were per-
formed using GraphPad Prism version 5.00 for Windows
(San Diego, CA, USA).
Results
Chemical profile of OBE and daily intake
of ellagitannins
OBE contained vescalagin (1.2 mg/mL), castalagin (0.8 mg/
mL), roburin E (0.8 mg/mL) and grandinin (2 mg/mL) as
major ellagitannins as well as ellagic acid (0.1 mg/mL).
Daily intakes of individual ellagitannins have been calcu-
lated from these values for CO, HO and SO rats (Table 1).
Effects of OBE on H-induced metabolic syndrome
Physiological and metabolic parameters
Body weights of H rats were higher than those of C rats after
16 weeks and HO rats had lower body weight (Table 2).
Water intake was lower in H rats than in C rats. HO rats had
lower water intake when compared to H rats (Table 2). H
rats consumed less food than C rats, although the energy
intake was higher for H rats. OBE did not change food
intake or energy intake in CO and HO rats (Table 2). H rats
showed abdominal obesity measured as higher abdominal
circumferences and increased abdominal fat pads than C
rats. These signs of obesity were attenuated with OBE
treatment in HO rats (Table 2). BMI and feed efficiency
were higher in H rats than in C rats, and both parameters
were lower in CO and HO rats when compared to C rats and
H rats, respectively (Table 2). H rats showed higher basal
blood glucose concentrations when compared to C rats after
16 weeks, whereas HO rats had lower basal blood glucose
concentrations (Table 2). H feeding impaired oral glucose
tolerance, while OBE treatment improved it (Fig. 1a).
Plasma concentrations of triglycerides, total cholesterol and
NEFA were higher in H rats than in C rats. HO rats had
lower plasma concentrations of these lipid components
(Table 2). H rats showed lower plasma urea concentrations
and higher plasma uric acid concentrations than C rats.
Plasma urea concentrations were higher and plasma uric
Table 1 Daily intake of ellagitannins in OBE-treated rats
Components from OBE CO HO SO
OBE (lL) 16.41 ± 0.37 10.66 ± 0.48 15. 21 ± 0.23
Vescalagin (lg) 19.70 ± 0.44 12.79 ± 0.57 18.25 ± 0.28
Castalagin (lg) 13.13 ± 0.30 8.52 ± 0.38 12.17 ± 0.19
Grandinin (lg) 32.83 ± 0.74 21.31 ± 0.95 30.42 ± 0.46
Roburin E (lg) 13.13 ± 0.30 8.52 ± 0.38 12.17 ± 0.19
Total ellagitannin intake (lg) 78.79 ± 1.77 51.15 ± 2.29 73.00 ± 1.11
Ellagic acid (lg) 1.64 ± 0.04 1.07 ± 0.05 1.52 ± 0.02
Values are mean ± SEM and n = 10 for each group. Daily intake of OBE and individual ellagitannins from extract was calculated based on the
daily intake of food
CO cornstarch diet ? OBE–fed rats, HO high-carbohydrate, high-fat diet ? OBE–fed rats, SO SHR supplemented with OBE
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acid concentrations were lower in HO rats when compared
to H rats (Table 2).
Cardiovascular structure and function
Systolic blood pressure was higher in H rats than in C rats
(Fig. 1b). Left ventricular internal diameter during diastole
(LVIDd), left ventricular wall thickness during diastole
(LVPWd) and systolic volume were higher, whereas frac-
tional shortening and ejection fraction were lower in H rats
than in C rats after 16 weeks (Table 3). HO rats had lower
systolic blood pressure, LVIDd and systolic volume with-
out any change in LVPWd (Fig. 1b and Table 3). HO rats
had higher fractional shortening and ejection fraction than
H rats (Table 3). Left ventricular masses were higher in H
rats than C rats, whereas HO rats showed lower left ven-
tricular masses (Table 3). Infiltration of inflammatory cells
was observed in the hearts of H rats after 16 weeks
(Fig. 2c); this was not observed in HO rats (Fig. 2d).
Left ventricular diastolic stiffness (Table 3) and fibrosis
(Fig. 2g) were higher in H rats than in C rats (Table 3 and
Fig. 2e) after 16 weeks. HO rats had lower left ventricular
diastolic stiffness (Table 3) and fibrosis (Fig. 2h). Impair-
ment in vascular contraction with noradrenaline (Fig. 3a)
and vascular relaxation with acetylcholine and sodium
nitroprusside (Fig. 3b and c) induced by H feeding were
attenuated in HO rats.
Hepatic structure and function
Livers from H rats were higher in wet weight than those
from C rats after 16 weeks, whereas liver wet weights were
lower in HO rats (Table 3). H feeding for 16 weeks caused
hepatic steatosis (Fig. 4c) and fibrosis (Fig. 4k) with infil-
tration of inflammatory cells in liver (Fig. 4g). These
changes in the liver were attenuated in HO rats (Fig. 4d, l,
and h). H rats showed higher plasma activities of ALT,
AST, ALP and LDH when compared to C rats. HO rats had
Table 2 Effects of OBE on H-induced physiological, metabolic and oxidative stress variables in C, CO, H and HO rats
Variables C CO H HO P value
Diet OBE Diet 9 OBE
Physiological variables
Initial body weight (g) 334 ± 7 329 ± 8 332 ± 9 336 ± 6 [0.05 [0.05 [0.05
Final body weight (g) 424 ± 11bc 401 ± 6c 510 ± 10a 440 ± 8b \0.001 \0.001 \0.05
Water intake (mL/day) 30.2 ± 0.6a 31.5 ± 0.4a 20.1 ± 0.4b 18.6 ± 0.5c \0.001 [0.05 \0.01
Food intake (g/day) 30.7 ± 0.7a 32.8 ± 0.8a 22.5 ± 0.8b 22.3 ± 1.0b \0.001 [0.05 [0.05
Energy intake (kJ/day) 345 ± 10b 365 ± 11b 479 ± 15a 476 ± 16a \0.001 [0.05 [0.05
BMI (g/cm2) 0.70 ± 0.01b 0.65 ± 0.01c 0.78 ± 0.01a 0.69 ± 0.01b \0.001 \0.001 [0.05
Feed efficiency (g/kJ) 0.26 ± 0.02b 0.20 ± 0.01c 0.37 ± 0.02a 0.22 ± 0.01bc \0.001 \0.001 \0.05
Abdominal circumference (cm) 21.4 ± 0.3b 19.6 ± 0.2c 23.8 ± 0.3a 20.0 ± 0.2c \0.001 \0.001 \0.001
Abdominal fat pads (mg/mm tibial
length)
407 ± 48b 206 ± 31c 805 ± 53a 415 ± 47b \0.001 \0.001 \0.05
Metabolic variables
Basal blood glucose (mmol/L) 4.2 ± 0.2b 3.8 ± 0.2bc 4.9 ± 0.2a 3.3 ± 0.2c [0.05 \0.001 \0.01
AUC (mmol/L.min) 688 ± 13b 626 ± 18c 768 ± 12a 664 ± 16bc \0.001 \0.001 [0.05
Plasma total cholesterol (mmol/L) 1.5 ± 0.1b 1.3 ± 0.1b 2.0 ± 0.1a 1.4 ± 0.1b \0.01 \0.001 [0.05
Plasma triglycerides (mmol/L) 0.4 ± 0.1b 0.4 ± 0.1b 0.9 ± 0.1a 0.5 ± 0.1b \0.01 [0.05 [0.05
Plasma non-esterified fatty acids
(mmol/L)
1.3 ± 0.1b 1.1 ± 0.1b 2.6 ± 0.2a 1.4 ± 0.1b \0.001 \0.001 \0.001
Plasma urea (mmol/L) 5.5 ± 0.3ab 6.1 ± 0.3a 3.4 ± 0.2c 4.8 ± 0.3b \0.001 \0.01 [0.05
Plasma uric acid (lmol/L) 35.2 ± 1.8b 37.2 ± 2.1b 52.6 ± 2.6a 33.1 ± 1.9b \0.01 \0.001 \0.001
Oxidative stress and inflammatory markers
Plasma malondialdehyde (lmol/L) 27.1 ± 1.1b 27.5 ± 1.0b 31.5 ± 1.2a 28.0 ± 1.2b \0.05 [0.05 [0.05
Plasma glutathione peroxidase activity
(U/L)
1,165 ± 39a 1,135 ± 26a 880 ± 27b 1,063 ± 27a \0.001 \0.05 \0.01
Plasma C-reactive protein (lmol/L) 2.60 ± 0.13bc 3.27 ± 0.17a 2.76 ± 0.08b 2.36 ± 0.10c \0.01 [0.05 \0.001
Values are mean ± SEM and n = 8–10 for each group. Means without a common letter differ, P \ 0.05
C cornstarch diet–fed rats, CO cornstarch diet ? OBE–fed rats, H high-carbohydrate, high-fat diet–fed rats, HO high-carbohydrate, high-fat
diet ? OBE–fed rats
Eur J Nutr
123
Page 134
lower plasma activities of ALT, AST, ALP and LDH than
H rats (Table 3). Plasma bilirubin concentrations were
higher in H rats than in C rats, whereas HO rats had lower
plasma bilirubin concentrations than H rats (Table 3). No
changes were observed in plasma concentrations of albu-
min between the groups (Table 3).
Oxidative stress and inflammatory markers
H rats had higher plasma malondialdehyde concentrations
and lower plasma glutathione peroxidase activities than C
rats. HO rats showed lower plasma malondialdehyde con-
centrations and higher plasma glutathione peroxidase
activities than H rats (Table 2). There was no difference
between the plasma C-reactive concentrations of C and H
rats. C-reactive protein concentrations in plasma were lower
in HR and higher in CR rats when compared to H and C rats,
respectively (Table 2). The heart and the liver from H rats
showed up-regulation of NF-jB expression and down-reg-
ulation of Nrf2 expression. These changes in the expression
of NF-jB and Nrf2 were normalised in HO rats (Fig. 5).
Effects of OBE in SHRs
Physiological and metabolic parameters
OBE extract did not affect body weight, water, food and
energy intake and plasma lipid components in SO rats
(Online Resource 1). Basal blood glucose concentrations,
abdominal obesity and plasma malondialdehyde concen-
trations were lower in SO rats when compared to S rats
(Online Resource 1). Oral glucose tolerance was improved
in SO rats (Online Resource 2).
Cardiovascular structure and function
SO rats had lower systolic blood pressure after 6 weeks of
treatment, and systolic blood pressure was lower in SO rats
than in S rats until 12 weeks of treatment (Fig. 6a). LVIDd
and systolic volumes were lower in SO rats than in S rats
without affecting LVPWd (Table 4). Fractional shortening
and ejection fraction were higher, whereas left ventricular
masses were lower in SO rats than in S rats (Table 4). Left
ventricular diastolic stiffness was lower in SO rats when
compared to S rats as shown by lower diastolic stiffness
constant (Table 4). Vascular responses to noradrenaline
(Fig. 6b), acetylcholine (Fig. 6c) and sodium nitroprusside
(Fig. 6d) were improved in SO rats when compared with S
rats. Infiltration of inflammatory cells was not observed in
SO rats, and fibrosis was lower in SO rats than in S rats
(Online Resource 3).
Oxidative stress and inflammatory markers
SO rats had lower plasma malondialdehyde concentrations
and higher plasma glutathione peroxidase activities than S
rats (Online Resource 1). Plasma C-reactive protein con-
centrations were lower in SO rats when compared to S rats
(Online Resource 1).
Discussion
Red wine contains many polyphenols with potential bio-
logical activities [26], especially resveratrol and catechins
[8, 26, 27], but few other compounds from red wine have
been evaluated. This study has shown that an ellagitannin
mixture extracted from European oak bark used in red wine
maturation produces both cardiac and liver protection as
well as improved metabolic profile in high-carbohydrate,
high-fat diet–fed Wistar rats. In addition, OBE improved
cardiovascular structure and function in the SHR.
Limited studies with related ellagitannins from other
sources, such as punicalagin from pomegranates, have
shown cardiovascular improvement in rat models of
Fig. 1 Effects of OBE on oral glucose tolerance (a) and systolic
blood pressure (b). Values are mean ± SEM and n = 10 for each
group. End-point means without a common letter differ, P \ 0.05.
D, O and D 9 O represent effects of diet, OBE and interaction of diet
and OBE. C cornstarch diet–fed rats, CO cornstarch diet ? OBE–fed
rats, H high-carbohydrate, high-fat diet–fed rats, HO high-carbohy-
drate, high-fat diet ? OBE–fed rats
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Table 3 Effects of OBE on cardiovascular and hepatic variables in H-induced metabolic syndrome in C, CO, H and HO rats
Variables C CO H HO P value
Diet OBE Diet 9 OBE
Cardiovascular variables
LVIDd (mm) 6.46 ± 0.16b 6.40 ± 0.15b 7.21 ± 0.20a 6.56 ± 0.18b \0.05 \0.05 [0.05
LVPWd (mm) 1.58 ± 0.03b 1.60 ± 0.04b 1.75 ± 0.05a 1.66 ± 0.05ab \0.05 [0.05 [0.05
Systolic volume (lL) 54.6 ± 5.1b 50.2 ± 4.0b 115.1 ± 4.8a 58.9 ± 4.1b \0.001 \0.001 \0.001
Relative wall thickness 0.49 ± 0.01 0.48 ± 0.01 0.49 ± 0.01 0.49 ± 0.01 [0.05 [0.05 [0.05
Fractional shortening (%) 53.2 ± 1.3a 52.2 ± 1.4a 42.4 ± 1.0b 51.0 ± 1.5a \0.001 \0.01 \0.001
Ejection fraction (%) 85.1 ± 1.2a 82.6 ± 1.4a 73.0 ± 1.1b 82.1 ± 1.4a \0.001 \0.05 \0.001
Estimated left ventricular mass (g) 0.69 ± 0.02b 0.68 ± 0.02b 0.82 ± 0.03a 0.71 ± 0.02b \0.01 \0.05 \0.05
Left ventricular ? septum wet
weight (mg/mm tibial length)
20.1 ± 0.8b 19.4 ± 0.7b 22.5 ± 0.8a 19.9 ± 0.6b [0.05 \0.05 [0.05
Right ventricular weight
(mg/mm tibial length)
4.1 ± 0.3 4.3 ± 0.3 4.5 ± 0.4 4.2 ± 0.3 [0.05 [0.05 [0.05
Left ventricular diastolic stiffness
constant, j
19.1 ± 0.8c 18.4 ± 0.9c 28.2 ± 1.1a 22.8 ± 0.8b \0.001 \0.01 \0.05
Hepatic variables
Liver wet weight (mg/mm tibial length) 265 ± 10b 232 ± 11b 297 ± 9a 256 ± 10b \0.01 \0.001 [0.05
Plasma ALT (U/L) 35.6 ± 0.7b 32.5 ± 0.6c 48.2 ± 0.6a 36.9 ± 0.9b \0.001 \0.001 \0.001
Plasma AST (U/L) 75.1 ± 4.8b 77.8 ± 5.3b 101.2 ± 6.6a 82.3 ± 5.9b \0.05 [0.05 [0.05
Plasma ALP (U/L) 165 ± 15b 172 ± 15b 257 ± 20a 192 ± 18b \0.01 [0.05 \0.05
Plasma LDH (U/L) 220 ± 20b 206 ± 22b 451 ± 28a 262 ± 25b \0.001 \0.001 \0.001
Plasma albumin (g/L) 27.9 ± 0.3 28.1 ± 0.3 28.5 ± 0.3 28.0 ± 0.3 [0.05 [0.05 [0.05
Plasma total bilirubin (lmol/L) 2.0 ± 0.1b 1.9 ± 0.1b 2.5 ± 0.1a 2.0 ± 0.1b \0.01 \0.01 [0.05
Values are mean ± SEM and n = 8–10 for each group. Means without a common letter differ, P \ 0.05
C cornstarch diet–fed rats, CO cornstarch diet ? OBE–fed rats, H high-carbohydrate, high-fat diet–fed rats, HO high-carbohydrate, high-fat
diet ? OBE–fed rats
Fig. 2 Effects of OBE on inflammation and fibrosis in the heart
induced by H feeding. Haematoxylin and eosin staining of left
ventricle showing infiltration of inflammatory cells (a–d, inflamma-
tory cells as dark spots surrounding the myocytes marked as in) (940)
from cornstarch diet–fed rats (a), cornstarch diet ? OBE–fed rats (b),
high-carbohydrate, high-fat diet–fed rats (c) and high-carbohydrate,
high-fat diet ? OBE–fed rats (d). Picrosirius red staining of left
ventricle showing collagen deposition (e–h, fibrosis marked as fi and
hypertrophied cardiomyocytes as hy) (940) from cornstarch diet–fed
rats (e), cornstarch diet ? OBE–fed rats (f), high-carbohydrate, high-
fat diet–fed rats (g) and high-carbohydrate, high-fat diet ? OBE–fed
rats (h)
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isoproterenol-induced cardiac necrosis and angiotensin-
induced hypertension [12, 13] with no adverse effects even
at high doses [28]. The pharmacokinetics of ellagitannins
from pomegranate have been studied in humans as well as
in rats [29, 30]. Ellagitannins are not absorbed directly due
to their large molecular size [29, 30]. Earlier studies
showed that urolithins, as metabolites of ellagitannins,
were found in the urine of human subjects even 48 h after
pomegranate juice consumption [9]. Ellagic acid, the
hydrolysis product of ellagitannins, was not found in the
blood within a few hours after pomegranate juice con-
sumption [29]. Thus, the bioactive metabolites from el-
lagitannins are likely to be urolithins rather than ellagic
acid.
H feeding in rats leads to the development of signs of
metabolic syndrome and associated end-organ damage
[20]. H rats developed abdominal obesity, hypertension,
dyslipidaemia and impaired glucose tolerance. These
changes were accompanied by cardiovascular remodelling
and non-alcoholic steatohepatitis [20]. Thus, rats fed with
H diet are suitable as a model to demonstrate the major
changes found in human metabolic syndrome [20, 21]. We
have previously shown that these diet-induced signs of the
metabolic syndrome can be reversed by natural products
with antioxidant and anti-inflammatory properties includ-
ing rutin, olive leaf, purple carrots and chia seeds [23, 31–
33]. Ellagitannins from oak bark showed similar biological
activity to these other natural products.
The protective effects mediated by the oak-derived
ellagitannins could relate to free radical scavenging and
anti-inflammatory properties as with pomegranate-derived
ellagitannins [34, 35]. The reduced plasma malondialde-
hyde concentrations and increased plasma glutathione
peroxidase activity along with increased expression of Nrf2
in both the heart and the liver strongly support an antiox-
idant mechanism. The antioxidant activity of ellagitannins
may lead to higher NO bioavailability by removal of
superoxide, leading to reduction in blood pressure.
Increased expression of eNOS, as shown with punicalagin
in hypercholesterolaemic mice [36], would also increase
NO bioavailability. Further, the improvement in vascular
relaxation responses of OBE-treated rats is supportive of a
reduction in blood pressure, especially the improvement
in acetylcholine-induced relaxation, by a response depen-
dent on endothelium-derived NO. In our study, the anti-
inflammatory mechanism is supported by the lower
expression of NF-jB, lower infiltration of inflammatory
cells in the heart and lower collagen deposition in OBE-
treated rats. These outcomes are associated with lower
ventricular stiffness, possibly improving ventricular func-
tion. Similar anti-inflammatory activities of ellagitannins
from pomegranate have been reported in a model of
rheumatoid arthritis and in a colon inflammation model
[35, 37]. The hepatoprotective responses with oak-derived
ellagitannins are shown by reduced plasma activities of
transaminases, attenuation of fat deposition and fibrosis,
and inhibition of infiltration of inflammatory cells in the
liver. The altered expression of NF-jB and Nrf2 in the liver
confirms the antioxidative and anti-inflammatory effects of
Fig. 3 Effects of OBE on vascular responses in rats. Noradrenaline-
induced contraction (a), acetylcholine-induced relaxation (b) and
sodium nitroprusside-induced relaxation (c) in thoracic aortic rings
from C, CO, H and HO rats. Values are mean ± SEM and n = 10 for
each group. End-point means without a common letter differ,
P \ 0.05. D, O and DxO represent effects of diet, OBE and
interaction of diet and OBE. C cornstarch diet–fed rats, CO cornstarch
diet ? OBE–fed rats, H high-carbohydrate, high-fat diet–fed rats,
HO high-carbohydrate, high-fat diet ? OBE–fed rats
Eur J Nutr
123
Page 137
ellagitannins from OBE. Thus, ellagitannins derived from
oak bark ameliorated the changes associated with diet-
induced cardiovascular remodelling and non-alcoholic
fatty liver disease probably by both antioxidant and anti-
inflammatory mechanisms.
OBE-treated rats presented improved metabolic param-
eters including lower abdominal fat deposition and
improved glucose tolerance, as well as protection of the
heart and the liver. Tannins from pomegranate leaf pro-
duced antiobesity effects by inhibiting energy intake in
high–fat diet–fed mice [38], unlike the unchanged energy
intake in our study. Decreased oxidative stress and
inflammation may also be the mechanism responsible for
improving metabolic parameters [39].
The improved cardiovascular parameters were also
measured in adult SHR, the genetic model of choice to
mimic human essential hypertension with extensive car-
diovascular remodelling [19, 22]. OBE-treated rats had
lower systolic blood pressure, ventricular collagen depo-
sition and diastolic cardiac stiffness. Similar effects were
previously reported with the ellagitannin-rich pomegranate
juice in isoproterenol-induced cardiac necrosis model and
Fig. 4 Effects of OBE on fat deposition, inflammation and fibrosis in
rat livers. Haematoxylin and eosin staining of liver showing enlarged
fat vacuoles (a–d, marked as fv) (940) and inflammatory cells (e–h,
marked as in) (920) from cornstarch diet–fed rats (a, e), cornstarch
diet ? OBE–fed rats (b, f), high-carbohydrate, high-fat diet–fed rats
(c, g) and high-carbohydrate, high-fat diet ? OBE–fed rats (d, h) rats.
Milligan’s Trichrome staining of hepatic portal regions showing
fibrosis (i–l, marked as fi) (920) from cornstarch diet–fed rats (i),
cornstarch diet ? OBE–fed rats (j), high-carbohydrate, high-fat diet–
fed rats (k) and high-carbohydrate, high-fat diet ? OBE–fed rats (l)
Fig. 5 Effects of OBE on
expression of Nrf2 and NF-jB
in the heart (a) and the liver (b).
For quantitative analysis, the
expression of these proteins was
normalised against the
expression of b-actin in the
heart (c) and the liver (d).
Values are mean ± SEM,
n = 3. Means without a
common letter differ, P \ 0.05.
C cornstarch diet–fed rats,
CO cornstarch diet ? OBE–fed
rats, H high-carbohydrate,
high-fat diet–fed rats,
HO high-carbohydrate, high-fat
diet ? OBE–fed rats
Eur J Nutr
123
Page 138
in angiotensin II-induced hypertension in streptozotocin-
induced diabetic rats [12, 13]. Improvement in vascular
responses in OBE-treated SHR also suggests higher bio-
availability of NO [36]. Hence, these results with SHR
support the cardioprotective roles of ellagitannins derived
from oak bark.
In conclusion, the health effects of red wine have been
attributed to polyphenols such as resveratrol, rather than to
oak-derived ellagitannins. This study has defined the pro-
tective effects of an oak bark extract containing vescalagin,
castalagin, grandinin and roburin E on the heart and the
liver together with an improved metabolic profile in two rat
models of human metabolic syndrome and human hyper-
tension. These results imply that the ellagitannins from oak
may be important mediators of the benefits of red wine in
humans due to their antioxidant and anti-inflammatory
responses. Clinical trials should be considered with these
ellagitannin extracts.
Acknowledgments This study was supported by The Prince Charles
Hospital Foundation, Brisbane, Australia. We thank Mr. Paul Addi-
son, School of Biomedical Sciences, and Mr. Gary Wilson, School of
Human Movement Studies, both at The University of Queensland,
Australia, for their help with histopathological studies and plasma
oxidant analyses, respectively. We also thank Dr. Fiona Campbell and
Mr. Brian Bynon both at School of Veterinary Science, The Uni-
versity of Queensland, Australia, for their assistance with echocar-
diography and plasma analyses, respectively; Dr Thiruma Arumugam
(The University of Queensland) for assistance with expression studies
and Dr Kate Kauter (University of Southern Queensland) for assis-
tance with C-reactive protein measurements. We also thank Prof.
Ste´phane Quideau, European Institute of Chemistry and Biology,
University of Bordeaux I, France, and Dr. Daniel Jardine, Flinders
Table 4 Effects of OBE on
cardiovascular structure and
function in SHR
Values are mean ± SEM and
n = 8–10 for each group.
* versus S and P \ 0.05,
** versus S and P \ 0.01,
*** versus S and P \ 0.001.
S SHR, SO SHR supplemented
with OBE
Variables S SO
LVIDd (mm) 8.01 ± 0.28 7.05 ± 0.22*
LVPWd (mm) 1.86 ± 0.08 1.72 ± 0.06
Systolic volume (lL) 138 ± 4 112 ± 4***
Relative wall thickness 0.54 ± 0.01 0.53 ± 0.01
Fractional shortening (%) 32.2 ± 1.2 38.5 ± 1.4**
Ejection fraction (%) 68.1 ± 1.0 74.6 ± 1.2***
Estimated left ventricular mass (g) 0.96 ± 0.04 0.82 ± 0.04*
Left ventricular ? septum wet weight (mg/mm tibial length) 28.2 ± 0.8 25.3 ± 0.6**
Right ventricular weight (mg/mm tibial length) 4.5 ± 0.3 4.5 ± 0.2
Left ventricular diastolic stiffness constant, j 32.4 ± 1.3 28.6 ± 1.1*
Fig. 6 Effects of OBE on
systolic blood pressure (a),
vascular contraction by
noradrenaline (b) and vascular
relaxation by acetylcholine
(c) and sodium nitroprusside
(d) in SHR (S) and SHR
supplemented with OBE (SO).
Values are mean ± SEM and
n = 10 for each group. * versus
S (P \ 0.05), ** versus S
(P \ 0.01) and *** versus S
(P \ 0.001)
Eur J Nutr
123
Page 139
University, Australia, for providing ellagitannin standards and ellag-
itannin analyses in the extract, respectively.
Conflict of interest No conflicts of interest.
References
1. Saucier C, Jourdes M, Glories Y, Quideau S (2006) Extraction,
detection, and quantification of flavano-ellagitannins and eth-
ylvescalagin in a Bordeaux red wine aged in oak barrels. J Agric
Food Chem 54:7349–7354
2. Garcia-Estevez I, Escribano-Bailon MT, Rivas-Gonzalo JC,
Alcalde-Eon C (2010) Development of a fractionation method for
the detection and identification of oak ellagitannins in red wines.
Anal Chim Acta 660:171–176
3. Karonen M, Parker J, Agrawal A, Salminen JP (2010) First evi-
dence of hexameric and heptameric ellagitannins in plants
detected by liquid chromatography/electrospray ionisation mass
spectrometry. Rapid Commun Mass Spectrom 24:3151–3156
4. Yoshida T, Amakura Y, Yoshimura M (2010) Structural features
and biological properties of ellagitannins in some plant families
of the order Myrtales. Int J Mol Sci 11:79–106
5. Cerda B, Tomas-Barberan FA, Espin JC (2005) Metabolism of
antioxidant and chemopreventive ellagitannins from strawberries,
raspberries, walnuts, and oak-aged wine in humans: identification
of biomarkers and individual variability. J Agric Food Chem
53:227–235
6. Bakkalbasi E, Mentes A˜z, Artik N (2009) Food ellagitannins-
occurrence, effects of processing and storage. Crit Rev Food Sci
Nutr 49:283–298
7. Puech JL, Mertz C, Michon V, Le Guerneve C, Doco T, Herve
Du Penhoat C (1999) Evolution of castalagin and vescalagin in
ethanol solutions. Identification of new derivatives. J Agric Food
Chem 47:2060–2066
8. Kroon PA, Iyer A, Chunduri P, Chan V, Brown L (2010) The
cardiovascular nutrapharmacology of resveratrol: pharmacoki-
netics, molecular mechanisms and therapeutic potential. Curr
Med Chem 17:2442–2455
9. Seeram NP, Henning SM, Zhang Y, Suchard M, Li Z, Heber D
(2006) Pomegranate juice ellagitannin metabolites are present in
human plasma and some persist in urine for up to 48 hours. J Nutr
136:2481–2485
10. Coates EM, Popa G, Gill CI, McCann MJ, McDougall GJ,
Stewart D, Rowland I (2006) Colon-available raspberry poly-
phenols exhibit anti-cancer effects on in vitro models of colon
cancer. J Carcinog 6:4
11. Basu A, Penugonda K (2009) Pomegranate juice: a heart-healthy
fruit juice. Nutr Rev 67:49–56
12. Jadeja R, Thounaojam M, Patel D, Devkar R, Ramachandran A
(2010) Pomegranate (Punica granatum L.) juice supplementation
attenuates isoproterenol-induced cardiac necrosis in rats. Car-
diovasc Toxicol 10:174–180
13. Mohan M, Waghulde H, Kasture S (2010) Effect of pomegranate
juice on angiotensin II-induced hypertension in diabetic Wistar
rats. Phytother Res 24:S196–S203
14. de Nigris F, Balestrieri ML, Williams-Ignarro S, D’Armiento FP,
Fiorito C, Ignarro LJ, Napoli C (2007) The influence of pome-
granate fruit extract in comparison to regular pomegranate juice
and seed oil on nitric oxide and arterial function in obese Zucker
rats. Nitric Oxide 17:50–54
15. Seeram NP, Lee R, Heber D (2004) Bioavailability of ellagic acid
in human plasma after consumption of ellagitannins from
pomegranate (Punica granatum L.) juice. Clinica Chimica Acta
348:63–68
16. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL
(2006) Global and regional burden of disease and risk factors,
2001: systematic analysis of population health data. Lancet
367:1747–1757
17. Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome-a
new worldwide definition. Lancet 366:1059–1062
18. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso
F, Cristanini G, Tiribelli C (2000) Prevalence of and risk factors
for hepatic steatosis in Northern Italy. Ann Intern Med
132:112–117
19. Doggrell SA, Brown L (1998) Rat models of hypertension, car-
diac hypertrophy and failure. Cardiovasc Res 39:89–105
20. Panchal SK, Poudyal H, Iyer A, Nazer R, Alam MA, Diwan V,
Kauter K, Sernia C, Campbell F et al (2011) High-carbohydrate
high-fat diet-induced metabolic syndrome and cardiovascular
remodeling in rats. J Cardiovasc Pharmacol 57:611–624
21. Panchal SK, Brown L (2011) Rodent models for metabolic syn-
drome research. J Biomed Biotechnol 2011:351982
22. Chan V, Fenning A, Levick SP, Loch D, Chunduri P, Iyer A, Teo
YL, Hoey A, Wilson K et al (2011) Cardiovascular changes
during maturation and ageing in male and female Spontaneously
Hypertensive Rats. J Cardiovasc Pharmacol 57:469–478
23. Poudyal H, Campbell F, Brown L (2010) Olive leaf extract
attenuates cardiac, hepatic, and metabolic changes in high car-
bohydrate-, high fat-fed rats. J Nutr 140:946–953
24. Sim AS, Salonikas C, Naidoo D, Wilcken DE (2003) Improved
method for plasma malondialdehyde measurement by high-per-
formance liquid chromatography using methyl malondialdehyde
as an internal standard. J Chromatogr B Anal Technol Biomed
Life Sci 785:337–344
25. Lexis LA, Fenning A, Brown L, Fassett RG, Coombes JS (2006)
Antioxidant supplementation enhances erythrocyte antioxidant
status and attenuates cyclosporine-induced vascular dysfunction.
Am J Transpl 6:41–49
26. Bertelli AA, Das DK (2009) Grapes, wines, resveratrol, and heart
health. J Cardiovasc Pharmacol 54:468–476
27. Waterhouse AL (2002) Wine phenolics. Ann N Y Acad Sci
957:21–36
28. Cerda B, Ceron JJ, Tomas-Barberan FA, Espin JC (2003)
Repeated oral administration of high doses of the pomegranate
ellagitannin punicalagin to rats for 37 days is not toxic. J Agric
Food Chem 51:3493–3501
29. Seeram NP, Lee R, Heber D (2004) Bioavailability of ellagic acid in
human plasma after consumption of ellagitannins from pomegran-
ate (Punica granatum L.) juice. Clin Chim Acta 348:63–68
30. Cerda B, Llorach R, Ceron JJ, Espin JC, Tomas-Barberan FA
(2003) Evaluation of the bioavailability and metabolism in the rat
of punicalagin, an antioxidant polyphenol from pomegranate
juice. Eur J Nutr 42:18–28
31. Panchal SK, Poudyal H, Arumugam TV, Brown L (2011) Rutin
attenuates metabolic changes, non-alcoholic steatohepatitis, and
cardiovascular remodeling in high carbohydrate-, high-fat diet-
fed rats. J Nutr 141:1062–1069
32. Poudyal H, Panchal S, Brown L (2010) Comparison of purple
carrot juice and beta-carotene in a high-carbohydrate, high-fat
diet-fed rat model of the metabolic syndrome. Br J Nutr
104:1322–1332
33. Poudyal H, Panchal SK, Waanders J, Ward L, Brown L (2011)
Lipid redistribution by a-linolenic acid-rich chia seed inhibits
stearoyl-CoA desaturase-1 and induces cardiac and hepatic pro-
tection in diet-induced obese rats. J Nutr Biochem. doi:
10.1016/j.jnutbio.2010.11.011
34. Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG,
Heber D (2005) In vitro antiproliferative, apoptotic and
Eur J Nutr
123
Page 140
antioxidant activities of punicalagin, ellagic acid and a total
pomegranate tannin extract are enhanced in combination with
other polyphenols as found in pomegranate juice. J Nutr Biochem
16:360–367
35. Larrosa M, Gonzalez-Sarrias A, Yanez-Gascon MJ, Selma MV,
Azorin-Ortuno M, Toti S, Tomas-Barberan F, Dolara P, Espin JC
(2010) Anti-inflammatory properties of a pomegranate extract
and its metabolite urolithin-A in a colitis rat model and the effect
of colon inflammation on phenolic metabolism. J Nutr Biochem
21:717–725
36. de Nigris F, Williams-Ignarro S, Sica V, Lerman LO, D’Armi-
ento FP, Byrns RE, Casamassimi A, Carpentiero D, Schiano C
et al (2007) Effects of a pomegranate fruit extract rich in puni-
calagin on oxidation-sensitive genes and eNOS activity at sites of
perturbed shear stress and atherogenesis. Cardiovasc Res
73:414–423
37. Shukla M, Gupta K, Rasheed Z, Khan KA, Haqqi TM (2008)
Consumption of hydrolyzable tannins-rich pomegranate extract
suppresses inflammation and joint damage in rheumatoid arthri-
tis. Nutrition 24:733–743
38. Lei F, Zhang XN, Wang W, Xing DM, Xie WD, Su H, Du LJ
(2007) Evidence of anti-obesity effects of the pomegranate leaf
extract in high-fat diet induced obese mice. Int J Obes (Lond)
31:1023–1029
39. Iyer A, Brown L (2010) Lipid mediators and inflammation in
glucose intolerance and insulin resistance. Drug Discov Today
Dis Mech 7(3–4):e191–e197
Eur J Nutr
123
Page 141
Online Resource 
Online Resource 1. Effects of OBE on physiological, metabolic, oxidative stress and 
inflammatory parameters in SHR. 
Variables S SO 
Physiological variables 
Initial body weight (g) 426  10 418  6 
Final body weight (g) 467  6 466  8 
Water intake (mL/day) 34.5  0.8 36.4  1.1 
Food intake (g/day) 30.3  0.8 30.4  0.6 
Energy intake (kJ/day) 418  11 450  14 
BMI (g/cm
2
) 0.78  0.01 0.76  0.01 
Feed efficiency (g/kJ) 0.10  0.01 0.11  0.01 
Abdominal circumference (cm) 21.8  0.4 22.3  0.5 
Abdominal fat pads (mg/mm tibial length) 226  17 147  20
**
 
Metabolic variables 
Basal blood glucose (mmol/L) 4.8  0.3 4.0  0.2
*
 
AUC (mmol/L
.
min) 745  15 668  13
**
 
Plasma total cholesterol (mmol/L) 1.7  0.1 1.5  0.1 
Plasma triglycerides (mmol/L) 0.6  0.1 0.5  0.1 
Plasma non-esterified fatty acids (mmol/L) 1.8  0.1 1.6  0.1 
Plasma urea (mmol/L) 4.0  0.2 4.4  0.3 
Plasma uric acid ( mol/L) 44.2  2.2 40.2  1.8 
Oxidative stress and inflammatory markers 
Plasma malondialdehyde ( mol/L) 32.5  1.1 28.1  1.2
*
 
Plasma glutathione peroxidase activity (U/L) 926  31 1015  22
* 
Plasma C-reactive protein ( mol/L) 3.53  0.15 2.12  0.16
*** 
 
Values are mean  SEM and n = 8 - 10 for each group. 
*
 vs. S and P < 0.05, 
** 
vs. S and P < 0.01, 
***
 vs. S and P 
< 0.001. S, SHR; SO, SHR supplemented with OBE. 
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Online Resource 
 
Online Resource 2. Effects of OBE on oral glucose tolerance in S and SO rats. Values are 
mean  SEM and n = 10 for each group. 
***
 vs. S (P < 0.001). S, SHR; SO, SHR 
supplemented with OBE. 
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Online Resource 
 
Online Resource 3. Inflammation and fibrosis in the hearts from SHR and SHR 
supplemented with OBE. Haematoxylin and eosin staining of left ventricle showing 
infiltration of inflammatory cells (A & B, inflammatory cells as dark spots surrounding the 
myocytes marked as “in”) (×40) from SHR (A) and SHR supplemented with OBE (B) rats. 
Picrosirius red staining of left ventricle showing collagen deposition (C & D, fibrosis marked 
as “fi” and hypertrophied cardiomyocytes as “hy”) (×40) from SHR (C) and SHR 
supplemented with OBE (D) rats. 
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Abstract
Background Fruits and nuts may prevent or reverse
common human health conditions such as obesity, diabetes
and hypertension; together, these conditions are referred to
as metabolic syndrome, an increasing problem. This study
has investigated the responses to ellagic acid, present in
many fruits and nuts, in a diet-induced rat model of met-
abolic syndrome.
Methods Eight- to nine-week-old male Wistar rats were
divided into four groups for 16-week feeding with corn-
starch diet (C), cornstarch diet supplemented with ellagic
acid (CE), high-carbohydrate, high-fat diet (H) and high-
carbohydrate, high-fat diet supplemented with ellagic acid
(HE). CE and HE rats were given 0.8 g/kg ellagic acid in
food from week 8 to 16 only. At the end of 16 weeks,
cardiovascular, hepatic and metabolic parameters along
with protein levels of Nrf2, NF-jB and CPT1 in the heart
and the liver were characterised.
Results High-carbohydrate, high-fat diet-fed rats devel-
oped cardiovascular remodelling, impaired ventricular
function, impaired glucose tolerance, non-alcoholic fatty
liver disease with increased protein levels of NF-jB and
decreased protein levels of Nrf2 and CPT1 in the heart and
the liver. Ellagic acid attenuated these diet-induced
symptoms of metabolic syndrome with normalisation of
protein levels of Nrf2, NF-jB and CPT1.
Conclusions Ellagic acid derived from nuts and fruits
such as raspberries and pomegranates may provide a useful
dietary supplement to decrease the characteristic changes
in metabolism and in cardiac and hepatic structure and
function induced by a high-carbohydrate, high-fat diet by
suppressing oxidative stress and inflammation.
Keywords Cardiovascular remodelling  Ellagic acid 
Metabolic syndrome  Non-alcoholic fatty liver disease 
Obesity
Introduction
Metabolic syndrome is the presence of multiple risk factors
for the development of cardiovascular disease and non-
alcoholic fatty liver disease (NAFLD) including hyperten-
sion, insulin resistance, obesity and dyslipidaemia [1–4].
The prevalence of metabolic syndrome, cardiovascular
disease and NAFLD is increasing throughout the world, in
both developed and developing countries [5–7]. Thus, it is
important to establish simple therapeutic concepts, such as
dietary interventions, that decrease the incidence and
symptoms of metabolic syndrome, as well as cardiovas-
cular disease and NAFLD. One of the target strategies in
the treatment of NAFLD is to increase the oxidation of fat
in the liver, for example, by activation of the mitochondrial
regulation of fatty acid oxidation by carnitine palmitoyl-
transferase 1 (CPT1) [8, 9]. Further targets include the
regulators of oxidative stress and inflammation such as
Nrf2 and NF-jB, respectively, that lead to cardiac and
S. K. Panchal  L. Brown (&)
Department of Biological and Physical Sciences,
University of Southern Queensland,
Toowoomba, QLD 4350, Australia
e-mail: Lindsay.Brown@usq.edu.au
S. K. Panchal
School of Biomedical Sciences,
The University of Queensland,
Brisbane, QLD 4072, Australia
L. Ward
School of Chemistry and Molecular Biosciences,
The University of Queensland, Brisbane, QLD 4072, Australia
123
Eur J Nutr
DOI 10.1007/s00394-012-0358-9
Page 145
hepatic damage [10, 11] associated with cardiovascular
disease and NAFLD [12–17]. Normalising the protein
levels of these two transcription factors could prevent
organ damage in these conditions.
A potential dietary intervention is ellagic acid, a poly-
phenol found in a wide variety of nuts as well as in fruits
such as raspberries, pomegranates, grapes and blackcur-
rants [18, 19]. Ellagic acid is a dilactone formed from two
moieties of gallic acid. Ellagic acid, a radical scavenger
[20–22], induced cardioprotection against isoproterenol-
induced myocardial infarction [23, 24] and also showed
anti-proliferative effects in cancerous cell lines [25]. Fur-
ther, ellagic acid reduced the damage in a rat model of
Crohn’s disease, alleviated the oxidative events and
returned the levels of pro-inflammatory proteins to basal
levels probably through MAPKs and NF-jB signalling
pathways [26]. Increased Cu and Zn concentrations in the
liver and serum of cholestatic rats were controlled by
ellagic acid [27]. Hepatoprotective effects with ellagic acid
were measured in vitro and in vivo in models of hepatic
damage [28, 29]. We have previously reported that oak
ellagitannins, complex esters of ellagic acid with glucose,
improved the symptoms of metabolic syndrome in diet-
induced obese rats [30].
This study has defined the responses following chronic
treatment with ellagic acid on the components of metabolic
syndrome and the associated complications including car-
diovascular remodelling and fatty liver in a rodent model of
diet-induced metabolic syndrome. Rats were fed with either
cornstarch or high-carbohydrate, high-fat diets for 16 weeks.
These diets were supplemented with ellagic acid for the last
8 weeks of the protocol. At the end of 16 weeks, metabolic
parameters and structure and function of the heart and the
liver were assessed. Protein levels of CPT1, NF-jB and Nrf2
in the heart and the liver were measured to study potential
mechanisms for the action of ellagic acid.
Materials and methods
Rats and diets
All experimental protocols were approved by The Uni-
versity of Queensland Animal Experimentation Ethics
Committee, under the guidelines of the National Health
and Medical Research Council of Australia. Male Wistar
rats (8–9 weeks old, 337 ± 2 g, n = 47) were obtained
from The University of Queensland Biological Resources
facility. Rats were randomly divided into four groups:
cornstarch diet-fed rats (C; n = 12), cornstarch diet-fed
rats supplemented with ellagic acid (CE; 0.8 g/kg food;
n = 11; MP Biomedicals, Seven Hills, Australia), high-
carbohydrate, high-fat diet-fed rats (H; n = 12) and high-
carbohydrate, high-fat diet-fed rats supplemented with
ellagic acid (HE; 0.8 g/kg food; n = 12). C and H rats
were fed with cornstarch and high-carbohydrate, high-fat
diets, respectively, for 16 weeks. CE and HE rats were also
fed with cornstarch and high-carbohydrate, high-fat diets,
respectively, for 16 weeks with the diets supplemented
with ellagic acid (0.8 g/kg food) for the last 8 weeks of the
protocol. The cornstarch and high-carbohydrate, high-fat
diets have been previously described in detail [31–33].
Drinking water for H and HE rats was supplemented with
25 % fructose, whereas C and CE rats were given drinking
water without any additive. All the rats were individually
housed in temperature-controlled 12-h light/dark condi-
tions and were given ad libitum access to food and water.
Physiological measurements
Body weight, food and water intakes were measured daily for
all rats. Abdominal circumference and body length were
measured at the end of the protocol using a standard mea-
suring tape under light anaesthesia with Zoletil (tiletamine
10 mg/kg, zolazepam 10 mg/kg, i.p.; Virbac, Peakhurst,
Australia) [31]. Energy intake, body mass index and feed
efficiency were calculated as in previous study [31].
Systolic blood pressure measurements
Systolic blood pressure of rats was measured at the end of
the protocol under light anaesthesia with Zoletil (tiletamine
10 mg/kg, zolazepam 10 mg/kg, i.p.), using an MLT1010
Piezo-Electric Pulse Transducer (ADInstruments, Sydney,
Australia) and inflatable tail cuff connected to a MLT844
Piezo-Electric Pressure Transducer (ADInstruments, Syd-
ney, Australia) and PowerLab data acquisition unit
(ADInstruments, Sydney, Australia) [31].
Echocardiography
Echocardiographic examinations (Phillips iE33, 12-MHz
transducer) were performed in all rats at the end of protocol
as previously described [31]. Briefly, rats were anaesthe-
tised using Zoletil (tiletamine 25 mg/kg and zolazepam
25 mg/kg, i.p.; Virbac, Peakhurst, Australia) and Ilium
Xylazil (xylazine 15 mg/kg, i.p.; Troy Laboratories,
Smithfield, Australia) and positioned in dorsal recumbency.
Electrodes attached to the skin overlying the elbows and
right stifle facilitated the simultaneous recording of a lead
II electrocardiogram [31].
Body composition measurements
Dual-energy X-ray absorptiometric measurements were
performed at the end of the protocol using a Norland XR36
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DXA instrument (Norland Corp, Fort Atkinson, WI) under
anaesthesia with Zoletil (tiletamine 25 mg/kg and zolaze-
pam 25 mg/kg, i.p.) and Ilium Xylazil (xylazine 15 mg/kg,
i.p.). Scans were analysed using the manufacturer’s rec-
ommended software for use in laboratory animals (Small
Subject Analysis Software, version 2.5.3/1.3.1; Norland
Corp) as previously described [34]. The precision error of
lean mass for replicate measurements, with repositioning,
was 3.2 %.
Oral glucose tolerance test
At the end of the protocol, rats were deprived of food for
12 h for oral glucose tolerance testing. During this food
deprivation period, fructose-supplemented drinking water
in H and HE groups was replaced with normal drinking
water. Oral glucose tolerance tests were performed after
determining basal blood glucose concentrations in tail vein
blood using Medisense Precision Q.I.D. glucose meters
(Abbott Laboratories, Bedford, MA). Rats were given a
glucose load of 2 g/kg body weight as 40 % glucose
solution via oral gavage and blood glucose concentrations
were measured again 30, 60, 90 and 120 min after oral
glucose administration [31]. Blood glucose concentrations
over the period of 120 min were used to calculate area
under the curve.
Terminal experiments
Rats were euthanised with Lethabarb (pentobarbitone
sodium, 100 mg/kg, i.p.; Virbac, Peakhurst, Australia).
After euthanasia, heparin (200 IU; Sigma-Aldrich Austra-
lia, Sydney, Australia) was injected through the right
femoral vein. The abdomen was then opened and blood
(*5 mL) was withdrawn from the abdominal aorta and
collected into heparinised tubes. Blood was centrifuged at
5,0009g for 15 min to obtain plasma. Hearts were
removed and were used as an isolated Langendorff heart
preparation.
Isolated Langendorff heart preparation
The isolated Langendorff heart preparation assessed left
ventricular function of the rats in all the groups as in pre-
vious studies [31–33]. Hearts isolated from euthanised rats
were perfused with modified Krebs–Henseleit bicarbonate
buffer bubbled with 95 % O2–5 % CO2 and maintained at
35 C. Isovolumetric ventricular function was measured by
inserting a latex balloon catheter into the left ventricle
connected to a Capto SP844 MLT844 physiological pres-
sure transducer and Chart software on a Maclab system
(ADInstruments, Sydney, Australia). All left ventricular
end-diastolic pressure values were measured during pacing
of the heart at 250 beats per min using an electrical stim-
ulator. End-diastolic pressures were obtained from 0 to
30 mmHg for the calculation of diastolic stiffness con-
stant (j, dimensionless) as described in previous studies
[31–33].
Vascular reactivity
Thoracic aortic rings (*4 mm in length; n = 11–12 from
each group) were suspended in an organ bath filled with
Tyrode physiological salt solution bubbled with 95 % O2–
5 % CO2, maintained at 35 C and allowed to stabilise at a
resting tension of *10 mN. Cumulative concentration–
response curves (contraction) were obtained for noradren-
aline (Sigma-Aldrich Australia, Sydney, Australia) and
cumulative concentration–response curves (relaxation)
were obtained for sodium nitroprusside (Sigma-Aldrich
Australia, Sydney, Australia) and acetylcholine (Sigma-
Aldrich Australia, Sydney, Australia) following submaxi-
mal (70 %) contraction to noradrenaline [31].
Organ weights
After isolated heart perfusion studies, hearts (n = 8–9 from
each group) were separated into left ventricles (with sep-
tum) and right ventricles and weighed. Livers (n = 8–9
from each group) were isolated and weighed. Retroperi-
toneal, epididymal and omental abdominal fat pads were
removed separately and weighed. These organ weights
were normalised against the tibial length (48.2 ± 0.1 mm,
n = 35) at the time of organ removal and expressed as
mg/mm of tibial length [31].
Histology
Histology of the heart
Hearts were removed from the rats (n = 3 from each
group) soon after euthanasia and these hearts were fixed in
10 % neutral buffered formalin for 3 days. The samples
were then dehydrated and embedded in paraffin wax. Thin
sections (5 lm) of left ventricle were cut and stained with
haematoxylin and eosin to study infiltration of inflamma-
tory cells and picrosirius red to study collagen deposition
[31].
Histology of the liver
Liver portions were isolated (n = 3) and fixed in 10 %
neutral buffered formalin for three days. These tissue
samples were dehydrated and then embedded in paraffin
wax. Thin sections (5 lm) of these tissues were cut and
stained with haematoxylin and eosin for the determination
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of inflammatory cell infiltration (209) and for determining
the fat vacuoles (409) in liver. Liver sections were also
stained with Milligan’s trichrome stain to determine portal
fibrosis (209) [31].
Plasma biochemistry
Plasma concentrations of total cholesterol and triglycerides
were determined using kits and controls supplied by
Olympus using an Olympus analyser (AU 400, Tokyo,
Japan) [31]. Non-esterified fatty acids (NEFA) in plasma
were determined using a commercial kit (Wako, Osaka,
Japan) [31]. Plasma activity of alanine transaminase
(ALT), aspartate transaminase (AST), alkaline phosphatase
(ALP), lactate dehydrogenase (LDH) and the concentra-
tions of albumin, total bilirubin, urea and uric acid were
determined using kits and controls supplied by Olympus
using an Olympus analyser (AU 400, Tokyo, Japan) [31].
Plasma C-reactive protein (BD Bioscience, Brisbane,
Australia) concentrations were measured using commercial
kits according to manufacturer-provided standards and
protocols.
Regulatory protein levels in the heart and the liver
Heart and liver samples isolated from rats (n = 3 from
each group) were stored at -80 C. These samples were
homogenised and sonicated after adding cell lysis buffer
followed by ultracentrifugation at 100,0009g for 30 min at
4 C. Supernatants were used to measure protein concen-
tration in each sample by bicinconinic acid method
(Thermo Scientific). Supernatants with equal protein
amounts (40 lg) from each group were used in Western
blot analysis to study the protein levels of CPT-1, Nrf2
(antibodies from Santa Cruz Biotechnology, Santa Cruz,
CA), NF-jB (antibody from Cell Signaling Technology,
Danvers, MA) and b-actin (antibody from Sigma-Aldrich
Corp., St. Louis, MO) in the heart and the liver.
Statistical analysis
Values are presented as mean ± SEM. Results were tested
for variance using Bartlett’s test and variables that were not
normally distributed were transformed (using log 10
function) prior to statistical analyses. All the groups were
tested for effects of diet (D), treatment (E) and their
interactions (D 9 E) by two-way ANOVA. When inter-
action and/or the main effects were significant, means were
compared using Newman–Keuls multiple comparison post-
test. Mean ellagic acid intakes between CE and HE groups
were compared using Student’s t-test. P \ 0.05 was con-
sidered significant. All statistical analyses were performed
using GraphPad Prism version 5.00 for Windows.
Results
Physiological and metabolic parameters
Table 1 presents the effects of ellagic acid on physiological
and metabolic parameters in rats. Mean ellagic acid intake
was higher in CE rats (63.4 ± 1.8 mg/kg/day) compared
with HE rats (35.6 ± 1.0 mg/kg/day) due to differences in
food intake and body weights. Food intake and water intake
were decreased in H rats compared with C rats; ellagic acid
reduced food intake in HE rats without changing water
intake, whereas it reduced water intake in CE rats without
changing food intake. Energy intake was increased due to
higher energy content of H diet and H rats showed higher
feed efficiency than C rats. Energy intake was unaffected
by ellagic acid supplementation in both CE and HE rats.
Feed efficiency was lower in HE rats than in H rats. H rats
gained more weight than C rats over the period of
16 weeks. The whole-body fat mass was almost doubled in
H rats compared to C rats without any change in lean mass.
The increase in abdominal fat deposition, as indicated by
increases in abdominal circumference and body mass
index, included the increases in the retroperitoneal, epi-
didymal and omental fat deposits. Body weight and lean
mass were lowered with ellagic acid supplementation in
HE rats without any change in whole-body fat mass. Body
weight and lean mass were unchanged in CE rats. Retro-
peritoneal and omental fat were normalised in HE rats,
while epididymal fat was lowered. Retroperitoneal and
omental fat were lowered in CE rats compared to C rats
without any change in epididymal fat. Total abdominal fat
deposition was lowered in both HE and CE rats compared
with H and C rats, respectively. Basal blood glucose con-
centrations were increased in H rats compared with C rats.
During oral glucose tolerance test, area under the curve
was increased for H rats compared with C rats. During oral
glucose tolerance test, ellagic acid supplementation low-
ered fasting blood glucose concentrations along with area
under the curve in HE rats compared with H rats. Plasma
concentrations of triglycerides, total cholesterol and NEFA
were increased in H rats compared with C rats. Plasma
concentrations of triglycerides, total cholesterol and NEFA
were decreased in HE rats. Plasma concentrations of total
cholesterol were decreased in CE rats without any changes
in plasma concentrations of triglycerides and NEFA.
Plasma uric acid concentrations were increased, whereas
plasma urea concentrations were decreased in H rats.
Plasma uric acid concentrations were decreased, whereas
plasma urea concentrations were increased in HE rats;
these parameters were unaffected in CE rats. Plasma
C-reactive protein concentrations were higher in H rats
than in C rats and were decreased in HE rats compared with
H rats.
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Cardiovascular structure and function
H rats showed cardiovascular abnormalities as increases in
systolic blood pressure, left ventricular internal diameter
during diastole and systole (LVIDd and LVIDs, respec-
tively), systolic volume and diastolic stiffness along with
increased infiltration of inflammatory cells and increased
collagen deposition (Table 2; Fig. 1c, g) compared to
C rats (Fig. 1a, e). These changes were associated with
decreases in left ventricular function including fractional
shortening and ejection fraction (Table 2). Ellagic acid
reduced systolic blood pressure in both CE and HE rats
compared with C and H rats, respectively (Table 2),
whereas it improved structural and functional parameters in
HE rats without changing those parameters in CE rats. Left
ventricular wet weights (with septum) and right ventricular
wet weights were unchanged between the groups (Table 2).
Infiltration of inflammatory cells and collagen deposition
were reduced in left ventricle of HE rats (Fig. 1d, h).
H rats showed reduced aortic contractile responses to
noradrenaline and relaxation responses to sodium nitro-
prusside and acetylcholine. Ellagic acid improved these
responses in HE rats without changing responses in CE rats
(Fig. 2a–c).
Hepatic structure and function
Livers from H rats showed infiltration of inflammatory
cells, steatosis and portal fibrosis (Fig. 3c, g, k). These
livers also showed higher wet weights along with
increased plasma activities of ALT, AST, ALP and LDH
indicating the liver damage caused by H diet (Table 2).
Ellagic acid supplementation in the diet attenuated the
high-carbohydrate, high-fat diet-induced changes in the
liver and plasma activities of the enzymes from HE rats
(Fig. 3d, h, l; Table 2). Plasma concentrations of albumin
and total bilirubin were unchanged between the groups
(Table 2).
Table 1 Effects of ellagic acid on physiological and metabolic variables in C, CE, H and HE rats
Variables P value
C CE H HE D E D 9 E
Physiological variables
Initial body weight (g) 338 ± 2 339 ± 2 342 ± 2 336 ± 2 0.77 0.14 0.06
Final body weight (g) 421 ± 4c 427 ± 8c 515 ± 8a 473 ± 11b \0.0001 0.031 0.005
Food intake (g/day) 30.9 ± 0.7a 31.6 ± 0.5a 23.2 ± 0.6b 21.0 ± 0.4c \0.0001 0.19 0.014
Water intake (mL/day) 32.1 ± 0.7a 30.1 ± 0.5b 20.2 ± 0.7c 19.0 ± 0.4c \0.0001 0.01 0.50
Energy intake (kJ/day) 359 ± 8b 355 ± 5b 466 ± 8a 447 ± 6a \0.0001 0.11 0.29
Feed efficiency (g/kJ) 0.23 ± 0.01c 0.25 ± 0.02c 0.39 ± 0.01a 0.31 ± 0.02b \0.0001 0.06 0.003
Body mass index (g/cm2) 0.63 ± 0.01b 0.66 ± 0.01b 0.72 ± 0.01a 0.72 ± 0.02a \0.0001 0.27 0.27
Abdominal circumference (cm) 19.6 ± 0.4c 19.6 ± 0.2c 23.3 ± 0.4a 21.3 ± 0.3b \0.0001 0.005 0.005
Retroperitoneal fat (mg/mm tibial length) 231 ± 13b 146 ± 12c 378 ± 31a 247 ± 13b \0.0001 \0.0001 0.24
Epididymal fat (mg/mm tibial length) 120 ± 10c 91 ± 7c 240 ± 12a 157 ± 11b \0.0001 \0.0001 0.012
Omental fat (mg/mm tibial length) 103 ± 9b 67 ± 5c 199 ± 10a 116 ± 7b \0.0001 \0.0001 0.006
Total abdominal fat (mg/mm tibial length) 454 ± 20b 303 ± 24c 817 ± 32a 520 ± 29b \0.0001 \0.0001 0.009
Whole-body fat mass (g) 81 ± 7b 113 ± 12b 151 ± 11a 156 ± 16a \0.0001 0.13 0.27
Whole-body lean mass (g) 307 ± 8ab 298 ± 8b 326 ± 9a 281 ± 4b 0.89 0.001 0.023
Metabolic variables
Basal blood glucose (mmol/L) 4.1 ± 0.1b 4.3 ± 0.1b 5.1 ± 0.1a 3.9 ± 0.2b 0.03 0.0005 \0.0001
Area under the curve (mmol/L.min) 685 ± 16b 666 ± 14b 776 ± 12a 696 ± 11b \0.0001 0.0006 0.028
Plasma triglyceride (mmol/L) 0.5 ± 0.1b 0.7 ± 0.1b 1.2 ± 0.1a 0.5 ± 0.1b 0.017 0.017 \0.0001
Plasma total cholesterol (mmol/L) 1.5 ± 0.1a 0.8 ± 0.1c 2.1 ± 0.2a 1.5 ± 0.1b \0.0001 \0.0001 0.71
Plasma NEFA (mmol/L) 1.3 ± 0.2b 1.4 ± 0.1b 2.9 ± 0.4a 1.7 ± 0.2b 0.0006 0.037 0.014
Plasma uric acid (lmol/L) 36.5 ± 3.3b 40.5 ± 3.9b 58.9 ± 6.2a 44.3 ± 3.8b 0.005 0.24 0.043
Plasma urea (mmol/L) 6.0 ± 0.3a 6.9 ± 0.3a 3.3 ± 0.2b 6.2 ± 0.4a \0.0001 \0.0001 0.002
Plasma C-reactive protein (lmol/L) 2.22 ± 0.09b 2.35 ± 0.07b 2.69 ± 0.08a 2.40 ± 0.07b 0.002 0.31 0.011
Values are mean ± SEM and n = 8–12 for each group. Mean values within a row with unlike superscript letters are significantly different
(P \ 0.05)
C cornstarch diet-fed rats, CE cornstarch diet-fed rats supplemented with ellagic acid, H high-carbohydrate, high-fat diet-fed rats, HE high-
carbohydrate, high-fat diet-fed rats supplemented with ellagic acid
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Table 2 Effects of ellagic acid on cardiovascular and hepatic variables in C, CE, H and HE rats
Variables P value
C CE H HE D E D 9 E
Cardiovascular variables
Systolic blood pressure (mmHg) 129 ± 1c 112 ± 1d 145 ± 1a 133 ± 2b \0.0001 \0.0001 0.07
LVIDd (mm) 6.62 ± 0.14b 6.28 ± 0.14b 7.39 ± 0.10a 6.66 ± 0.12b \0.0001 0.0001 0.13
LVIDs (mm) 3.35 ± 0.20b 3.46 ± 0.15b 4.84 ± 0.14a 3.70 ± 0.26b \0.0001 0.012 0.003
Systolic volume (lL) 42.5 ± 7.4b 45.3 ± 5.5b 109.2 ± 8.3a 59.3 ± 6.3b \0.0001 0.002 0.0005
Fractional shortening (%) 51.9 ± 1.2a 53.1 ± 2.4a 38.6 ± 1.5b 48.4 ± 2.3a \0.0001 0.006 0.029
Ejection fraction (%) 86.6 ± 1.8a 82.5 ± 2.0a 71.5 ± 1.3b 81.1 ± 2.7a 0.0002 0.18 0.002
Estimated left ventricular mass (g) 0.67 ± 0.02c 0.66 ± 0.02c 0.91 ± 0.03a 0.79 ± 0.03b \0.0001 0.015 0.038
Left ventricular ? septum wet weight
(mg/mm tibial length)
20.5 ± 0.6 21.1 ± 0.7 22.1 ± 0.7 21.0 ± 0.4 0.23 0.68 0.17
Right ventricular wet weight
(mg/mm tibial length)
4.63 ± 0.21 4.58 ± 0.16 4.48 ± 0.25 4.56 ± 0.19 0.68 0.94 0.76
Left ventricular diastolic stiffness constant, j 20.5 ± 0.8b 21.2 ± 1.1b 27.3 ± 1.3a 23.1 ± 0.9b 0.0002 0.10 0.025
Hepatic variables
Liver wet weight (mg/mm tibial length) 259 ± 11b 270 ± 8b 302 ± 10a 272 ± 5b 0.015 0.29 0.025
Plasma ALT activity (U/L) 35.3 ± 2.7b 34.4 ± 2.1b 57.6 ± 3.5a 34.5 ± 2.9b 0.0003 0.0001 0.0004
Plasma AST activity (U/L) 77 ± 6b 87 ± 4b 105 ± 8a 86 ± 5b 0.007 0.22 0.04
Plasma ALP activity (U/L) 177 ± 14b 174 ± 16b 279 ± 18a 149 ± 18b 0.026 0.0002 0.0004
Plasma LDH activity (U/L) 272 ± 33b 283 ± 23b 417 ± 31a 287 ± 27b 0.014 0.047 0.019
Plasma albumin concentration (g/L) 28.1 ± 0.5 28.6 ± 0.3 28.5 ± 0.5 28.5 ± 0.4 0.73 0.57 0.57
Plasma total bilirubin (lmol/L) 2.3 ± 0.1 2.6 ± 0.2 2.5 ± 0.2 2.5 ± 0.1 0.75 0.34 0.34
Values are mean ± SEM and n = 8–12 for each group. Mean values within a row with unlike superscript letters are significantly different
(P \ 0.05)
C cornstarch diet-fed rats, CE cornstarch diet-fed rats supplemented with ellagic acid, H high-carbohydrate, high-fat diet-fed rats, HE high-
carbohydrate, high-fat diet-fed rats supplemented with ellagic acid
Fig. 1 Effects of ellagic acid supplementation on inflammation and
fibrosis in the heart (n = 3 per group). Haematoxylin and eosin
staining of left ventricle showing infiltration of inflammatory cells (a–d,
inflammatory cells marked as ‘in’; 920) from cornstarch diet-fed
rats (a), cornstarch diet-fed rats supplemented with ellagic acid (b),
high-carbohydrate, high-fat diet-fed rats (c) and high-carbohydrate,
high-fat diet-fed rats supplemented with ellagic acid (d). Picrosirius
red staining of left ventricle showing collagen deposition and
hypertrophy (e–h, fibrosis marked as ‘fi’ and hypertrophied cardio-
myocytes as ‘hy’; 940) from cornstarch diet-fed rats (e), cornstarch
diet-fed rats supplemented with ellagic acid (f), high-carbohydrate,
high-fat diet-fed rats (g) and high-carbohydrate, high-fat diet-fed rats
supplemented with ellagic acid (h)
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Regulatory protein levels in the heart and the liver
In the hearts of H rats, protein levels of NF-jB were higher
than in C rats, whereas the protein levels of CPT1 were
lower than in C rats. These changes were normalised in HE
rats. There was no difference in the cardiac protein levels
of Nrf2 between the groups (Fig. 4a, c). In the liver from
H rats, protein levels of Nrf2 and CPT1 were decreased,
whereas NF-jB protein levels were enhanced compared
with C rats. Protein levels of Nrf2 and CPT1 in the liver
were increased in both CE and HE rats compared with
C and H rats, respectively, whereas NF-jB protein levels
were lowered in both CE and HE rats compared with C and
H rats, respectively (Fig. 4b, d).
Discussion
Metabolic syndrome is the clustering of risk factors for
cardiovascular disease, NAFLD and type 2 diabetes. These
risk factors, such as hypertension and dyslipidaemia, are
also responsible for the increased morbidity and mortality
in humans. Thus, it is important to establish biological
targets for the reduction of risk factors and treatment of this
syndrome. Natural products that are rich in phytochemicals
may be effective against this syndrome. Our previous
studies with natural products including oak bark extract
(rich in ellagitannins) [30], purple carrot juice (rich in
anthocyanins) [35], olive leaf extract (rich in oleorupein)
[32], chia seeds (rich in a-linolenic acid) [33] and studies
with pure phytochemicals from natural products including
rutin [36] and piperine [37] in diet-induced obese rats have
shown promising results against metabolic syndrome.
These studies have also defined the in vivo antioxidant and
anti-inflammatory effects of these natural products. Ellagic
acid is a phytochemical found in nuts and fruits and is part
of the human diet. Thus, we investigated the responses to
dietary ellagic acid supplementation on the targets in
metabolic syndrome.
Rats fed with H diet for 16 weeks presented with the
symptoms as well as the associated complications of met-
abolic syndrome, including central obesity, dyslipidaemia,
hypertension and impaired glucose tolerance. The cardio-
vascular complications included inflammation, cardiac
hypertrophy, fibrosis, increased diastolic stiffness,
increased ventricular dimensions, decreased ventricular
function and decreased vascular responses. The hepatic
complications included steatosis, inflammation and portal
fibrosis along with increased plasma activities of trans-
aminases. These results have previously been characterised
in detail [31]. These changes were accompanied by
decreased protein levels of Nrf2 and CPT1 and increased
protein levels of NF-jB in the heart and the liver together
with increased plasma C-reactive protein concentrations.
Ellagic acid improved hepatic and cardiovascular
structure and function, and normalised metabolic parame-
ters such as glucose tolerance, blood lipid components,
central obesity and physiological parameters such as body
Fig. 2 Effects of ellagic acid supplementation on vascular responses.
Noradrenaline-induced contraction (a), sodium nitroprusside-induced
relaxation (b) and acetylcholine-induced relaxation (c) in thoracic
aortic preparations from C, CE, H and HE rats. Values are
mean ± SEM, n = 10–12. End-point means without a common
letter differ, P \ 0.05. C, cornstarch diet-fed rats; CE, cornstarch diet-
fed rats supplemented with ellagic acid; H, high-carbohydrate, high-
fat diet-fed rats; HE, high-carbohydrate, high-fat diet-fed rats
supplemented with ellagic acid
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weight. Reduced abdominal fat deposition without change
in whole-body fat indicates lipid redistribution as seen with
a-linolenic acid-rich chia seeds [33]. This redistribution of
fat was accompanied by reduction in the blood lipid
components and hepatic steatosis. The increased CPT1
protein levels in both the heart and the liver indicate that
the redistribution of fat was accompanied by increased
fatty acid oxidation.
Oxidative stress and inflammation, causing damage to
the heart and the liver, were also targeted with ellagic acid
Fig. 3 Effects of ellagic acid supplementation on inflammation, fat
deposition and fibrosis in the liver (n = 3 per group). Haematoxylin
and eosin staining of the liver showing inflammatory cells (a–d,
marked as ‘in’; 920) and enlarged fat vacuoles (e–h, marked as ‘fv’;
940) from cornstarch diet-fed rats (a, e), cornstarch diet-fed rats
supplemented with ellagic acid (b, f), high-carbohydrate, high-fat
diet-fed rats (c, g) and high-carbohydrate, high-fat diet-fed rats
supplemented with ellagic acid (d, h) rats. Milligan’s Trichrome
staining of the liver showing fibrosis in the hepatic portal region (i–l,
marked as ‘fi’; 920) from cornstarch diet-fed rats (i), cornstarch diet-
fed rats supplemented with ellagic acid (j), high-carbohydrate, high-
fat diet-fed rats (k) and high-carbohydrate, high-fat diet-fed rats
supplemented with ellagic acid (l)
Fig. 4 Effects of ellagic acid
supplementation on protein
levels of Nrf2, NF-jB and
CPT1 in the heart (a) and the
liver (b). For quantitative
analysis, the protein levels of
these proteins were normalised
against the protein levels of
b-actin in the heart (c) and the
liver (d). Values are
mean ± SEM, n = 3. Means
without a common letter differ,
P \ 0.05. C, cornstarch diet-fed
rats; CE, cornstarch diet-fed rats
supplemented with ellagic acid;
H, high-carbohydrate, high-fat
diet-fed rats; HE, high-
carbohydrate, high-fat diet-fed
rats supplemented with ellagic
acid
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in this study. Nrf2 and NF-jB are important regulators of
the oxidative stress and inflammation pathways, respec-
tively [10, 38]. H diet decreased the protein levels of Nrf2
in the liver and increased NF-jB protein levels in the heart
and the liver. Supplementation with ellagic acid reversed
these changes and attenuated oxidative stress and inflam-
mation in the heart and the liver.
The rats were given 0.8 g ellagic acid/kg of food for a
dose of *50 mg/kg body weight/day. This dose corre-
sponds to *1 g ellagic acid/day in a 70-kg human
according to scaling equation [39] or *0.6 g/day accord-
ing to body surface area comparisons between rats and
humans [40]. Although the average daily human intake of
ellagic acid is not known, the total intake of polyphenols is
*1 g/day [41]. If the majority of polyphenols in the diet
are taken from the fruits and nuts containing ellagic acid,
then the above-mentioned dose is realistic in humans. One
viable approach could be to provide this required amount
through nutraceutical products containing partly purified
ellagic acid from fruits and nuts as the major constituent.
In conclusion, high-carbohydrate, high-fat diet-induced
symptoms of metabolic syndrome in rats were reversed by
ellagic acid, accompanied by changes in protein levels of
Nrf2, CPT1 and NF-jB. These results indicated that these
proteins play important roles in the damage associated
with metabolic syndrome and targeting these proteins
with natural products can attenuate the complications in
metabolic syndrome. Since the prevalence of metabolic
syndrome, NAFLD and cardiovascular disease is still
increasing in the population, the use of either purified ellagic
acid as a complementary medicine or an increased dietary
intake of fruits and nuts could be potentially effective
intervention strategies.
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Abstract
Coffee, a rich source of natural products, including caffeine, chlorogenic acid, and diterpenoid alcohols, has been part of
the human diet since the 15th century. In this study, we characterized the effects of Colombian coffee extract (CE), which
contains high concentrations of caffeine and diterpenoids, on a rat model of human metabolic syndrome. The 8–9 wk old
male Wistar rats were divided into four groups. Two groups of rats were fed a corn starch-rich diet whereas the other two
groups were given a high-carbohydrate, high-fat diet with 25% fructose in drinking water for 16 wk. One group fed each
diet was supplemented with 5% aqueous CE for the final 8 wk of this protocol. The corn starch diet contained ;68%
carbohydrates mainly as polysaccharides, whereas the high-carbohydrate, high-fat diet contained ;68% carbohydrates
mainly as fructose and sucrose together with 24% fat, mainly as saturated andmonounsaturated fat from beef tallow. The
high-carbohydrate, high-fat diet-fed rats showed the symptoms of metabolic syndrome leading to cardiovascular
remodeling and nonalcoholic fatty liver disease. CE supplementation attenuated impairment in glucose tolerance,
hypertension, cardiovascular remodeling, and nonalcoholic fatty liver disease without changing abdominal obesity and
dyslipidemia. This study suggests that CE can attenuate diet-induced changes in the structure and function of the heart
and the liver without changing the abdominal fat deposition. J. Nutr. 142: 690–697, 2012.
Introduction
Increased intake of cafeteria or Western diets with higher energy
content correlates with the deposition of excess energy in the
form of fat in adipose tissue, leading to obesity (1,2). The risk of
cardiovascular disease and nonalcoholic fatty liver disease in-
creases with obesity (3–5), increasing the burden on health costs
(6). Coffee, a widely consumed beverage in Western diets (7),
contains the alkaloid caffeine, the diterpenoid alcohols cafestol
and kahweol, potassium, niacin, magnesium, and antioxidant sub-
stances such as chlorogenic acid and tocopherols (8–11). Epide-
miological studies on the effects of coffee drinking have been
inconclusive, e.g., on hypertension (12), due to the association of
coffee drinking with smoking, higher food intake, less fruit intake,
and sedentary lifestyle compared to tea drinkers (13). An inverse
relationshipwas found between coffee consumption and serum uric
acid concentration, a risk factor for cardiovascular disease (14).
Coffee consumption may reduce the risks of type 2 diabetes,
cardiovascular disease, and some cancers (7,15–18). However,
nonfiltered, boiled coffee, in contrast to filtered coffee, increased
the serum LDL cholesterol concentrations in mildly to moder-
ately hypercholesterolemic middle-aged men and women with-
out affecting HDL cholesterol, VLDL cholesterol, and TG
concentrations in serum (19). This suggests that the brewing
process plays an important role in the effects of coffee (11,20),
because boiled coffee contains higher concentrations of diterpe-
noid alcohols compared to filtered coffee (20). Boiled coffee
consumption has been correlated with the increase in serum
cholesterol concentrations and subsequent increased risk of
cardiovascular disease (11). In atherogenic diet-fed hamsters,
coffee supplementation inhibited weight gain without changing
the lipid profile (20). The individual constituents of coffee may
alter components of metabolic syndrome. In Spontaneously
Hypertensive Rats, 0.5% chlorogenic acid supplementation in
the diet for 8 wk inhibited the increase in blood pressure,
reduced oxidative stress, and improved bioavailability of NO
(21). Caffeine treatment (0.1% in drinking water) to obese,
1 Supported by Dr. Red Nutraceuticals, Brisbane, Australia and The Prince
Charles Hospital Foundation, Brisbane, Australia.
2 Author disclosures: S. K. Panchal, H. Poudyal, J. Waanders, and L. Brown, no
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3 Supplemental Figures 1–3 are available from the “Online Supporting Material”
link in the online posting of the article and from the same link in the online table of
contents at http://jn.nutrition.org.
* To whom correspondence should be addressed. E-mail: Lindsay.Brown@usq.
edu.au.
ã 2012 American Society for Nutrition.
690 Manuscript received October 19, 2011. Initial review completed November 24, 2011. Revision accepted January 4, 2012.
First published online February 29, 2012; doi:10.3945/jn.111.153577.
 at UNIVERSITY O
F QUEENSLAND on April 1, 2012
jn.nutrition.org
D
ow
nloaded from
 
7.DC1.html 
http://jn.nutrition.org/content/suppl/2012/03/20/jn.111.15357
Supplemental Material can be found at:
Page 155
diabetic ZSF1 rats for 30 wk improved glucose and insulin
responses but induced adverse effects on kidney function and
increased plasma cholesterol concentrations (22).
This study measured the effects of CE on metabolic variables
and the structure and function of the cardiovascular system and
liver in high-carbohydrate, high-fat diet-fed rats. High-carbo-
hydrate, high-fat diet-fed rats showed symptoms of metabolic
syndrome with metabolic abnormalities, cardiovascular remod-
eling, and nonalcoholic steatohepatitis (23). Following CE
supplementation for 8 wk, the structure and function of the
heart were characterized through echocardiography, isolated
Langendorff heart preparation, and histopathology, and the
structure and function of the liver were characterized through
histopathology and plasma biochemical analyses. In addition,
metabolic function was characterized through glucose tolerance
testing and plasma insulin concentrations.
Materials and Methods
Rats, experimental diets, and treatment with CE. All experimental
protocols were approved by The University of Queensland Animal
Experimentation Ethics Committee under the guidelines of the
National Health and Medical Research Council of Australia. Male
Wistar rats (8–9 wk old, weighing 337 6 1 g, n = 40) were supplied by
The University of Queensland Biological Resources facility. Rats were
randomly divided into 4 experimental groups: corn starch-rich diet-fed
rats (C7; n = 10), corn starch-rich diet-fed rats treated with CE (CC; n =
10), high-carbohydrate, high-fat diet-fed rats (H; n = 10), and high-
carbohydrate, high-fat diet-fed rats treated with CE (HC, n = 10). The
micronutrient and macronutrient compositions of these diets was
previously described (23–25). H and HC rats were also given 25%
fructose in drinking water along with the diets, whereas normal
drinking water without any supplementation was given to C and CC
rats. C and H rats were fed with respective diets for 16 wk. CC and HC
rats were fed with C and H diets, respectively, for the first 8 wk and
then their diets were supplemented with 5%CE for an additional 8 wk.
CE was prepared by mixing Colombian coffee (50 g) with hot water
(100 mL) and then filtering after 5 min of mixing to obtain 50 mL of
extract. This extract was then mixed in the food by replacing 50 mL
water/kg food. Fresh extract was prepared during each food preparation.
All the rats consumed food and water ad libitum and were individually
housed in temperature-controlled, 12-h-light/-dark conditions.
Rats were monitored daily for bodyweight and food andwater intakes.
Daily coffee intake was calculated from the daily food intake. Oral glucose
tolerance tests and SBP measurements were performed on all group of
rats every 4th wk starting at wk 0 as in previous study (23). Abdominal
circumference and body length of rats were measured using a standard
measuring tape during the period of anesthesia for SBP measurements (23).
BMI and energy efficiency were calculated as in previous study (23). The
concentrations of caffeine, chlorogenic acid, kahweol, and cafestol in
coffee were measured by HPLC (Supplemental Figs. 1–3).
Echocardiography. Echocardiographic examinations (Phillips iE33, 12
MHz transducer) were performed to assess the cardiovascular structure
and function in all rats at the end of protocol as previously described
(23). Briefly, rats were anesthetized using Zoletil (25 mg/kg tiletamine
and 25 mg/kg zolazepam, i.p.; Virbac) and Ilium Xylazil (15 mg/kg
xylazine, i.p.; Troy Laboratories) and positioned in dorsal recumbency.
Electrodes attached to the skin overlying the elbows and right stifle
facilitated the simultaneous recording of a lead II electrocardiogram. A
short-axis view of the left ventricle at the level of the papillary muscles
was obtained and used to direct acquisition of Mmode images of the left
ventricle for measurement of IVSd, LVPWd, LVIDs, and LVIDd.
Measurements were taken in accordance with the guidelines of the
American Society of Echocardiography using the leading-edge method.
Details of this method were previously described (23). The ventricular
contractility indexes were calculated as described in previous studies
(26–28). These indexes included the ratios of SBP:LVIDs, SBP:systolic
volume, and ESS:LVIDs.
Isolated Langendorff heart preparation. Rats were killed with
Lethabarb (pentobarbitone sodium, 100 mg/kg, i.p.; Virbac). After
killing, heparin (200 IU; Sigma-Aldrich Australia) was injected through
the right femoral vein. The abdomen was then opened and blood (;5 mL)
was withdrawn from the abdominal aorta, collected into heparinized
tubes, and centrifuged at 5000 3 g for 15 min to obtain plasma. Plasma
was stored at 2208C before further biochemical analysis. Hearts were
removed and used in isolated Langendorff heart preparations to assess
left ventricular function of the rats, as in a previous study (23).
Hearts isolated from killed rats were perfused with modified Krebs-
Henseleit bicarbonate buffer containing (in mmol/L): NaCl, 119.1; KCl,
4.75; MgSO4, 1.19; KH2PO4, 1.19; NaHCO3, 25.0; glucose, 11.0; and
CaCl2, 2.16. Buffer was bubbled with 95%O2–5%CO2 and maintained
at 358C. Isovolumetric ventricular function was measured by inserting a
latex balloon catheter into the left ventricle connected to a Capto SP844
MLT844 physiological pressure transducer and Chart software on a
Maclab system (ADInstruments). All left ventricular end-diastolic
pressure values were measured during pacing of the heart at 250 beats/
min using an electrical stimulator. End-diastolic pressures were obtained
from 0 to 30 mm Hg for calculation of diastolic stiffness constant (k,
dimensionless) (23).
Vascular reactivity. Thoracic aortic rings (;4 mm in length) were
suspended in an organ bath filled with Tyrode physiological salt solution
bubbled with 95% O2–5% CO2 and maintained at 358C and allowed to
stabilize at a resting tension of;10 mN (23). Cumulative concentration-
response curves (contraction) were obtained for noradrenaline (Sigma-
Aldrich Australia) and cumulative concentration-response curves (re-
laxation) were obtained for acetylcholine (Sigma-Aldrich Australia) and
sodium nitroprusside (Sigma-Aldrich Australia) following submaximal
(70%) contraction to noradrenaline (23).
Organ weights and histology. After performing Langendorff heart
perfusion, hearts were separated into right ventricle and left ventricle
(with septum) (n = 8) for weighing. Livers and abdominal fat pads
(retroperitoneal, epididymal, and omental) were isolated and weighed (n =
8). These organ weights were normalized to the tibial length at the time of
removal and expressed as mg of tissue/mm of tibial length (23). The heart
and liver of rats (n = 2 from each group) were exclusively used for
histopathological analysis as in previous study (23). For staining, thin
sections (5 mm) of tissues were cut and fixed on slides. Heart sections were
stainedwith picrosirius red to study collagen deposition andwere analyzed
using laser confocal microscopy (Zeiss LSM 510 upright confocal
microscope).Hematoxylin and eosin stainwas used to visualize infiltration
of inflammatory cells in both the heart and the liver, whereas Milligan’s
stain was used to study the perivascular fibrosis in the liver. After staining
with hematoxylin and eosin orMilligan’s stains, pictureswere taken with a
ZeissMicroscope. From each tissue sample, three slides were prepared and
two random, nonoverlapping fields were selected from each slide. A
representative picture was randomly selected from each group.
Biochemical analysis of plasma samples. Plasma activities of ALT,
AST, ALP, and LDH, and plasma concentrations of total cholesterol, TG,
albumin, total proteins, total bilirubin, urea, and uric acid were
determined. All these variables were measured using kits and controls
supplied by Olympus using an Olympus analyzer (AU 400) (23). NEFA
in plasma were determined using a commercial kit (Wako) (23). Plasma
concentrations of insulin (Laboratory Diagnostics) were measured using
7 Abbreviations used: ALP, alkaline phosphatase; ALT, alanine transaminase; AST,
aspartate transaminase; C, corn starch-rich diet-fed rats; CC, corn starch-rich diet-
fed rats treated with coffee extract; CE, coffee extract; ESS, end-systolic wall
stress; H, high-carbohydrate, high-fat diet-fed rats; HC, high-carbohydrate, high-fat
diet-fed rats treated with coffee extract; IVSd, interventricular septum thickness
during diastole; LDH, lactate dehydrogenase; LVIDd, left ventriclar internal di-
ameter during diastole; LVIDs, left ventriclar internal diameter during systole;
LVPWd, left ventricular posterior wall thickness during diastole; NEFA, nonester-
ified fatty acids; SBP, systolic blood pressure.
Coffee in diet-induced metabolic syndrome 691
 at UNIVERSITY O
F QUEENSLAND on April 1, 2012
jn.nutrition.org
D
ow
nloaded from
 
Page 156
commercial kits according to manufacturer-provided standards and
protocols using a Titertek Multiskan MCC/340 spectrophotometer
(Flow Laboratories) (23).
Statistical analysis. All data are presented as mean 6 SEM. All the
groups were tested for variance using Bartlett’s test and variables that
were not normally distributed were transformed (using log 10 function)
prior to statistical analyses. All groups were tested for the effects of diets,
treatment, and their interactions by 2-way ANOVA. When interaction
and/or the main effects were significant, means were compared using
Newman-Keuls multiple comparison post-test. Mean daily doses of
caffeine, chlorogenic acid, cafestol, and kahweol between CC and HC
rats were compared using Student’s t test. P , 0.05 was considered
significant. All statistical analyses were performed using GraphPad Prism
version 5.00 for Windows.
Results
Coffee composition and dosage. Coffee contained 12.5 6
0.4 mg/g caffeine (Supplemental Fig. 1), 1.5 6 0.1 mg/g
chlorogenic acid (Supplemental Fig. 2), 4.2 6 0.1 mg/g
cafestol, and 4.9 6 0.1 mg/g kahweol (Supplemental Fig. 3).
The daily doses (mg/kg) were higher in CC rats (caffeine, 68.36
2.6; chlorogenic acid, 8.2 6 0.3; cafestol, 23.0 6 0.9;
kahweol, 26.8 6 1.0) than in HC rats (caffeine, 32.0 6 1.3;
chlorogenic acid, 3.8 6 0.2; cafestol, 10.8 6 0.4; kahweol,
12.5 6 0.5) due to higher food consumption by CC rats (P ,
0.0001) (Table 1).
Physiological and metabolic variables. The H rats had
higher body weights compared to C rats. HC rats had even
higher body weights compared to H rats, whereas the body
weight of CC rats did not differ from C rats (Fig. 1A). Although
H rats consumed less food and water compared to C rats, H rats
had higher energy intake compared to C rats. CC rats had higher
water intake compared to C rats, whereas water intake did not
differ between H and HC rats. CC and HC rats consumed more
food and had higher energy intake compared to C and H rats,
respectively (Table 1). Energy efficiency and BMI were higher in
H rats compared with C rats. These variables did not differ in
CC and HC rats compared with C and H rats, respectively
(Table 1).
Basal blood glucose concentrations were higher in H rats
compared to C rats and these were normalized in HC rats (Table
1). H rats had lower glucose tolerance with a higher AUC
compared to C rats. CE attenuated this impairment of glucose
tolerance with lower AUC in HC rats compared to H rats (Fig.
1B; Table 1). Plasma insulin was higher in H rats compared to C
rats and it was lower in HC rats than H rats (Table 1). Plasma
concentrations of total cholesterol, TG, and NEFA were higher
in H rats compared to C rats. Plasma concentrations of total
cholesterol were lower in HC rats than in H rats (Table 1).
Plasma TG concentrations were higher in HC rats compared to
H rats, whereas their plasma NEFA concentrations did not differ.
Plasma total cholesterol and TG concentrations did not differ
between the C and CC rats, whereas plasmaNEFA concentrations
were higher in CC rats compared to C rats (Table 1).
Abdominal circumference was higher in H rats compared to
C rats. Abdominal circumference was higher in CC rats
compared to C rats, whereas it did not differ between H and
HC rats (Fig. 1C). Similarly, the total abdominal fat deposition
was higher in H rats compared to C rats. Total abdominal fat
deposition as well as retroperitoneal, epididymal, and omental
fat did not differ in CC and HC rats compared to C rats and H
rats, respectively (Table 1).
Cardiovascular structure and function. SBP was higher in H
rats compared to C rats. HC rats had lower SBP than H rats,
whereas SBP in CC rats did not differ from that in C rats (Fig.
1D). LVIDd and LVPWd were higher in H rats compared to C
rats. LVIDd was lower whereas LVPWd was higher in HC rats
compared to H rats. These variables did not differ between CC
and C rats (Table 2). Systolic volume was higher in H rats
TABLE 1 Effects of CE on physiological and metabolic variables in C, CC, H, and HC rats1
Variables
P value
C CC H HC Diet CE Diet 3 CE
Physiological variables
Water intake, mL/d 32.1 6 1.3b 36.7 6 2.0a 18.8 6 1.0c 18.2 6 0.9c ,0.0001 0.15 0.07
Food intake, g/d 31.9 6 0.7b 40.6 6 1.1a 20.7 6 0.5d 23.4 6 0.8c ,0.0001 ,0.0001 0.0007
Energy intake, kJ/d 358 6 8c 433 6 12b 442 6 10b 484 6 10a ,0.0001 ,0.0001 0.11
Energy efficiency, kJ/g 0.23 6 0.02b 0.21 6 0.02b 0.40 6 0.02a 0.45 6 0.03a ,0.0001 0.52 0.14
BMI, g/cm2 0.67 6 0.02b 0.70 6 0.02b 0.78 6 0.02a 0.82 6 0.02a ,0.0001 0.09 0.80
Metabolic variables
Basal blood glucose, mmol/L 4.0 6 0.2b 3.6 6 0.1b 5.0 6 0.2a 4.1 6 0.1b ,0.0001 0.0002 0.12
Blood glucose AUC2, mmol/L  min 680 6 12b 706 6 15b 782 6 16a 710 6 12b 0.0005 0.11 0.001
Plasma insulin, pmol/L 0.22 6 0.01b 0.24 6 0.01b 0.39 6 0.03a 0.26 6 0.03b 0.0002 0.020 0.002
Plasma total cholesterol, mmol/L 1.4 6 0.1b 1.5 6 0.1b 2.0 6 0.1a 1.6 6 0.1b 0.001 0.14 0.017
Plasma TG, mmol/L 0.4 6 0.1b 0.7 6 0.1b 0.7 6 0.1b 1.2 6 0.2a 0.0003 0.0003 0.32
Plasma NEFA, mmol/L 1.2 6 0.2b 2.3 6 0.2a 2.6 6 0.3a 2.6 6 0.3a 0.002 0.038 0.038
Retroperitoneal fat, mg/mm tibial length 184 6 15b 179 6 14b 381 6 22a 347 6 22a ,0.0001 0.30 0.44
Epididymal fat, mg/mm tibial length 110 6 8b 116 6 11b 232 6 16a 268 6 17a ,0.0001 0.13 0.27
Omental fat, mg/mm tibial length 89 6 10b 76 6 9b 183 6 15a 173 6 16a ,0.0001 0.38 0.91
Total abdominal fat, mg/mm tibial length 383 6 35b 370 6 28b 796 6 56a 788 6 73a ,0.0001 0.84 0.96
1 Values are mean6 SEM, n = 8–10. Means in a row with superscripts without a common letter differ, P , 0.05. C, corn starch-rich diet-fed rats; CC, corn starch-rich diet-fed rats
treated with coffee extract; CE, coffee extract; H, high-carbohydrate, high-fat diet-fed rats; HC, high-carbohydrate, high-fat diet-fed rats treated with coffee extract; NEFA,
nonesterified fatty acids.
2 AUC was calculated with x axis as the baseline.
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compared to C rats and it was lower in HC rats compared to H
rats (Table 2). IVSd was higher in H rats than in C rats and it
did not differ in CC and HC rats compared with C and H rats,
respectively. LVIDs was higher in H rats than in C rats and this
was normalized in HC rats (Table 2). The ratios of SBP:LVIDs
and SBP:systolic volume were lower and ESS:LVIDs was higher
in H rats compared to C rats. These indexes for ventricular
contractility were normalized in HC rats. Although relative
wall thickness did not differ between C and H rats, HC rats had
a higher relative wall thickness (Table 2). Fractional shortening
and ejection fractions were lower in H rats compared to C rats;
these variables were higher in HC rats than in H rats and did
not differ in CC rats compared to C rats (Table 2). Time from
mitral valve closure to opening, ejection time, and deceleration
time did not differ between the groups (Table 2). The ratio of
early mitral inflow velocity to late mitral inflow velocity was
lower in H rats compared to C rats, whereas it was higher in
HC rats compared to H rats without being affected in CC rats
compared to C rats (Table 2). Left ventricular mass estimated
from echocardiographic examination was higher in H rats
compared to C rats and it was lower in HC rats compared to H
rats. Wet weight of left ventricle (with septum) was higher in H
rats compared to C rats and was not affected by CE in both CC
and HC rats (Table 2). Right ventricular wet weight did not
differ between H and C rats, whereas right ventricular wet
weights were higher in CC and HC rats compared to those in C
and H rats, respectively (Table 2).
Left ventricle from H rats had a higher infiltration of
inflammatory cells (Fig. 2C) and collagen deposition (Fig. 2G)
than C rats (Fig. 2A,E). CE prevented the infiltration of
inflammatory cells (Fig. 2D) and collagen deposition (Fig. 2H)
in left ventricle of HC rats. Diastolic stiffness measured through
diastolic stiffness constant was higher in H rats compared to C
rats and was lower in HC rats than in H rats (Table 2).
Noradrenaline-induced contraction (Fig. 3A) and sodium
nitroprusside- (Fig. 3B) and acetylcholine- (Fig. 3C) induced
relaxations of isolated thoracic aortic rings were lower in H rats
than in C rats; these responses were normalized in HC rats. In
CC rats, acetylcholine-induced relaxation was higher than in C
rats (Fig. 3C) and noradrenaline-induced contraction (Fig. 3A)
and sodium nitroprusside-induced relaxation (Fig. 3B) did not
differ from C rats.
Hepatic structure and function. Liver from H rats had a
higher infiltration of inflammatory cells (Fig. 4C) and presence
of fat vacuoles (Fig. 4G) than did C rats (Fig. 4A,E) along with
higher liver wet weights (Table 3). Portal fibrosis was higher in
livers from H rats (Fig. 4K) compared to those from C rats (Fig.
4I). Although the fat deposition was attenuated in HC rats (Fig.
4H), the liver wet weights did not differ compared to H rats
(Table 3). CE prevented the infiltration of inflammatory cell and
portal fibrosis in HC rats (Fig. 4D,L).
Plasma activities of ALT, AST, ALP, and LDH were higher in
H rats than in C rats (Table 3). HC rats had lower plasma
activities of these enzymes compared to H rats (Table 3). CC rats
had lower plasma activities of ALT and ALP than C rats where
ASTand LDH did not differ compared to C rats (Table 3). Plasma
concentrations of albumin and total bilirubin did not differ
between the groups (Table 3). Plasma urea concentrations were
lower and plasma uric acid concentrations were higher in H rats
than in C rats. These changes were attenuated inHC rats (Table 3).
Discussion
Coffee is a complex beverage with potential health benefits and
problems, containing many bioactive compounds, including
phenolic acids with antioxidant properties, diterpenoid alco-
hols, and caffeine (20). Thus, understanding the overall effect of
the mixture of all the constituents in coffee is necessary. The
brewing process determines the constituents of CE (11,20);
FIGURE 1 Effects of CE on body weight (A), oral glucose tolerance
(B), abdominal circumference (C), and systolic blood pressure (D) in C,
CC, H, and HC rats. Values are mean6 SEM, n = 10. End-point means
without a common letter differ, P , 0.05. C, corn starch-rich diet-fed
rats; CC, corn starch-rich diet-fed rats treated with coffee extract; CE,
coffee extract; H, high-carbohydrate, high-fat diet-fed rats; HC, high-
carbohydrate, high-fat diet-fed rats treated with coffee extract.
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filtering was preferred to keep the phenolic acids intact and
reduce the diterpenoid content. In most previous studies, coffee
responses were characterized by focusing on one particular
condition, e.g., hypercholesterolemia (11,14,19–21,29). To
overcome this problem, we characterized the effects of CE in a
model with most of the complications of metabolic syndrome,
including obesity, hypertension, impaired glucose tolerance,
cardiovascular remodeling, nonalcoholic fatty liver disease, and
dyslipidemia (23).
High-carbohydrate, high-fat diet induced the symptoms of
metabolic syndrome in rats as in our previous studies (23–25).
We reported that these diet-induced symptoms can be either
reversed or prevented from further progression by intervention
with natural products such as purple carrots (30), olive leaf (24),
TABLE 2 Effects of CE on cardiovascular structure and function in C, CC, H, and HC rats1
Variables
P value
C CC H HC Diet CE Diet 3 CE
LVIDd, mm 6.61 6 0.12b 6.33 6 0.14b 7.46 6 0.11a 6.54 6 0.27b 0.004 0.001 0.07
LVPWd, mm 1.58 6 0.03c 1.62 6 0.04c 1.83 6 0.05b 2.06 6 0.04a ,0.0001 0.002 0.025
IVSd, mm 1.57 6 0.02b 1.62 6 0.04b 1.74 6 0.04a 1.78 6 0.04a ,0.0001 0.22 0.89
LVIDs, mm 3.31 6 0.18b 3.44 6 0.17b 4.86 6 0.14a 3.70 6 0.23b ,0.0001 0.008 0.001
Systolic volume, mL 41.1 6 6.8b 44.6 6 6.2b 120.2 6 7.8a 58.5 6 7.0b ,0.0001 0.0002 ,0.0001
SBP:LVIDs 40.1 6 2.1a 38.0 6 2.3a 30.9 6 1.4b 36.8 6 2.1a 0.014 0.35 0.05
SBP:systolic volume 3930 6 590a 3400 6 640a 1250 6 230b 2950 6 540a 0.005 0.28 0.041
ESS:LVIDs 0.92 6 0.08b 0.98 6 0.08b 1.15 6 0.07a 0.75 6 0.06b 0.73 0.011 0.001
Relative wall thickness 0.48 6 0.01b 0.51 6 0.02b 0.48 6 0.02b 0.60 6 0.02a 0.017 0.0002 0.017
Fractional shortening, % 52.6 6 1.6a 52.9 6 1.9a 38.3 6 1.4b 47.6 6 1.8a ,0.0001 0.007 0.011
Ejection fraction, % 86.9 6 1.6a 83.3 6 2.0ab 72.1 6 1.3c 80.9 6 1.4b ,0.0001 0.11 0.0004
MCMO, ms 114 6 4 114 6 4 114 6 4 104 6 4 0.22 0.22 0.22
Ejection time, ms 91 6 2 91 6 3 88 6 3 86 6 2 0.13 0.70 0.70
E:A ratio 1.91 6 0.12a 1.89 6 0.12a 1.61 6 0.11b 1.78 6 0.10a 0.04 0.17 0.049
Deceleration time, ms 52.1 6 2.0 55.0 6 2.3 55.5 6 4.0 61.2 6 3.3 0.12 0.16 0.64
Estimated left ventricular mass, g 0.67 6 0.02c 0.66 6 0.02c 0.91 6 0.03a 0.81 6 0.03b ,0.0001 0.038 0.09
Left ventricle + septum wet weight, mg/mm tibial length 18.7 6 0.8b 19.9 6 0.8ab 22.1 6 0.9a 21.5 6 1.0ab 0.007 0.74 0.31
Right ventricular wet weight, mg/mm tibial length 4.21 6 0.24b 5.02 6 0.27a 4.49 6 0.32b 5.14 6 0.29a 0.48 0.014 0.78
Left ventricular diastolic stiffness constant (k) 21.1 6 1.3b 20.2 6 1.2b 28.1 6 1.4a 24.1 6 1.5b 0.0003 0.07 0.28
1 Values are mean 6 SEM, n = 8–10. Means in a row with superscripts without a common letter differ, P , 0.05. C, corn starch-rich diet-fed rats; CC, corn starch-rich diet-fed rats
treated with coffee extract; CE, coffee extract; E:A, ratio of early mitral inflow velocity to late mitral inflow velocity; ESS, end-systolic wall stress; H, high-carbohydrate, high-fat
diet-fed rats; HC, high-carbohydrate, high-fat diet-fed rats treated with coffee extract; IVSd, interventricular septum thickness during diastole; LVIDd, left ventricular internal
diameter during diastole; LVIDs, left ventricular internal diameter during systole; LVPWd, left ventricular posterior wall thickness during diastole; MCMO, time from mitral valve
closure to opening; SBP, systolic blood pressure.
FIGURE 2 Effects of CE on inflammation and fibrosis in the heart. Hematoxylin and eosin staining of left ventricle showing infiltration of
inflammatory cells (A–D, inflammatory cells marked as “in”) from C (A), CC (B), H (C), and HC (D) rats. Picrosirius red staining of left ventricle
showing collagen deposition and hypertrophy (E–H, fibrosis marked as “fi” and hypertrophied cardiomyocytes as “hy”) from C (E), CC (F), H (G),
and HC (H) rats. C, corn starch-rich diet-fed rats; CC, corn starch-rich diet-fed rats treated with coffee extract; CE, coffee extract; H, high-
carbohydrate, high-fat diet-fed rats; HC, high-carbohydrate, high-fat diet-fed rats treated with coffee extract.
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chia seeds (25), and rutin (31). The same protocol was used in
this study to show that CE attenuated most of the changes in
cardiovascular and liver structure and function and in glucose
tolerance, whereas abdominal central obesity and dyslipidemia
were unaffected. Although previous studies of coffee have shown
higher serum cholesterol without changing TG concentrations
(19), we found that cholesterol was lower, with higher concen-
trations of TG and NEFA. This inability to lower TG and NEFA
may explain the lack of effect of CE on obesity.
In this study, CE supplementation in diet-induced metabolic
syndrome in rats lowered blood pressure, although earlier
studies characterizing the effects of coffee on hypertension in
humans reported conflicting results (32–34). Earlier reports
support a lowered risk for type 2 diabetes with coffee con-
sumption (35). This study shows that coffee intake in rats is
associated with lower basal blood glucose concentrations and
attenuation of impairment in glucose tolerance despite the
chronic consumption of a diet that impairs the glucose tolerance.
Similarly, plasma insulin was lower in CE-supplemented rats.
The cardiovascular structure showed attenuation of the
dilation and fibrosis in the left ventricle, whereas left ventricular
wall thickness was higher, indicating the presence of hypertro-
phy. Apart from these structural changes, ventricular contrac-
tility was enhanced with CE supplementation. These conditions
resemble the physiological hypertrophy seen in athletes where
the heart becomes more efficient. Recent studies have also
shown beneficial effects of coffee on liver disease, lower bright
liver score indicating fatty liver and liver cancer, because an
inverse relation was found between coffee consumption and the
development of liver complications (36,37). In this study, we
found protective effects of CE on the liver. In diet-induced
metabolic syndrome, there is development of nonalcoholic fatty
liver disease (23,31). Steatosis, inflammation, and fibrosis in the
liver developed by the H diet were attenuated with CE supple-
mentation along with improvements in liver function measured
through plasma liver enzymes.
In nonobese healthy men and women, caffeinated coffee
reduced flow-mediated dilation of brachial artery, indicating the
induction of endothelial dysfunction. This response was induced
by caffeine, because this detrimental effect was not seen with
decaffeinated coffee (38,39). However, these studies measured
acute effects. In healthy as well as diabetic women, long-term
caffeinated and decaffeinated coffee consumption was inversely
associated with the markers of inflammation and endothelial
dysfunction (40). Our study has shown that coffee attenuated
the vascular damage induced by the H diet. These results were
shown as higher vascular contraction with noradrenaline and
higher vascular relaxation with both sodium nitroprusside and
acetylcholine after precontraction with noradrenaline.
Abdominal obesity has been associated with the occurrence
of cardiovascular disease, nonalcoholic fatty liver disease, and
impairment in metabolic function, including glucose tolerance
(41,42). In this study, CE supplementation did not alter the
amount of fat present in the abdominal areas and the plasma
compared to H rats. However, the changes in structure and
function of the heart, blood vessels, and the liver in H rats were
attenuated. These results may classify the CE-supplemented rats
as metabolically healthy. One of the possible reasons could be
the change in types of fatty acid that were stored in the adipose
tissues. A further study determining the types of fatty acid
present in the abdominal area will help in understanding the
mechanisms.
The diterpenoid alcohols cafestol and kahweol may cause
deleterious effects of coffee (11,19,20,43,44), with the coffee
polyphenols producing benefits (20) and caffeine showing
contrasting results, including increases in cholesterol (22). Our
results suggest that all these components were active and the
effects observed were cumulative.
In this study, 50 g of Colombian coffee was used to make
50mL of CE, which was thenmixed in 1 kg of food. This provided
a daily dose of ~3 g coffee/kg body weight in rats. This dose
corresponds to 60 g coffee/d in a 70-kg human based on scaling
equation (45) or 35 g/d based on body surface area comparisons
between rats and humans (46). Generally, 7–8 g coffee is re-
quired to make a cup of coffee (19). Thus, the dose of coffee used
in this study corresponds to ~4–5 cups/d of coffee according to
body surface area comparisons and ~7–8 cups/d of coffee ac-
cording to scaling equations. Similarly, the daily dose of caffeine
from CE corresponds to 30–35 mg/kg in rats depending on their
body weight. This dose corresponds to ~0.6 g/d for a 70-kg
human (according to scaling equation) (45) and 0.35 g/d
FIGURE 3 Effects of CE on noradrenaline-induced contraction (A),
sodium nitroprusside-induced relaxation (B), and acetylcholine-induced
relaxation (C) in thoracic aortic preparations from C, CC, H, and HC rats.
Values are mean 6 SEM, n = 10. End-point means without a common
letter differ, P, 0.05. C, corn starch-rich diet-fed rats; CC, corn starch-
rich diet-fed rats treated with coffee extract; CE, coffee extract; H, high-
carbohydrate, high-fat diet-fed rats; HC, high-carbohydrate, high-fat
diet-fed rats treated with coffee extract.
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(according to body surface area calculations) (46). An earlier
report associated best performance with an intake of 0.4 g/d
caffeine in humans (47).
In conclusion, CE attenuated hypertension and impairment
in glucose homeostasis without affecting abdominal fat deposi-
tion and plasma lipid profile in diet-induced metabolic syndrome
in rats. It also attenuated the changes in structure and function of
the heart and the liver in these rats. A study in humans with .2
variables of metabolic syndrome could determine its beneficial
effects. Because coffee is one of the major nonalcoholic bev-
erages throughout the world, it is important to estimate the
extent of its effects on human health.
Acknowledgments
The authors thank Paul Addison, School of Biomedical Sciences,
and Brian Bynon, School of Veterinary Science, both at The
University of Queensland, for their help with histopathological
studies and plasma biochemical analyses, respectively. The
authors also thank Dr. Fiona Campbell, School of Veterinary
Science, The University of Queensland, and Jason Brightwell,
The Prince Charles Hospital, Brisbane, for their assistance with
echocardiography, and Dr. Kate Kauter, University of Southern
Queensland, for assistance with measurement of plasma insulin
concentrations. S.K.P. and L.B. designed the research protocol;
S.K.P. and H.P. conducted the animal experiments and analyzed
FIGURE 4 Effects of CE on inflammation, fat deposition, and fibrosis in the liver. Top and middle rows represent hematoxylin and eosin
staining of the liver showing inflammatory cells (A–D, marked as “in”) (320) and enlarged fat vacuoles (E–H, marked as “fv”) (340) from C (A,E),
CC (B,F), H (C,G), and HC (D,H) rats. Bottom row represents Milligan’s Trichrome staining of the liver showing fibrosis in the hepatic portal region (I–
L, marked as “fi”) (320) from C (I), CC (J), H (K), and HC (L) rats. C, corn starch-rich diet-fed rats; CC, corn starch-rich diet-fed rats treated with coffee
extract; CE, coffee extract; H, high-carbohydrate, high-fat diet-fed rats; HC, high-carbohydrate, high-fat diet-fed rats treated with coffee extract.
TABLE 3 Effects of CE on hepatic structure and function in C, CC, H, and HC rats1
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Plasma ALP activity, U/L 172 6 11c 125 6 6d 247 6 12a 206 6 14b ,0.0001 0.0004 0.79
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Supplemental Figure 3. HPLC analysis of kahweol and cafestol in Colombian coffee. 
 
Kahweol and cafestol measurements: 0.2 g of coffee powder was accurately weighed.  To this, 2 mL of 
2.5 mol/L KOH in ethanol was added and the solution was heated at 80° C for one hour to release the 
diterpenes from the fatty acids. 2 mL of water and 2 mL of methyl t-butyl ether was added. The sample 
was vortexed for 30 s and then centrifuged at 1800 × g. The upper ether layer was transferred to a 
separate tube and the sample was re-extracted with ether two more times. All ether extracts were 
combined and the ether was evaporated under nitrogen. Resulting solids were resuspended in 20 mL of 
50% methanol in water and filtered through a Millipore filter and injected into the HPLC. HPLC analysis 
was performed on an Waters 2690 with Waters XTerra C18 column (3.5 µm, 150 mm x 2.1 mm). A flow 
rate of 1 mL/min was used with injection volume of 10 µL. For detection, 290 nm (kahweol) and 230 nm 
(cafestol) wavelengths were used. Cafestol (MP Biomedicals, Seven Hills, Australia) and kahweol (Santa 
Cruz Biotechnology, Santa Cruz, CA) were used as standards in this procedure and calibration for 
kahweol and cafestol were carried out on concentrations between 3 and 80 mg/L. 
Kahweol 
Cafestol 
Kahweol 
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Caffeine attenuates metabolic syndrome in diet-induced obese rats
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Objective: Caffeine is a constituent of many non-alcoholic beverages. The pharmacologic actions of
caffeine include the antagonism of adenosine receptors and the inhibition of phosphodiesterase
activity. The A1 adenosine receptors present on adipocytes are involved in the control of fatty acid
uptake and lipolysis. In this study, the effects of caffeine were characterized in a diet-induced
metabolic syndrome in rats.
Methods: Rats were given a high-carbohydrate, high-fat diet (mainly containing fructose and beef
tallow) for 16 wk. The control rats were given a corn starch diet. These two treatment groups were
given caffeine 0.5 g/kg of food for the last 8 wk of the 16-wk protocol. The structure and function of
the heart and the liver were investigated in addition to the metabolic parameters including the
plasma lipid components.
Results: The high-carbohydrate, high-fat diet induced symptoms of the metabolic syndrome,
including obesity, dyslipidemia, impaired glucose tolerance, decreased insulin sensitivity, and
increased systolic blood pressure, associated with the development of cardiovascular remodeling
and non-alcoholic steatohepatitis. The treatment with caffeine in the rats fed the high-
carbohydrate, high-fat diet decreased body fat and systolic blood pressure, improved glucose
tolerance and insulin sensitivity, and attenuated cardiovascular and hepatic abnormalities,
although the plasma lipid concentrations were further increased.
Conclusion: A decreased total body fat, concurrent with increased plasma lipid concentrations,
reflects the lipolytic effects of caffeine in adipocytes, likely owing to the caffeine antagonism of A1
adenosine receptors on adipocytes.
 2012 Elsevier Inc. All rights reserved.
Introduction
Caffeine is an alkaloid found in many food products including
coffee and tea. It is probably the most widely used psychoactive
drug [1]. Caffeine is a central nervous system stimulant, with
additional effects including increases in resting energy expen-
diture, endurance, physical performance, and cognitive function
and improvements in behavioral functions such as mood [2].
Caffeine from beverages is rapidly and completely absorbed from
the gastrointestinal tract and reaches peak concentrations in the
serum within 30 to 60 min [3]. Only 1% to 3% of caffeine is
excreted unchanged in the urine. The rate of caffeine metabolism
is variable, with a half-life of 4 to 6 h [3,4].
The most important mechanism of the action of caffeine
appears to be the antagonism of adenosine receptors, although
caffeine also inhibits phosphodiesterase [5]. Phosphodiesterase
inhibition is minimal at the serum caffeine concentrations found
after the consumption of beverages or food [5]. Adenosine
receptors are found throughout the body, mainly in the brain,
heart and blood vessels, respiratory tree, kidneys, adipose tissue,
and gastrointestinal tract [6]. The cardiovascular responses
to adenosine receptor activation have been studied for many
years [7]. However, adenosine receptor densities are w10-fold
higher in adipose tissue than in cardiac tissue [8]. Mature adipo-
cytes contain A1 adenosine receptors that inhibit lipolysis by
decreasing adenylate cyclase activity, suggesting that adenosine
receptors are a target for the control of obesity and diabetes [9].
Previous studies have shown the therapeutic effects of
caffeine in hypertension, metabolic parameters, and hepatic
fibrosis, which are components of the metabolic syndrome.
* Corresponding author. Tel.: þ61-7-4631-1319; fax: þ61-7-4631-1530.
E-mail address: Lindsay.Brown@usq.edu.au (L. Brown).
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Caffeine (0.1% in drinking water) decreased plasma glucose and
insulin concentrations in rats fed high-sucrose and high-fat diets,
respectively, with a decrease of mean arterial pressure in the two
models [10]. Caffeine also decreased the increase in body weight
and visceral adiposity observed in rats fed a high-fat diet [10]. A
higher daily caffeine consumption in patients undergoing a liver
biopsy for clinical indications was associated with less severe
fibrosis at liver biopsy [11].
In our previous studies, rats fed a high-carbohydrate, high-fat
diet showed symptoms of the metabolic syndrome, with meta-
bolic abnormalities, cardiovascular remodeling, and non-
alcoholic steatohepatitis [12]. In the present study, we have
characterized the effects of caffeine in this diet-induced ratmodel
of the metabolic syndrome. This study included the character-
ization of the structure and function of the cardiovascular system
through echocardiography, systolic blood pressure measure-
ments, an isolated Langendorff heart preparation, histopa-
thology, and the vascular reactivity of the aorta. The structure and
function of the liver were studied by histopathologic and plasma
biochemical analyses. Similarly, body composition, abdominal fat
deposition, and plasma lipid profiles weremeasured to assess the
metabolic effects of caffeine.
Materials and methods
Rats and diets
All experimental protocols were approved by the University of Southern
Queensland animal experimentation ethics committee under the guidelines of
the National Health and Medical Research Council of Australia. Male Wistar rats
(8–9 wk old, weight 337  2 g, n ¼ 40) were supplied by The University of
Queensland biological resources facility. The rats were randomly assigned to one
of four experimental dietary groups: a corn starch diet (C; n ¼ 10), a corn starch
diet plus caffeine (CC; caffeine 0.5 g/kg of food, n ¼ 10), a high-carbohydrate,
high-fat diet (H; n ¼ 10), or a high-carbohydrate, high-fat diet plus caffeine
(HC; caffeine 0.5 g/kg of food, n ¼ 10). The composition of the corn starch and
high-carbohydrate, high-fat diets has been described in detail in our previous
studies [12,13]. The H and HC rats were given 25% fructose in drinking water in
addition to their respective diets, whereas normal drinking water without any
supplementation was given to the C and CC rats. The C and H rats were fed with
the respective diets for 16 wk. The CC and HC rats were fed the on C and H diets,
respectively, for the first 8 wk and then the diets were supplemented with
caffeine (Sigma-Aldrich Australia, Sydney, Australia) for the last 8 wk of the
protocol. All rats were given access ad libitum to food andwater andwere housed
individually in temperature-controlled 12-h light/dark conditions.
The rats were monitored daily for body weight and food and water intakes.
Systolic blood pressure measurements were performed on all rats at the end of
protocol as described in our previous study [12]. The abdominal circumference
and body length of the rats were measured using a standard measuring tape
during the period of anesthesia for blood pressure measurements [12]. The body
mass index, energy intake, and feed efficiency were calculated as described
previously [12].
Oral glucose tolerance and insulin tolerance tests
The oral glucose tolerance and insulin tolerance tests were performed 2 d
apart at 16 wk. For the oral glucose tolerance testing, the rats were food deprived
for 12 h. The fructose-supplemented drinking water in the H and HC groups was
replaced with normal water for the food-deprivation period. After the food-
deprivation period, the basal blood glucose concentrations were measured in
blood taken from the tail vein using a Medisense Precision Q.I.D. glucose meter
(Abbott Laboratories, Bedford,Q1 USA). The rats were then given glucose 2 g/kg of
body weight as a 40% solution by oral gavage. The tail vein blood samples were
taken at 30, 60, 90, and 120 min after the glucose administration [12,13]. From
these data, the area under the curve was calculated taking the x axis as the
baseline.
For the insulin tolerance tests, the basal blood glucose concentrations were
measured after 4 to 5 h of food deprivation as described earlier. The rats were
injected with insulin-R 0.33 IU/kg (Eli Lilly Australia, West Ryde, Australia)
intraperitoneally and the tail vein blood samples were taken at 30, 60, 90, and 120
min after an insulin injection. The rats were withdrawn from the test if the blood
glucose concentration decreased below 1.1 mmol/L and the glucose solution 4
g/kg was immediately administered by oral gavage to prevent hypoglycemia [13].
Body composition measurements
The lean mass and fat masses were measured using dual-energy x-ray
absorptiometry in all groups as previously described [12,13].
Isolated Langendorff heart preparation
The rats were euthanized with Lethabarb (pentobarbitone sodium; 100 mg/
kg intraperitoneally; Virbac, Peakhurst, Australia). After euthanasia, heparin (200
IU; Sigma-Aldrich Australia) was injected through the right femoral vein. The
abdomen was then opened and blood (w5 mL) was withdrawn from the
abdominal aorta, collected into heparinized tubes, and centrifuged at 5000  g
for 15 min to obtain the plasma. The plasma was stored at 20C before further
Fig. 1. Effects of caffeine on body weight (A), oral glucose tolerance (B), and insulin
sensitivity (C) in a diet-induced metabolic syndrome in rats. Values are presented as
mean  SEM (n ¼ 8–10). Diet, Caff, and Diet  Caff represent effects of diet, caffeine,
and the interaction between diet and caffeine, respectively. C, rats fed a corn starch
diet; CC, rats fed a corn starch diet plus caffeine; H, rats fed a high-carbohydrate,
high-fat diet; HC, rats fed a high-carbohydrate, high-fat diet plus caffeine.
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biochemical analysis. The hearts were removed and used in the isolated
Langendorff heart preparation to assess the left ventricular function of the rats in
all groups, as in our previous study [12].
Vascular reactivity
The thoracic aortic rings (w4mm in length) were suspended in an organ bath
filled with Tyrode physiologic salt solution bubbled with 95% O2–5% CO2, main-
tained at 35C, and allowed to stabilize at a resting tension ofw10 mN [12]. The
cumulative concentration–response curves (contraction) were obtained for
noradrenaline (Sigma-Aldrich Australia) and the cumulative concentration–
response curves (relaxation) were obtained for sodium nitroprusside (Sigma-
Aldrich Australia) and acetylcholine (Sigma-Aldrich Australia) after a submaximal
(w70%) contraction to noradrenaline [12].
Organ weights and histology
After performing the Langendorff heart perfusion studies, the hearts were
separated into right and left ventricles (with the septum, n ¼ 8). The two
ventricles were weighed. The livers and abdominal fat pads (retroperitoneal,
epididymal, and omental) were isolated and weighed (n ¼ 8). These organ
weights were normalized to the tibial length at the time of removal and
expressed as milligrams of tissue per millimeter of tibial length [12]. The heart
and liver from two rats in each group were used exclusively for the histopath-
ologic analysis, as in our previous study [12].
Biochemical analysis of plasma samples
The plasma activities of alanine transaminase, aspartate transaminase,
alkaline phosphatase, and lactate dehydrogenase and the plasma concentrations
of total cholesterol, triacylglycerols, albumin, total proteins, total bilirubin, urea,
and uric acid were determined using kits and controls supplied by Olympus using
an Olympus analyzer (AU 400, Olympus, Tokyo, Japan) [12]. Non-esterified fatty
acids (NEFAs) in the plasma were determined using a commercial kit (Wako,
Osaka, Japan) [12]. The plasma concentrations of insulin (Laboratory Diagnostics,
Kurnell, Australia) were measured with a commercial kit according to the
manufacturer-provided standards and protocols using a Titertek Multiskan MCC/
340 spectrophotometer (Flow Laboratories)Q2 [12].
Statistical analysis
All data are presented as mean  standard error of the mean. All the groups
were tested for variance using the Bartlett test and the variables that were not
normally distributed were transformed (using the log10 function) before
Table 1
Effects of caffeine on physiologic and metabolic parameters
Variables C CC H HC P
Diet Caffeine Diet  Caffeine
Initial body weight (g) 337  2 336  1 338  2 339  1 0.21 1.00 0.53
Final body weight (g) 395  7b 360  5c 480  8a 396  6b <0.0001 <0.0001 0.0007
Water intake (mL/d) 31.3  1.2a 29.5  1.9a 18.8  1.1b 19.5  1.4b <0.0001 0.70 0.39
Food intake (g/d) 30.8  0.6b 37.5  0.5a 23.2  0.6c 23.4  0.4c <0.0001 <0.0001 <0.0001
Energy intake (kJ/d) 350  14c 421  16b 478  11a 492  15a <0.0001 0.005 0.05
Feed efficiency (kJ/g) 0.16  0.02b 0.06  0.01c 0.32  0.02a 0.12  0.01b <0.0001 <0.0001 0.003
BMI (g/cm2) 0.63  0.01b 0.59  0.01c 0.72  0.01a 0.62  0.01b <0.0001 <0.0001 0.005
Caffeine intake (mg ∙ kg1 ∙ d1) 0 28.1  0.5 0 47.9  1.0* d d d
Abdominal circumference (cm) 19.6  0.4b 17.9  0.3c 23.3  0.4a 19.2  0.2b <0.0001 <0.0001 0.001
Whole-body lean mass (g) 317  4b 306  5bc 348  4a 295  5c 0.034 <0.0001 <0.0001
Whole-body fat mass (g) 71  4b 66  6b 152  7a 80  6b <0.0001 <0.0001 <0.0001
Basal blood glucose concentration (mmol/L) 4.0  0.1b 3.6  0.1c 5.0  0.1a 4.1  0.2b <0.0001 <0.0001 0.07
Area under curve (mmol ∙ L1 ∙ min1) 680  13b 480  15d 771  10a 562  14c <0.0001 <0.0001 0.73
Plasma insulin (pmol/L) 0.41  0.11 0.39  0.07 0.55  0.11 0.65  0.06 0.05 0.66 0.51
Total cholesterol (mmol/L) 1.3  0.1c 2.0  0.2b 2.0  0.1b 2.6  0.1a <0.0001 <0.0001 0.71
Triacylglycerols (mmol/L) 0.4  0.1c 0.5  0.0c 1.0  0.1b 1.5  0.2a <0.0001 0.02 0.11
NEFA (mmol/L) 1.1  0.2c 2.2  0.2b 2.8  0.3b 5.1  0.4a <0.0001 <0.0001 0.04
Retroperitoneal fat pads (mg/mm tibial length) 214  9b 132  6c 357  21a 198  10b <0.0001 <0.0001 0.005
Epididymal fat pads (mg/mm tibial length) 129  11b 104  8b 225  13a 122  7b <0.0001 <0.0001 0.0004
Omental fat pads (mg/mm tibial length) 93  6b 70  5b 194  12a 83  6b <0.0001 <0.0001 <0.0001
Total abdominal fat pads (mg/mm tibial length) 435  24b 305  18c 775  46a 402  21b <0.0001 <0.0001 0.0002
BMI, body mass index; C, rats fed a corn starch diet; CC, rats fed a corn starch diet plus caffeine; H, rats fed a high-carbohydrate, high-fat diet; HC, rats fed a high-
carbohydrate, high-fat diet plus caffeine; NEFA, non-esterified fatty acid
Values are presented as mean  SEM (n ¼ 8–10). Means without a common superscript letter in a row differ (P < 0.05)
* P < 0.0001 (Student’s t test) versus CC for caffeine intake.
Fig. 2. Effects of caffeine on trends in weekly mean energy intake (A) and weekly
feed efficiency (B) in a diet-induced metabolic syndrome in rats. Values are pre-
sented as mean and pooled SD at the end of the graph (n ¼ 10). C, rats fed a corn
starch diet; CC, rats fed a corn starch diet plus caffeine; H, rats fed a high-
carbohydrate, high-fat diet; HC, rats fed a high-carbohydrate, high-fat diet plus
caffeine.
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statistical analyses. These groups were tested for the effects of diets, treatment,
and/or their interactions by two-way analysis of variance. When the interaction
and/or the main effects were significant, the group means were compared using
the Newman–Keuls multiple-comparison post test. The weekly mean energy
intake and weekly mean feed efficiency were tested with one-way repeated
measures analysis of variance for trend analysis. P < 0.05 was considered
statistically significant. All statistical analyses were performed using GraphPad
Prism 5.00 for Windows (GraphPad, San Diego, CA, USA).
Results
Physiologic parameters and body composition
The H rats showed greater body weight, daily energy intake,
body mass index, and abdominal circumference than the C rats,
although they had lower daily water and food intakes compared
with C rats (Fig. 1A, Table 1). The caffeine treatment decreased
the body mass index and abdominal circumference in the CC and
HC compared with the C and H rats, respectively (Table 1). The
decrease in body weight started from the beginning of the
caffeine treatment in the CC rats, whereas it started after 4 wk of
treatment in the HC rats (Fig. 1A). The caffeine treatment in the
CC and HC rats did not affect daily water intake compared with
the C and H rats, respectively. The caffeine treatment increased
the daily food intake in the CC rats compared with the C rats
without the changing daily food intake of the HC rats compared
with the H rats (Table 1). The caffeine did not affect the daily
energy intake in the HC rats comparedwith the H rats, whereas it
increased the daily energy intake in the CC rats by increasing
daily food intake (Table 1). The whole-body lean mass and fat
mass were greater in the H rats than in the C rats. The lean and fat
masses were decreased in the HC rats compared with the H rats
but not in the CC rats (Table 1).
Metabolic parameters
The basal blood glucose concentrations and the area under
the curve for the oral glucose tolerance test were higher in the H
Table 2
Effects of caffeine on cardiovascular and hepatic functions
Variables C CC H HC P
Diet Caffeine Diet  Caffeine
Systolic blood pressure (mmHg) 129  1b 118  1c 145  1a 118  1c <0.0001 <0.0001 <0.0001
Left ventricular (with septum) wet weight
(mg/mm tibial length)
20.3  0.7ab 19.0  0.4b 21.8  1.1a 18.2  0.7b 0.65 0.003 0.14
Right ventricular wet weight (mg/mm tibial length) 4.82  0.23 4.57  0.39 4.47  0.32 3.81  0.18 0.07 0.13 0.49
Left ventricular diastolic stiffness constant 21.1  1.7b 20.4  1.4b 28.2  1.3a 22.5  1.6b 0.005 0.043 0.11
Liver wet weight (mg/mm tibial length) 257  13b 245  13b 297  11a 331  17a <0.0001 0.43 0.10
Plasma ALT activity (U/L) 38  3b 39  4b 55  3a 42  3b 0.004 0.08 0.04
Plasma AST activity (U/L) 75  4b 83  6b 102  5a 80  5b 0.02 0.17 0.005
Plasma ALP activity (U/L) 181  13c 148  13c 261  18b 363  20a <0.0001 0.04 0.0002
Plasma LDH activity (U/L) 253  29b 218  26b 458  31a 233  35b 0.0009 0.0001 0.004
Plasma albumin (mg/ml) 28.1  0.5 28.8  0.4 28.6  0.4 28.4  0.6 0.92 0.61 0.36
Plasma total bilirubin (mmol/L) 2.2  0.1ab 1.9  0.1bc 2.4  0.1a 1.6  0.2c 0.71 0.0002 0.07
Plasma urea (mmol/L) 5.2  0.2a 5.0  0.3a 3.3  0.3b 4.6  0.2a <0.0001 0.04 0.006
Plasma uric acid (mmol/L) 36  3b 33  4b 55  4a 30  5b 0.06 0.002 0.01
ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; C, rats fed a corn starch diet; CC, rats fed a corn starch diet plus caffeine; H, rats fed
a high-carbohydrate, high-fat diet; HC, rats fed a high-carbohydrate, high-fat diet plus caffeine; LDH, lactate dehydrogenase
Values are presented as mean  SEM (n ¼ 8–10). Means without a common superscript letter in a row differ (P < 0.05)
Fig. 3. Effects of caffeine on inflammation and fibrosis in the heart. (A–D) Hematoxylin and eosin staining of the left ventricle showing infiltration of inflammatory cells from
rats fed a corn starch diet (A), a corn starch diet plus caffeine (B), a high-carbohydrate, high-fat diet (C), and a high-carbohydrate, high-fat diet plus caffeine (D). (E–H)
Picrosirius red staining of the left ventricle showing collagen deposition and hypertrophy from rats fed a corn starch diet (E), a corn starch diet plus caffeine (F), a high-
carbohydrate, high-fat diet (G), and a high-carbohydrate, high-fat diet plus caffeine (H). fi, fibrosis; hy, hypertrophied cardiomyocytes; in, inflammatory cells.
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rats than in the C rats, and these were lowered in the CC and HC
rats compared with the C and H rats, respectively (Table 1,
Fig.1B). The decreased response to insulin in the H rats compared
with the C rats was also improved in the HC rats (Fig. 1C). The
plasma insulin concentrations were unchanged between the
groups (Table 1). The plasma concentrations of total cholesterol,
triacylglycerols, and NEFAwere higher in the H rats than in the C
rats. The plasma concentrations of total cholesterol and NEFA
were higher in the CC and HC rats than in the C and H rats,
respectively, whereas triacylglycerols were higher only in the HC
rats than in H rats (Table 1). The retroperitoneal, epididymal, and
omental fat pads were larger in the H rats than in the C rats. The
HC rats showed a lowering of all three locations of abdominal fat,
whereas the CC rats showed a decrease only in the retroperito-
neal fat. The total abdominal fat pads were smaller in the CC and
HC rats compared with the C and H rats, respectively (Table 1).
The weekly mean energy intakes and feed efficiencies are
presented in Figure 2A and Figure 2B, respectively. For clarity,
only the group mean values are presented, with animal variance
indicated by the pooled standard deviations for each group. The
feed efficiencies were negative during the first week of feeding
the experimental diets in all groups but then recovered such that
all were positive by week 2, with no significant differences
between the treatment groups in weeks 5 to 8. The administra-
tion of caffeine fromweek 8 onward progressively decreased the
feed efficiency in the CC and HC rats compared with the C and H
rats, respectively, such that by weeks 13 through 16, the feed
efficiencies were negative for the CC and HC rats but remained
positive for the C and H rats (P < 0.0001). This decrease in feed
conversion efficiency in the caffeine-fed animals paralleled the
decreases in body weight seen in these animals (Fig. 1A).
Cardiovascular and hepatic parameters
The systolic blood pressurewas higher in the H rats than the C
rats, and this was normalized in the CC and HC rats (Table 2). The
left ventricular wet weights were unchanged between the C and
H rats, whereas this parameter was lowered in the HC rats
compared with the H rats. The right ventricular wet weights
were unchanged between the groups (Table 2). The heart tissue
from the H rats had more infiltration of inflammatory cells
(Fig. 3C) and collagen deposition (Fig. 3G) than from the C rats
(Fig. 3A, E) and this was prevented in the HC rats (Fig. 3D, H). The
left ventricular diastolic stiffness was greater in the H rats than in
the C rats, and this was lowered in the HC rats comparedwith the
H rats (Table 2). The H rats showed impaired vascular reactivity
compared with the C rats, including deceased contractile
responses to noradrenaline (Fig. 4A) and decreased relaxant
responses to sodium nitroprusside (Fig. 4B) and acetylcholine
(Fig. 4C). The CC and HC rats showed greater vascular responses
to noradrenaline-induced contraction compared with the C and
H rats, respectively (Fig. 4A). The HC rats showed normalized
relaxant responses to sodium nitroprusside (Fig. 4B) and
acetylcholine (Fig. 4C).
The livers from the H rats showed an increased infiltration of
inflammatory cells (Fig. 5C) compared with the C rats (Fig. 5A).
The fat vacuoles as evidence of steatosis were present in the
livers from the H rats (Fig. 5G) but were absent in the livers from
the C rats (Fig. 5E). The livers from the H rats but not the C rats
showed mild portal fibrosis (Fig. 5K). Caffeine inhibited the
infiltration of inflammatory cells (Fig. 5D), steatosis (Fig. 5H), and
portal fibrosis (Fig. 5L) in the HC rats. The liver wet weights were
greater for the H rats compared with the C rats, and this was
unchanged by the caffeine administration in the CC and HC rats
(Table 2). The plasma activities of alanine transaminase, aspar-
tate transaminase, alkaline phosphatase, and lactate dehydro-
genase were greater in the H rats than in the C rats. Caffeine
decreased the plasma activities of alanine transaminase, aspar-
tate transaminase, and lactate dehydrogenase in the HC rats
without affecting these activities in the CC rats, whereas caffeine
Fig. 4. Effect of caffeine on concentration–response curves of the thoracic aortic
rings to noradrenaline (A), sodium nitroprusside (B), and acetylcholine (C). Values
are presented as mean  SEM (n ¼ 8–10). Diet, Caff, and Diet  Caff represent the
effects of diet, caffeine, and the interaction between diet and caffeine, respectively.
C, rats fed a corn starch diet; CC, rats fed a corn starch diet plus caffeine; H, rats fed
a high-carbohydrate, high-fat diet; HC, rats fed a high-carbohydrate, high-fat diet
plus caffeine.
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increased the plasma activity of alkaline phosphatase in the HC
rats without changing it in the CC rats (Table 2). Although total
plasma bilirubin was unchanged between the C and H rats, the
HC rats showed lower plasma concentrations of total bilirubin
(Table 2). The plasma concentrations of urea decreased and uric
acid increased in the H rats compared with the C rats. The plasma
concentrations of urea and uric acid were normalized in the HC
rats (Table 2).
Discussion
The metabolic syndrome is the clustering of various risk
factors for cardiovascular disease and non-alcoholic fatty liver
disease [14]. These risk factors include central obesity, hyper-
tension, impaired glucose tolerance, dyslipidemia, and insulin
resistance [14]. Because caffeine is readily available in the diet
from widely consumed non-alcoholic beverages [15], it is
important to understand its effects on the functioning of organs
in chronic conditions such as the metabolic syndrome. Epide-
miologic studies have suggested that the incidence of the
metabolic syndrome is increasing in the worldwide population
[16]. In this study, we have evaluated the responses to caffeine in
rats fed a high-carbohydrate, high-fat diet as an appropriate
model for the human metabolic syndrome.
The physiologic and pharmacologic effects of caffeine have
been extensively studied and reviewed [1,2,17]. Although
caffeine has beneficial effects, including central nervous system
stimulant responses, the long-term consumption of caffeine has
been associated with the development of tolerance to caffeine
leading to lowered responses to caffeine after long-term
administration [18]. Thus, it will be an important issue to
adjust the dose of caffeine such that the development of
tolerance can be delayed. The role of adenosine receptors in the
development of tolerance to caffeine has been controversial
[19,20]. There are also possible adverse effects of caffeine during
pregnancy and fetal growth [21].
In this study, the rats fed the high-carbohydrate, high-fat diet
developed most of the symptoms associated with the human
metabolic syndrome, including central obesity, hypertension,
dyslipidemia, impaired glucose tolerance, cardiovascular
remodeling, and non-alcoholic fatty liver disease [12]. Caffeine
supplementation in these rats attenuated the obesity, hyper-
tension, cardiovascular remodeling, non-alcoholic fatty liver
disease, and metabolic parameters, including glucose tolerance
and insulin sensitivity. However, dyslipidemia was worsened.
Caffeine decreased the whole-body fat mass and the
abdominal fat pads. This indicates that there was a removal of fat
from the abdominal area, and this fat was not transported to the
other fat-storing areas, including subcutaneous fat, unlike in chia
seed-fed rats in which redistribution of abdominal fat occurs
[13]. The increase in plasma lipid components, especially NEFAs,
reflects the removal of fat from the abdomen after its conversion
to NEFAs by the process of lipolysis. These results suggest that
caffeine induced the lipolysis in adipocytes and, hence,
decreased the abdominal fat pads. The overall decreases in the
fat mass in the absence of a fat redistribution suggest that the
excess plasma lipids are being metabolized rather than stored in
the organs.
The rats, once adapted to the C or H diet, did not show any
change in energy intake. With caffeine administration, the rats
having a similar energy intake as their controls showed
a decrease in feed efficiency and, hence, body weight. The
decrease in feed efficiency may result from an increased energy
expenditure, thermogenesis, maldigestion, or malabsorption. In
Fig. 5. Effects of caffeine on inflammation, fat deposition, and fibrosis in the liver. (A–H) Hematoxylin and eosin staining of the liver showing inflammatory cells (A–D,
magnification 20) and enlarged fat vacuoles (E–H, magnification 40), respectively, from rats fed a corn starch diet (A, E), a corn starch diet plus caffeine (B, F), a high-
carbohydrate, high-fat diet (C, G), and a high-carbohydrate, high-fat diet plus caffeine (D, H). (I–L) Milligan trichrome staining of the liver showing fibrosis in the hepatic
portal region (magnification 20) from rats fed a corn starch diet (I), a corn starch diet plus caffeine (J), a high-carbohydrate, high-fat diet (K), and a high-carbohydrate, high-
fat diet plus caffeine (L). fi, fibrosis; fv, fat vacuoles; in, inflammatory cells.
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previous studies, caffeine has shown thermogenic effects in lean
and obese subjects [22]. In another study, 0.025% caffeine
decreased the body fat in rats fed a high-fat diet by inducing
lipolysis and, hence, increasing NEFAs in the blood [23].
Adenosine strongly inhibited hormone-induced lipolysis [9]
and adenosine receptor agonists have been evaluated as lipid-
lowering agents [6], lowering plasma NEFAs and triacylglycer-
ols by suppressing lipolysis and triacylglycerol secretion [24]. In
the cardiovascular system, the activation of A1 receptors
decreased cardiac contractility and contributed to adverse
ventricular remodeling [25]. In contrast, 8-cyclopentyl-1,3-
dipropylxanthine, a selective A1 receptor antagonist, increased
lipolysis in isolated rat adipocytes without affecting lipogenesis
[26]. Caffeine acts as a non-selective antagonist on adenosine
receptors [5]. The antagonism of A1 adenosine receptors with
caffeine increased cyclic adenosine monophosphate production,
thereby increasing lipolysis and, hence, the removal of fat from
the adipocytes in the abdomen. This increased lipolysis was
observed as a further increase in the plasma concentrations of
triacylglycerols, total cholesterol, and NEFAs in the HC rats. The
antiobesity and cardioprotective effects of caffeine in this study
are consistent with the antagonism of adipocyte and car-
diomyocyte A1 adenosine receptors. Further, the improvements
in the liver structure and function could be due to liver A1
receptor antagonism because adenosine production and adeno-
sine receptor activation in the liver play critical roles in the
development of hepatic fibrosis [27,28]. Although serum
concentrations of caffeine after food or beverage consumption
have shown a minimal inhibition of phosphodiesterase activity
[5], the inhibition of phosphodiesterases has shown promise
against obesity and diabetes [29,30].
Although high NEFA concentrations increase the risk of
cardiovascular dysfunction and hepatic steatosis [31], such
complications did not present in this study despite much higher
plasma concentrations of NEFAs in the caffeine-supplemented
rats. These rats showed a decreased infiltration of inflamma-
tory cells, decreased collagen deposition, and decreased diastolic
stiffness in the left ventricle, an attenuation of non-alcoholic
steatohepatitis, and high plasma NEFA concentrations.
In our previous study, we investigated the effects of the H diet
on metabolic parameters [12]. Among these metabolic parame-
ters, the basal blood glucose concentrations and glucose toler-
ance were improved with caffeine supplementation. Other
changes included normalization of the plasma urea and uric acid
concentrations. Previous studies have reported that caffeine
increases serum urea concentrations [32], and the lowering of
serum uric acid concentrations has been attributed to compo-
nents of coffee other than caffeine [33].
The toxicityof caffeine is rarelyassociatedwithdeath, although
psychologic disturbances have been reported with very high
caffeine intakes inhumanstudies [1,17,34]. Theavailable data from
extensive literature surveys of human studies with caffeine have
indicated that the consumptionof caffeine0.4 g/d in adults is not
associatedwith any adverse effects on health [2,17]. The dose used
in this study corresponds to caffeine w0.6 g/d according to
a scaling equation [35] andw0.35 g/d based on body surface area
calculations [36]. These doses are achievable in humans and are in
the range of safe doses for caffeine.
Conclusion
This study has defined the cardioprotective and hep-
atoprotective effects of caffeine in a diet-induced rat model of
the human metabolic syndrome. These protective effects were
accompanied by decreases in body weight and abdominal fat.
The decrease in abdominal fat could be due to an antagonism by
caffeine of A1 adenosine receptors present on adipocytes,
leading to lipolysis. Although the protective effects of caffeine
have been indicated with long-term feeding in the rats, the
translation of these results to humans could be compromised by
the development of caffeine tolerance after a long-term caffeine
intake.
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Abstract 
Obesity and dyslipidemia are metabolic defects resulting from impaired 
lipid metabolism. In turn, these disorders are associated with the development 
of cardiovascular disease and non-alcoholic fatty liver disease. Measures to 
correct the defects in lipid metabolism may attenuate obesity, dyslipidemia, and 
associated complications. ʟ-Carnitine supplementation was used in this study to 
enhance fatty acid oxidation to ameliorate these disturbances in lipid 
metabolism. Male Wistar rats (8-9 weeks old) were fed with either corn starch-
rich or high-carbohydrate, high-fat diets for 16 week. Separate groups were 
selected for ʟ-carnitine supplementation (1.2% in food) on either diet for the 
last 8 w eek of the protocol. High-carbohydrate, high-fat diet-fed rats showed 
central obesity, dyslipidemia, hypertension, impaired glucose tolerance, 
hyperinsulinemia, cardiovascular remodeling and nonalcoholic fatty liver 
disease. ʟ-Carnitine supplementation attenuated these high-carbohydrate, high-
fat diet-induced changes, together with modifications in lipid metabolism. This 
included inhibition of stearoyl-CoA desaturase-1 (SCD-1) activity in the tissues 
measured through SCD-1 activity index, reduced short-chain monounsaturated 
fatty acids storage in the tissues, and decreased polyunsaturated fatty acids 
contents in the tissues. Thus, ʟ-carnitine supplementation attenuated obesity, 
dyslipidemia, and complications associated with metabolic syndrome through 
inhibition of SCD-1 activity, preferential oxidation of polyunsaturated fatty 
acids, and storage of saturated fatty acids and relatively inert oleic acid in the 
tissues. 
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Keywords: Metabolism, Fatty acids, ʟ-carnitine, Obesity, Cardiovascular 
remodeling. 
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Introduction 
Obesity is a chronic pathological condition characterized by excess fat 
deposition in the adipose tissue. A major reason for the increasing incidence of 
obesity around the world is the combination of a cafeteria-style diet with higher 
energy densities together with lower expenditure of this energy (21,24,34). 
Cafeteria/Western diet is rich in saturated fats and carbohydrates, mainly 
fructose and sucrose. Increasing intake of lipogenic carbohydrates such as 
fructose (18) and saturated fats can lead to disturbance in the metabolism of 
these macronutrients in the body (38). Decreased insulin sensitivity, 
hyperinsulinemia, and dyslipidemia are the other factors associated with obesity 
(15) that contribute towards the imbalance in metabolism of fat and 
carbohydrate (11,14). These metabolic disturbances can worsen the structure 
and function of tissues including the heart, liver, and skeletal muscle (2), 
including cardiovascular remodeling and nonalcoholic fatty liver disease (26). 
ʟ-Carnitine is a quaternary amine synthesized from lysine and methionine 
in the liver and kidneys. ʟ-Carnitine is involved in fatty acid transport across 
mitochondrial membranes by carnitine palmitoyltransferase 1 (CPT1) for β-
oxidation (4). In humans, ʟ-carnitine is generally taken in the diet through meat 
products. If the requirement of ʟ-carnitine is not fulfilled from the diet, as in 
vegetarians, it is synthesized in the body along with an increase in the 
absorption from the diet (9). Deficiency of ʟ-carnitine in the body leads to 
pathophysiological complications including cardiomyopathy, encephalopathy, 
and skeletal muscle myopathy (8,37). 
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ʟ-Carnitine enhanced oxidation of long chain fatty acids in the liver and 
the heart (10). Oral ʟ-carnitine supplementation led to an increase in the total 
concentration of ʟ-carnitine in humans (3). Further, ʟ-carnitine supplementation 
decreased post-exercise venous concentrations of lactic acid (3). Athletes use ʟ-
carnitine for reducing body fat in order to lose weight by metabolism of long 
chain fatty acids (16).  
Administration of ʟ-carnitine could alleviate hypertension, obesity, 
dyslipidemia, insulin resistance, and fatty liver as the major signs of metabolic 
syndrome. ʟ-Carnitine decreased blood pressure and improved the structure and 
function of the heart in DOCA-salt-induced cardiovascular remodeling in rats 
(23). In fructose-fed rats, ʟ-carnitine reduced plasma concentrations of glucose, 
insulin, free fatty acids, and triglycerides, improved glucose tolerance, and 
showed protective effects on kidneys (32,33). A combination of either orlistat 
or sibutramine with ʟ-carnitine improved lipid profile, insulin resistance, body 
weight, and inflammation in type 2 diabetic patients more than with either 
orlistat or sibutramine (5,6). ʟ-Carnitine supplementation in type 2 di abetic 
patients did not change body weight, body mass index, fasting plasma glucose, 
and plasma total cholesterol, but reduced plasma triglycerides and total body fat 
(19). ʟ-Carnitine reduced plasma activities of aspartate transaminase (AST), 
alanine transaminase (ALT), and γ-glutamyl transpeptidase (GGT) and plasma 
concentrations of total cholesterol, triglycerides, and inflammatory markers 
along with attenuation of nonalcoholic steatohepatitis in patients (20). 
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In this study, we increased dietary ʟ-carnitine in high-carbohydrate, high-
fat diet-fed male Wistar rats to increase the oxidation of stored fat. The 
metabolic effects of ʟ-carnitine were characterized through measurements of 
body composition, glucose tolerance, and plasma lipid profile. Fatty acid 
composition of plasma, heart, liver, skeletal muscle, and retroperitoneal fat pads 
was measured to study the changes in metabolism and storage of fatty acids. 
Changes in cardiovascular structure and functions were evaluated through 
systolic blood pressure measurements, echocardiography, isolated Langendorff 
heart preparation, vascular responses including contraction and relaxation 
properties of thoracic aorta, and histopathology. Hepatic structure and function 
were determined through liver function tests and histopathology.  
Experimental procedure 
Rats, diets, and ʟ-carnitine supplementation 
All experimental protocols were approved by The University of 
Queensland and University of Southern Queensland Animal Experimentation 
Ethics Committees, under the guidelines of the National Health and Medical 
Research Council of Australia. Male Wistar rats (8-9 weeks old, weighing 339 
± 4 g, n =  48) were supplied by The University of Queensland Biological 
Resources facility. Rats were randomly divided into two experimental diet 
groups and were fed with either corn starch diet (C; n = 24) or high-
carbohydrate, high-fat diet (H; n = 24) for 16 weeks. After 8 weeks of feeding 
with respective diets, 12 r ats from each group were randomly separated and 
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treated with 1.2 %  ʟ-carnitine in food with same diet continued for further 8 
weeks (CLC and HLC, respectively). The remaining 12 r ats from both diet 
groups (C and H) were continued on the original diet without any treatment for 
further 8 w eeks. The diet of C rats mainly consisted of corn starch 
(polysaccharides) while the diet of H rats contained beef tallow (saturated and 
monounsaturated fats), fructose, and condensed milk. Compositions of C and H 
diets used in this study have been described in detail in our previous studies 
(25,29,30). C and CLC rats were given drinking water without any additives 
whereas drinking water for H and HLC rats were supplemented with 25% 
fructose. All rats were provided ad libitum access to food and water and were 
individually housed in temperature-controlled 12 hour light-dark conditions. 
Physiological and metabolic parameters 
Rats were monitored daily for body weight, food and water intakes. 
Abdominal circumference, body mass index (BMI), energy intake, and feed 
efficiency were measured as described (25). At the end of the protocol, rats 
were food-deprived for 12 hour s and oral glucose tolerance tests were 
performed as described (25). The blood glucose concentrations obtained from 
oral glucose tolerance tests were used to calculate the area under the curve by 
taking x-axis as the baseline. Body compositions of rats were measured at the 
end of the protocol (25,30). During terminal experiments, abdominal fat pads 
(separately as retroperitoneal, epididymal, and omental) were removed, 
weighed, and normalized to tibial length at the time of terminal experiments 
(25). Plasma concentrations of albumin, total bilirubin, urea, uric acid, total 
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cholesterol, and triglycerides were determined using kits and controls supplied 
by Olympus using an Olympus analyzer (AU 400, Tokyo, Japan) (25). Non-
esterified fatty acids (NEFA) in plasma were determined using a commercial kit 
(Wako, Osaka, Japan) (25). 
Cardiovascular structure and function 
Systolic blood pressure measurements: Systolic blood pressures of rats 
were measured under light sedation with Zoletil (tiletamine 10 mg/kg, 
zolazepam 10 mg/kg intraperitoneally), using an MLT1010 Piezo-Electric Pulse 
Transducer (ADInstruments, Sydney, Australia) and inflatable tail-cuff 
connected to a MLT844 Physiological Pressure Transducer (ADInstruments, 
Sydney, Australia) and PowerLab data acquisition unit (ADInstruments, 
Sydney, Australia). These measurements were performed every fourth week 
(25). 
Echocardiography: At the end of the protocol, echocardiographic 
examinations (Phillips iE33, 12MHz transducer) were performed to assess the 
cardiovascular structure and function in rats (25). 
Isolated Langendorff heart preparation: During terminal experiments, 
rats were euthanized with Lethabarb (pentobarbitone sodium, 100 mg/kg 
intraperitoneally; Virbac, Peakhurst, NSW, Australia). After euthanasia, heparin 
(200 IU; Sigma-Aldrich Australia, Sydney, Australia) was injected through the 
right femoral vein. The abdomen was then opened and blood (~6-8 ml) was 
withdrawn from the abdominal aorta, collected into heparinized tubes, and 
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centrifuged at 5,000 × g for 15 minutes to obtain plasma. Plasma was stored at -
20°C before further analysis. Hearts were removed and were used in isolated 
Langendorff heart preparation to assess left ventricular function of the rats (n = 
9 from each group) (25). After performing Langendorff heart perfusion studies, 
hearts were separated into right ventricle and left ventricle (with septum). Both 
ventricles were weighed. 
Vascular reactivity: Thoracic aortic rings from rats (~4 mm in length; n = 
10-12 from each group) were suspended in an organ bath maintained at 35˚C 
and filled with Tyrode physiological salt solution bubbled with 95% O2-5% 
CO2 and allowed to stabilize at a resting tension of ~10 mN. Cumulative 
concentration-response curves (contraction) were obtained for norepinephrine 
(Sigma-Aldrich Australia, Sydney, Australia) and cumulative concentration-
response curves (relaxation) were obtained for ACh (Sigma-Aldrich Australia) 
and sodium nitroprusside (Sigma-Aldrich Australia) following submaximal 
(70%) contraction to norepinephrine (25). 
Histology of the heart: Three rats were exclusively used for histology 
from each group. Hearts were removed from these rats soon after euthanasia 
and were processed for histological assessments for inflammatory cells and 
collagen deposition (25). 
Hepatic structure and function 
Livers (n = 9 from each group) were isolated and weighed. Liver portions 
from histology rats were isolated (n = 3 f rom each group) and fixed in 10% 
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neutral buffered formalin for three days. These portions were used to determine 
fat deposition, infiltration of inflammatory cells, and portal fibrosis (25). 
Plasma activities of ALT, AST, alkaline phosphatase (ALP), and lactate 
dehydrogenase (LDH) were measured to determine hepatic function (25). 
Fatty acid analysis 
Hearts (immediately after perfusion studies), liver portions (~6-8 g), 
retroperitoneal fat (~6-8 g), epididymal fat (~6-8 g), skeletal muscle (~6-8 g), 
and plasma (~2 ml) were isolated during terminal experiments (n = 6 from each 
group) and were stored at -20°C. These samples were then used for fatty acid 
analysis (30). The concentrations of the following fatty acids were determined 
in these samples: capric acid (C10:0), lauric acid (C12:0), dodecenoic acid 
(C12:1n-9), myristic acid (C14:0), myristoleic acid (C14:1n-5), palmitic acid 
(C16:0), palmitoleic acid (C16:1n-7), stearic acid (C18:0), vaccenic acid 
(C18:1trans-7), oleic acid (C18:1n-9), linoleic acid (C18:2n-6), α-linolenic acid 
(C18:3n-3), γ-linolenic acid (C18:3n-6), eicosanoic acid (C20:0), eicosenoic 
acid (C20:1n-9), eicosadienoic acid (C20:2n-6), dihomo-γ-linolenic acid 
(C20:3n-6), eicosatrienoic acid (C20:3n-3), arachidonic acid (C20:4n-6), 
eicosapentaenoic acid (C20:5n-3), behenic acid (C22:0), erucic acid (C22:1n-
9), docosadienoic acid (C22:2n-6), docosatetraenoic acid (C22:4n-6), 
docosapentaenoic acid (C22:5n-3), docosahexaenoic acid (C22:6n-3), 
lignoceric acid (C24:0), and nervonic acid (C24:1n-9). Margaric acid (C17:0) 
was used as an internal standard in this procedure. All fatty acids were 
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expressed as % of total recovered fatty acids. The n-3:n-6 ratio and stearoyl-
CoA desaturase-1 (SCD-1) activity index were calculated from fatty acid 
concentrations obtained (30).  
Statistical analysis 
All data are presented as mean ± SEM. Groups of rats were tested for 
variance using Bartlett’s test and variables that were not normally distributed 
were transformed (using log 10 f unction) prior to statistical analyses. These 
groups were tested for effects of diet, ʟ-carnitine, and their interactions by two-
way ANOVA. When interaction and/or the main effects were significant, means 
were compared using Newman-Keuls multiple comparison post-test. P < 0.05 
was considered significant. All statistical analyses were performed using 
GraphPad Prism version 5.00 for Windows (San Diego, California, USA). 
Results 
Physiological, compositional, and metabolic parameters 
H rats had higher body weight compared to C rats at 16 week and HLC 
rats showed lower body weight than H rats at 16 week. Food and water intakes 
were lower in H rats compared to C rats. Food and water intakes were 
unchanged in both HLC and CLC rats. Abdominal circumference along with 
retroperitoneal, epididymal, and omental fat pads were higher in H rats 
compared to C rats. These parameters were lowered in both CLC and HLC rats 
compared to C and H rats, respectively. HLC rats had lower fat mass compared 
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to H rats with no di fference in lean mass between the groups. Basal blood 
glucose concentrations, AUC during oral glucose tolerance test, and plasma 
insulin concentrations were normalized in HLC rats. Plasma lipid components 
including total cholesterol, triglycerides, and non-esterified fatty acids were 
normalized in HLC rats (Table 1).  
Plasma fatty acid composition: C16:0 and C16:1n-7 were increased and 
decreased, respectively, in plasma by ʟ-carnitine in both CLC and HLC rats 
compared to C and H rats, respectively. C18:0 and C18:2n-6 concentrations 
were unchanged between the groups. C18:1n-9 was increased while 
C18:1trans-7 was decreased in HLC rats compared to H rats. C20:4n-6 
concentrations were lower in H rats than in C rats and were unaffected by ʟ-
carnitine in plasma of both CLC and HLC rats. The remaining fatty acids were 
undetectable in plasma in all groups. Overall, saturated fatty acids (SFA) that 
were decreased in H rats compared to C rats were increased with ʟ-carnitine 
supplementation in both CLC and HLC rats whereas monounsaturated fatty 
acids (MUFA) were decreased in CLC and HLC rats compared to C and H rats, 
respectively. Polyunsaturated fatty acids (PUFA) were unchanged between the 
groups. SCD-1 activity was decreased in both CLC and HLC rats compared to 
C and H rats, respectively (Table 1).  
Cardiovascular structure and function 
Hearts from H rats showed presence of inflammatory cells (Figure 1C) 
and collagen deposition (Figure 1G). The infiltration of inflammatory cells and 
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collagen deposition were inhibited in HLC rats (Figure 1D and 1H). Systolic 
blood pressure was higher in H rats and lowered in HLC rats. Hearts from H 
rats showed higher left ventricular internal diameter during diastole (LVIDd), 
indicative of ventricular dilation, increasing systolic volume. These changes 
affected the ventricular functional parameters including fractional shortening, 
ejection fraction, E/A ratio, and left ventricular diastolic stiffness (Table 2). 
HLC rats showed normalized LVIDd, systolic volume, ejection fraction, 
fractional shortening, E/A ratio, and left ventricular stiffness (Table 2). 
Thoracic aortic responses to norepinephrine (Figure 2A), sodium nitroprusside 
(Figure 2B), and ACh (Figure 2C) were diminished in H rats but improved in 
thoracic aorta from HLC rats (Figure 2A, 2B, and 2C). 
Cardiac fatty acid composition: C16:0, C18:0, and C18:1n-9 were 
increased while C14:1n-5, C16:1n-7, C18:1trans-7, C18:3n-6, and C20:4n-6 
were decreased in both CLC and HLC rats. C18:2n-6 was increased only in 
CLC. Other fatty acids were not detected in any of the groups. Total 
concentrations of SFA in cardiac tissue were increased in both CLC and HLC 
rats whereas MUFA and PUFA were decreased in both CLC and HLC rats. 
Within PUFA, n-3 fatty acids were lower than n-6 fatty acids in both CLC and 
HLC rats. This was indicated by the decreased n-3:n-6 ratio. SCD-1 activity 
was completely inhibited in both CLC and HLC rats (Table 2). 
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Hepatic structure and function 
H rats showed presence of inflammatory cells (Figure 4C), fat vacuoles 
(Figure 4G), and mild portal fibrosis (Figure 4K) in the liver. HLC rats showed 
inhibition of infiltration of inflammatory cells (Figure 4D) and absence of fat 
vacuoles (Figure 4H) and portal fibrosis (Figure 4L). Livers from H rats 
showed higher wet weight and this was unaffected by ʟ-carnitine 
supplementation in HLC rats. However, the markers of hepatic function in 
plasma including ALT, AST, ALP, and LDH, which were increased in H rats, 
were normalized in HLC rats. No differences were observed in the plasma 
concentrations of albumin and total bilirubin between the groups. Plasma uric 
acid concentrations were higher while plasma urea concentrations were higher 
in H rats than in C rats. These biochemical changes were attenuated in HLC rats 
(Table 3). 
Hepatic fatty acid composition: C16:0, C18:0, and C18:1n-9 were 
increased whereas C14:1n-5, C16:1n-7, C18:1trans-7, and C18:2n-6 were 
decreased in both CLC and HLC rats. C14:0 was lower only in CLC rats 
whereas C20:3n-6 was unchanged between the groups. C20:4n-6 was lower in 
HLC rats. Other fatty acids were undetectable in liver. Overall, SFA were 
increased in both CLC and HLC rats while MUFA were increased only in HLC 
rats. PUFA were decreased in both CLC and HLC rats. n-3:n-6 fatty acids ratio 
was lower in both CLC and HLC rats compared to C and H rats, respectively 
(Table 3).  
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Skeletal muscle 
Fatty acid composition: C16:0, C18:0, and C18:1n-9 were increased 
whereas C14:0, C14:1n-5, C16:1n-7, C18:2n-6, and C18:3n-6 were decreased 
in both CLC and HLC rats. C18:1trans-7 was increased only in CLC rats. 
C20:4n-6 was lower in H rats than in C rats and it was increased in HLC 
compared to H rats. Total SFA and MUFA were increased while total PUFA 
were decreased in both CLC and HLC rats. n-3:n-6 ratio was unchanged 
between the groups. SCD-1 activities were lower in both CLC and HLC rats 
(Table 4). 
Fatty acid composition of retroperitoneal fat 
C14:0, C16:0, C18:0, and C18:3n-3 were increased while C14:1n-5, 
C16:1n-7, C18:2n-6, and C18:3n-3 were decreased in retroperitoneal fat pads 
from both CLC and HLC. In CLC rats, mostly C18:1n-9 was stored whereas in 
HLC rats, C18:1trans-7 was stored in the retroperitoneal fat pads. C20:0 was 
lowered in CLC whereas it was increased in HLC rats. All other fatty acids 
were not detected in retroperitoneal fat pads. Total SFA and MUFA were 
increased in retroperitoneal fat pads whereas PUFA were decreased in both 
CLC and HLC rats. n-3:n-6 ratio was unchanged between the groups. SCD-1 
activity was lowered in both CLC and HLC rats (Table 5).  
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Discussion 
This study has characterized the metabolic and physiological effects of ʟ-
carnitine in a model of diet-induced metabolic syndrome in rats. This model 
mimics the human metabolic syndrome including the development of 
cardiovascular remodeling, nonalcoholic steatohepatitis, renal damage, 
pancreatic hypertrophy, and hyperinsulinemia (25). ʟ-Carnitine 
supplementation in these rats attenuated the symptoms of metabolic syndrome 
including hypertension, impaired glucose tolerance, central obesity, 
dyslipidemia, and hyperinsulinemia. ʟ-Carnitine also attenuated ventricular 
remodeling including dilation and fibrosis, as well as hepatic steatosis and 
fibrosis, and improved the function of the left ventricle and the liver. 
Obesity is a chronic condition where excess fat is deposited in the body, 
especially the abdomen. Deposition of this excess fat in the abdomen is 
associated with the development of inflammatory organ damage including 
cardiovascular remodeling and nonalcoholic fatty liver disease (7,39). The 
presence of these complications is increasing throughout the world and the cost 
of health management is proportionately increasing (1). 
Removal of fat from the abdomen, with reduced triglycerides and NEFA 
in plasma confirms increased β-oxidation in obese rats due to ʟ-carnitine 
supplementation. In the heart, fatty acids are the major fuel source for energy 
supply (12). With addition of ʟ-carnitine to the diet, increased availability of ʟ-
carnitine may shift the energy supply in the heart to fatty acid oxidation. In our 
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previous study, ʟ-carnitine supplementation in an acute model of cardiovascular 
remodeling improved cardiac function (23). Reduced β-oxidation of fatty acids 
coupled with increased lipogenesis in the liver leads to steatosis followed by 
steatohepatitis (36) while increasing fatty acid oxidation by ʟ-carnitine 
attenuated steatohepatitis (20,40). 
ʟ-Carnitine decreased the proportion of pro-inflammatory n-6 and trans 
fatty acids in the heart and the liver leading to the accumulation of C18:1n-9 in 
all tissues. However, C20:4n-6 and C18:1trans-7 were increased in the skeletal 
muscle suggesting a substrate bias in different tissues. Importantly, 18:2n-6 in 
the adipose tissue of ʟ-carnitine-supplemented rats was substituted with 
equivalent amounts of C18:1n-9 and C18:1trans-7, respectively. This result 
strongly suggests that ʟ-carnitine selectively facilitated the transport and 
oxidation of C18:2n-6 therefore limiting the production of C20:4n-6 to exert its 
pro-inflammatory effects. All the tissues showed extremely low indexes for 
SCD-1 activity indicating the inhibition of conversion of SFA to MUFA. Thus, 
SFA were increased in the plasma and the tissues. At the same time, only 
plasma and the heart showed reductions in total MUFA whereas the liver and 
the skeletal muscle preferentially stored MUFA in the form of C18:1n-9. 
Retroperitoneal fat from CLC rats stored C18:1n-9 whereas HLC rats stored 
C18:1trans-7 in retroperitoneal fat. Similar results were obtained in our 
previous study with chia seed in obese rats (30). Higher SCD-1 activity has 
been implicated in obesity and cardiovascular disease with inhibition of SCD-1 
activity inducing an increase in fatty acid oxidation and decrease in body fat 
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(29). These results have been confirmed in this study with the decrease in the 
activity index of SCD-1 in all the tissues and attenuation of obesity and 
cardiovascular disease. Further study will be required to determine the 
mechanism of inhibition of SCD-1 by ʟ-carnitine. 
In fructose-fed rats, ʟ-carnitine supplementation reduced plasma 
concentrations of glucose, insulin, triglycerides, and NEFA, and the liver and 
muscle content of triglycerides and NEFA (31). Also, glycogen content in the 
liver and the muscle were increased along with reduced activity of glycogen 
phosphorylase. Similarly, ʟ-carnitine-treated rats showed reduced 
gluconeogenesis from different sources such as lactic acid, pyruvic acid, etc. 
(31). These observations clearly suggest that ʟ-carnitine supplementation 
increased glycogenesis and reduced glycogenolysis and gluconeogenesis in 
fructose-fed rats. These effects of ʟ-carnitine were observed in this study as 
lower blood glucose concentrations and plasma concentrations of insulin, 
triglyceride, and NEFA. These effects are supported by a recent study in piglets 
supplemented with ʟ-carnitine where 563 genes were differentially expressed 
by ʟ-carnitine supplementation, especially genes for the proteins and enzymes 
encoding for fatty acid uptake, fatty acid activation, and fatty acid oxidation 
(17). Similarly, genes for glycolysis were up-regulated and genes involved in 
gluconeogenesis were down-regulated (17).  
This study along with earlier studies supports that ʟ-carnitine 
supplementation attenuates the complications in carbohydrate and lipid 
metabolism in high carbohydrate, high fat-fed rats (4,22,27). Also, these 
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metabolic complications have been implicated in oxidative stress (35) including 
diminishing aortic relaxant responses (13). ʟ-Carnitine supplementation 
attenuated the metabolic complications and hence improved aortic responses to 
sodium nitroprusside and acetylcholine were observed in this study. 
In conclusion, high-carbohydrate, high fat diet-fed rats serve as a suitable 
animal model for the metabolic, cardiovascular and hepatic complications seen 
in human metabolic syndrome. ʟ-Carnitine supplementation in these rats 
attenuated the symptoms of metabolic syndrome, cardiovascular remodeling 
and non-alcoholic fatty liver disease. Also, SCD-1 activity was inhibited by ʟ-
carnitine and hence reduced short chain MUFA in the tissues. At the same time, 
PUFA, specially C18:2n-6, were preferentially subjected to oxidation whereas 
SFA and C18:1n-9 were stored in the tissues.  
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Figure 1. Effects of ʟ-carnitine supplementation on inflammation and fibrosis 
in rat heart. Top row represents hematoxylin and eosin staining of left ventricle 
showing infiltration of inflammatory cells (A-D, inflammatory cells marked as 
“in”; ×20) from C (A), CLC (B), H (C), and HLC (D) rats. Bottom row 
represents picrosirius red staining of left ventricle showing collagen deposition 
and hypertrophy (E-H, fibrosis marked as “fi” and hypertrophied 
cardiomyocytes as “hy”; ×40) from C (E), CLC (F), H (G), and HLC (H) rats. 
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 Figure 2. Effects of L-carnitine supplementation on va scular responses of 
thoracic aortic preparations. Norepinephrine-induced contraction (A), sodium 
nitroprusside-induced relaxation (B), and ACh-induced relaxation (C). Values 
are mean ± SEM, n = 10 - 12. End-point means without a common letter differ, 
P < 0.05. D, LC, and D×LC represent effects of diet, effects of L-carnitine, and 
interaction between effects of diet and L-carnitine, respectively. 
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Figure 3. Effects of L-carnitine supplementation on i nflammation, fat 
deposition, and fibrosis in the liver. Top and middle rows represent 
hematoxylin and eosin staining of the liver showing inflammatory cells (A-D, 
marked as “in”; ×20) and enlarged fat vacuoles (E-H, marked as “fv”; ×40), 
respectively, from C (A,E), CLC (B,F), H (C,G), and HLC (D,H) rats. Bottom 
row represents Milligan’s trichrome staining of the liver showing fibrosis in the 
hepatic portal region (I-L, marked as “fi”; ×20) from C (I), CLC (J), H (K), and 
HLC (L) rats. 
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Chapter 8: Chronic ethanol consumption in rats fed a 
high-carbohydrate, high-fat diet  
Introduction 
Ethanol consumption is very common throughout the world as part of 
many beverages including beer, wine and whiskey [1]. Ethanol is a substantial 
source of energy (29.7 kJ/g), providing more energy than carbohydrates or 
proteins. Being a rich source of energy, it interferes with the handling of other 
nutrients and is responsible for malnutrition through impairment of 
gastrointestinal absorption and hepatic metabolism [2]. Chronic ethanol 
consumption leads to changes in the structure and function of the liver, 
including lipid accumulation (steatosis), steatohepatitis (steatosis, fibrosis and 
inflammation in the liver) and ultimately cirrhosis (advanced fibrosis and liver 
degeneration) [3]. Hepatic steatosis may originate from dietary lipids as 
chylomicrons, from adipose tissue as non-esterified fatty acids or from 
synthesis in the liver. Ethanol increases peripheral fat mobilisation, enhances 
hepatic triglyceride synthesis, decreases lipid oxidation in the liver and 
decreases hepatic lipoprotein release [4]. Fibrosis starts in the liver once these 
changes are initiated and the ethanol intake is chronic. Severe fibrosis leads to 
cirrhosis of the liver [4]. 
We have shown that a high-carbohydrate, high-fat diet induces non-
alcoholic steatohepatitis with fat accumulation, infiltration of inflammatory 
cells, perivascular fibrosis and increased plasma markers of liver function as 
part of diet-induced metabolic syndrome [5-8]. Other researchers have reported 
similar outcomes with diets rich in simple carbohydrates (such as fructose and 
sucrose) and animal fat [9-13]. Since ethanol causes a s imilar range of liver 
changes, ethanol administration may accelerate the changes in high-
carbohydrate, high-fat diet-fed rats, in the liver as well as in the heart and on 
metabolic function. The combination of ethanol with a high carbohydrate, high 
fat diet, analogous to modern dietary practice in countries such as Australia, 
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would then be predicted to worsen the myriad changes in metabolic syndrome.  
In contradiction to these findings, moderate consumption of red wine as 
part of the Mediterranean diet has been associated with decreased 
cardiovascular disease [14]; moderate, regular ethanol intake could then be a 
key ingredient in the French paradox. Further, ethanol administration decreased 
infarct size in ischaemia-reperfusion injury in rat hearts [15,16]. Thus, the 
responses to chronic moderate ethanol intake are difficult to predict, but could 
attenuate or worsen the responses to a high-carbohydrate, high-fat diet. 
This study measured the effects of chronic moderate ethanol feeding on 
metabolic parameters and structure and function of cardiovascular system and 
the liver in high-carbohydrate, high-fat diet-fed rats. The effects of ethanol 
feeding on the structure and function of the heart were characterised through 
echocardiography, isolated Langendorff heart preparation and histopathology 
while the structure and function of the liver were characterised through 
histopathology and plasma biochemical analyses. In addition, metabolic 
function was characterised through glucose tolerance testing and plasma lipid 
profile assessment. 
Methods and materials 
Rats and diets 
All experimental protocols were approved by University of Southern 
Queensland Animal Experimentation Ethics Committee, under the guidelines of 
the National Health and Medical Research Council of Australia. Male Wistar 
rats (8-9 weeks old, weighing 337 ± 1 g, n = 48) were obtained from The 
University of Queensland Biological Resources facility. The rats were 
randomly divided into four experimental groups and were fed with one of the 
following diets; corn starch diet with normal drinking water (C1; n = 12), corn 
1 Abbreviations used: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate 
transaminase; CS, corn starch diet-fed rats; CE, corn starch diet-fed rats given 10% ethanol; 
DXA, Dual-energy X-ray absorptiometry; H, high-carbohydrate, high-fat diet-fed rats; HE, 
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starch diet with 10% (v/v) ethanol in drinking water (CE; n = 12), high-
carbohydrate, high-fat diet with 25% (w/v) fructose-supplemented drinking 
water (H; n = 12) and high-carbohydrate, high-fat diet with 10% (v/v) ethanol 
in 25% (w/v) fructose-supplemented drinking water (HE; n = 12). All groups 
were fed with these diets for 16 weeks. Compositions of C and H diets have 
been previously described in detail [5,7,8]. All the rats were given ad libitum 
access to food and water and were individually housed in temperature-
controlled 12-hour light/dark conditions.  
Physiological parameters 
Rats were monitored daily for body weight, food and water intakes. Oral 
glucose tolerance tests and systolic blood pressure measurements were 
performed on a ll groups of rats after 16 w eek as in previous study [5]. 
Abdominal circumference of rats was measured using a standard measuring 
tape while sedated for systolic blood pressure measurements [5]. 
Body composition measurements 
Dual-energy X-ray absorptiometric (DXA) measurements were 
performed on the rats after 16 weeks of feeding (2 days before rats were 
euthanased for pathophysiological assessments) using a Norland XR36 DXA 
instrument (Norland Corp., Fort Atkinson, USA). DXA scans were analysed 
using the manufacturer’s recommended software for use in laboratory animals 
(Small Subject Analysis Software, version 2.5.3/1.3.1, Norland Corp., Fort 
Atkinson, USA) as previously described [17]. The precision error of lean mass 
for replicate measurements, with repositioning, was 3.2%. 
Echocardiography 
high-carbohydrate, high-fat diet-fed rats given 10% ethanol; IVSd, interventricular septum 
thickness during diastole; LDH, lactate dehydrogenase; LVIDd, left ventriclar internal diameter 
during diastole; LVIDs, left ventriclar internal diameter during systole; LVPWd, left ventricular 
posterior wall thickness during diastole; MCMO, time from mitral valve closure to opening; 
NEFA, non-esterified fatty acids. 
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Echocardiographic examinations (Phillips iE33, 12MHz transducer) were 
performed to assess the cardiovascular structure and function in all rats at the 
end of protocol as previously described [5]. Briefly, rats were anaesthetised 
using Zoletil (tiletamine 25 mg/kg and zolazepam 25 mg/kg, i.p.; Virbac, 
Peakhurst, Australia) and Ilium Xylazil (xylazine 15 m g/kg, i.p.; Troy 
Laboratories, Smithfield, Australia) and positioned in dorsal recumbency. 
Electrodes attached to the skin overlying the elbows and right stifle facilitated 
the simultaneous recording of a lead II ECG. A short-axis view of the left 
ventricle at the level of the papillary muscles was obtained and used to direct 
acquisition of M mode images of the left ventricle for measurement of 
interventricular septum thickness during diastole (IVSd), left ventricular 
posterior wall thickness during diastole (LVPWd), left ventricular internal 
diameter during systole (LVIDs) and left ventricular internal diameter during 
diastole (LVIDd). Measurements were taken in accordance with the guidelines 
of the American Society of Echocardiography using the leading-edge method. 
Details of this method have been described previously [5,18]. 
Isolated Langendorff heart preparation 
Rats were euthanised with Lethabarb (pentobarbitone sodium, 100 mg/kg, 
i.p.; Virbac, Peakhurst, Australia). After euthanasia, heparin (200 IU; Sigma-
Aldrich Australia) was injected through the right femoral vein. The abdomen 
was then opened and blood (~5 mL) was withdrawn from the abdominal aorta, 
collected into heparinised tubes and centrifuged at 5000 × g for 15 minutes to 
obtain plasma. Plasma was stored at -20°C before further biochemical analysis. 
Hearts were removed and were used in isolated Langendorff heart preparations 
to assess left ventricular function of the rats as in previous study [5]. 
Hearts isolated from euthanased rats (n = 9) were perfused with modified 
Krebs–Henseleit bicarbonate buffer, containing (in millimolar): NaCl, 119.1; 
KCl, 4.75; MgSO4, 1.19; KH2PO4, 1.19; NaHCO3, 25.0; glucose, 11.0; and 
CaCl2, 2.16. B uffer was bubbled with 95% O2-5% CO2 and maintained at 
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35°C. Isovolumetric ventricular function was measured by inserting a latex 
balloon catheter into the left ventricle connected to a Capto SP844 MLT844 
physiological pressure transducer and Chart software on a Maclab system 
(ADInstruments). All left ventricular end-diastolic pressure values were 
measured during pacing of the heart at 250 beats per minute using an electrical 
stimulator. End-diastolic pressures were obtained from 0 up t o 30 m mHg for 
calculation of diastolic stiffness constant (κ, dimensionless) [5]. 
Vascular reactivity 
Thoracic aortic rings (~4 mm in length) were suspended in an organ bath 
filled with Tyrode physiological salt solution bubbled with 95% O2-5% CO2 
and maintained at 35˚C and allowed to stabilise at a resting tension of 
approximately 10 mN [5]. Cumulative concentration-response curves 
(contraction) were obtained for noradrenaline (Sigma-Aldrich Australia) and 
cumulative concentration-response curves (relaxation) were obtained for 
acetylcholine (Sigma-Aldrich Australia) and sodium nitroprusside (Sigma-
Aldrich Australia) following submaximal (70%) contraction to noradrenaline 
[5]. 
Organ weights and histology 
After performing Langendorff heart perfusion, hearts were separated into 
right ventricle and left ventricle (with septum) (n = 9) for weighing. Livers and 
abdominal fat pads (retroperitoneal, epididymal and omental) were isolated and 
weighed (n = 9). These organ weights were normalised to the tibial length at the 
time of removal and expressed as mg of tissue/mm of tibial length [5]. The 
heart and the liver of rats (n = 3 f rom each group) were exclusively used for 
histopathological analysis as in previous study [5]. Tissues were fixed in 10% 
neutral buffered formalin for 3 days. The tissue samples were then dehydrated 
and embedded in paraffin wax. For staining, thin sections (5 µm) of tissues 
were cut and fixed on slides. Heart sections were stained with picrosirius red to 
study collagen deposition and were analysed using laser confocal microscopy 
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(Zeiss LSM 510 upright Confocal Microscope). Haematoxylin and eosin stain 
was used to visualise infiltration of inflammatory cells in both the heart and the 
liver whereas Milligan’s stain was used to study the perivascular fibrosis in the 
liver. Haematoxylin and eosin stain was also used to visualise the presence of 
fat vacuoles in the liver. After staining with haematoxylin and eosin or 
Milligan’s stains, pictures were taken with a Zeiss Microscope. From each 
tissue sample, three slides were prepared and two random, non-overlapping 
fields were selected from each slide. A representative picture was randomly 
selected from each group. 
Biochemical analysis of plasma samples 
Plasma activities of alanine transaminase (ALT), aspartate transaminase 
(AST), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) and 
plasma concentrations of total cholesterol, triglycerides, albumin, total 
bilirubin, urea and uric acid were determined. These variables were measured 
using kits and controls supplied by Olympus using an Olympus analyser (AU 
400, Tokyo, Japan) [5]. Plasma non-esterified fatty acids (NEFA) were 
determined using a commercial kit (Wako, Osaka, Japan) [5]. 
Statistical analysis 
All data are presented as mean ± SEM. All the groups were tested for 
variance using Bartlett’s test and variables that were not normally distributed 
were transformed (using log 10 f unction) prior to statistical analyses. All 
groups were tested for effects of diet, ethanol, and their interactions by two-way 
ANOVA. When interaction and/or the main effects were significant, means 
were compared using Newman-Keuls multiple comparison post-test. Mean 
daily ethanol intake of CE and HE rats were compared using Student’s t test. P 
< 0.05 was considered significant. All statistical analyses were performed using 
GraphPad Prism version 5.00 for Windows (San Diego, California, USA). 
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Results 
Physiological and metabolic parameters 
As a preliminary study, rats fed with standard chow diet were given 5%, 
10% and 20% ethanol (n = 8-10 for each group) in drinking water for 16 weeks. 
No changes were observed in body parameters, cardiovascular and hepatic 
functions compared to chow-fed controls with 5% ethanol in drinking water 
(results not shown). With 20% ethanol in drinking water, rats did not gain body 
weight and showed less physical activity (results not shown). With 10% ethanol 
in drinking water, rats showed slight decreases in body weight. In terms of 
blood and plasma characteristics, there were minor differences between 10% 
and 20% ethanol feeding (results not shown). Thus 10% ethanol was selected 
for the study of the effects of a combination of ethanol and high-carbohydrate, 
high-fat diet. 
High-carbohydrate, high-fat diet-fed rats (H) had higher body weight than 
corn starch diet-fed rats (C). H rats fed ethanol (HE) had lower body weight 
compared to H rats whereas the body weights of C and corn starch rats fed 
ethanol (CE) did not differ (Table 1). C rats consumed more water than H rats. 
Water consumption was higher in HE rats than in H rats whereas water 
consumption of C and CE rats did not differ (Table 1). C rats ate more food 
than H rats. Food consumption of CE and HE rats did not differ compared to C 
and H rats, respectively (Table 1). Abdominal circumference was higher in H 
rats compared to C rats. Abdominal circumference was greater in CE rats than 
in C rats whereas abdominal circumference did not differ between H and HE 
rats (Table 1). Daily ethanol intake of CE rats was 6.31 ± 0.28 g/kg body 
weight and 4.49 ± 0.18 g/kg body weight in HE rats. 
Basal blood glucose concentrations were higher in H rats compared to C 
rats. CE and HE rats had lower blood glucose concentrations than C and H rats, 
respectively (Table 1). During oral glucose tolerance test, H rats showed 
impaired glucose tolerance indicated by higher blood glucose concentrations 
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compared to C rats after 120 m inutes of glucose load. After 120 m inutes of 
glucose loading, CE rats had lower blood glucose concentrations than C rats 
whereas blood glucose concentrations did not differ between H and HE rats 
(Figure 1A). Plasma total cholesterol, plasma triglyceride and plasma NEFA 
concentrations were higher in H rats compared to C rats, and lower in HE rats 
compared to H rats. Plasma total cholesterol and plasma triglycerides 
concentrations did not differ between C and CE rats whereas CE rats had higher 
plasma NEFA concentrations than C rats (Table 1). Retroperitoneal, epididymal 
and omental fat pads were increased in H rats compared to C rats, and lower in 
HE rats than in H rats. In CE rats, retroperitoneal fat was lower than in C rats 
whereas epididymal and omental fat content did not differ between C and CE 
rats (Table 1). Whole-body fat mass and lean mass were higher in H rats than in 
C rats. CE and HE rats did not differ in whole-body fat mass compared to C and 
H rats, respectively whereas the lean masses were lower in CE and HE rats 
compared to C and H rats, respectively (Table 1). 
Cardiovascular structure and function 
Systolic blood pressure was higher in H rats than in C rats after 16 weeks 
of the protocol. Systolic blood pressure did not differ in CE and HE rats 
compared to C and H rats, respectively (Figure 1B). LVIDd and LVIDs were 
higher in H rats compared to C rats, but did not differ in CE and HE rats 
compared to C and H rats, respectively (Table 2). Although LVPWd did not 
differ between C and H rats, CE and HE rats had lower LVPWd than C and H 
rats, respectively (Table 2). Relative wall thickness did not differ between C 
and H rats. CE rats had higher relative wall thickness than C rats whereas H and 
HE rats did not differ in relative wall thickness (Table 2). Fractional shortening 
and ejection fraction were lower in H rats compared to C rats. Ethanol feeding 
did not change fractional shortening in CE and HE rats compared to C and H 
rats, respectively. Ejection fraction was lower in CE rats than in C rats while it 
was higher in HE rats compared to H rats (Table 2). Ejection time did not differ
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between C and H rats while it was lower in CE rats than in C rats. Ejection time 
did not differ between H and HE rats. HCHF-fed rats had higher estimated left 
ventricular mass compared to CHOW- and CS-fed rats. Estimated left 
ventricular mass was higher in H rats than in C rats and this was unaffected by 
ethanol feeding (Table 2). Left and right ventricular wet weights did not differ 
between the groups (Table 2). Left ventricular diastolic stiffness was higher in 
H rats compared to C rats. Left ventricular diastolic stiffness did not change 
with ethanol feeding in both CE and HE rats (Table 2). Left ventricles from H 
rats showed infiltration of inflammatory cells (Figure 2C), fibrosis and 
hypertrophy (Figure 2G). These changes were absent in the left ventricles from 
C rats (Figure 2A & 2E). Left ventricles from HE rats showed infiltration of 
inflammatory cells (Figure 2D) whereas fibrosis was attenuated with ethanol 
feeding in HE rats (Figure 2H). Ethanol feeding did not affect infiltration of 
inflammatory cells, fibrosis and hypertrophy in CE rats (Figure 2B & 2F). 
Thoracic aortic contraction with noradrenaline was lower in H rats 
compared to C rats. Thoracic aortic rings from HE rats had higher contractile 
response to noradrenaline than H rats while this contractile response did not 
differ between C and CE rats (Figure 3A). Sodium nitroprusside-induced 
relaxation was lower in H rats compared to C rats. HE rats showed higher 
relaxant response to sodium nitroprusside than H rats while this response did 
not differ between C and CE rats (Figure 3B). H rats had lower relaxant 
response to acetylcholine compared to C rats. CE and HE rats showed higher 
relaxant responses to acetylcholine compared to C and H rats, respectively 
(Figure 3C).  
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Figure 1. Effects of 
combination of high-
carbohydrate, high-
fat diet and ethanol 
on oral glucose 
tolerance (A) and 
systolic blood 
pressure (B) in rats. 
Values are mean ± 
SEM, n = 12. E nd-
point means without 
a common letter 
differ, P < 0.05.  
C, corn starch diet-
fed rats; CE, corn 
starch diet-fed rats 
given 10% ethanol; 
H, high-
carbohydrate, high-
fat diet-fed rats; HE, 
high-carbohydrate, 
high-fat diet-fed rats 
given 10% ethanol. 
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 Figure 2. Effects of combination of high-carbohydrate, high-fat diet and 
ethanol on inflammation and fibrosis in the heart from rats fed with different 
diets. Haematoxylin and eosin staining of left ventricle showing infiltration of 
inflammatory cells (A-D, inflammatory cells marked as “in”) from corn starch 
diet-fed rats (A), corn starch diet-fed rats given 10% ethanol (B), high-
carbohydrate, high-fat diet-fed rats (C) and high-carbohydrate, high-fat diet-fed 
rats given 10% ethanol (D). Picrosirius red staining of left ventricle showing 
collagen deposition and hypertrophy (E-H, fibrosis marked as “fi” and 
hypertrophied cardiomyocytes as “hy”) from corn starch diet-fed rats (E), corn 
starch diet-fed rats given 10% ethanol (F), high-carbohydrate, high-fat diet-fed 
rats (G) and high-carbohydrate, high-fat diet-fed rats given 10% ethanol (H). 
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Figure 3. Effects of 
combination of high-
carbohydrate, high-fat 
diet and ethanol on 
noradrenaline- induced 
contraction (A), sodium 
nitroprusside-induced 
relaxation (B) and 
acetylcholine-induced 
relaxation (C) in 
thoracic aortic 
preparations from rats. 
Values are mean ± 
SEM, n = 12. End-point 
means without a 
common letter differ, P 
< 0.05. 
C, corn starch diet-fed 
rats; CE, corn starch 
diet-fed rats given 10% 
ethanol; H, high-
carbohydrate, high-fat 
diet-fed rats; HE, high-
carbohydrate, high-fat 
diet-fed rats given 10% 
ethanol. 
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Hepatic structure and function  
Livers from H rats showed infiltration of inflammatory cells (Figure 4C), 
fat deposition (Figure 4G) and perivascular fibrosis (Figure K). These changes 
were not seen in the livers from C rats (Figure 4A, 4E & 4I). In HE rats, livers 
showed infiltration of inflammatory cells (Figure 4D), a further increase in fat 
deposition in the form of fat vacuoles (Figure 4H) as well as perivascular 
fibrosis (Figure 4L). In CE rats, infiltration of inflammatory cells (Figure 4B) 
and fibrosis (Figure 4F) were not observed whereas fat vacuoles were present 
(Figure 4J). 
Liver wet weight was higher in H rats compared to C rats. CE rats 
showed higher liver wet weight than C rats whereas HE rats showed lower liver 
wet weights compared to H rats (Table 3). H rats had higher plasma activities of 
ALT, AST, ALP and LDH compared to C rats, while these activities were 
lower in HE rats than H rats. C and CE rats did not differ in plasma activities of 
ALT, AST and LDH whereas plasma activity of ALP was lower in CE rats than 
in C rats (Table 3). Plasma albumin concentrations did not differ between C and 
H rats. HE rats had lower plasma albumin concentrations than H rats whereas 
plasma albumin concentrations did not differ between C and CE rats (Table 3). 
Plasma total bilirubin concentrations did not differ between C and H rats. CE 
rats had lower plasma concentrations of total bilirubin than C rats while plasma 
total bilirubin concentrations did not differ between H and HE rats (Table 3). 
Plasma urea concentrations were lower in H rats than in C rats. Plasma urea 
concentrations were higher in HE rats compared to H rats, although this 
parameter was not normalised. Plasma urea concentrations did not differ 
between C and CE rats. Plasma uric acid concentrations were higher in H rats 
compared to C. Plasma uric acid concentrations did not differ in CE and HE 
rats compared to C and H rats, respectively (Table 3). 
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 Figure 4. Effects of combination of high-carbohydrate, high-fat diet and 
ethanol on inflammation, fat deposition and fibrosis in the liver from rats fed 
with different diets. Top and middle rows represent hematoxylin and eosin 
staining of the liver showing inflammatory cells (A-D, marked as “in”) (×20) 
and enlarged fat vacuoles (E-H, marked as “fv”) (×40) from corn starch diet-fed 
rats (A,E), corn starch diet-fed rats given 10% ethanol (B,F), high-
carbohydrate, high-fat diet-fed rats (C,G) and high-carbohydrate, high-fat diet-
fed rats given 10% ethanol (D,H). Bottom row represents Milligan’s trichrome 
staining of the liver showing fibrosis in the hepatic portal region (I-L, marked 
as “fi”) (×20) from corn starch diet-fed rats (I), corn starch diet-fed rats given 
10% ethanol (J), high-carbohydrate, high-fat diet-fed rats (K) and high-
carbohydrate, high-fat diet-fed rats given 10% ethanol (L). 
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Discussion 
Ethanol consumption is very common in most countries. In Australia, 
approximately 3,000 people die and 65,000 people are hospitalised every year 
as a result of excess ethanol consumption [19,20]. Ethanol-related deaths in 
Australia included a significant involvement of end-stage alcoholic liver 
cirrhosis as a cause of death [21]. A we b-based survey has shown a high 
prevalence of ethanol consumption among Australian University students [22]. 
Similar results have been obtained from different countries [23-25]. National 
Health and Medical Research Council guidelines recommend no more than two 
standard drinks (20 g alcohol/day) on any day for healthy men and women to 
reduce the risk of harm from alcohol-related diseases [26]. It is proposed that 
cirrhosis occurs faster in the presence of conditions such as viral hepatitis, 
obesity or iron overload [21]. 
Ethanol is absorbed very rapidly and without metabolism from the 
gastrointestinal tract (about 20% in stomach and 80% in small intestine). After 
absorption, it is distributed throughout the body and then metabolised. The 
main organ responsible for the metabolism of ethanol is the liver [27]. Initially, 
ethanol is converted to acetaldehyde by alcohol dehydrogenase in the 
cytoplasm of the hepatocytes. Nicotinamide adenine dinucleotide (NAD) acts 
as an electron acceptor in this reaction. Liver microsomes can oxidise alcohol 
with the use of NADP instead of NAD. Acetaldehyde is then converted to 
acetic acid by aldehyde dehydrogenase, using NAD as the electron acceptor. 
The acetic acid thus produced is then converted to acetyl-CoA, which is an 
intermediate of Krebs cycle and de novo lipogenesis [27]. Many mechanisms 
have been validated for the development of fatty liver with chronic ethanol 
consumption [28].  
Acetic acid produced from metabolism of ethanol decreases plasma non-
esterified fatty acids [29]. A similar decrease occurs in plasma glycerol 
concentrations [30]. Also, being a major site for glycerol metabolism, liver had 
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reduced glycerol clearance in presence of ethanol [31]. These studies conclude 
that consumption of ethanol leads to decreased lipolysis in the peripheral tissues 
and hence lower concentrations of non-esterified fatty acids and glycerol in 
plasma. However, these effects are seen with a lower dose of ethanol. Non-
esterified fatty acids have been involved increasing the risk of cardiovascular 
disease [32,33]. Thus, the reduction in plasma concentrations of non-esterified 
fatty acids with acute alcohol consumption may explain the cardioprotective 
effects of lower intake of alcohol. With higher dose of ethanol, the mobilisation 
of fatty acids from adipose tissue increased the plasma non-esterified fatty acid 
concentrations, although plasma triglycerides concentrations were lower [34]. 
The shift from NAD to NADH by ethanol inhibits the citric acid cycle 
and β-oxidation of fatty acids. At the same time, conversion of pyruvate to 
lactate is favoured. The increase in the ratios of NADH/NAD and 
lactate/pyruvate leads to inhibition of gluconeogenesis. These results were 
confirmed in both rat livers [35] as well as in humans [36]. When supply of 
glucose is limited as in the case of starvation, glucose is released from glycogen 
stores in the liver. In the case of chronic alcohol consumption, glycogenolysis is 
also impaired. Thus alcohol causes hypoglycaemia with impaired 
glycogenolysis and gluconeogenesis [36-38].  
In our previous studies, we have shown that a high-carbohydrate, high-fat 
diet in rats induced symptoms of non-alcoholic fatty liver disease, including the 
presence of fat vacuoles in the liver, infiltration of inflammatory cells, 
perivascular fibrosis and increased plasma activities of liver enzymes including 
transaminases [5]. Although these changes were seen in high-carbohydrate, 
high-fat diet-fed rats, it was concluded that these symptoms were only mild, as 
expected with this diet for a relatively short period. Since ethanol is a dietary 
component that causes severe damage to the liver in humans when taken 
chronically [3], this study was designed to measure the effects of a combination 
of high-carbohydrate, high-fat diet and ethanol. It was hypothesised that this 
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combination would cause more damage to the liver than the high-carbohydrate, 
high-fat diet alone. 
A combination of ethanol and high-carbohydrate, high-fat diet did not 
worsen the symptoms of metabolic syndrome in rats. Rather, some of the 
symptoms of metabolic syndrome including central obesity and dyslipidaemia 
were improved. Cardiovascular changes including left ventricular diameter, 
fractional shortening, ventricular diastolic stiffness and cardiac inflammation 
were similar to high-carbohydrate, high-fat diet alone whereas cardiac fibrosis 
and hypertrophy were attenuated with ethanol in high-carbohydrate, high-fat 
diet-fed rats. Vascular responses including smooth muscle contraction, 
endothelium-dependent and endothelium-independent vascular relaxations were 
improved in the ethanol and high-carbohydrate, high-fat diet-fed rats. 
Specifically, livers from high-carbohydrate, high-fat diet-fed rats given ethanol 
showed lower liver wet weight and plasma activities of liver enzymes compared 
to high-carbohydrate, high-fat diet-fed rats. However, the livers from ethanol-
fed rats with both corn starch diet and high-carbohydrate, high-fat diet showed 
more fat vacuoles than high-carbohydrate, high-fat diet alone. These results in 
rats showed that ethanol feeding (5-6 g/kg body weight/day) in rats caused 
hepatic steatosis. This effect of ethanol was independent of high-carbohydrate, 
high-fat diet as it was also observed in corn starch diet-fed rats. 
In conclusion, ethanol caused hepatic steatosis with both corn starch diet 
and high-carbohydrate, high-fat diet. However, hepatic inflammation and 
fibrosis were only observed with a combination of ethanol and high-
carbohydrate, high-fat diet. Also, this combination either improved the 
cardiovascular complications or did not affect them, consistent with responses 
to ethanol expected as part of the Mediterranean diet. It can be concluded that a 
combination of high-carbohydrate, high-fat diet and 10% ethanol can be used to 
mimic alcoholic steatohepatitis, but this model does not mimic the 
cardiovascular complications observed with high-carbohydrate, high-fat diet 
alone due to the cardioprotective effect of ethanol. 
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Chapter 9: Discussion and conclusion 
This thesis has firstly characterised an appropriate rat model to mimic 
diet-induced metabolic syndrome in humans and secondly evaluated the 
potential therapeutic benefits of interventions with natural products found in 
foods. Chapter 1 describes metabolic syndrome, cardiovascular remodelling 
and non-alcoholic fatty liver disease. Metabolic syndrome is prevalent 
throughout the world [1]. This combination of obesity, hypertension, 
dyslipidaemia and insulin resistance markedly increases the risk for 
development of cardiovascular disease, non-alcoholic fatty liver disease and 
diabetes, increasing both morbidity and mortality. The major players in the 
development of cardiovascular disease and non-alcoholic fatty liver disease are 
oxidative stress and inflammation.  
Chapter 2 describes the potential therapeutic benefits of polyphenols 
from natural products and some of the Indian spices on t he symptoms of 
metabolic syndrome. Polyphenols are plant secondary metabolites derived 
exclusively from the shikimate-derived phenylpropanoid and/or the polyketide 
pathway(s), featuring more than one phenolic ring and being devoid of any 
nitrogen-based functional group in their most basic structural expressions [2]. 
In this study, we focused on polyphenols or polyphenol-rich natural products as 
potential treatment strategies for metabolic syndrome. 
Research in metabolic syndrome, as in other human diseases, relies on 
appropriate animal models to test possible interventions in humans. Many 
rodent models are available, including genetic/spontaneous models, genetically-
engineered models, chemically-induced models and diet-induced models [1]. 
Since the human syndrome is mainly diet-induced rather than genetic, Chapter 
3.1 has argued that a diet-induced model in rats is the most appropriate model 
to mimic the human metabolic syndrome. Many different diets are available in 
the literature to induce obesity in rats and mice, usually with increased content 
of either simple carbohydrates such as fructose or sucrose, or increased 
Page 239
saturated fats. However, the high carbohydrate diet does not induce obesity and 
the high saturated fat diet does not mimic the human diet. The most appropriate 
model therefore incorporates a d iet with increased simple sugars as well as 
saturated fats, including trans fats.  
Characterisation of the chronic changes induced by this diet on metabolic, 
cardiovascular and liver parameters is given as Chapter 3.2 of this thesis. 
Young adult male Wistar rats were given a diet of 20% beef tallow, 17.5% 
fructose and 39.5% condensed milk along with 25% fructose in drinking water 
for 16 weeks [3-5]. A corn starch rich diet was used as a control for this diet, 
aiming to provide the same proportion of carbohydrates in the form of 
polysaccharides. Corn starch is a slowly digestible carbohydrate whereas 
fructose and sucrose are simple lipogenic carbohydrates which are absorbed 
easily in the gastrointestinal tract. Also, corn starch did not increase blood 
glucose concentrations, systolic blood pressure, abdominal fat deposition, 
plasma insulin or plasma lipid concentrations [3]. Thus, corn starch diet served 
as an appropriate control diet for comparison with the high-carbohydrate, high-
fat diet [3-5]. High-carbohydrate, high-fat diet-fed rats developed progressive 
increases in body weight, energy intake, central obesity, systolic blood 
pressure, dyslipidaemia and hyperinsulinaemia [3]. These changes were 
associated with development of cardiovascular remodelling including 
ventricular dilatation, ventricular stiffness and fibrosis and reduced ventricular 
function and non-alcoholic steatohepatitis including fat deposition, 
inflammation and fibrosis in the liver with increases in the plasma activities of 
marker enzymes for liver dysfunction [3]. This model was used to investigate 
the potential therapeutic effects of natural products since pathophysiological 
responses mimicking human metabolic syndrome were shown. The different 
responses to natural products used in this study have been summarised in Table 
1. 
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Initially, two flavonoids, rutin and its aglycone, quercetin, were studied 
for their effects in diet-induced metabolic syndrome in rats. Both rutin and 
quercetin inhibited infiltration of inflammatory cells in the heart and the liver, 
reduced collagen deposition in the left ventricle and perivascular fibrosis in the 
liver, improved ventricular and liver functions, reduced diastolic stiffness, 
improved vascular contraction and relaxation, prevented hepatic steatosis and 
improved glucose tolerance, although they had different effects on central 
obesity and dyslipidaemia. Rutin (100 mg/kg body weight/day) reduced 
abdominal fat, body weight and plasma lipid contents suggesting that the excess 
fat was either oxidised or excreted from the body (Chapter 4.1). In contrast, 
quercetin (50 mg/kg body weight/day) reduced abdominal fat without changing 
body weight and plasma lipid components. This suggests that the fat was 
moved from the abdominal area and either stored in subcutaneous areas or 
converted into muscle mass, hence producing no c hange in body weight 
(Chapter 4.2). Although the only chemical difference between rutin and 
quercetin is the presence of glucose and rhamnose moieties in rutin, there were 
differences in the responses to these compounds in diet-induced metabolic 
syndrome. These differences might arise from differences in the absorption and 
metabolism of these phytochemicals [6]. Molecular weights of rutin and 
quercetin are 610 and 302, respectively. Since rutin is almost double the 
molecular weight of quercetin and one molecule of rutin contains only one 
quercetin, the dose of rutin given was double the dose of quercetin. This was 
done in order to ensure that the effects seen from both rutin and quercetin were 
equivalent in terms of active constituents as the glycosidic part of rutin is 
cleaved before it is absorbed in the gastrointestinal tract.  
Similar results were shown with ellagic acid and ellagitannins. 
Ellagitannins are complex esters of ellagic acid with glucose while ellagic acid 
is a dilactone formed from 2 molecules of gallic acid. Ellagitannins induced 
reduction in body weight as well as abdominal fat, which indicates that the 
abdominal fat was either oxidised or excreted from the body, an effect also 
observed with rutin (Chapter 5.1). Unlike ellagitannins, ellagic acid-
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supplemented rats did not show reductions in total body fat whereas the 
abdominal fat was reduced (Chapter 5.2). This clearly indicates that the fat was 
removed from the abdominal area and stored in the subcutaneous areas without 
being converted into muscle mass. Thus, there were differences between the 
effects of ellagic acid and ellagitannins on body fat and body weight. However, 
both ellagitannins and ellagic acid prevented infiltration of inflammatory cells 
in the heart and the liver, reduced collagen deposition in the left ventricle and 
perivascular fibrosis in the liver, improved left ventricular and liver functions, 
reduced ventricular diastolic stiffness, improved vascular contraction and 
relaxation, prevented hepatic steatosis and improved glucose tolerance. 
Colombian coffee extract (Chapter 6.1) containing caffeine, chlorogenic 
acid and diterpenoids such as cafestol and kahweol was the only treatment in 
this thesis that did not reduce abdominal fat content. High-carbohydrate, high-
fat diet-fed rats given 5% coffee extract showed attenuation of cardiovascular 
remodelling and dysfunction, non-alcoholic steatohepatitis, impaired glucose 
tolerance and hypertension whereas central obesity and dyslipidaemia were 
unaffected. Other studies have shown correlations between presence of excess 
abdominal fat and dyslipidaemia with the occurrence of cardiovascular disease 
and non-alcoholic fatty liver disease [7-10]. Although abdominal fat and plasma 
lipids were not reduced by coffee extract, there were improvements in glucose 
tolerance, left ventricular function and liver function, prevention of cardiac and 
hepatic infiltration of inflammatory cells, prevention of hepatic steatosis and 
lowering of ventricular dimensions and ventricular diastolic stiffness. Among 
the major constituents of coffee, chlorogenic acid has been studied for its 
beneficial effects in metabolic syndrome [11-13]. Results with caffeine have 
been inconclusive [14-17] and there have been no s tudies with pure 
diterpenoids to show any effects in metabolic syndrome. Thus, we tested 
caffeine at approximately the same dose given through coffee extract (~30 
mg/kg body weight/day). When caffeine was given to the high-carbohydrate, 
high-fat diet-fed rats, they showed normalisation of body fat, glucose tolerance 
and insulin sensitivity along with lowering of systolic blood pressure, body 
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weight and abdominal fat. These effects were also accompanied by 
improvements in glucose tolerance, liver function, prevention of cardiac and 
hepatic infiltration of inflammatory cells, prevention of hepatic steatosis and 
lowering of ventricular diastolic stiffness. However, plasma lipid components 
were increased. These effects of caffeine were attributed to the antagonism of 
A1 adenosine receptors by caffeine (Chapter 6.2). Inhibition of A1 adenosine 
receptors activates lipolysis in the adipocytes hence reducing the abdominal fat 
and increasing plasma non-esterified fatty acids. The comparison between the 
two studies indicates that the effects of caffeine in reducing abdominal fat in 
coffee-fed rats were overpowered by responses to other constituents. 
Previously, diterpenoids from coffee have been reported to induce 
hyperlipidaemia [18-22]. Thus, the lack of change in abdominal fat with coffee 
extract is probably due to the opposing responses to caffeine and the 
diterpenoids. 
High fructose and fat in the diet are responsible for the increased 
incidence and prevalence of metabolic syndrome and associated complications. 
In obesity, de novo lipogenesis is increased and fat oxidation is decreased. ʟ-
Carnitine, the fatty acid transporter across the mitochondrial membrane, was 
given to the rats to increase the availability of ʟ-carnitine for increased fatty 
acid oxidation. ʟ-Carnitine treatment for the last 8 weeks of the protocol after 
induction of metabolic syndrome in high-carbohydrate, high-fat diet fed-rats 
reduced central obesity and dyslipidaemia, improved glucose tolerance and 
insulin sensitivity, and improved cardiovascular and hepatic structure and 
function. These improvements were accompanied by reduced stearoyl CoA 
desaturase-1 activity in the plasma, heart, liver, skeletal muscle and abdominal 
fat pads. Also, polyunsaturated fatty acids, mainly linoleic acid (C18:2n-6), 
were preferred for oxidation and saturated fatty acids and oleic acid were stored 
in the body (Chapter 7). Thus, ʟ-carnitine supplementation in obese rats 
attenuated the symptoms of metabolic syndrome, cardiovascular remodelling 
and non-alcoholic fatty liver disease through inhibition of stearoyl CoA 
desaturase-1 activity leading to reduced short chain monounsaturated fatty acids 
Page 244
in the tissues. Further, ʟ-carnitine directed C18:2n-6 preferentially for oxidation 
hence reducing n-6 fatty acid pathway to reduce inflammatory responses. 
The Western diet includes cafeteria diet combined with the consumption 
of ethanol, commonly as beer, wine or spirits. Both cafeteria diet and ethanol 
ingestion can induce steatohepatitis yet ethanol has been claimed to be 
cardioprotective. In combination, ethanol (10% in drinking water) and high-
carbohydrate, high-fat diet worsened hepatic steatosis without worsening 
inflammation or fibrosis. However, the combination diet improved left 
ventricular fibrosis and function but high-carbohydrate, high-fat induced 
changes in cardiac dimensions and diastolic stiffness were unchanged in 
ethanol-fed rats. These results support the French paradox where ingestion of 
alcoholic beverages such as wine with high-fat diet reduces the risk of 
cardiovascular disease (Chapter 8). 
Overall, this thesis has examined the effects of individual polyphenolic 
compounds or extracts produced from a single natural product. Some of the 
possible mechanisms of actions of these natural products have been described 
in Table 2. Literature studies have examined the effects of a combination of 
various natural products. A recent study investigated the effects of a 
combination of curcumin with piperine and quercetin in high-fat diet and low-
dose streptozotocin-induced diabetic rats [23]. In this study, Curcuma longa, 
Piper nigrum and Allium cepa were used to provide curcumin, piperine and 
quercetin, respectively. This combination of compounds improved plasma lipid 
profile and also reduced plasma glucose concentrations in diabetic rats [23]. In 
another study, a combination of quercetin (10 mg/kg/day) and α-tocopherol (10 
mg/kg/day) was effective in attenuating the isoproterenol-induced cardiac 
changes [24]. An in vitro study with MOLT-4 cells suggested that combination 
of quercetin and ellagic acid increased the activation of p53 and p21cip1/waf1 and 
the MAP kinases, JNK1/2 and p38, in a more than additive manner. This study 
suggested that quercetin and ellagic acid synergistically induced apoptosis in 
cancer cells [25]. The synergistic effects of fish oil and green tea extract with 
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querectin have recently been reviewed indicating the positive effects of the 
addition of these components with quercetin in the diet [26]. In contrast, 
another study with a combination of quercetin and coenzyme Q10 did not 
support the synergistic effects of these two molecules. This study indicated that 
the combination of quercetin and coenzyme Q10 was as effective as the 
individual compounds in diabetic rats [27]. 
 
Table 2. Possible mechanisms of action for treatments used in this thesis 
Treatment Possible mechanisms of action 
Rutin (1.6 g/kg in 
food) 
Increased energy expenditure, anti-oxidative and 
anti-inflammatory effects, increased apoptosis in 
liver 
Quercetin (0.8 g/kg in 
food) 
Fat distribution away from abdomen, anti-oxidative 
and anti-inflammatory effects, increased oxidation of 
fat, increased apoptosis in liver 
Oak bark extract (0.5 
ml/kg food) 
Anti-oxidative and anti-inflammatory effects 
Ellagic acid (0.8 g/kg 
in food) 
Fat distribution away from abdomen, anti-oxidative 
and anti-inflammatory effects, increased oxidation of 
fat 
Coffee extract (5% in 
food) 
Anti-oxidative and anti-inflammatory effects 
Caffeine (0.5 g/kg 
food) 
Inhibition of A1 adenosine receptors in adipocytes, 
cardiomyocyte and hepatocytes 
ʟ-Carnitine (1.2 % in 
food) 
Increased fat oxidation, stearoyl-CoA desaturase-1 
inhibition, preferential oxidation of n-6 fatty acids 
The results from studies described in this thesis were used to deduce the possible 
mechanisms of actions. 
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In conclusion, natural products, that are part of food, can be used as 
medicines to reduce the symptoms of metabolic syndrome, cardiovascular 
disease and fatty liver disease. Onions, apples, red wine, grapes, coffee and 
berries have been part of the human diet since antiquity. This study has 
certainly shown that these constituents of diet or the individual components of 
these constituents can improve many or even all of the symptoms of the 
metabolic syndrome and associated complications. However, every natural 
product has a different type of action and these actions can be seen to a 
different extent with each natural product. Overall, food can be medicine if 
taken in the proper amount and in the proper way. 
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Comparison of purple carrot juice and b-carotene in a high-carbohydrate,
high-fat diet-fed rat model of the metabolic syndrome
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Anthocyanins, phenolic acids and carotenoids are the predominant phytochemicals present in purple carrots. These phytochemicals could be
useful in treatment of the metabolic syndrome since anthocyanins improve dyslipidaemia, glucose tolerance, hypertension and insulin resistance;
the phenolic acids may also protect against CVD and b-carotene may protect against oxidative processes. In the present study, we have
compared the ability of purple carrot juice and b-carotene to reverse the structural and functional changes in rats fed a high-carbohydrate,
high-fat diet as a model of the metabolic syndrome induced by diet. Cardiac structure and function were defined by histology, echocardiography
and in isolated hearts and blood vessels; liver structure and function, oxidative stress and inflammation were defined by histology and
plasma markers. High-carbohydrate, high-fat diet-fed rats developed hypertension, cardiac fibrosis, increased cardiac stiffness, endothelial
dysfunction, impaired glucose tolerance, increased abdominal fat deposition, altered plasma lipid profile, liver fibrosis and increased
plasma liver enzymes together with increased plasma markers of oxidative stress and inflammation as well as increased inflammatory cell
infiltration. Purple carrot juice attenuated or reversed all changes while b-carotene did not reduce oxidative stress, cardiac stiffness or
hepatic fat deposition. As the juice itself contained low concentrations of carotenoids, it is likely that the anthocyanins are responsible
for the antioxidant and anti-inflammatory properties of purple carrot juice to improve glucose tolerance as well as cardiovascular and hepatic
structure and function.
Purple carrots: Anthocyanins: b-Carotene: Metabolic syndrome: High-carbohydrate, high-fat diet-fed rats
Diet plays an important role in the aetiology and prevention of
the risk factors of the metabolic syndrome(1). Many epidemio-
logical studies have shown a strong inverse association between
an increased consumption of fruits and vegetables and a
decreased incidence of CVD(2 – 5), especially stroke(3),
IHD(2,3), CHD(4) and blood pressure(5). Although the risk of
type 2 diabetes is not related to the consumption of fruit or
vegetables, the intake of antioxidant phytochemicals has been
associated with reduction in the risk of type 2 diabetes(6,7).
Close relationships between obesity, the metabolic syndrome
and the development of non-alcoholic fatty liver disease
(NAFLD) have been described, with most NAFLD
patients displaying multiple components of the metabolic
syndrome(8). However, the effects of increased intakes of fruit
and vegetables on NAFLD patients have not been studied.
Glucosinolates, flavonoids, tannins, carotenoids, phytates
and phyto-oestrogens represent the major classes of phyto-
chemicals present in fruits and vegetables(9). These nutrients
may improve health through many mechanisms, such as
reducing oxidative stress and inflammation, improving lipid
profiles, lowering blood pressure and enhancing glucose
metabolism(9). Anthocyanins, a subclass of flavonoids, are
pigments of red fruits such as cherries, plums, strawberries,
raspberries, blackberries, grapes, red and black currants and,
together with the phenolic acids, are the major phytochemicals
in the human diet(10). Although research on the therapeutic
uses of the phytochemicals in carrots started with the
demonstration of pro-vitamin A activity by Moore in
1929(11), few data exist on possible therapeutic benefits from
carrot varieties other than orange carrots where b-carotene
is the predominant phytochemical component.
Carrot varieties differ in colour from white to orange,
yellow, red and purple and contain different combinations
and quantities of macronutrients, fibre, vitamins, minerals
and phytochemicals including carotenoids, phenolic acids,
anthocyanins, isocoumarins, terpenes and sesquiterpenes(12,13).
The colour of orange carrots is due to higher concentra-
tions of a- and b-carotene; red carrots contain increased
lycopene and yellow carrots contain increased lutein
concentrations while white carrots have lower concentrations
of all carotenoids(13). The anthocyanidins and chlorogenic
acid are the major antioxidants in purple carrots(13,14).
The colour of purple carrots (Daucus carota L. ssp. sativus
var. atrorubens Alef.) comes from the presence of
*Corresponding author: Professor Lindsay Brown, fax þ61 7 4631 1530, email Lindsay.Brown@usq.edu.au
Abbreviations: CRP, C-reactive protein; H (8 weeks or 16 weeks), high-carbohydrate, high-fat; HC, high-carbohydrate, high-fat þ b-carotene; HP, high-
carbohydrate, high-fat þ purple carrot juice; NAFLD, non-alcoholic fatty liver disease.
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anthocyanins such as cyanidin-3-(200-xylose-600-sinapoyl-
glucose-galactoside)(13,15). Additionally, at least forty phenolic
acids are present in purple carrots including chlorogenic and
caffeic acids as the predominant compounds(13). Purple carrots
also contain polyacetylene compounds such as falcarindiol,
falcarindiol 3-acetate and falcarinol(16). Purple carrots
remain a sparsely studied potential dietary component that
are rich in anthocyanins, phenolic acids and carotenoids(13).
b-Carotene, the best known of the large carotenoid family
of phytochemicals, is the major dietary source of vitamin A
(retinol). Epidemiological studies have inversely associated
circulating b-carotene concentrations with the risk of
hypertension(17,18) but not with type 2 diabetes(19,20). The
antioxidant as well as pro-oxidant actions of b-carotene are
widely known(21,22). Carotenoids, particularly b-carotene
and lycopene, protect animals and humans against oxidative
processes, especially in lipophilic environments such as
cell membranes by acting as free radical scavengers(23).
Carotenoids have been proposed as a dietary strategy to
prevent cancers, possibly by antioxidant actions and the
stimulation of intercellular communication via gap junc-
tions(23). In vivo, b-carotene prevented ethanol-induced liver
damage and improved hepatic antioxidant enzyme status in
rats(24). In streptozotocin-induced diabetic rats, b-carotene
treatment increased hepatic and cardiac antioxidant
enzymes(25), improved circulatory insulin and glucose
concentrations(26) but increased lipid peroxidation(25).
Epidemiological studies have shown that plant-based
diets protect against CVD and cancer; flavonoids, including
the anthocyanins, occur widely in plants and may
improve human health(27,28). In particular, the anthocyanins
may improve the symptoms of the metabolic syndrome
such as dyslipidaemia, impaired glucose tolerance and
hypertension(27,28). Anthocyanin-rich plant extracts lowered
plasma lipid concentrations in rat models of hyperlipidae-
mia(29,30) and an extract from black rice (Oryza sativa
L. indica) lowered plasma lipid concentrations and improved
insulin resistance in fructose-fed rats(31). Spontaneously
hypertensive rats fed on anthocyanin-rich purple maize,
purple sweet potato and red radish showed reduced blood
pressure and heart rate(32). Other constituents of carrots such
as the polyacetylenes may suppress inflammation in the
metabolic syndrome by decreasing lipopolysaccharide-
induced expression of inflammatory proteins in macrophages
and endothelial cells(12).
Although the phytochemical profile of purple carrots has
been reported, sparse information exists on the pharmacologi-
cal activity of purple carrot juice. The aims of the present
study were to determine whether purple carrot juice attenuates
or reverses the cardiovascular, liver and metabolic changes
produced in a high-carbohydrate, high-fat diet-fed rat model
of the metabolic syndrome and whether these responses are
comparable with that of b-carotene.
Diets with increased carbohydrates, mainly as fructose(33),
increased fats(34) or a combination of both(35) in rats have
been studied to mimic the human metabolic syndrome.
Maize starch is a slowly digestible carbohydrate(36) and
served as a control for the high-carbohydrate, high-fat diet in
the present study where the primary carbohydrate is fructose.
Unlike fructose, maize starch does not increase blood glucose,
plasma insulin or NEFA concentrations(35,36).
The present study characterised structural changes in the rat
heart by histology and echocardiography, while heart function
was assessed in vivo using echocardiography and ex vivo in
isolated perfused hearts. Systolic blood pressure was measured
and isolated thoracic rings were used to measure vascular
reactivity. Biochemical parameters (enzyme activities of
alanine transaminase, aspartate transaminase and alkaline
phosphatase as well as total plasma bilirubin concentrations)
were assessed, and along with histology, were used to define
structural and functional changes in the liver. Circulatory
markers of impaired metabolism (lactate dehydrogenase,
urea and oral glucose tolerance test), oxidative stress
(malondialdehyde and uric acid) and inflammation (C-reactive
protein; CRP) were measured.
Materials and methods
Purple carrot juice
Purple carrot juice was prepared by SDS Beverages Pty Ltd
(Irymple, VIC, Australia). Purple carrots were crushed in a
hammer mill with water acidified with citric acid. Following
separation of solids, pectinases were added to the juice and
mixed at 50–558C for clarification. The juice was then
subjected to pasteurisation, chilling and filtering through a
200mm mesh before evaporation was carried out to concen-
trate the juice to 60 brix. This 60 brix purple carrot juice
was processed through another 200mm mesh and a metal
analyser and stored at 48C. This product was added as a 5 %
supplement to either the maize starch or high-carbohydrate,
high-fat diet described below (Table 1).
Total monomeric anthocyanins were determined using
the pH differential method as previously described(37). Absor-
bance was measured at 520 and 700 nm. Total monomeric
anthocyanins were expressed as cyanidin-3-glucoside (molar
extinction coefficient of 26 900 litres/cm per mol and
molecular weight of 449·2 g/mol).
Carotenoid concentrations in purple carrot juice were
analysed on an Agilent 1100 series HPLC system equipped
with a photodiode array UV-visible detector (Agilent Technol-
ogies, Waldbronn, Germany). Separations were achieved on a
150 £ 3·0 mm internal diameter, 3mm particle size, analytical
scale YMC C30 reversed-phase column (YMC, Wilmington,
MA, USA). Elution was performed at a solvent flow rate of
1·0 ml/min and detection at 450 nm. The mobile phases
consisted of acetone and Milli-Q water. For routine analysis,
a 10–95 % linear gradient elution of acetonitrile and Milli-Q
water was pumped through the column at 1·0 ml/min over
30 min. All solvents were HPLC grade and contained
0·005 % trifluoroacetic acid (Sigma-Aldrich Australia,
Sydney, NSW, Australia) to enhance peak shape. Purple
carrot juice was dissolved in 100 % analytical grade methanol
and filtered through a Whatman polytetrafluoroethylene
(PTFE) membrane filter (0·45mm; Whatman PLC,
Maidstone, Kent, UK) before loading the sample (10ml
injection volume). The UV spectra of the different carotenoid
(all-trans-b-carotene, zeaxanthin and lutein) compounds
were recorded with a diode array detector. Carotenoids were
quantified using calibration curves of the corresponding
standard compounds at the specific absorption maximum.
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Rats
The experimental groups consisted of eighty-four male
Wistar rats (aged 8–9 weeks; weight 337 ^ 5 g) supplied by
The University of Queensland Biological Resources unit and
individually housed at the School of Biomedical Sciences
Animal House Facility. All experimental procedures were
approved by the Animal Experimentation Ethics Committee
of The University of Queensland under the guidelines of the
National Health and Medical Research Council of Australia.
All experimental groups were housed in a temperature-
controlled, 12 h light–dark cycle environment with ad libitum
access to water and the group-specific rat diet. Daily body
weight, feed and water measurements were taken to monitor
the day-to-day health of the rats. The rats were randomly
divided into six separate groups based on their diet: maize
starch (n 12); maize starch þ b-carotene (n 12); maize starch þ
purple carrot juice (n 12); high-carbohydrate, high-fat (H;
n 24); high-carbohydrate, high-fat þ b-carotene (HC; n 12);
high-carbohydrate, high-fat þ purple carrot juice (HP; n 12).
The full description of the diets is given in Table 1. In addition,
the drinking water of all high-carbohydrate, high-fat diet-fed
rats contained 25 % fructose. Both purple carrot juice and
b-carotene (Sigma-Aldrich Australia) were administered for
8 weeks starting 8 weeks after the initiation of the maize
starch or high-carbohydrate, high-fat diets. Twelve rats were
killed from the high-carbohydrate, high-fat diet group at
8 weeks to assess the pathophysiological state before purple
carrot or b-carotene intervention (H 8 weeks). Two rats
per group were taken for histological analysis. Two slides
were prepared per tissue specimen and two random, non-
overlapping fields pictured for analysis. Organs were also
collected from rats used for perfusion studies.
Systolic blood pressure was measured under light sedation
with intraperitoneal injection of Zoletil (tiletamine 15 mg/kg,
zolazepam 15 mg/kg; Virbac, Peakhurst, NSW, Australia).
Measurements were taken using an MLT1010 Piezo-Electric
Pulse Transducer (ADInstruments, Sydney, NSW, Australia)
and inflatable tail-cuff connected to a MLT844 Physiological
Pressure Transducer (ADInstruments) and PowerLab data
acquisition unit (ADInstruments).
For the oral glucose tolerance test, basal blood glucose
concentrations were measured in tail-vein blood using a
Medisense Precision Q.I.D glucose meter (Abbott Labora-
tories, Bedford, MA, USA) after an overnight (10–12 h)
feed deprivation. Fructose-supplemented drinking water in
H, HC and HP groups was replaced with normal water for
the overnight feed-deprivation period for the measurement
of basal blood glucose concentrations. The rats were given
glucose at 2 g/kg body weight as a 40 % solution via oral
administration. Tail-vein blood samples were taken at 0, 30,
60, 90 and 120 min following glucose administration.
Echocardiography
Echocardiographic examination (Philips iE33 system, 12 MHz
transducer; Philips Medical System, Andover, MA, USA) was
performed at 8 and 16 weeks as previously described(35,38).
Briefly, rats were anaesthetised using intraperitoneal Zoletil
(toletamine 15 mg/kg and zolazepam 15 mg/kg intraperi-
toneally; Virbac, Peakhurst, NSW, Australia) combined
with xylazine (10 mg/kg) (Ilium Xylazil; Troy Laboratories,
Sydney, NSW, Australia) and positioned in dorsal recum-
bency. Electrodes attached to the skin overlying the elbows
and right stifle facilitated the simultaneous recording of a
lead II electrocardiogram.
Table 1. Diet composition and energy contents of diets
Ingredient M MC MP H HC HP
Maize starch (g/kg) 570·00 570·00 570·00 – – –
Powdered rat feed (g/kg)* 155·00 155·00 155·00 155·00 155·00 155·00
HMW salt mixture (g/kg)† 25·00 25·00 25·00 25·00 25·00 25·00
Fructose (g/kg) – – – 175·00 175·00 175·00
Beef tallow (g/kg) – – – 200·00 200·00 200·00
Condensed milk (g/kg) – – – 395·00 395·00 395·00
Water (ml/kg) 250·00 250·00 200·00 50·00 50·00 –
Purple carrot juice (ml/kg) – – 50·00 – – 50·00
b-Carotene (mg/kg) – 400 – – 400 –
Energy (kJ/g) 11·23 11·23 11·67 17·93 17·93 18·37
Macronutrient composition‡
Total carbohydrates (g/kg) 600·25 600·25 600·25 515·67 515·67 515·67
Total fat (g/kg) 8·07 8·07 8·07 239·04 239·04 239·04
Total proteins (g/kg)§ 31·78 31·78 31·78 58·12 58·12 58·12
Total fibres (g/kg) 7·44 7·44 7·44 7·44 7·44 7·44
Total vitamins (g/kg) 0·32 0·32 0·32 0·32 0·32 0·32
Retinol (mg/kg) 4·0 4·0 4·0 4·0 4·0 4·0
Total minerals (g/kg)§ 0·13 0·13 0·13 0·44 0·44 0·44
Ash (g/kg) 0·63 0·63 0·63 0·00 0·00 0·00
Total moisture (g/kg) 326·4 326·4 276·4 154·0 154·0 104·0
M, maize starch diet; MC, maize starch þ b-carotene diet; MP, maize starch þ purple carrot juice diet; H, high-carbohydrate, high-fat diet; HC, high-
carbohydrate, high-fat þ b-carotene diet; HP, high-carbohydrate, high-fat þ purple carrot juice diet.
* Meat-free rat and mouse feed (Specialty Feeds) contained (g/kg feed): carbohydrate, 707·07; protein, 194·00; fat, 48·00; fibre, 48·00; total
vitamins, 2·08; total minerals, 0·85.
† Hubble, Mendel and Wakeman salt mixture(54) (MP Biochemicals, Seven Hills, NSW, Australia).
‡ Derived from powdered rat feed.
§ H, HC and HP diets additionally derive these micronutrients from condensed milk.
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A short axis view of the left ventricle at the level of the
papillary muscles was obtained and used for direct acquisition
of M-mode images of the left ventricle for measurement of
diastolic posterior wall thickness, left ventricular internal
systolic dimension and left ventricular end-diastolic diameter.
For these parameters, diastole was defined by the beginning of
the QRS complex on the simultaneously recorded electrocar-
diogram and systole identified as the nadir of systolic anterior
wall motion independent of the electrocardiogram complex.
Pulsed-wave Doppler velocity profiles of mitral inflow was
obtained from the left apical four-chamber view for measure-
ment of early (EM) and late (AM) mitral inflow velocity, mitral
inflow E-wave deceleration time, and time from mitral valve
closure to opening (MCMO). A pulsed-wave Doppler velocity
profile of the ascending aorta was obtained from a suprasternal
view for measurement of aortic (Ao) velocity, ejection time
(ET) and the diameter of the ascending aorta at the point of
transition to the transverse aorta.
Derived indices of left ventricular systolic function
(fractional shortening (FS%), ejection fraction (EF%)) were
calculated using well-established formulae(38). Left ventricular
mass was estimated using the standard cube equation as
previously described(35,38).
Isolated heart preparation
The left ventricular function of the rats in all treatment groups
was assessed using the Langendorff heart preparation.
Terminal anaesthesia was induced via intraperitoneal injection
of pentobarbitone sodium (Lethabarbw, 100 mg/kg). After
heparin (Sigma-Aldrich Australia) administration (100 IU)
through the right femoral vein, blood (about 5 ml) was taken
from the abdominal aorta. Isovolumetric ventricular function
was measured by inserting a latex balloon catheter into the
left ventricle connected to a Capto SP844 MLT844 physio-
logical pressure transducer and Chart software on a Maclab
system (ADInstruments Australia and Pacific Islands, Bella
Vista, NSW, Australia). All left ventricular end-diastolic
pressure values were measured while pacing the heart at 250
beats per min using an electrical stimulator. End-diastolic
pressures were obtained starting from 0 mmHg up to
30 mmHg. The diastolic stiffness constant (k, dimensionless)
was calculated as in previous studies(35,39).
Organ bath studies
Thoracic aortic rings (4 mm in length) were suspended in
an organ bath chamber with a resting tension of 10 mN.
Cumulative concentration–response (contraction) curves
were measured for noradrenaline (Sigma-Aldrich Australia);
concentration–response (relaxation) curves were measured
for acetylcholine (Sigma-Aldrich Australia) and sodium
nitroprusside (Sigma-Aldrich Australia) in the presence of a
submaximal (70 %) contraction to noradrenaline(35).
Organ weights
The right and left ventricles were separated after perfusion
experiments and weighed. Liver and abdominal fat were
removed following heart removal and blotted dry for
weighing. Perirenal, epididymal and omental fat were together
weighed as abdominal fat. Organ weights were normalised
relative to the tibial length at the time of their removal
(in mg/mm).
Histology
Immediately after removal, heart and liver tissues were fixed
in 10 % buffered formalin for 3 d with change of formalin
every day to remove traces of blood from the tissue. The
samples were then dehydrated and embedded in paraffin
wax. Thin sections (10mm) of left ventricle and the liver
were cut and stained with haematoxylin and eosin stain for
determination of inflammatory cell infiltration. Liver sections
were also stained with Milligan’s Trichrome stain to deter-
mine fibrosis. Collagen distribution was measured in the left
ventricle with picrosirius red stain. Laser confocal microscopy
(Zeiss LSM 510 upright Confocal Microscope)(35) with colour
intensity quantitatively analysed using NIH-imageJ software
(National Institutes of Health, Bethesda, MD, USA) was
used to determine the extent of collagen deposition in selected
tissue sections.
Plasma analysis
Briefly, blood was centrifuged at 5000 g for 15 min within
30 min after collection into heparinised tubes. Plasma samples
were separated and transferred to Eppendorf tubes for ana-
lysis. Plasma enzymic activities and analyte concentrations
were determined using kits and controls supplied by
Olympus using an Olympus analyser (AU 400; Olympus,
Tokyo, Japan): cholesterol, Olympus OSR6516 enzymic
colour test; TAG, Olympus OSR 6133 enzymic colour test;
lactate dehydrogenase, Olympus OSR6127 kinetic UV test;
urea, Olympus OSR 6134 kinetic UV test; uric acid, Olympus
OSR 6098 enzymic colour test; alanine transaminase, Olym-
pus OSR 6107 kinetic UV test; aspartate transaminase,
Olympus OSR 6109 kinetic UV test; alkaline phosphatase,
Olympus OSR 6004 knetic UV test; albumin, Olympus OSR
6101 photometric colour test; total bilirubin, Olympus
OSR 6111 photometric colour test. Globulin was calculated
as total protein-albumin. Plasma malondialdehyde concen-
trations were measured by HPLC (Shimadzuw) as previously
described(40). Plasma CRP was estimated using a commercial
kit (Kamiya Biomedical, CA, USA) according to manufacturer-
provided standards and protocols using a Cobas-Mira
automated analyzer (Roche Diagnostics, Basel, Switzerland).
Statistical analysis
All data are presented as mean values with their standard
errors. Results were tested for variance using Bartlett’s test
and data that were not normally distributed were transformed
(using log 10 function) before statistical analyses. Differences
between the groups were determined by one-way ANOVA
with the Newman–Keuls multiple comparison post test. For
non-parametric data (total plasma cholesterol, plasma NEFA,
lactate dehydrogenase, malondialdehyde and plasma urea
concentrations and feed intake), Kruskal–Wallis tests were
performed. All statistical analysis was performed using
GraphPad Prism version 5.00 for Windows (San Diego, CA,
USA). P,0·05 was considered as statistically significant.
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Results
Diet and supplement intake, body weight and metabolic
parameters
Purple carrot juice contained anthocyanins (total 5·53 mg/ml)
and traces of b-carotene (0·75mg/ml), lutein (0·54mg/ml) and
zeaxanthin (4·4mg/ml). The mean daily intakes of total antho-
cyanins and carotenoids were higher in the maize starch þ
purple carrot juice and maize starch þ b-carotene groups than
in the HP and HC groups, respectively, as the feed intake was
higher in all maize starch diet-fed rats (Table 2). However, the
carotenoid intakes in the maize starch þ purple carrot juice
and HP rats were extremely low due to the low carotenoid
content of the juice (Table 2).
The high-carbohydrate, high-fat diet induced an increased
body weight, especially with increased abdominal fat pads
and abdominal circumference, compared with maize starch
diet-fed rats (Table 2). Although high-carbohydrate, high-fat
diet feeding reduced feed and water intake, rats on this diet
had higher daily energy intake compared with maize starch
diet-fed rats (Table 2). Neither purple carrot juice nor
b-carotene supplementation altered daily feed, water or
energy intake. However, purple carrot juice supplementation
reduced percentage gain in body weight, abdominal fat pads
and abdominal circumference (Table 2). The high-carbo-
hydrate, high-fat diet produced impaired glucose tolerance,
increased plasma concentrations of total cholesterol, TAG,
NEFA, malondialdehyde, CRP and uric acid, increased lactate
dehydrogenase activity and decreased plasma urea concen-
tration (Table 2). Purple carrot juice supplementation
improved oral glucose tolerance (Table 2) and reduced
plasma total cholesterol, TAG, NEFA and CRP concentrations
(Table 2). Although b-carotene improved oral glucose
tolerance and reduced plasma CRP concentrations (Table 2),
it further increased plasma TAG and NEFA concentrations
(Table 2). Further, purple carrot juice supplementation
attenuated the changes in lactate dehydrogenase activity,
plasma uric acid, malondialdehyde and urea concentrations
in high-carbohydrate, high-fat diet-fed rats; these parameters
were unaltered by b-carotene supplementation (Table 2).
Cardiovascular structure and function
High-carbohydrate, high-fat diet-fed rats showed increased
left ventricular diastolic internal diameter and relative wall
thickness with increased estimated left ventricular mass and
wet weight in comparison with the maize starch diet-fed
rats (Table 3). Moreover, the high-carbohydrate, high-fat
diet reduced fractional shortening and ejection fraction and
increased ejection time (Table 3). Both b-carotene and
purple carrot juice supplementation reduced estimated left
ventricular mass and wet weight. In addition, b-carotene
reduced left ventricular diastolic internal diameter, increased
fractional shortening and ejection fraction and decreased
ejection time (Table 3). High-carbohydrate, high-fat diet-fed
rats showed sustained elevation in systolic blood pressure
after 4 weeks of diet administration as compared with maize
starch diet-fed rats (Table 3). Purple carrot juice as well as
b-carotene supplementation normalised blood pressure as
early as 4 weeks post-intervention (Table 3). Following
high-carbohydrate, high-fat diet feeding for 16 weeks,
diminished vascular responses were observed in isolated
thoracic aortic rings to noradrenaline, sodium nitroprusside
and acetylcholine when compared with maize starch diet-fed
rats (Fig. 1). However, this reduced thoracic aortic reactivity
was not observed after 8 weeks of high-carbohydrate,
high-fat diet feeding. Purple carrot juice and b-carotene
supplementation prevented any further decrease in sodium
nitroprusside- and acetylcholine-dependent vasorelaxation
(Fig. 1(B) and (C)) as compared with high-carbohydrate,
high-fat diet-fed rats at 8 weeks but failed to attenuate the
reduced contractility with noradrenaline (Fig. 1(A)).
Ex vivo cardiac function as measured in the Langendorff
isolated heart showed an increased diastolic stiffness
(Table 3) in the high-carbohydrate, high-fat diet-fed rats as
compared with the maize starch diet-fed group (Table 3).
Reduction in diastolic stiffness was only observed in purple
carrot juice-supplemented rats. Histological analysis revealed
that high-carbohydrate, high-fat diet-fed rats showed increased
infiltration by inflammatory cells into the left ventricle
(Fig. 2(E)) and increased interstitial collagen deposition and
hypertrophy (Fig. 2(I); Table 3) when compared with the
maize starch diet-fed rats (Fig. 2(A) and (H); Table 3).
Both purple carrot juice- and b-carotene-supplemented high-
carbohydrate, high-fat diet-fed rats showed normalised infiltra-
tion of inflammatory cells (Fig. 2(G); Fig. 2(F)) and reduced
collagen deposition with normalised hypertrophy (Fig. 2(N);
Fig. 2(M); Table 3). No major changes were observed in
purple carrot juice- and b-carotene-supplemented maize
starch diet-fed rats (Fig. 2(B), (C), (I) and (J); Table 3).
Hepatic structure and function
In comparison with maize starch diet-fed rats, high-
carbohydrate, high-fat diet-fed rats had elevated plasma
alanine transaminase, aspartate transaminase and alkaline
phosphatase activities although the albumin:globulin ratio
and plasma bilirubin concentrations remained unaffected
(Table 4). Purple carrot juice supplementation reversed liver
function abnormalities indicated by normalised activity of
these enzymes (Table 4). Although b-carotene supplementation
normalised transaminases activities in high-carbohydrate,
high-fat diet-fed rats, alkaline phosphatase activity remained
elevated (Table 4).
By histological examination, high-carbohydrate, high-fat diet
feeding to rats caused macrovesicular steatosis (Fig. 3(E))
resulting from accumulation of lipids in large and small droplets
within hepatocytes with markedly high portal inflammation
(Fig. 3(M)) and portal fibrosis (Fig. 3(T); Table 4) as
compared with the maize starch diet-fed rats (Fig. 3(A),
(H) and (P); Table 4). The purple carrot juice-supplemented
high-carbohydrate, high-fat diet-fed rats displayed minimal
signs of macrovesicular steatosis (Fig. 3(G)), portal
inflammation (Fig. 3(O)) or fibrosis (Fig. 3(V); Table 4). The
b-carotene-supplemented high-carbohydrate, high-fat diet-fed
rats displayed normalised portal inflammation (Fig. 3(N)) and
fibrosis (Fig. 3(P); Table 4) but showed obvious hepatocyte
ballooning and increased fat vacuole size and number
(Fig. 3(F)). No major hepatic changes were observed in purple
carrot juice- and b-carotene-supplemented maize starch diet-
fed rats (Fig. 3(C), (K) and (R) and 3(B), (J) and (Q); Table 4).
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Discussion
A combination of high carbohydrate and high fat in the diet
was used in the present study to mimic human diets that
have been associated with the development of the metabolic
syndrome. This diet produced changes in metabolic, cardio-
vascular and hepatic structure and functions such as excessive
abdominal fat deposition, impaired glucose tolerance, elevated
blood pressure and increased plasma lipid concentrations
together with increased plasma oxidative stress markers and
liver enzymes compared with maize starch diet-fed rats.
Further, histological evaluation of heart and liver showed
increased infiltration of inflammatory cells and increased
collagen deposition in addition to increased fat vacuoles in
the liver. This was accompanied by increased left ventricular
stiffness and decreased aortic reactivity.
The present study compares therapeutic responses from
anthocyanin-rich purple carrot juice with responses to
b-carotene in high-carbohydrate, high-fat diet-fed rats. Since
carotenoids are sparsely soluble in water, unlike anthocyanins,
the purple carrot juice was very low in carotenoids but high
in total anthocyanins. The present results suggest that many
responses to purple carrot juice differ from those following
b-carotene supplementation. b-Carotene and purple carrot
juice produced different responses on blood lipid profiles,
lipid deposition in the liver, plasma alkaline phosphatase
and lactate dehydrogenase activities, left ventricular stiffness
and plasma markers of oxidative stress such as uric acid and
malondialdehyde. The responses to b-carotene may be pro-
duced by vitamin A and its major metabolites, retinoic acid
and retinaldehyde. Rats fed with vitamin A and retinoic acid
showed a marked increase in hepatic and plasma concen-
trations of glycogen, cholesterol and acylglycerols with elev-
ated plasma NEFA and increased glucose incorporation into
liver lipids(41,42). Vitamin A stimulated fatty acid mobilisation
from adipose tissue and enhanced formation of glyceropho-
sphate through glycolysis, with consequent increases in the
acylglycerol synthesis in the liver(41). Additionally, both
retinoic acid and retinaldehyde inhibited adipogenesis(43).
Here we show that b-carotene prevented further increases in
abdominal fat weight after treatment. It is therefore likely
that b-carotene and its major metabolites suppress adipo-
genesis, thereby allowing excess accumulation of lipids in
the liver and the plasma.
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Fig. 1. Cumulative concentration–response curves for noradrenaline (A), sodium nitroprusside (B) and acetylcholine (C) in thoracic aortic rings from maize starch
diet (W), maize starch diet þ b-carotene (K), maize starch diet þ purple carrot juice (S), high-carbohydrate, high-fat diet for 8 weeks (L), high-carbohydrate, high-
fat diet for 16 weeks (A), high-carbohydrate, high-fat diet þ b-carotene (X) and high-carbohydrate, high-fat diet þ purple carrot juice (P)-fed rats. Values are
means for eight to ten rats per group, with standard errors represented by vertical bars. a,b Mean values with an unlike letter were significantly different (P,0·05).
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Fig. 2. Haematoxylin and eosin staining of left ventricle ( £ 20) showing inflammatory cells (marked as ‘in’) as dark spots outside the myocytes in maize starch
diet (A), maize starch diet þ b-carotene (B), maize starch diet þ purple carrot juice (C), high-carbohydrate, high-fat diet for 8 weeks (D), high-carbohydrate,
high-fat diet for 16 weeks (E), high-carbohydrate, high-fat diet þ b-carotene (F) and high-carbohydrate, high-fat diet þ purple carrot juice (G)-fed rats. Picrosirius
red staining of left ventricular interstitial collagen deposition (40 £ ) in maize starch diet (H), maize starch diet þ b-carotene (I), maize starch diet þ purple carrot
juice (J), high-carbohydrate, high-fat diet for 8 weeks (K), high-carbohydrate, high-fat diet for 16 weeks (L), high-carbohydrate, high-fat diet þ b-carotene (M) and
high-carbohydrate, high-fat diet þ purple carrot juice (N)-fed rats; fibrosis is marked as ‘fi’ and hypertrophied cardiomyocytes are marked as ‘hy’.
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In the heart, retinoic acid inhibited G protein-coupled recep-
tor-mediated hypertrophy as well as angiotensin II-induced
increases in intracellular Ca2þ in neonatal cardiomyocytes(44).
In vivo, retinoic acid suppressed myocardial cell hypertro-
phy(44) and prevented ventricular fibrosis and remodelling in
spontaneously hypertensive rats(45). b-Carotene and caroten-
oid breakdown products induced apoptosis in Jurkat E6.1
malignant T-lymphoblast cells(46) and human neutrophils(47)
but impaired mitochondrial respiration and elevated accumu-
lation of malondialdehyde(48). Thus, b-carotene as a precursor
of vitamin A and retinoic acid may increase lipid peroxidation,
decrease cardiac hypertrophy, and prevent cardiac fibrosis and
inflammation.
In contrast, purple carrot juice supplementation normalised
plasma TAG, total cholesterol and NEFA concentrations, con-
sistent with the hypolipidaemic responses to other anthocya-
nin-rich plant extracts such as blueberry leaf(29). NEFA is
involved both in insulin resistance and hypertension by
inhibiting aortic endothelial NO synthase activity through an
oxidative mechanism(49,50). The present results demonstrated
enhanced vascular relaxant responses, consistent with
improved NO production and lowered blood pressure.
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Fig. 3. Haematoxylin and eosin staining of hepatocytes ( £ 40) showing hepatocytes with enlarged fat vacuoles (marked as ‘fv’) and inflammatory cells (marked as
‘in’) (20 £ ) from maize starch diet (A, H), maize starch diet þ b-carotene (B, I), maize starch diet þ purple carrot juice (C, J), high-carbohydrate, high-fat diet for 8
weeks (D, K), high-carbohydrate, high-fat diet for 16 weeks (E, L), high-carbohydrate, high-fat diet þ b-carotene (F, M) and high-carbohydrate, high-fat diet þ
purple carrot juice (G, N)-fed rats. Milligan’s trichrome staining of the hepatic portal regions showing collagen (marked as ‘pf’) (20 £ ) in maize starch diet (O),
maize starch diet þ b-carotene (P), maize starch diet þ purple carrot juice (Q), high-carbohydrate, high-fat diet for 8 weeks (R), high-carbohydrate, high-fat diet
for 16 weeks (S), high-carbohydrate, high-fat diet þ b-carotene (T) and high-carbohydrate, high-fat diet þ purple carrot juice (U)-fed rats. bl, Hepatocyte
ballooning.
Table 4. Changes in hepatic structure and function
(Mean values with their standard errors for ten animals per group)
M MC MP H (8 weeks) H (16 weeks) HC HP
Parameter Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Liver wet
weight
(mg/mm)
303·3b,g,i 9·8 222·1a 7·0 231·2a 13·0 302·8c,f,h,i 12·9 328·5e,h 10·0 297·0d,e,f,g 8·9 273·7b,c,d 13·0
Liver fibrosis
(% surface
area)*
0·9a,b,c,d 0·02 1·1a,e,h,i 0·1 1·0b,e,f,g 0·1 3·6k 0·8 5·7 0·5 2·4c,f,h,j,k 0·3 1·8d,g,i,j 0·7
ALT (U/l) 32·9d,g,h,i 2·0 59·8k 7·0 31·0a,b,c,d 1·9 36·1c,f,h,j 2·2 55·3k 3·7 31·0a,e,f,g 3·6 41·2b,e,i,j 3·4
AST (U/l) 71·0a,h,g,i 4·0 118·1k 14·2 70·8a,b,c,d 5·1 77b,f,i,j,k 2·5 101·7 5·4 65·2c,e,f,h 3·0 75·3d,e,g,j 3·8
ALP (U/l) 154·7a,d,e 2·0 167·6c,e 6·5 133·6a,b 7·1 192·4f 5·2 208·4f,g 0·6 224·8g 14·3 153·5b,c,d 6·2
Albumin (g/l) 28·5a,b 0·6 27·7a 0·4 29·1a,b 0·6 28·0a 0·6 28·0a 0·2 27·4a 0·2 29·9b 0·5
Globulin (g/l) 29·6a,b 1·0 26·2b 0·8 29·4a,b 0·8 28·2a,b 0·8 28·7a,b 0·7 27·6a,b 0·7 29·9a 1·0
Total bilirubin
(mmol/l)
2·2a,b 0·1 3·0a 0·6 1·5b 0·07 2·2a,b 0·07 2·3a,b 0·05 2·1a,b 0·2 2·1a,b 0·1
M, maize starch diet; MC, maize starch þ b-carotene diet; MP, maize starch þ purple carrot juice diet; H, high-carbohydrate, high-fat diet; HC, high-carbohydrate, high-fat þ b-
carotene diet; HP, high-carbohydrate, high-fat þ purple carrot juice diet; ALT, alanine transaminase; AST, aspartate transaminase; ALP, alkaline phosphatase.
a–k Mean values within a row with unlike superscript letters were significantly different (P,0·05).
* Four animals per group.
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Left ventricular dysfunction has been correlated with
metabolic disturbances, oxidative stress and the appearance
of inflammatory cells preceding left ventricular fibrosis and
left ventricular stiffness(51). Purple carrot juice supple-
mentation reduced left ventricular stiffness, the number of
inflammatory cells and left ventricular collagen deposition.
Echocardiographic assessment showed improved systolic
function and decreased left ventricular dimensions following
purple carrot treatment. Along with other results, reduction
in lactate dehydrogenase activity and improved N homeo-
stasis with purple carrot juice supplementation could be indi-
cative of normalised metabolism leading to cardioprotective
effects. Our data also showed that uric acid concentrations
decreased in the purple carrot juice-treated rats. Uric acid,
the endproduct of purine metabolism and a major endogenous
water-soluble antioxidant(52), is increased in fructose-fed rats
following increased production of reactive oxygen species(33).
Additionally, the reduction in plasma malondialdehyde con-
centrations, a major product of PUFA peroxidation, suggests
in vivo antioxidant activity of purple carrot juice.
In contrast to b-carotene, purple carrot juice supple-
mentation reduced liver wet weight, portal inflammation, fat
deposition and portal fibrosis in the liver and showed total
restoration of liver function. We have shown that purple
carrot juice reversed the pathological features of NAFLD
in the high-carbohydrate, high-fat diet-fed rats. Increased
activities of the serum enzymes including aspartate trans-
aminase, alanine transaminase and alkaline phosphatase reflect
active liver damage. Inflammatory hepatocellular disorders
result in extremely elevated transaminase levels(53). Thus,
purple carrot juice treatment has a significant role in the
decrease or reversal of liver dysfunction since the activity of
these plasma enzymes was lower than in high-carbohydrate-
high-fat diet-fed rats and similar to maize starch diet-fed
rats. Both b-carotene and purple carrot juice reduced plasma
CRP concentrations, suggesting their possible in vivo
anti-inflammatory effects.
The present study demonstrates for the first time that
treatment of the metabolic syndrome induced by diet in rats
with purple carrot juice attenuates or reverses the changes in
cardiovascular and liver structure and functions as well as in
metabolic parameters, especially abdominal fat deposition
and plasma lipid profiles. As the juice itself contained low
concentrations of carotenoids, it is likely that the anthocyanins
are responsible for the antioxidant and anti-inflammatory
properties of purple carrot juice. Furthermore, b-carotene
alone produces limited and sometimes contradictory responses
compared with purple carrot juice in this rat model of the
metabolic syndrome.
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Chia seeds contain the essential fatty acid, α-linolenic acid (ALA). This study has assessed whether chia seeds attenuated the metabolic, cardiovascular and
hepatic signs of a high-carbohydrate, high-fat (H) diet [carbohydrates, 52% (wt/wt); fat, 24% (wt/wt) with 25% (wt/vol) fructose in drinking water] in rats. Diets
of the treatment groups were supplemented with 5% chia seeds after 8 weeks on H diet for a further 8 weeks. Compared with the H rats, chia seed-supplemented
rats had improved insulin sensitivity and glucose tolerance, reduced visceral adiposity, decreased hepatic steatosis and reduced cardiac and hepatic inflammation
and fibrosis without changes in plasma lipids or blood pressure. Chia seeds induced lipid redistribution with lipid trafficking away from the visceral fat and liver
with an increased accumulation in the heart. The stearoyl-CoA desaturase-1 products were depleted in the heart, liver and the adipose tissue of chia seed-
supplemented rats together with an increase in the substrate concentrations. The C18:1trans-7 was preferentially stored in the adipose tissue; the relatively inert
C18:1n-9 was stored in sensitive organs such as liver and heart and C18:2n-6, the parent fatty acid of the n-6 pathway, was preferentially metabolized. Thus, chia
seeds as a source of ALA induce lipid redistribution associated with cardioprotection and hepatoprotection.
© 2012 Elsevier Inc. All rights reserved.Keywords: Chia seed; α-Linolenic acid; Metabolic syndrome; High-carbohydrate, high-fat diet1. Introduction
All three nutritionally important n-3 fatty acids, α-linolenic acid
(ALA; C18:3n-3), eicosapentaenoic acid (EPA; C20:5n-3) and
docosahexaenoic acid (DHA; C22:6n-3), reduce one or more risk
factors of cardiovascular disease as shown by epidemiological,
human, animal and cell culture studies [1–5]. In human diets, ALA,Abbreviations: ALA, α-linolenic acid; ALP, alkaline phosphatase; ALT,
alanine transaminase; AST, aspartate transaminase; C, corn starch diet; CC,
corn starch+chia seed diet; CK, creatine kinase; CPT-1, carnitine palmitoyl-
transferase I; CRP, C-reactive protein; DHA, docosahexaenoic acid; DXA, dual-
energy X-ray absorptiometry; EPA, eicosapentaenoic acid; H, high–carbohy-
drate, high-fat diet; HC, high-carbohydrate, high-fat diet+chia seed; LDH,
lactate dehydrogenase; LV, left ventricle; LVIDd, left ventricle internal
diameter in diastole; LVIDs, left ventricle internal diameter in systole;
LVPWd, left ventricle posterior wall thickness in diastole; NEFA, nonesterified
fatty acids; SCD, stearoyl-CoA 9-desaturase; SREBP-1, sterol regulatory
element binding protein-1.
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Sciences, University of Southern Queensland, Toowoomba 4350, Australia.
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Page 262the essential n-3 fatty acid, is usually derived from plant sources
such as flax seed, while EPA and DHA are ingested from fish, fish
oil supplements and other sea foods [1]. The richest botanical
source of ALA is the oil from chia seeds containing about 60% (wt/
vol) [6–10]. Chia seed (Salvia hispanica L.) was a major dietary
component in the Mayan and Aztec populations [6]. In sucrose-fed
rats, dietary chia seed prevented the onset of dyslipidemia and
insulin resistance and reduced visceral adiposity without affecting
glucose homeostasis [10]. Rats fed a 16% chia seed diet showed
increased plasma ALA, EPA and DHA concentrations, decreased
serum triglyceride content and increased serum high-density
lipoprotein content [9]. In humans receiving conventional therapy
for diabetes, chia seed reduced systolic blood pressure and C-
reactive protein (CRP) concentrations and increased serum ALA and
EPA concentrations without affecting body weight [11]. In another
human intervention study, dietary chia seed increased plasma
ALA concentrations, but EPA and DHA concentrations, body com-
position, biomarkers of inflammation and oxidative stress were
unchanged [12].
Despite ALA being the primary fatty acid of the pathway, it has
generated less scientific interest than EPA or DHA among the n-3 fatty
acids possibly due to the inefficient conversion of ALA to EPA and
DHA by humans [13]. Epidemiological and clinical evidence suggests
154 H. Poudyal et al. / Journal of Nutritional Biochemistry 23 (2012) 153–162that higher consumption of ALA is associated with reduced risk of
cardiovascular diseases [14–20]. A meta-analysis of five prospective
cohort studies showed that increased ALA consumption reduced
heart disease mortality [14]. The Lyon Heart Study concluded that
diets rich in ALA were more efficient than presently used diets in the
secondary prevention of cardiovascular diseases [15]. The cardiovas-
cular health study [16]; The Nurses' Health study [17,18]; the
National Heart, Lung, and Blood Institute Family Heart Study [19]
and the Health Professionals Study [20] concluded that higher ALA
intake was associated with a reduced risk of coronary heart disease
and related mortalities.
Metabolic syndrome is a clustering of interrelated risk factors
for cardiovascular disease and diabetes. These factors include
hyperglycemia, hypertension, dyslipidemia, central adiposity and
nonalcoholic fatty liver disease [21]. We have previously shown
that rats fed a high-carbohydrate, high-fat diet mimic many signs
of human metabolic syndrome [22,23]. Therefore, to determine the
responses of chia seed as a rich source of ALA on the signs of
metabolic syndrome, we investigated metabolic changes, cardio-
vascular and hepatic structure and function, lipid content and fatty
acid profiles in the liver, retroperitoneal adipose tissue and the
heart of rats fed either corn starch diet, high-carbohydrate, high-fat
diet or either diet containing 5% whole chia seed supplement. Liver
and adipose tissue were selected for their major role in fatty acid
metabolism, while the heart was selected because fatty acids
modulate its functions. Corn starch is a slowly digestible
carbohydrate [24] and served as a control for the high-carbohy-
drate, high-fat diet in this study where the primary carbohydratesTable 1
Fatty acid profile and energy density of chia seed, C, CC, H and HC diets
Constituent Chia seed Diets
C
Corn starch, g/kg – 570.00
Powdered rat feeda, g/kg – 155.00
HMW salt mixture, g/kg – 25.00
Fructose, g/kg – –
Beef tallow, g/kg – –
Condensed milk, g/kg – –
Water, ml/kg – 250.00
Chia seed, g/kg – –
Macronutrient composition
Total carbohydrate, g/kg – 600.25
Total fat, g/kg – 8.07
Total protein, g/kg – 31.78
Total fiber, g/kg – 7.44
Total vitamins, g/kg – 0.32
Total minerals, g/kg – 0.13
Ash, g/kg – 0.63
Total moisture, g/kg – 326.38
Total calculated energy density, kJ/g 18.6 11.2
Total extractable lipids, g/kg (n=3) 272.6±0.1 6.2±0.1
Fatty acid, g/100g of total fatty acid content (n=3)
C14:0 2.8±0.4 10.0±0.9
C16:0 7.6±0.2 17.5±0.4
C18 3.4±0.6 0.6±0.0
C18:1n-9 8.7±0.4 34.5±2.3
C18:1trans-7 0.0±0.0 0.0±0.0
C18:2n-6 20.5±0.2 30.5±0.8
C18:3n-3 56.1±0.5 4.7±0.1
C20:0 0.3±0.1 0.0±0.0
Total SFA 14.1±0.5 28.3±1.4
Total MUFA 9.3±0.6 35.7±2.3
Total PUFA 76.7±0.8 36.0±0.9
For the dietary fatty acid compositions, each value is a mean±S.E.M. Number of repetitive exp
saturated fatty acid; PUFA, polyunsaturated fatty acid; MUFA, monounsaturated fatty acid.
a Meat-free rat and mouse feed (Speciality Feeds) contains the following (in g/kg of feed): c
total minerals, 0.85.
Pageare fructose and sucrose. Unlike fructose, corn starch does not
increase blood glucose, plasma insulin or nonesterified fatty acid
(NEFA) concentrations [22,24].2. Materials and methods
2.1. Animals and diets
The experimental groups consisted of 48maleWistar rats (8–9 weeks old, 338±4 g)
supplied by The University of Queensland Biological Resources unit and individually
housed at the University of Southern Queensland Animal House. All experimentation was
approved by the Animal Experimentation Ethics Committee of the University of Southern
Queensland under the guidelines of the National Health and Medical Research Council of
Australia. The ratswere randomly divided into four separate groups (n=12 each) fed corn
starch (C), corn starch+chia seed (CC), high-carbohydrate, high-fat (H) and high-
carbohydrate, high-fat+chia seed (HC). All experimental groups were housed in a tem-
perature-controlled, 12-h light/dark cycle environment with ad libitum access to water
and the group-specific rat diet. Measurements of bodyweight and food andwater intakes
were taken daily to monitor the day-to-day health of the rats. Feed conversion efficiency
(%) was calculated as [mean body weight gain [g]/daily energy intake (kJ)]×100 [25].
All group-specific diets were custom prepared in our laboratory. Corn starch diet
was prepared by thorough mixing of corn starch, powdered rat feed (meat-free rat and
mouse feed; Speciality Feeds, Glen Forrest, WA, Australia), Hubble, Mendel and
Wakeman salt mixture (MP Biochemicals, Seven Hills, NSW, Australia) and water,
while the corn starch and part of water were replaced with condensed milk, fructose
and beef tallow in the high-carbohydrate, high-fat diet (Table 1). The drinking water in
all high-carbohydrate, high fat-fed rats was augmented with 25% fructose. Chia seed-
supplemented diets were prepared by replacing an equivalent amount of water in the
diet with thewhole seed (Table 1). The fatty acid composition of all group-specific diets
and chia seed is described in Table 1. Five percent of chia seed supplementation was
administered for 8weeks starting 8 weeks after the initiation of the corn starch or high-
carbohydrate, high-fat diet.CC H HC
570.00 – –
155.00 155.00 155.00
25.00 25.00 25.00
– 175.00 175.00
– 200.00 200.00
– 395.00 395.00
200.00 50.00 –
50.00 – 50.00
600.25 515.67 515.67
8.07 239.04 239.04
31.78 58.12 58.12
7.44 7.44 7.44
0.32 0.32 0.32
0.13 0.44 0.44
0.63 0.00 0.00
296.38 153.98 123.98
12.2 17.9 18.7
11.6±0.1 187.0±2.3 193.9±0.4
15.6±0.2 3.7±0.1 4.7±0.1
14.5±0.1 24.6±0.5 26.9±0.5
4.9±0.1 24.2±0.2 21.9±0.4
24.7±0.4 0.9±0.5 3.4±0.6
0.0±0.0 40.8±0.8 34.1±0.2
25.5±0.0 2.7±0.1 3.0±0.1
12.6±0.0 0.1±0.1 2.1±0.4
0.4±0.0 0.2±0.1 0.3±0.1
35.5±0.3 53.1±0.7 54.9±1.0
25.5±0.4 44.1±0.6 40.0±0.7
39.1±0.1 2.8±0.0 5.1±0.3
eriments are indicated within parenthesis. HMW, Hubble, Mendel and Wakeman; SFA,
arbohydrates, 707.07; proteins, 194.00; fat, 48.00; fiber, 48.00; total vitamins, 2.08 and
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Systolic blood pressure was measured as previously described [22] under light
sedation following intraperitoneal (ip) injection of Zoletil (tiletamine 15 mg/kg,
zolazepam 15 mg/kg; Virbac, Peakhurst, NSW, Australia). Measurements were taken
using an MLT1010 Piezo-Electric Pulse Transducer (ADInstruments, Sydney, Australia)
and inflatable tail-cuff connected to an MLT844 Physiological Pressure Transducer
(ADInstruments) and PowerLab data acquisition unit (ADInstruments).
2.3. Oral glucose tolerance and insulin tolerance tests
The oral glucose tolerance and the insulin tolerance tests were performed 2 days
apart from each other at 16weeks. For oral glucose tolerance after 10–12 h of overnight
food deprivation, basal blood glucose concentrations were measured in blood taken
from the tail vein using Medisense Precision Q.I.D glucose meter (Abbott Laboratories,
Bedford, MA, USA). Fructose-supplemented drinking water in the H and HC groups was
replaced with normal water for the overnight food deprivation period. The rats were
given 2 g/kg body weight of glucose as a 40% solution via oral gavage. Tail vein blood
samples were taken at 30, 60, 90 and 120 min following glucose administration.
For insulin tolerance, basal blood glucose concentrations were measured after
4–5 h of food deprivation as above. The rats were injected ip 0.75 IU/kg insulin-R (Eli
Lilly Australia, West Ryde, NSW, Australia), and tail vein blood samples were taken at
0, 30, 60, 90 and 120 min. Rats were withdrawn from the test if the blood glucose
dropped below 1.1 mmol/L, and 4 g/kg glucose was immediately administered by oral
gavage to prevent hypoglycemia.
2.4. Echocardiography
Echocardiographic examination (Phillips iE33, 12MHz transducer) was performed
at 16 weeks as previously described [22,26]. Measurements were taken in accordance
with the guidelines of the American Society of Echocardiography using the leading-
edge method [27]. Briefly, rats were anesthetized using intraperitoneal Zoletil
(tiletamine 15 mg/kg and zolazepam 15 mg/kg ip; Virbac) and Ilium Xylazil (xylazine
15 mg/kg ip; Troy Laboratories, Smithfield, NSW, Australia) and positioned in dorsal
recumbency. Electrodes attached to the skin overlying the elbows and right stifle
facilitated the simultaneous recording of a lead II electrocardiogram. A short-axis view
of the left ventricle (LV) at the level of the papillary muscles was obtained and used for
direct acquisition of M-mode images of the LV for measurement of diastolic posterior
wall thickness (LVPWd), LV internal systolic dimension and LV end-diastolic
dimension (LVIDd).
2.5. Body composition measurements
Dual-energy X-ray absorptiometric (DXA) measurements were performed on the
rats after 8 and 16 weeks of feeding, 2 days before rats were killed for
pathophysiological assessments, using a Norland XR36 DXA instrument (Norland
Corp., Fort Atkinson, WI, USA). DXA scans were analyzed using the manufacturer's
recommended software for use in laboratory animals (Small Subject Analysis Software,
version 2.5.3/1.3.1; Norland Corp) as previously described [28]. The precision error of
lean mass for replicate measurements, with repositioning, was 3.2%. Visceral adiposity
index (%) was calculated as: ([retroperitoneal fat (g)+omental fat (g)+epididymal fat
(g)]/[body weight (g)])×100 and expressed as adiposity percent [29].
2.6. Isolated heart preparation
The left ventricular function of the rats in all treatment groups was assessed using
the Langendorff heart preparation. Terminal anesthesia was induced via ip injection of
pentobarbitone sodium (Lethabarb, 100 mg/kgip). After heparin (Sigma-Aldrich
Australia, Sydney, Australia) administration (200 IU) through the right femoral vein,
blood (∼5 ml) was taken from the abdominal aorta. Isovolumetric ventricular function
was measured by inserting a latex balloon catheter into the LV of the isolated heart
connected to a Capto SP844 MLT844 physiological pressure transducer and Chart
software on a Maclab system (ADInstruments Australia and Pacific Islands, Bella Vista,
NSW, Australia). All left ventricular end-diastolic pressure values were measured while
pacing the heart at 250 beats/min using an electrical stimulator. End-diastolic
pressures were obtained starting from 0 up to 30 mmHg. Diastolic stiffness constant
(κ, dimensionless) was calculated as in previous studies [22,30]. +dP/dt and −dP/dt
were calculated as the mean rate of contraction and relaxation, respectively, of at least
50 beats with the heart paced at 250 beats/min, and the end-diastolic pressure was
maintained at approximately 10 mmHg.
2.7. Aortic contractility
Thoracic aortic rings (4 mm in length) were suspended in an organ bath chamber
with a resting tension of approximately 10 mN. Cumulative concentration–response
(contraction) curves were measured for noradrenaline (Sigma-Aldrich Australia);
concentration–response (relaxation) curves were measured for acetylcholine (Sigma-
Aldrich Australia) and sodium nitroprusside (Sigma-Aldrich Australia) in the presence
of a submaximal (70%) contraction to noradrenaline [22].Page 2642.8. Organ weights
The right and left ventricles were separated after perfusion experiments and
weighed. Liver, retroperitoneal, epididymal and omental fat were removed following
heart removal and blotted dry for weighing. Organ weights were normalized relative to
the tibial length at the time of their removal (in mg/mm). Immediately after weighing,
the LV, liver and retroperitoneal fat were stored at −20°C in a 50-ml polypropylene
centrifuge tube for fatty acid analysis.2.9. Fatty acid analysis
The extraction of tissue and dietary lipids was undertaken by manual solvent
extraction using a 2:1 chloroform/methanol mixture with 0.1% butylated hydro-
xytoluene as an antioxidant. Approximately 1–5 g of retroperitoneal fat, heart and liver
and 2 ml plasma were macerated into a 50-ml polypropylene centrifuge tube and were
mixed on a rotating device for 40 min with 20 ml of chloroform/methanol solvent and
then centrifuged at 2500 rpm for 5 min. The extraction procedure was repeated twice,
combining all of the extracting solvent and subsequently washing with ddH2O to
remove all polar material. Chloroform was evaporated under a stream of nitrogen on a
hot plate set at 60°C until the beakers reached constant weight. The beaker weights
were recorded for the calculation of gravimetric extractable lipid content [31].
Approximately 15–20 mg of extracted lipid samples with 1 mg of heptadecanoic
acid (C17) added as an internal standard was methylated in a clean 10-ml test tube.
Saponified lipids were extracted with 2 ml heptane and then transferred into an
autosampler vial for gas chromatography. Fatty acidmethyl esters were analyzed on an
Agilent J&W DB-23 column (60 m×0.25 mm×0.25 μm) (Agilent Technologies, Santa
Clara, CA, USA) by a Shimadzu GC-17A equipped with a flame ionization detector. The
injection and the detector temperatures were set at 250°C and 285°C, respectively. The
column temperature was set at 100°C for 2 min, raised at 10°C/min to 180°C, held for 5
min, raised at 5°C/min to 240°C and held for 25min. Carrier gas (helium) was passed at
110 kPa, with constant linear velocity of 15cm/s. A sample of 1 μL was injected with a
split ratio of 25. A multi-acid standard mixture was used for checking the performance
of the gas chromatography and as a recovery test for the sample preparation procedure.
Quantitation of the fatty acids in all samples was based on a linear calibration equation
obtained from the C17 standards. For identification purposes, a 28-fatty-acid methyl
ester mixture standard (Nu-Check Prep. Inc, Elysian, MN, USA) was used for retention
time (RT) calibration. A plot of carbon number versus log RT for the saturated series, 1°
of unsaturation and 2° of unsaturation allowed a relationship to be developed for
identification purposes.
All fatty acids were expressed as grams per 100 g of total recovered fatty acids. The
n-3:n-6 ratio was derived using the following formula:
n3:n6=[C18:3n-3+C20:3n-3+C20:5n-3+C22:5n-3+C22:6n-3]/
[C18:2n-6+C18:3n-6+C20:2n-6+C20:3n-6+C20:4n
-6+C22:2n-6+C22:4]n-6
As the diets were rich in C18:1n-9, the stearoyl-CoA 9-desaturase (SCD) index was
calculated as the ratio between C16:1n-7 and C16:0, and the ratio between C18:1n-9
and C18:0 was not considered.2.10. Histology
Two rats per group were taken exclusively for histological analysis. Two slides
were prepared per tissue specimen and two random, nonoverlapping fields per slide
were taken to avoid biased analysis. Organs were also collected from rats used for
perfusion studies. Immediately after removal, heart and liver tissues were fixed in 10%
buffered formalin for 3 days and then dehydrated and embedded in paraffin wax as
previously described [22]. Thin sections (7 μm) of LV and the liver were cut and stained
with hematoxylin and eosin stain for determination of inflammatory cell infiltration.
Liver sections were also stained with Milligan's trichrome stain to determine fibrosis.
Collagen distribution was measured in the LV with picrosirius red stain. Laser confocal
microscopy (Zeiss LSM 510 upright Confocal Microscope) with color intensity
quantitatively analyzed using NIH-imageJ software (National Institute of Health,
USA) was used to determine the extent of collagen deposition in selected tissue
sections [22].2.11. Plasma biochemistry
Briefly, blood was centrifuged at 5000×g for 15minwithin 30min of collection into
heparinized tubes. Plasma was separated and transferred to Eppendorf tubes for
storage at −20°C before analysis. Activities of plasma enzymes and analyte
concentrations were determined using kits and controls supplied by Olympus using
an Olympus analyzer (AU 400, Tokyo, Japan) as previously described [22]. Plasma CRP
was estimated using a commercial kit (Kamiya Biomedical, Thousand Oaks, CA, USA)
according to the manufacturer-provided standards and protocols using a Cobas-Mira
automated analyser.
156 H. Poudyal et al. / Journal of Nutritional Biochemistry 23 (2012) 153–1622.12. Statistical analysis
All data are presented as mean±S.E.M. Results were tested for variance using
Bartlett's test and variables that were not normally distributed were transformed
(using log 10 function) prior to statistical analyses. Data from C, CC, H and HC groups
were tested by two-way analysis of variance. When interaction and/or the main effects
were significant, means were compared using Newman-Keuls multiple-comparison
post hoc test. Where transformations did not result in normality or constant variance, a
Kruskal-Wallis nonparametric test was performed. A P value of b.05 was considered as
statistically significant. All statistical analyses were performed using GraphPad Prism
version 5.00 for Windows (San Diego, CA, USA).
3. Results
3.1. Dietary intake, body parameters and plasma biochemistry
Food intake was decreased in H and HC rats compared with C
and CC groups (Table 2). Chia seed supplementation did not change
water intake in either group, but food consumption was increased in
CC rats (Table 2). Chia seed supplementation increased energyTable 2
Dietary intakes, body composition and anthropometrics, organ wet weights, tissue fatty acid
Variable C CC
Food intake, g/d (n=10) 33.9±0.9b 42.1±2.1a
Water intake, ml/d (n=10) 31.4±0.4a 31.7±0.8a
Chia seed intake, g/d (n=10) 0.0±0.0c 2.1±0.1a
Energy intake, kJ/d (n=10) 400.8±9.3b 503.1±18.1a
Body weight gain (8–16 weeks), % (n=10) 11.0±1.3b 22.6±1.5a
Feed conversion efficiency, % (n=10) 2.7± 0.1c 4.5± 0.3a
Bone mineral content, g (n=10) 12.4±0.2c 13.3±0.3bc
Total body fat mass, g (n=10) 75.5±4.4b 82.8±8.7b
Total body lean mass, g (n=10) 325.9±4.5b 343.5±9.2ab
Abdominal circumference, cm (n=10) 20.0±0.3b 20.4±0.3b
Visceral adiposity index, % (n=10) 4.4±0.3c 2.1±0.2d
Tissue wet weightse, mg/mm (n=10)
Retroperitoneal fat 169.4±12.6c 126.0±14.5c
Epididymal fat 105.3±7.0b 85.8±10.5b
Omental fat 102.8±11.4b 69.5±6.5c
Liver 204.2±22.2b 223.0±6.6b
Heart 22.3±0.3b 22.7±0.8b
Tissue lipid content, mg/g (n=6)
Retroperitoneal adipose tissue 396.2±25.3c 453.9±12.9c
Liver 25.9±2.4b 26.0±3.2b
Heart 29.8±0.7b 38.4±2.7b
Plasma 11.5±0.8 13.9±1.7
Plasma urea, mmol/L (n=10) 5.6±0.6a 5.1±0.4a
Plasma LDH, U/L (n=10) 191.1±18.2c 122.0±12.2c
Plasma uric acid, μmol/L (n=10) 25.9±1.4b 24.0±1.9b
Plasma CRP, μmol/L (n=10) 59.3±7.4b 58.2±5.9b
Plasma total cholesterol, mmol/L (n=10) 1.3±0.1b 1.4±0.1b
Plasma triglyceride, mmol/L (n=10) 0.4±0.0c 0.6±0.1c
Plasma NEFA, mmol/L (n=10) 1.2±0.1c 1.7±0.3bc
Plasma fatty acid, g/100g of total fatty acid content (n=6)
C14:0 75.56±2.32 73.24±3.27
C14:1n-5 1.01±0.18a 0.00±0.00b
C16:0 0.02±0.02b 2.75±0.2a
C16:1n-7 14.99±1.95a 9.24±1.21b
C18:1n-9 0.00±0.00b 2.25±0.34a
C18:1trans-7 3.20±0.13b 2.71±0.34b
C18:2n-6 1.71±0.18a 0.00±0.00b
C18:3n-6 0.00±0.00 1.32±0.50
C18:3n-3 1.45±0.16a 2.98±0.56b
C20:3n-3 0.00±0.00b 1.79±0.43a
C20:5n-3 2.07±0.07b 0.86±0.09c
C24:0 0.00±0.00b 0.33±0.02a
C22:6n-3 0.00±0.00c 0.64±0.08b
Total SFA 75.58±2.31 78.22±1.90
Total MUFA 19.19±2.22 14.19±1.42
Total PUFA 5.23±0.30 7.59±0.73
n3:n6 ratio 2.15±0.21b 9.10±2.41a
Each value is a mean±S.E.M. Means with superscript lettersa,b,c,d without a common letter d
saturated fatty acid; PUFA, polyunsaturated fatty acid; MUFA, monounsaturated fatty acid.
e Normalized against tibial length.
Pageintake compared with C and H diet-fed rats (Table 2). This increased
energy intake in the chia seed-supplemented rats corresponded with
increased body weight gain and feed conversion efficiency in both
groups without any change in abdominal circumference or total body
fat mass. However, chia seed supplementation reduced the visceral
adiposity index and increased bone mineral content in both groups
without altering the body lean mass (Table 2). The reduction in
visceral adiposity index was due to decreased retroperitoneal and
omental but not epididymal fat deposition in HC rats. In CC rats,
selective lowering of omental fat was observed (Table 2). Chia seed
supplementation decreased the total lipid content in the retroperi-
toneal fat and liver but increased the content in the heart (Table 2).
This lipid redistribution induced by chia seed supplementation was
associated with increased plasma triglycerides and NEFA, although
plasma total cholesterol concentrations were not affected (Table 2).
Chia seed supplementation also reduced heart wet weights.
Furthermore, chia seed supplementation normalized plasma urea
concentrations suppressed by H diet feeding and reduced lactatecomposition and plasma biochemistry in C, CC, H and HC diet-fed rats
H HC P
Diet Treatment Interaction
22.9±0.3c 22.8±0.4c b.0001 .0014 .0011
19.7±0.3b 19.1±0.4b b.0001 .7714 .3856
0.0±0.0c 1.1±0.0b b.0001 b.0001 b.0001
452.5±12.4b 507.7±13.6a .0475 b.0001 .0946
15.2±1.9b 23.8±1.7a .1033 b.0001 .3593
3.3± 0.2b 4.6± 0.2a .0801 b.0001 .1913
13.9±0.1b 15.4±0.6a b.0001 .0017 .4018
153.9±6.6a 153.1±12.3a b.0001 .7049 .6371
345.9±8.9ab 368.1±10.0a .012 .0237 .7865
22.2±0.4a 22.0±0.2a b.0001 .7475 .3369
7.9±0.5a 5.9±0.3b b.0001 b.0001 .4479
387.6±26.0a 296.6±19.1b b.0001 .001 .2141
192.8±13.5a 169.6±13.4a b.0001 .0697 .8742
175.0±10.3a 147.4±5.7b b.0001 .0014 .7469
318.5±12.0a 288.6±5.8a b.0001 .6741 .0723
25.6±1.0a 23.4±0.4b .006 .2077 .0555
632.3±22.4a 527.1±19.4b b.0001 .2676 .0008
60.2±2.9a 29.8±3.2b b.0001 b.0001 b.0001
36.7±2.2b 47.5±4.4a .0106 .0029 .7012
13.5±2.8 14.2±1.1 .5385 .3834 .6233
3.7±0.3b 2.6±0.2b b.0001 .0549 .4616
386.6±34.8a 302.7±38.0b b.0001 .0097 .793
54.7±5.2a 32.9±3.7b b.0001 .0013 .0059
102.3±4.6a 54.6±2.6b .0009 b.0001 .0001
2.0±0.1a 1.8±0.1a b.0001 .6201 .1423
1.0±0.1b 1.6±0.2a b.0001 .0024 .1112
2.2±0.1b 4.7±0.3a b.0001 b.0001 b.0001
75.20±1.37 71.79±3.44 .7436 .3063 .8437
0.80±0.07a 0.29±0.11b .7227 b.0001 .0359
0.14±0.14b 2.34±0.31a .5064 b.0001 .2306
13.85±0.71a 7.59±0.89b .2891 .0001 .8442
0.00±0.00b 2.25±0.28a 1 b.0001 1
3.73±0.19b 8.75±1.07a b.0001 .0008 .0001
2.02±0.22a 0.00±0.00b .2884 b.0001 .2884
0.00±0.00 1.12±0.48 .7759 .0022 .7759
1.62±0.13a 2.22±0.93b .3456 .0023 .1435
0.00±0.00b 1.89±0.17a .831 b.0001 .831
2.65±0.34a 0.57±0.06c .4345 b.0001 .0267
0.00±0.00b 0.28±0.05a .3642 b.0001 .3642
0.00±0.00c 0.91±0.09a .0364 b.0001 .0364
75.34±1.35 74.41±3.17 .3853 .7118 .4431
18.38±0.89 18.88±1.96 .2676 .2009 .1217
6.28±0.65 6.71±1.26 .9176 .101 .2482
2.15±0.15b 10.99±4.26a .5748 .0001 .5748
iffer (P b.05). Number of repetitive experiments are indicated within parenthesis. SFA,
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Fig. 1. Glucose (2 g/kg) (A) and insulin (0.75 IU/kg) (B) tolerance in C, CC, H and HC diet-fed rats. Data are shown as means±S.E.M. Means of values at 120 min without a common
alphabet significantly differ. n=10/group.
157H. Poudyal et al. / Journal of Nutritional Biochemistry 23 (2012) 153–162dehydrogenase (LDH) activity as a marker of decreased metabolic
activity, uric acid concentrations as a marker of fructose-induced
oxidative stress and plasma CRP concentrations as a marker of
inflammation (Table 1). In addition, chia seed-supplemented groups
showed improved glucose and insulin tolerance (Fig. 1).Table 3
Changes in cardiovascular structure, function and fatty acid composition in C, CC, H and HC d
Variable C CC
LVIDd, mm (n=10) 6.4±0.2b 6.7±0.2b
LVPWd, mm (n=10) 1.7±0.0b 1.8±0.1b
Relative wall thickness (n=10) 0.4±0.01c 0.5±0.01b
Fractional shortening, % (n=10) 60.8±1.4a 64.0±1.9a
Ejection fraction, % (n=10) 84.8±1.6 89.0±1.1
Ejection time, ms (n=10) 85.1±4.0 85.8±3.3
Deceleration time, ms (n=10) 61.3±1.6c 70.8±1.4b
LV developed pressure, mmHg (n=10) 64.7±6.1a 51.3±4.5ab
+dP/dt, mmHg×s−1 (n=10) 1078.9±104.3a 1009.1±62.8a
−dP/dt, mmHg×s−1 (n=10) −613.5±66.2a −616.3±57.2a
Diastolic stiffness (k), (n=10) 22.8±0.7c 22.9±0.6c
Estimated LV mass, g (n=10) 0.7±0.0b 0.8±0.0b
LV+septum wet weighte, mg/mm (n=10) 19.0±0.4b 19.4±0.7b
Right ventricle wet weighte, mg/mm (n=10) 3.2±0.2b 3.3±0.2b
LV fibrosis, % surface area (n=4) 3.6±0.9b 3.5±0.7b
Systolic blood pressure, mmHg (n=10) 123.7±1.8c 138.3±3.3b
Fatty acids, g/100g of total fatty acid content (n=6)
C14:0 42.49±3.73b 53.44±3.72ab
C14:1n-5 0.72±0.15a 0.22±0.14b
C16:0 1.22±0.13b 8.45±0.70a
C16:1n-7 14.83±1.08a 1.01±0.29c
C18:0 0.49±0.04a 2.48±0.06b
C18:1n-9 0.53±0.05b 11.28±0.65a
C18:1trans-7 12.96±1.00a 2.05±0.09b
C18:2n-6 6.79±0.79 6.67±1.17
C18:3n-6 7.47±0.63a 0.00±0.00b
C18:3n-3 0.00±0.00b 0.60±0.15a
C20:4n-6 0.04±0.04a 0.23±0.07b
C20:5n-3 11.31±0.95a 6.19±0.34c
C22:5n-3 0.05±0.05b 1.29±0.41a
C24:0 0.29±0.19c 3.19±0.93a
C22:6n-3 0.77±0.16b 2.67±0.91c
Total SFA 44.53±3.60d 67.73±1.43b
Total MUFA 29.04±1.79a 14.56±0.89b
Total PUFA 26.43±2.18a 17.71±1.07b
n3:n6 ratio 0.86±0.06b 2.05±0.05a
Stearoyl-CoA 9-desaturase index 12.43±0.94a 0.11±0.02b
Each value is a mean±S.E.M. Means with superscript lettersa,b,c,d without a common letter d
saturated fatty acid; PUFA, polyunsaturated fatty acid; MUFA, monounsaturated fatty acid.
e Normalized against tibial length.
Page 266The plasma fatty acid profile suggests that the chia seed-
supplemented rats resisted desaturation of C14:0 and C16:0 fatty
acids by SCD (Table 2). The SCD index could not be calculated in C and
H rats due to low concentrations of the saturated substrate. Both chia
seed-supplemented groups had increased plasma concentrations ofiet-fed rats
H HC P
Diet Treatment Interaction
7.7±0.2a 6.1±0.3b .1354 .0074 .0002
1.9±0.0ab 2.1±0.1a .0011 .0408 .4841
0.6±0.02a 0.4±0.01c .0006 .0006 b.0001
50.5±2.1b 59.2±2.2a .0004 .0038 .1617
83.8±1.3 84.4±1.6 .0557 .0987 .2118
86.9±2.6 89.6±6.6 .528 .7011 .8212
56.2±1.6c 64.2±1.5a .0005 b.0001 .6264
41.1±3.7b 57.4±3.8a .0674 .7596 .003
753.6±37.3b 1052.5±81.2a .0701 .1378 .0197
−373.9±21.9b −601.3±43.8a .0156 .0277 .0314
29.4±0.6a 26.5±0.6b b.0001 .8741 b.0001
1.1±0.1a 0.8±0.1b .0076 .1659 .0076
21.4±1.0a 19.2±0.3b .0847 .1503 .0466
4.2±0.2a 4.2±0.2a b.0001 .8625 .7107
12.6±1.2a 4.4±0.2a b.0001 .0003 .0004
150.7±3.6a 153.2±5.6a b.0001 .0316 .1222
54.07±5.35ab 58.05±1.18a .0458 .0635 .37
0.71±0.17a 0.00±0.00b .3983 .0002 .4399
2.26±1.49b 6.75±0.34a .6996 b.0001 .1198
10.23±2.00b 0.45±0.02c .0357 b.0001 .0932
0.69±0.08c 1.18±0.08d b.0001 b.0001 b.0001
0.31±0.07b 11.90±0.65a .6695 b.0001 .3738
11.41±1.57a 1.58±0.04b .2914 b.0001 .5688
4.75±0.82 5.23±0.31 .0492 .8307 .7218
4.26±1.02a 0.00±0.00b .0145 b.0001 .0145
0.0±0.0b 0.41±0.07a .2646 b.0001 .2646
0.49±0.05c 0.24±0.02b .0001 .543 .0002
8.92±0.95b 6.44±0.05c .1385 b.0001 .0714
0.00±0.00b 0.07±0.01b .006 .0048 .0103
0.21±0.12c 1.82±0.01b .1453 .0001 .1927
0.96±0.23b 5.60±0.23a .0047 b.0001 .0111
57.33±5.98c 67.95±0.87a .0847 .0001 .095
22.66±3.55c 13.93±0.63b .1046 b.0001 .1784
20.01±2.55b 18.12±0.3b .1053 .0072 .0682
1.28±0.28b 2.27±0.15a .0645 b.0001 .5478
13.47±2.94a 0.07±0.00b .7493 b.0001 .7301
iffer (P b.05). Number of repetitive experiments are indicated within parenthesis. SFA,
Fig. 2. Hematoxylin and eosin staining of LV (×20) showing inflammatory cells (marked as “in”) as dark spots outside the myocytes; C (A), CC (B), H (C) and HC (D) diet-fed rats.
Picrosirius red staining of left ventricular interstitial collagen deposition (×40) in C (E), CC (F), H (G) and HC (H) diet-fed rats. Collagen deposition is marked as “cd” and hypertrophied
cardiomyocytes are marked as “hy.”
158 H. Poudyal et al. / Journal of Nutritional Biochemistry 23 (2012) 153–162C18:1n-9, but increased concentrations of C18:1trans-7 were ob-
served only in HC group (Table 2). Both chia seed-supplemented
groups had depleted plasma C18:2n-6 and C20:5n-3 but increased
C18:3n-6, C18:3n-3, C20:4n-3 and C22:6 n-3 concentrations (Table 2).
Although the total saturated and unsaturated fatty acids remained
unchanged, the n3:n6 ratio was markedly enhanced in the plasma of
the chia seed-supplemented groups (Table 2).3.2. Cardiovascular changes
Comparedwith H rats, HC groups had smaller LV internal diameter
with increased fractional shortening and deceleration time (Table 3).
In addition, chia seed reduced LV wet weight and reduced estimatedFig. 3. Cumulative concentration–response curves for noradrenaline (A), sodium nitroprusside
are shown as means±S.E.M. Endpoint means without a common alphabet in each data set si
PageLV mass (Table 3). However, chia seed supplementation did not
reduce blood pressure in either group.
After 16weeks, H rats showed greater infiltration by inflammatory
cells into the LV (Fig. 2C) as well as increased interstitial collagen
deposition (Fig. 2G; Table 3) compared with C rats (Fig. 2A and E;
Table 3). HC rats showed normalized inflammatory state (Fig. 2D) and
markedly reduced collagen deposition (Fig. 2H; Table 3), but no
changes in inflammatory cell infiltration or collagen deposition were
seen in CC rats (Fig. 2B and F; Table 3). The reduction in LV fibrosis is
consistent with reduced diastolic stiffness constant in HC diet-fed rats
(Fig. 2D and H; Table 3).
Furthermore, H feeding diminished vascular responses in isolated
thoracic aortic rings to noradrenaline, sodium nitroprusside and acetyl-
choline when compared with C rats (Fig. 3A-C). In isolated thoracic(B) and acetylcholine (C) in thoracic aortic rings from C, CC, H and HC diet-fed rats. Data
gnificantly differ. n=8–10/group.
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159H. Poudyal et al. / Journal of Nutritional Biochemistry 23 (2012) 153–162aortic rings from HC rats, increased vasorelaxation was induced by
sodium nitroprusside and acetylcholine (Fig. 3B and C) in addition to
increased contractility to noradrenaline (Fig. 3A). Vascular responses in
isolated thoracic aortic rings from CC rats remained unchanged
compared with C rats (Fig. 3A-C).
Similar to the plasma fatty acid profile, chia seed-supplemented
rats resisted SCD action on C14:0 and C16:0 fatty acids in the heart
(Table 3). Both chia seed-supplemented groups had increased
concentrations of C18:0, C18:1n-9 but decreased concentrations of
C18:1trans-7 in the heart together with depleted C18:3n-6 and
C20:5n-3 but increased C18:3n-3, 22:5n-3, C22:6n-3 and C24:0
concentrations (Table 3). As a result of decreased desaturation of
C14:0 and C16:0, the total saturated fatty acid increased, and total
unsaturated fatty acid content decreased (Table 3). However, the
cardiac n-3:n-6 ratio was increased in the chia seed-supplemented
groups (Table 3).
3.3. Hepatic structure and function
H diet feeding elevated plasma markers of liver function in
comparison with C-fed rats (Table 4). HC diet feeding did not alter the
elevated alanine transaminase (ALT) activity but decreased the
aspartate transaminase (AST) activity (Table 4). ALP activity was
increased in the HC group (Table 4). Creatine kinase (CK) activity
decreased in both chia seed-supplemented groups, but none of the
other enzymes were affected in CC group (Table 4).
C (Fig. 4A, E and I) and CC (Fig. 4B, F and J) groups showed
negligible lipid accumulation, inflammatory cell infiltration or
fibrosis in the liver. H feeding for 16 weeks increased the size of
the fat vacuoles within the hepatocytes (Fig. 4C) with increased
portal inflammatory cell infiltration (Fig. 4G) and portal fibrosis
(Fig. 4K; Table 4). The HC diet-fed rats displayed normalized
macrovesicular steatosis (Fig. 4D), portal inflammation (Fig. 4H) and
fibrosis (Fig. 4I; Table 4).Table 4
Changes in hepatic structure, function and fatty acid composition in C, CC, H and HC diet-fed
Variable C CC H
ALT, U/L (n=10) 31.0±1.8b 31.6±3.0b 46.2
AST, U/L (n=10) 76.0±3.5b 75.0±3.2b 104.8
ALP, U/L (n=10) 154.9±11.9b 188.4±30.5b 181.4
CK, U/L (n=10) 165.3±13.2b 70.4±11.0c 243.4
Liver fibrosis, % surface area (n=4) 1.6±0.2c 1.8±0.1c 7.4
Fatty acid, g/100g of total fatty acid content (n=6)
C14:0 6.69±0.98b 14.16±1.30a 3.10
C14:1n-5 1.72±0.14a 0.72±0.06b 0.79
C16 0.03±0.03b 19.96±0.41a 0.25
C16:1n-7 25.40±1.10a 3.74±0.75b 23.30
C18:0 0.00±0.00d 1.04±0.14a 0.32
C18:1n-9 0.00±0.00c 29.25±1.35b 1.52
C18:1trans-7 14.23±1.93a 0.00±0.00b 10.86
C18:2n-6 26.58±4.73b 8.60±0.96b 44.26
C18:3n-3 7.42±0.47a 3.42±0.30c 4.93
C20:0 0.40±0.02c 0.17±0.02b 0.19
C20:4n-6 0.64±0.07 0.67±0.34 0.73
C20:5n-3 10.85±2.89a 8.33±0.53b 7.96
C22:5n-3 0.16±0.07c 2.81±0.19b 0.05
C24:0 0.39±0.13b 4.11±0.68a 0.06
C22:6n-3 0.24±0.15c 2.16±0.16a 0.03
Total SFA 10.26±3.20b 39.46±1.40a 3.91
Total MUFA 40.35±1.07ab 33.75±1.83c 36.65
Total PUFA 49.38±3.93b 26.79±0.82c 59.43
n3:n6 ratio 0.99±0.23b 1.78±0.30a 0.35
Stearoyl-CoA 9-desaturase indexd – 0.19±0.04 78.84
Each value is a mean±S.E.M. Means with superscript lettersa,b,c,d without a common letter d
saturated fatty acid; PUFA, polyunsaturated fatty acid; MUFA, monounsaturated fatty acid.
d Negligible C16:0 fatty acid was detected in C diet-fed group, therefore showing a very h
Page 268Similar to cardiac and plasma fatty acid profile, chia seed-
supplemented rats resisted stearoyl-CoA 9-desaturation of C14:0
and C16:0 fatty acids in the liver (Table 4). Both chia seed-
supplemented groups had increased concentrations of C14:0, C16:0,
C18:0 and C18:1n-9 but decreased concentrations of C18:1trans-7
and C18:2n-6 (Table 4). Although C20:4n-6 content in the liver
remained unchanged across all groups, both chia seed-supplemented
groups had depleted C18:3n-3 and C20:5n-3 but increased C22:5n-3,
C22:6n-3 and C24:0 concentrations (Table 4). As a result of decreased
desaturation of C14:0 and C16:0, the total saturated fatty acid
increased and total unsaturated fatty acid content decreased (Table
4). However, the liver n-3:n-6 ratio was increased in the chia seed-
supplemented groups (Table 4).
3.4. Retroperitoneal adipose tissue fatty acid composition
Similar to other tissues, chia seed-supplemented rats resisted
stearoyl-CoA 9-desaturation of C14:0 and C16:0 fatty acids (Table 5)
in the retroperitoneal adipose tissue. Both chia seed-supplemented
groups had increased concentrations of C14:0, C16:0 and C18:1trans-
7 but decreased concentrations of C18:2n-6 and C18:3n-6 (Table 5).
C18:3n-3 was increased in HC group (Table 5) despite the extremely
small amounts of fatty acids with chain length of more than 20 carbon
atoms detected in the adipose tissue of all groups, making accurate
quantification difficult. Consequently, the total saturated fatty acid
increased and total unsaturated fatty acid content decreased, but the
n-3:n-6 ratio in retroperitoneal fat was increased in the chia seed-
supplemented groups (Table 5).
4. Discussion
The aim of this study was to assess the metabolic, cardiac and
liver changes following 5% chia seed supplementation in high-
carbohydrate, high-fat (H) diet-fed rats with low n-3 fatty acids.rats
HC P
Diet Treatment Interaction
±3.8a 45.4±4.9a .0002 .9777 .8452
±5.9a 76.4±8.1b .0099 .0118 .0183
±11.6b 251.1±12.5a .0209 .0083 .3333
±28.2a 122.3±17.3bc .0013 b.0001 .4867
±0.5a 3.6±0.2b b.0001 b.0001 b.0001
±0.59c 9.92±1.56b .0031 b.0001 .7832
±0.09a 1.05±0.09c .0575 b.0001 .2051
±0.05b 21.28±0.80a .1028 b.0001 .2363
±0.75a 1.31±0.32c .0088 b.0001 .8347
±0.07c 0.64±0.05b .6316 b.0001 .0003
±1.52c 40.16±1.34a b.0001 b.0001 .001
±3.37a 0.00±0.00b .3958 b.0001 .3958
±4.93a 7.18±0.29c .0289 b.0001 .0119
±0.15b 3.23±0.18c .0003 b.0001 .0011
±0.02b 0.47±0.04a .1045 .356 b.0001
±0.11 0.83±0.28 .5923 .7801 .8804
±2.31b 6.34±0.46c b.0001 .0001 .3082
±0.03c 1.56±0.08a b.0001 b.0001 b.0001
±0.06b 3.64±0.77a .4495 b.0001 .894
±0.03c 1.38±0.13b .001 b.0001 .0381
±0.61c 35.96±1.85b .023 b.0001 .4843
±1.86bc 42.70±1.26a .1047 .8605 .0006
±2.08a 21.34±1.16c .3362 b.0001 .0034
±0.12c 1.44±0.16ab .0329 .0003 .4911
±2.44 0.06±0.02 – – –
iffer (P b.05). Number of repetitive experiments is indicated within parenthesis. SFA,
igh stearoyl-CoA 9-desatururation index in this group.
Fig. 4. Hematoxylin and eosin staining of hepatocytes (×20) showing hepatocytes with enlarged fat vacuole (marked as “fv”) and inflammatory cells around the portal region (marked
as “pi”) (×20) from C (A, E), CC (B, F), H (C, G) and HC (D, H) diet-fed rats. Milligan's trichrome staining of the hepatic portal regions showing collagen (marked as “pf”) (×20) in C (I),
CC (J), H (K) and HC (L) diet-fed rats.
160 H. Poudyal et al. / Journal of Nutritional Biochemistry 23 (2012) 153–162Rats fed H diet developed hypertension, impaired glucose and insulin
tolerance, dyslipidemia, hepatic steatosis, cardiac fibrosis and func-
tional deterioration, inflammation and abdominal obesity. With the
exception of elevated blood pressure and some plasma markers of
liver function, dietary chia seed supplementation attenuated struc-
tural and functional changes caused by H feeding. Chia seed
supplementation caused lipid redistribution away from the abdom-
inal cavity, suppressed stearoyl-CoA desaturase index and increased
n-3:n-6 ratio in various tissues.
Chia seed-supplemented rats improved insulin and glucose
tolerance, reduced visceral adiposity, decreased hepatic steatosis,
reduced cardiac and hepatic fibrosis and inflammation withoutTable 5
Fatty acid composition of retroperitoneal fat and desaturase index from C, CC, H and HC diet-
Fatty acid, g/100g of total fatty
acid content (n=6)
C CC H
C14:0 0.00±0.00c 1.75±0.08b 0.00
C14:1n-5 2.17±0.04b 0.12±0.01c 2.81
C16:0 0.22±0.05b 31.15±1.60a 0.42
C16:1n-7 31.48±1.06a 2.44±0.27b 22.40
C18:0 0.22±0.03c 0.47±0.09c 0.62
C18:1trans-7 3.46±0.23c 40.99±1.52b 6.97
C18:2n-6 51.18±0.96b 10.78±0.80c 60.76
C18:3n-6 0.08±0.04b 0.33±0.21b 5.18
C18:3n-3 10.11±0.32a 10.45±0.80a 0.07
C20:0 0.66±0.13a 0.14±0.05c 0.35
Total SFA 1.10±0.14c 33.78±1.44a 1.48
Total MUFA 37.21±0.86c 43.98±1.37b 32.40
Total PUFA 61.70±0.92b 22.18±0.78c 66.12
n3:n6 ratio 0.20±0.01c 1.02±0.18a 0.00
Stearoyl-CoA 9-desaturase index 129.55±16.75a 0.08±0.01c 44.38
Each value is a mean±S.E.M. Means with superscript lettersa,b,c,d without a common letter di
saturated fatty acid; PUFA, polyunsaturated fatty acid; MUFA, monounsaturated fatty acid.
Pagechanges in plasma lipids or blood pressure. However, the most
notable result from our study is the chia seed-induced lipid
redistribution with lipid trafficking away from the visceral fat and
liver with increased accumulation in the heart. Furthermore, the
selectivity for different fatty acids for the unsaturated and the
desaturated products of the 18 carbon length fatty acids was altered
in different tissues by chia seed supplementation.
The relative abundance of the C18:1n-9 was increased in the heart
and the liver of the chia seed-supplemented groups. The C18:1trans-7
was more selectively stored in the adipose tissue than the heart and
the liver, and the C18:2n-6 or its elongated Δ5 and Δ6 desaturase
products were depleted in all tissues suggesting that C18:2n-6 isfed rats
HC P
Diet Treatment Interaction
±0.00c 2.55±0.11a b.0001 b.0001 b.0001
±0.10a 0.22±0.02c b.0001 b.0001 b.0001
±0.08b 23.62±0.68c .0004 b.0001 .0003
±0.21c 1.47±0.46b b.0001 b.0001 b.0001
±0.02c 1.10±0.10a b.0001 b.0001 .1143
±0.45d 59.91±1.29a b.0001 b.0001 b.0001
±0.47a 6.51±0.49d .0013 b.0001 b.0001
±0.08a 0.09±0.01b b.0001 b.0001 b.0001
±0.07c 3.12±0.42b b.0001 .0021 .0106
±0.02bc 0.54±0.04ab .5453 .0354 b.0001
±0.13c 28.09±0.50b .0025 b.0001 .0008
±0.43d 62.03±1.23a b.0001 b.0001 b.0001
±0.48a 9.85±0.93d b.0001 b.0001 b.0001
±0.00c 0.48±0.03b .0006 b.0001 .0776
±0.51b 0.06±0.02c b.0001 b.0001 b.0001
ffer (P b.05). Number of repetitive experiments are indicated within parenthesis. SFA,
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undergo partial β-oxidation and are not the preferred substrate [32].
However, C18:1trans-7 can be efficiently converted to conjugated
linoleic acid by the action of stearoyl-CoA desaturase 1 (SCD-1) [33],
the activity of which is inhibited by C18:3n-3-enriched chia seed. The
fatty acid homeostasis in tissues of the chia seed-supplemented rats
was maintained so that the C18:1trans-7 was preferentially stored in
the adipose tissue; the relatively inert C18:1n-9 was stored in sen-
sitive organs such as liver and heart and the C18:2, n-6, the parent
fatty acid of the n-6 pathway, was preferentially oxidized. It is
therefore plausible that the mechanism of down-regulation of the n-6
pathway by n-3 fatty acids involves increasing the transport and
oxidation of C18:2n-6 into the mitochondria.
Our results are consistent with the inhibition of SCD-1 by ALA-
rich chia seed. SCD-1 is a Δ9 fatty acid desaturase that catalyzes the
rate-limiting step in the production of monounsaturated from
saturated fatty acids [34]. In addition to reduced MUFA synthesis,
SCD-1 deficiency or treatment with SCD-1-targeted antisense
oligonucleotides induced protection from obesity, cellular lipid
accumulation and insulin resistance in mice [35–37]. Fructose,
being more lipogenic than glucose, is a potent inducer of hepatic
Scd-1 [38–40], and this enzyme plays a pivotal role in fructose-
induced lipogenesis [41]. In addition to metabolic effects elicited by
dietary carbohydrates, fatty acids also modulate the transcriptional
activation of Scd-1 and other lipogenic genes [42, 43]. The binding of
sterol regulatory element binding protein-1 (SREBP-1) to the SREBP
response element of the Scd-1 promoter is decreased by dietary n-3
polyunsaturated fatty acid from fish oil [44]. In addition, increased
plasma palmitoleate, a product of SCD-1, in humans has been
independently associated with both hypertriglyceridemia and
abdominal adiposity [45]. Saturated fat-enriched diet induced
lipogenic genes in wild-type mice, with the induction of the Scd-1
and Cpt-1 gene [46]. On the contrary, in Scd-1-deficient mice, the
high saturated fat diet does not induce lipogenesis; instead,
mitochondrial fatty acid oxidation is increased [46]. However,
inhibition of SCD-1 in a low-fat diet could potentially increase the
diet intake to supplement the loss of unsaturated fatty acid due to
inhibition for normal metabolic function. This effect is clearly seen in
CC diet-fed rats where the dietary intake increases following chia
seed supplementation.
In Scd-1-deficient mice, a lack of functional SCD-1 decreases the
accumulation of hepatic triglycerides and cholesterol esters, down-
regulates de novo fatty acid synthesis in the liver and reduces
adiposity [37]. Furthermore, Scd-1−/− mice are resistant to high-
carbohydrate and high-fat diet-induced liver steatosis [47]. Scd-1−/−
mice have increased fatty acid β-oxidation in the liver [48], skeletal
muscle [49] and brown adipose tissue [50] and up-regulated AMP-
activated protein kinase pathway [48,49]. In addition to the
regulation of lipid metabolism, SCD-1 is involved in the regulation
of carbohydrate metabolism. Scd-1−/− mice have increased whole-
body glucose tolerance and elevated insulin sensitivity in skeletal
muscle and brown adipose tissue [51,52]. However, in the heart, the
lack of Scd-1 decreased mitochondrial fatty acid uptake and oxidation
while increasing glucose transport and oxidation [53]. In leptin-
deficient ob/ob mice, disruption of Scd-1 gene improved cardiac
function by correcting systolic and diastolic dysfunction without
altering plasma triglyceride and NEFA concentrations [54].
To the best of our knowledge, this is the first report of lipid
redistribution with a rich dietary source of any n-3 fatty acid
associated with cardioprotection and hepatoprotection. In addition,
we report an intricate pattern of fatty acid distribution in various
tissues from rats fed a chia seed-supplemented diet that would
probably lead to an improved lipid homeostatic condition. The results
warrant further research on the use of chia seed as a complimentary
therapy for treating some signs of metabolic syndrome.Page 270Acknowledgments
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Metabolic syndromehas usually beendefined as the clustering of
interrelated risk factors for cardiovascular disease and type 2 diabe-
tes, including hyperglycemia, insulin resistance, hypertension,
hypertriglyceridemia, decreased HDL-cholesterol concentration,
and obesity [1]. While the prevalence of metabolic syndrome is
reaching pandemic proportions worldwide [2], studies have shown
that dietarymodifications including low carbohydrate diets, low fat
diets, diets rich in fibers, Mediterranean diets and diets rich in phy-
tochemicals such as flavonoids and phenolic acids reduce one or
more risk factors of metabolic syndrome [3–5]. Another interven-Fig. 1. The n3 and n6 PUFAmetabolic pathways. PGE, prostaglandins; PGI, prostacyclin
5-HPEPE, 5-hydroperoxyeicosapentaenoic acid.
Page 27tion to reduce risk in patients with metabolic syndrome may be an
increase in the relative abundance of omega-3 (n3) polyunsatu-
rated fatty acids (PUFA) in the diet [5].
The cardioprotective effects of n3 fatty acids, especially a-lin-
olenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexae-
noic acid (DHA), have been defined by epidemiological, human,
animal, and cell culture studies [5–9]. Although ALA, EPA, and
DHA are grouped together as the n3 PUFA, there is substantial
evidence suggesting that the individual fatty acids may have selec-
tive and potentially independent effects on cardiovascular health
[5–9]. In human diets, ALA is usually derived from botanical
sources with chia seed and flax seed being the richest sources. Fish,s; LT, leukotriene; TX, thromboxane; 5-HPETE, 5-hydroperoxyeicosatetraenoic acid;
3
374 H. Poudyal et al. / Progress in Lipid Research 50 (2011) 372–387fish oil supplements, and other sea foods primarily account for the
EPA and DHA in human diets [6]. Fish do not synthesize these long
chain n3 fatty acids but accumulate EPA and DHA by consuming
plankton and algae as a part of the marine food chain [10].
Although humans and animals can synthesize saturated (SFA)
and monounsaturated (MUFA) fatty acids de novo, they lack the en-
zymes necessary to insert a cis double bond at the n3 or the n6
position of a fatty acid to synthesize ALA or linoleic acid (LA),
respectively [11]. The two essential fatty acids, ALA (n3) and LA
(n6), share a common metabolic pathway (Fig. 1) [12]. Conse-
quently, these fatty acids compete for the D6-desaturase in metab-
olism [13]. ALA as an essential fatty acid can be converted into EPA
and DHA. LA is a direct precursor of the pro-inflammatory arachi-
donic acid (AA) [14]. The ratio of n6 to n3 fatty acids in early hu-
man diets was probably almost equal. However, due to changes in
dietary habits, especially with the increased use of vegetable oils
such as soybean, corn, sunflower, safflower oil, and cotton seed oils
rich in LA [15], this ratio in the typical Western diet is now at least
10:1 [16].
Reducing the ratio of n6:n3 PUFA in the diet may reduce the
risk factors of metabolic syndrome, although an optimal ratio is yet
to be recommended [10,13,17]. However, whether n6 fatty acids
mitigate or worsen cardiovascular diseases is controversial [15,18–
20]. Some studies attribute the cardioprotective properties of n6
fatty acids to LDL-cholesterol lowering properties [19], while oth-
ers contradict these conclusions [20] mostly due to the potent
pro-inflammatory effects of specific eicosanoids derived from AA
[15]. Irrespective of the amount of n6 fatty acids in the diet, there
is a growing consensus that incorporation of high levels of ALA and
the metabolically more active EPA and DHA in the diet is important
for reducing the risks of cardiovascular diseases [13,17].
This review will assess our current understanding of the effects
and potential mechanisms of actions of n3 fatty acids on multiple
risk factors of metabolic syndrome leading to cardiovascular dis-
ease, especially hypertension, dyslipidemia, insulin resistance, oxi-
dative stress, and inflammation.2. Metabolism of n3 and n6 series fatty acids
The n3 and n6 PUFAs contain the first cis double bond be-
tween the third and fourth carbon atoms (n3) or the sixth and
seventh carbon atoms (n6) from the methyl end of the fatty acids
[11]. LA (18:2n6) and ALA (18:3n3) are the parent fatty acids of
the n6 and n3 series [11]. Two series of PUFA are derived from
either LA or ALA by an alternating series of desaturation and elon-
gation reactions using the same enzyme complexes for both path-
ways [12] (Fig. 1). The first metabolite of the n6 pathway in
mammals is c-linolenic acid (GLA; 18:3n–6) produced by the en-
zyme D6 desaturase [11,12]. This enzyme acts on ALA to produce
stearidonic acid (STA; 18:4n3), the first metabolite of the n3
pathway [11]. The major end-products of n6 and n3 pathways
are AA (20:4n6) and DHA (22:6n3), respectively, produced by
the action of D5 desaturases [11,12] with EPA (20:5n3) as an
important intermediate of the n3 pathway.
The lipoxygenase (LOX) and cyclooxygenase (COX) mediated
metabolism of AA and EPA has been the target in the management
of most inflammatory diseases. The action of LOX and COX on AA
and EPA generates a family of derivatives collectively called eicosa-
noids which includes prostaglandins (PG), thromboxanes (TX), leu-
kotrienes (LT), epoxides, and oxylipins [21]. The pro-inflammatory
series-4 leukotrienes are derived from AA by LOX and series-2
prostaglandins by the action of COX [22]. LOX/COX action on EPA
generates the anti-inflammatory series-5 leukotrienes and series-
3 prostaglandins and thromboxanes [22] (Fig. 1). Dihomogamma
linolenic acid (DGLA), the direct precursor of AA in the n6 fattyPageacid pathway, competes with both AA and EPA for LOX and COX
[23,24]. LOX/COX action on DGLA yields series-1 prostaglandins
and thromboxanes that have potent anti-inflammatory, vasodilato-
ry, and anti-aggregatory effects [23,24]. Apart from eicosanoid pro-
duction, metabolism of EPA and DHA also generates resolution
phase interaction products such as E series and D series resolvins,
respectively [25–27]. Additionally, DHA metabolism yields protec-
tins such as docosatrienes and maresins, a novel class of macro-
phage mediators [27,28]. All EPA and DHA-derived resolvins,
protectins, and maresins induce pro-resolving actions during an
inflammatory response [25–28]. AA and DHA are the major acyl
components of structural lipids found in most tissue types [29].
Although the same set of enzymes synthesize AA and DHA from
their parent fatty acids, it is now well established that increased
dietary ALA inhibits the synthesis of AA from LA [30]. In rats fed
equivalent amounts of LA and ALA, there was a 20–40% reduction
in LA-derived PUFA incorporation into liver phosphoglycerides,
and a higher dietary ALA:LA ratio reduced the LA-derived PUFA
incorporation even further [30,31]. The increased dietary intake
of ALA decreased the metabolites of the n6 pathway, especially
AA, the precursor of the 2-series prostaglandins. The metabolites
of n3 series increased, attributed to effective competition of
ALA over LA for the D6 desaturase [32]. Furthermore, rats receiving
more dietary ALA showed reduced PG synthesis from AA than
those receiving LA alone [33,34].
However, chronic dietary intervention as well as stable-isotope
studies using ALA show that humans as well as rodents amongst
othermammals do not efficiently convertmediumchainALA to long
chain EPA or DHA [35–37]. In neonatal rats as well as guinea pigs,
DHA concentrations in the brain, retina, liver, and heart remained
comparable in animals fed either an ALA-rich diet or a high LA diet
[36,37]. In guinea pigs fed an ALA-rich diet, increases in ALA and
EPA but not DHA were observed in heart, liver, and adipose tissue
[38]. In humans, ALA is converted to EPA in low amounts (8%)
and in even lower amounts to DHA (<0.1%) [35,39,40]. While most
radioactive tracer studies supporting this conclusion have used
5 min infusion and reported little or no newly synthesized EPA
and/or DHA [41–43], long chainmetabolites of ALAmay only appear
in the circulationafter 60 minof infusion [44]. Also, studieswithwo-
menand female rats show that females have higher conversion rates
than males, an effect mostly attributed to estrogen-mediated up-
regulation ofD5 andD6 desaturases [45]. Nevertheless, in obese hu-
mans, ALA fromflaxseed helpedmaintain plasma EPA andDHA con-
centrationswithout dietary fish or sea food andwas associatedwith
preventing increases in weight gain, body mass index, and hip cir-
cumference [46]. Therefore, it is plausible that the physiological re-
sponseswithALAmaybe independent of its conversion to the longer
chain n3 PUFA, particularly DHA. This would imply that themech-
anism of action of ALA would also differ from the longer chain com-
pounds. In subsequent sections, the differences in responses as well
as the likely mechanisms of action of ALA (18C, medium chain) and
the long chain n3 PUFAs (>18C) will be evaluated.3. n3 Fatty acids on risk factors of metabolic syndrome
3.1. Adiposity and dyslipidemia
The n3 fatty acids reduce the risk for cardiovascular disease
partly by improving the blood lipid profile. However, both re-
sponses and mechanism of actions of the medium chain and long
chain n3 fatty acids appear to be independent. ALA exerts most
of its effects by modulating lipoproteins, while EPA and DHA
may reduce triacylglycerol (TAG) synthesis and adiposity.
Daily supplementation with 20–50 g ALA-rich flaxseed reduced
total cholesterol and LDL-cholesterol concentrations in normolipi- 274
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Ground flaxseed (38–40 g/day) also reduced lipoprotein-A and
apolipoproteins A-1 and B in postmenopausal women [52–54].
However, in overweight adults, ingestion of ALA-rich chia seed
(50 g/day) for 12 weeks did not affect measures of body composi-
tion, lipoproteins, or plasma concentrations of EPA and DHA but
increased plasma concentrations of ALA [55]. Medium flaxseed
doses (12.5 g/day) prevented the increase in plasma TAG concentra-
tions in hypercholesterolemic rabbits while low doses (0.04–0.2 g/
day) prevented the increase in total cholesterol concentrations in
LDL receptor-deficient mice [56,57]. In 1% cholesterol-fed rats,
dietary supplementation with ALA-rich flax and pumpkin seeds
(33% wt/wt) decreased total cholesterol, TAG in plasma and liver,
plasma LDL-cholesterol, atherogenic index, and LDL/HDL ratio
[58]. In addition, the ALA-rich diet increased PUFA (ALA and LA)
andMUFA (oleic and eicosaenoic acids) but decreased SFA (palmitic
and stearic acids) in total plasma and hepatic fatty acid contentwith
reduced lipid storage in hepatocytes [58]. However, n3 fatty
acid-deprived rats, when given access to 5% flaxseed oil-enriched
diet, displayed increased bodyweight and adipose tissue mass [59].
In patients with type 2 diabetes and mixed hyperlipidemia who
were already receiving fluvastatin (80 mg/day), n3 fatty acids
(EPA + DHA 4 g/day) reduced TAG, VLDL, and TAG/HDL-cholesterol
ratio and increased HDL-cholesterol in blood [60]. In healthy
males, fish oil and DHA-oil supplementation (4 g/day) for 15 weeks
lowered fasting plasma TAG concentrations and postprandial total
chylomicron concentration while increasing the HDL2/HDL3-cho-
lesterol ratio [61]. Increased HDL3 was associated with increased
visceral fat deposition and impaired VLDL function [62]. The Look
AHEAD (Action for Health in Diabetes) study examined the effects
of marine n3 fatty acid intake in individuals with diabetes, its
association with adiposity, lipid profile and glucose homeostasis,
and its changes with behavioral lifestyle intervention for weight
loss in 2397 individuals [63]. Marine n3 fatty acid intake was in-
versely associated with blood TAG concentrations and weakly
associated with HDL-cholesterol concentrations but there was no
association with non-HDL-cholesterol or adiposity [63]. In women
with polycystic ovary syndrome, consumption of n3 fatty acids
(EPA + DHA 4 g/day) over 8 weeks reduced hepatic fat content
quantified using proton magnetic resonance spectroscopy [64]. In
addition, reductions in blood TAG concentrations and systolic
and diastolic blood pressure were observed [64]. In obese individ-
uals, body mass index, waist circumference, and hip circumference
were inversely correlated with EPA and DHA intakes [65]. In pa-
tients with dyslipidemia, consumption of EPA + DHA (3 g/day) in-
creased HDL-cholesterol and decreased TAG in blood after 3 and
6 months [66]. In another intervention study in patients with met-
abolic syndrome, purified fish oil n3 fatty acids supplementation
for 6 months reduced body weight and serum concentrations of
LDL-cholesterol, total cholesterol and TAG at a relatively low dose
(180 mg EPA + 120 mg DHA capsule/day) [67]. It has been sug-
gested that the TAG-lowering effects of DHA and EPA may be
caused by decreased hepatic TAG secretion and enhanced clear-
ance of TAG from the plasma [61,68].
Ethyl esters of DHA from microalgae (0.6–5.0 g/kg/day) caused
dose-dependent decreases in TAG and total cholesterol concentra-
tions in rats fed a high-fructose diet [69]. In Sprague–Dawley rats,
feeding of fish oil at 10% of total dietary fat for 3 weeks suppressed
postprandial hypertriglyceridemia, increased lipoprotein lipase
activity in heart and liver, and reduced hepatic triacylglycerol
lipase activity [68]. Although dietary fish oil did not alter the rate
of lymphatic absorption of TAG or influence the half-lives of chylo-
micron or its remnants, secretion of TAG from the liver of rats
injected with Triton WR-1339 (an inhibitor of lipoprotein lipase)
was lower in the rats fed with DHA [68]. In rats fed either 3%
DHA or EPA-supplemented diets, total cholesterol concentrationsPage 27were lower in the rats fed with DHA-supplemented diet, whereas
serum TAG concentrations were lower only in the rats fed with
EPA-supplemented diet [70]. In psychologically-stressed female
BALB/c mice, serum TAG concentrations were reduced by dietary
fish oil (17.6 g of DHA and 7.7 g of EPA per 100 g of fatty acid)
[71]. In Zucker rats, both dietary fish and krill oil (0.5% EPA + DHA
in the diet) reduced hepatic TAG concentration, but heart TAG con-
centrations were lower only in krill oil-fed rats [72].
In peroxisome proliferator-activated receptors-a (PPAR-a) null
mice, fish oil diet (8% of the total dietary fat) increased hepatic
diacylglycerol, TAG, and acyl-CoA [73]. However, in apolipoprotein
E (Apo-E)-knockout mice supplemented with 1% dietary fish oil,
atherosclerotic plaque formation was not prevented even though
concentrations of DHA and EPA were increased in plasma in differ-
ent forms (free fatty acids, TAG, phospholipids, and cholesteryl es-
ter fraction) [74]. Apo-E is required for clearance of TAG-rich
particles and it was therefore suggested that TAG-lowering effects
of long chain n3 fatty acids may be due to their Apo-E modulatory
properties [74]. Apo-E-knockout mice fed on a fish oil diet showed
40% reduction in thrombin generation in addition to up-regulation
of genes contributing to lipid catabolism and down-regulation of
genes for c-glutamyl carboxylase and transcription factors impli-
cated in lipid synthesis [75].
Fish oil, when used at a dose providing 15% of total energy,
lowered subcutaneous (inguinal) and visceral (retroperitoneal
and epididymal) adipose tissue weights in high fat (33% lard)-
fed Wistar rats [76]. Similarly, fish oil supplementation (providing
40% of energy) reduced epididymal [77,78] and retroperitoneal
[78] fat in high fat-fed rats. Reduction in fat accumulation with
n3 rich diet in rats was associated with reduction in adipocyte
hypertrophy [78,79]. In rats fed a high fat cafeteria style diet
(30% palmitic and 40% oleic acid) or 20% safflower oil, EPA (1 g/
kg/day) [80] and EPA + DHA mixture (5% dietary supplementa-
tion) [81] increased leptin gene expression and plasma leptin
concentrations with reduced retroperitoneal fat and food intake.
However, in high fat-fed C57BL/6J mice (20% dietary flax or corn
oil), dietary EPA/DHA (1–12% wt/wt of dietary lipids) reduced
mostly epididymal fat by limiting both hypertrophy and hyper-
plasia of adipocytes with lower EPA/DHA ratio favouring this ef-
fect [82].
The prevention of hypertrophy or hyperplasia of adipocytes
would ideally have to be followed by increased metabolism of
the dietary fat to prevent the accumulation of lipids in the liver
or circulation as there is decreased storage of lipids in the adipose
tissue. This is usually achieved by increased fatty acid oxidation in
liver, intestine, cardiac muscle, and skeletal muscle. Mitochondrial
carnitine palmitoyl transferase 1 (CPT1) facilitates fatty acid trans-
port in mitochondria for oxidation in these tissues. The mitochon-
drial expression of CPT1 is in turn regulated by PPARs [83]. In
C57BL/6J mice, feeding of ALA-rich semisynthetic high fat diet
(20% flax seed oil) with EPA/DHA (6% EPA, 51% DHA) concentrate
was associated with a three-fold stimulation of the expression of
genes encoding regulatory factors for mitochondrial biogenesis
and oxidative metabolism, mainly PPAR-c coactivator-1a and
nuclear respiratory factor-1 [84]. These effects were associated
with decreased lipogenesis in epididymal but not subcutaneous
fat [84]. Furthermore, rats fed with a non-purified high fat diet
supplemented with 15%, 20% or 44% fish oil had increased heart,
skeletal muscle, and adipocyte CPT1 specific activity and tissue
capacity, and a lower sensitivity of CPT1 to malonyl-CoA inhibition
[84,85]. Malonyl-CoA-mediated inhibition of CPT1 is reduced by
malonyl-CoA decarboxylase, which is regulated by AMP kinase
[85]. In primary cultured rat adipocytes, the stimulatory effect of
EPA on mRNA expression and secretion of visfatin, an adipokine
highly expressed in visceral adipose tissue, was dependent on
activation of AMP kinase by EPA [86].5
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isomal acyl-CoA oxidase, a relatively inefficient pathway for fat
oxidation, yielding over 30% more heat and therefore less ATP than
mitochondrial b-oxidation [87,88]. Dietary fish oil (40% energy) in
Fisher 344 rats induced peroxisomal acyl-CoA oxidase gene expres-
sion 2–3 fold in liver, skeletal muscle, and heart [77].
To reduce body fat storage, diet-derived or stored TAGs need to
be hydrolyzed into fatty acids for both CPT1 and peroxisomal acyl-
CoA oxidase to utilize. Lipoprotein lipase and adipose triacylglyc-
erol lipase play central roles in catalysing the hydrolysis of TAG
into fatty acids and monoacylglycerol in lipoproteins, skeletal mus-
cle and adipose tissue, respectively [89,90]. The evidence pre-
sented in this review strongly suggests that n3 fatty acids up-
regulate both these enzymes to exert their hypotriacylglycerolemic
and lipolytic effects in the adipocytes. The expression of both lipo-
protein lipase and adipose triacylglycerol lipase seems to be regu-
lated by PPAR-a and PPAR-c [89,91,92]. There is enough evidence
to suggest that n3 fatty acids and their metabolites are highly po-
tent ligands for PPAR-a and PPAR-c [73,93–97]. Even more intrigu-
ing is the existence of functional PPAR-a response elements in
genes encoding peroxisomal acyl-CoA oxidase [98], CPT [99],
HMG-CoA synthase [100], and mitochondrial uncoupling proteins
[101]. Furthermore, n3 fatty acids suppressed the hepatic expres-
sion of sterol regulatory element-binding protein-1 (SREBP-1), a
transcription factor responsible for activating genes involved in
fatty acid synthesis, in a PPAR-a dependent process [94]. Therefore,
PPARs could be one of the early targets of n3 fatty acids to main-
tain lipid homeostasis in the body by mechanisms outlined in
Fig. 2.Fig. 2. Control of lipid and glucose metabolism at an expressional level by the n3
fatty acids. TNF, tumor necrosis factor; TNFR, tumor necrosis factor receptor; PI3K,
phosphoinositide 3-kinase; AKT/PKB, thymoma viral proto-oncogene designated as
protein kinase B; PPAR, peroxisome proliferator-activated receptors; RXR, retinoid
X receptor; RA, retinoic acid; GPCR, G-protein coupled receptor; AC, adenylyl
cyclases; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A.
PageClearly, enough data has been accumulated over the last decade
to understand the mechanisms of action of the long chain n3 fatty
acids in reducing adiposity and dyslipidemia. However, the mech-
anism of action of ALA is not completely understood. Due to the
differences in pharmacological response to ALA and EPA/DHA, it
is plausible that ALA may exert its effects through alternate mech-
anisms and this warrants further investigation.
3.2. Glucose homeostasis and insulin resistance
Data with n3 fatty acids for glucose homeostasis and insulin
resistance from humans and animals studied are inconsistent. Hu-
man studies suggest that none of the nutritionally important n3
fatty acids improve insulin sensitivity. This is probably due to the
inverse association of insulin resistance and D5 desaturase activity
that could in turn reduce bioavailability of n3 PUFA [102].
In obese, hypertensive patients, dietary fish or fish oil supple-
mentation had no independent effects on insulin or glucose
[103,104]. In mildly obese subjects, 15 mL/day of fish oil did not al-
ter the metabolic clearance rates of glucose at plasma insulin con-
centrations of approximately 100 and 1400 lU/mL during a
hyperinsulinemic, isoglycemic clamp [105]. Also, no changes were
reported in insulin binding to erythrocytes [105]. In healthy elderly
patients, maintaining dietary SFA and MUFA with n6 and n3
PUFA ratio adjusted by replacing n6 PUFA with ALA, EPA, DHA,
or a mixture of EPA and DHA produced no differences in fasting
blood glucose, fasting insulin, or HOMA-IR [106]. In healthy indi-
viduals consuming fish oil (n3 fatty acids; 3.6 g/day), minimal ef-
fects on insulin sensitivity, first phase insulin response, and
glucose tolerance were reported [107]. In non-diabetic elderly sub-
jects, fish oil capsule supplementation for 6 months (1 g/day,
180 mg EPA and 120 mg DHA) had no effect on insulin sensitivity
[108]. In type 2 diabetic adults, neither milled flaxseed nor flaxseed
oil (13 g/day for 12 weeks) altered glycemic control [109].
Although the Inuit Health in Transition Study reported an in-
verse association between erythrocyte membrane EPA and DHA
concentrations and the n3/n6 ratio with insulin resistance, the
study showed a positive association between ALA concentrations
and insulin resistance [110]. However, in young iron-deficient wo-
men, an oily fish diet decreased plasma insulin concentrations with
improved insulin sensitivity as compared to a red meat diet [111].
In patients with myocardial infarction or unstable ischemic at-
tacks, multiple bioactive lipid components including ceramides,
lysophosphatidylcholines and diacylglycerols, which are potential
mediators of lipid-induced insulin resistance and inflammation,
were decreased in groups fed with fatty fish diet, whereas in the
groups fed with lean fish, cholesterol esters and specific long-chain
TAG were increased [112].
In contrast, data from animal studies show that the n3 fatty
acids strongly reduce insulin resistance and improve glucose toler-
ance, especially in murine models of metabolic syndrome and
type-2 diabetes. ALA deprivation in rats increased adipose tissue
mass, plasma glucose and insulin concentrations, and insulin resis-
tance index [59]. Rats deprived of n3 fatty acids given access to
flaxseed oil-enriched diet displayed increased body weight and
adipose tissue mass, whilst the plasma glucose concentrations
and insulin resistance index decreased [59]. In rats fed high fat
diets (59% safflower oil), replacement of only 6% of LA from saf-
flower oil with long chain n3 PUFAs from fish oil prevented the
development of insulin resistance, especially in liver and skeletal
muscle [113]. n3 fatty acid rich fish oil-fed rats (fish oil providing
59% of total energy) showed increased rate of glycolysis and in-
creased glycogenesis compared to an isocaloric n6 fatty acid-rich
sunflower oil-fed rats [114]. These effects were accompanied by
decreased intramuscular TAG content and increased percent pyru-
vate dehydrogenase versus tricarboxylic acid cycle flux [114]. In 276
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mented with DHA/EPA (replacing 15% dietary lipids), rosiglitazone
(10 mg/kg diet) or a combination of DHA/EPA and rosiglitazone ex-
erted additive effects in prevention of obesity, adipocyte hypertro-
phy, low-grade adipose tissue inflammation, dyslipidemia, and
insulin resistance, while inducing adiponectin production, sup-
pressing hepatic lipogenesis, decreasing muscle ceramide concen-
trations, and improving glucose tolerance [115].
In ob/ob mice, dietary intake of fish oil (8% wt/wt) had insulin-
sensitizing actions in adipose tissue and liver [116]. Additionally,
PPAR-c, glucose transporters (GLUT) 2 and 4, and insulin receptor
substrate-1 (IRS-1)/insulin receptor substrate-2 (IRS-2) genes were
up-regulated with increased adiponectin secretion and AMP kinase
phosphorylation in n3 fatty acid (EPA/DHA, 6% total dietary
lipid)-supplemented mice [116]. In this study, lipidomic analysis
showed thatn3PUFA inhibited the formationofn6PUFA-derived
eicosanoids, while triggering the formation of n3 PUFA-derived
resolvins and protectins, which mimicked the insulin-sensitizing
effects of n3 PUFA [116]. In rats fed 12% canola oil-based diet, sup-
plemented with either ALA, EPA, DHA, or 1:1 EPA/DHA mixture
(0.5 g/kg), reductions in fasting blood glucose concentration, fasting
plasma insulin concentration, andHOMA-IRwere observedwith the
EPA/DHAmixture being most effective and ALA having the least ef-
fect [117]. In high sucrose diet-fed rats, 7% fish oil supplementation
reversed the insulin resistance and increased plasma leptin and
adiponectin concentrations but not their mRNA expression in the
adipose tissue [118].
PPAR-a seems to play a critical role in modulating the effects of
at least the long chain n3 PUFAs. Fish oil supplementation (8% of
the total dietary fat) in wild-type mice restored hepatic insulin
sensitivity, whereas fish oil supplementation in PPAR-a null mice
failed to restore hepatic insulin sensitivity [73], suggesting that
EPA/DHA in fish oil may improve insulin sensitivity in a PPAR-a-
dependent manner. In high fat-fed rats (27% safflower oil), fish
oil feeding (8%, 13.5%, and 27% menhaden fish oil) almost exclu-
sively elevated plasma adiponectin concentrations and expression
in epididymal adipose tissue [119]. The increase of plasma adipo-
nectin by fish oil was completely blocked by administration of
the PPAR-c inhibitor, bisphenol-A-diglycidyl ether, in wild-type
mice but not in PPAR-a null mice [119]. In mice that were given
a single oral dose (400 ll) of synthetic TAG, hepatic expression of
genes encoding enzymes of the lipid and carbohydrate metabolism
pathways was affected most by DHA (519 out of 34000 genes stud-
ied) followed by ALA (400), LA (287), EPA (280), and oleic acid
(114) [120]. The majority of hepatic genes regulated by dietary
unsaturated fatty acids in wild-type mice did not show regulation
in PPAR-a-null mice. These results suggest that the effects of die-
tary unsaturated fatty acids on hepatic gene expression are almost
exclusively mediated through PPAR-a [120]. Increased IRS-1 phos-
phorylation is observed in insulin resistance and obesity with in-
creased c-Jun N-terminal kinase (JNK) activity [121]. In 3xTg-AD
transgenic mice, feeding of SFA (16% coconut oil) and n6 PUFA
(5% safflower oil)-rich diet increased activity of JNK, phosphory-
lated IRS-1, and tau protein [122]. Treatment with 2.4% fish oil
for 4 months in these mice reduced phosphorylated JNK, IRS-1
and tau, and prevented the degradation of total IRS-1 [122]. DHA
also inhibited JNK and the phosphorylation of IRS-1 and tau in cul-
tured hippocampal neurons [122]. PPAR-a suppression induced by
a high saturated fat-rich diet induced JNK-dependent IRS-1Ser307
phosphorylation and this effect was ameliorated by 3.3% dietary
fish oil (EPA, 146 mg/g diet and DHA, 353 mg/g diet) [123].
While PPAR-a and JNK are currently the most promising targets
for the n3 PUFAs to decrease blood glucose and insulin resistance,
data from last decade suggests that both PPAR-a and JNK are differ-
entially regulated in rodent andhumancell lines [124–126]. Thepri-
mary LOXproduct of LA, 13-hydroperoxy-9,11-octadecadienoic acidPage 27(13-HPODE), activated PPAR-a in rat FaO hepatoma cell line but not
in humanHepG2hepatoma cells [124]. PPAR-a agonists such as fen-
ofibric acid and phenylacetic acid up-regulated PPAR-a and associ-
ated genes in rat but not in human hepatocytes [125]. Humans, in
contrast to rodents, lack functional peroxisome proliferator re-
sponse elements in PPAR-a regulated genes encoding enzymes such
as acyl CoA oxidase [127,128]. This would invariably shift the lipid
homeostasis towards b-oxidation and less towards lipogenesis in
rodents but less so in humans thereby reducing lipids and
lipid-induced insulin resistance in rats. These species differences
demonstrate the inconsistencies in the insulin signaling and glucose
handling in response to n3 PUFA in rats and humans. These factors
have to be carefully consideredbefore extrapolating the results from
rodent studies to human trials.3.3. Hypertension
Essential hypertension, very common in metabolic syndrome,
considerably increases the risk of cardiovascular diseases, even in
the absence of overt diabetes [129]. The beneficial effects of ALA,
EPA, and DHA in reducing hypertension and related cardiovascular
remodeling are well-documented. Three meta-analyses of placebo-
controlled trials have concluded that the n3 PUFAs (3–15 g/day)
in fish oil, mainly EPA and DHA, cause small but clinically relevant
reductions in blood pressure (2–5 mmHg) in untreated hyperten-
sive individuals [130–132]. An international cross-sectional epide-
miologic study of 4680 men and women aged 40–59 from 17
population-based samples in China, Japan, United Kingdom, and
the U.S.A. reported that n3 PUFA intake was inversely related to
blood pressure, in both hypertensive as well as normotensive pa-
tients [133]. EPA/DHA-rich n3 capsules (4 g/day) lowered blood
pressure and heart rate in a double-blind, placebo-controlled inter-
vention in non-diabetic patients with chronic kidney disease stages
3–4 [134]. Purified fish oil n3 fatty acids (180 mg EPA + 120 mg
DHA capsule/day) also reduced systolic blood pressure in patients
with metabolic syndrome [67]. Reductions in both systolic and dia-
stolic blood pressure have been reported in healthy postmeno-
pausal women, obese subjects as well as dyslipidemic patients
after consuming 40 g/day of ALA-rich ground flaxseed or 15–
20 g/day of flaxseed oil [135–137]. Similar effects with fish oil have
also been reported, where in a double-blind, placebo-controlled,
cross-over trial, supplementation with fish oil (1 g capsule/day;
38% DHA, 47% EPA) reduced seated blood pressure by 3.1 ± 1.0/
1.8 ± 0.6 mm Hg [138].
A recent study has highlighted the relationship between die-
tary n3 PUFA deficiency (particularly ALA) and hypertension as
early as 24 weeks of age in female rats [139]. In conjunction
with this, ALA and fish oil as a source of n3 PUFAs at a large
dose range of 0.44–6 g modulated vascular responses induced
by angiotensin II infusion [140–142]. Furthermore, prenatal defi-
ciency of dietary n3 PUFAs induced hypertension in Sprague–
Dawley rats [143–145]. This was retained in later life even if
the concentrations were restored after supplementation of die-
tary canola oil, a rich source of ALA, as the n3 PUFA source
[143].
The antagonistic effects of n3 PUFA on angiotensin II receptors
may be responsible for modulation of hypertension (Fig. 3)
[146,147]. n3 PUFA play an important role in neural mem-
brane-based receptor systems, such as photo-transduction in the
retina [148] which shares common morphology with angiotensin
II receptors, both being G protein–coupled receptors belonging to
the 7-transmembrane domain superfamily. Increases in COX/LOX
metabolites of EPA such as the vasodilative eicosanoids including
the thromboxanes could also act as physiological antagonists,
counteracting vasoconstriction caused by angiotensin II [149].7
Fig. 3. Possible inhibitory effects of n3 PUFA (shown by dotted arrows) on pathways leading to hypertension. Ang II, Angiotensin II; ET-1, Endothelin-1; TX, thromboxane;
AT II-1, Angiotensin II receptor-1; TXR, thromboxane receptor; PLC, phospholipase C; PIP, Phosphatidylinositol phosphate; DAG, diacylglycerol; IP3, inositol triphosphate;
IP3R, inositol triphosphate receptor; PKC, protein kinase C; NHE, Na+-H+ exchanger; NCX, Na+-Ca2+ exchanger.
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of n3 fatty acids on the renin-angiotensin system, specifically
on renin secretion and angiotensin converting enzyme (ACE) activ-
ity. In isolated perfused rat kidneys, flaxseed oil feeding as 20% of
total energy intake lowered renal venous renin secretion rates
[145]. Further, reduced ACE activity as well as expression in the
aorta [150] and reduction in blood pressure [151] have been re-
ported in 6 week old Spontaneously Hypertensive Rats (SHR) fed
with a 10% ALA-enriched diet. These observations are supported
by in vitro assays where EPA most effectively inhibited purified
ACE activity (EPA > ALA > DHA > GLA > LA > AA) and DHA was most
effective in inhibiting cultured leukocyte ACE activity (DHA > E-
PA > ALA = AA > LA > GLA) [152].
Increased blood pressure may also result from damaged endo-
thelium exhibiting dysfunctional relaxation following mechanical
or biochemical insults. Incorporation of EPA and DHA into mem-
brane phospholipids increased systemic arterial compliance
[153] as the endothelium of arteries acts as a modulator of vas-
cular tone. Dietary supplementation (10–20% of the diet) of ALA-
rich flaxseed protected against the loss of endothelial-dependent
vascular relaxation in SHR and cholesterol-fed rabbits [56,154].
Both DHA and EPA relaxed aortic rings isolated from SHR and
normotensive Wistar–Kyoto rats in a concentration-dependent
and intact endothelium-independent manner [155]. EPA and
DHA possibly improved endothelial function by enhancing the
release of NO [156]. This effect seems to be due to the lipid
and structural modification of caveolae, plasma membrane mi-
cro-domains that act as regulators of endothelial NO synthase
(eNOS) activity [157].
Early studies with long chain n3 PUFA defined their involve-
ment in the calcium signaling process in contraction of the aorta.
In the presence of calcium-free medium, the n3 fatty acids abol-
ished sustained norepinephrine contractions in isolated rat aortic
rings but did not reduce the phasic contractions when incubated
prior to norepinephrine contraction [158]. This effect may be re-
lated to intracellular calcium mechanisms, since both EPA andPageDHA reversed norepinephrine-induced sustained contractions in
the absence of extracellular calcium [158]. The same group also
demonstrated that mechanisms of vascular relaxation, such as cyc-
lic nucleotide elevation and calcium antagonism of potential-oper-
ated channels, are different from those induced by the n3 PUFAs
[159]. DHA and EPA also inhibited a1-adrenoceptor mediated vas-
cular contractions induced by phenylephrine which were not al-
tered by the non-selective COX inhibitor indomethacin, the
potent antioxidant nordihydroguaiaretic acid or by removal of
the endothelium [160]. These results indicate the inhibition of
vasoconstriction by EPA and DHA is independent of vasodilators
such as prostaglandins, nitric oxide or other endothelium-derived
vasodilators. It is therefore plausible that n3 PUFAs prevent the
increase in blood pressure by decreasing the production of
vasoconstrictors.
Unlike SFA, n3 PUFAs reduced the formation of thromboxane
A2, a potent vasoconstrictor, and enhanced the production of
PGI3, a potent vasodilator [161,162]. In addition to this, EPA low-
ered the tissue concentrations of AA and enhanced those of GLA,
the precursor of the endogenous vasodilator, PGE1 [152]. Collec-
tively, these studies disprove the role of endothelium-derived
relaxing factors and cyclic nucleotide second messengers such as
cAMP and cGMP in the vasoactive properties of EPA and DHA.
The vasorelaxant properties of EPA and DHA may be mediated by
a specific inhibition downstream of a-adrenoceptor activation
(Fig. 3) [163]. KCl-induced contraction results from voltage-gated
channels and norepinephrine-induced contractions through li-
gand-gated calcium channels. Since both DHA and EPA evoked
greater relaxant responses in norepinephrine-contracted vessels
than in KCl-contracted vessels [158], it is most likely that the
vasorelaxant properties of at least the long chain n3 PUFAs may
be intracellularly mediated.
Inhibiting Na+/K+–ATPase, the sodium pump, leads to an in-
crease in cytosolic Na+ concentrations. Cellular Na+ accumulation
raises the cytosolic Ca2+ concentration through the involvement
of the Na+/Ca2+ exchanger and thereby increases contraction in 278
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may lead to hypertension [164]. Rats fed a 17% menhaden oil-sup-
plemented diet that contained DHA and EPA exhibited a decrease
in cardiac sarcoplasmic reticulum Ca2+-ATPase activity [165]. An
indirect inhibition of Na+/Ca2+ exchange by DHA and EPA [166]
would contribute as one of the mechanisms to lower blood pres-
sure (Fig. 3).
A growing body of evidence highlights the role of connexin 43
(Cx43), one of the major gap junction proteins in heart as well as
aorta, in regulating blood pressure. Cx43 activity is down-regu-
lated in protein kinase C (PKC)-independent hypertension models
such as SHR [167,168] and nitro-L-arginine methyl ester-induced
hypertension [169] and up-regulated in PKC-dependent models
of hypertension mediated by angiotensin II [170–173], endothe-
lin-1 [173,174], and a-adrenoceptor activation [175,176] thereby
suggesting the vital role of PKC in connexin activation. In SHR,
EPA (50 mg/day) and DHA treatment (30 mg/day EPA + DHA mix-
ture), besides reducing the elevated blood pressure, increased
Cx43 immunolabeling in endothelium and media with elevated
phosphorylation and reduced stimulated aortic NOS activity
[167,177]. The increase in functional Cx43 in these rats may there-
fore be due to increased PKC activity. Inhibiting JNK with SP600125
[anthra(1,9-cd)pyrazol-6(2H)-one 1,9-pyrazoloanthrone] or siRNA
up-regulated Cx43 protein concentrations in the presence of phen-
ylephrine [178]. Also, inhibition of reverse mode Na+/Ca2+ ex-
change with KB-R7943 (2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]
isothiourea mesylate) inhibited JNK activation and up-regulated
Cx43 protein expression [178].
Furthermore, emerging evidence also suggests that PKC and its
various isoforms directly regulate PPAR-a as well as PPAR-c [179–
181]. In COS-1 cells transfected with murine PPAR-a, inhibitors of
PKC (Go6976 and HBDDE – a-isoform inhibitors; rottlerin – d iso-
form inhibitor and staurosporine –non-specific inhibitor) decreased
Wy-14,643-induced PPAR-a activity [180]. Additionally, mutating
any of the four consensus PKC phosphorylation sites in PPAR-a
(S110, T129, S142, and S179) either prevented heterodimerization
of PPAR-awith retinoidX receptor-a, lowered the level of phosphor-
ylation of PPAR-a, or prevented PPAR-a from binding to DNA [180].
Furthermore, PPAR-c agonists such as rosiglitazone did not induce
edema or weight gain in PKC-ß knockout mice [179].
Since PKC is vital for functional PPARs and strong evidence ex-
ists for the action of n3 PUFAs through these receptors for lipid as
well as glucose homeostasis, it is unlikely that the blood pressure
lowering effects of n3 fatty acids are due to inhibition of PKC sig-
naling pathway. The blood pressure lowering effects of n3 PUFAs
may to a large extent be attributed to LOX/COX-mediated vasodi-
lative eicosanoids synthesized from dietary or ALA-derived EPA.
Additionally, EPA and DHA could have inhibitory effects on intra-
cellular pathways involved in hypertension.
3.4. Oxidative stress
The potential role of oxidative stress as an early event in the
pathology of metabolic syndrome and cardiovascular diseases
has been widely noted [182]. Oxidative stress may play an impor-
tant role in the etiology of various risk factors of metabolic syn-
drome-related manifestations, including atherosclerosis,
hypertension, type 2 diabetes, adiposity, and insulin resistance
[182]. The role of n3 PUFAs in reducing oxidative damage and
restoring free radical homeostasis is not completely understood.
Although some studies suggest that ALA, EPA, and DHAmay reduce
oxidative damage in humans and animals [183–185], the data re-
main inconclusive.
Currently available data suggests that at least the long chain
n3 PUFAs have no role in reducing the biomarkers of oxidative
damage. In judo athletes, 6 weeks of EPA + DHA supplementationPage 27(600 mg EPA + 400 mg DHA capsule/day) increased exercise-in-
duced oxidative stress defined as increased malondialdehyde, con-
jugated dienes, and NO concentrations [186]. In exercise-trained
men, daily supplementation with 2224 mg EPA + 2208 mg DHA
for six months had no effect on antioxidant capacity, oxidized
LDL, malondialdehyde, xanthine oxidase activity, and nitrate/ni-
trite ratio although blood hydrogen peroxide concentrations were
reduced in response to exercise [187]. In overweight or obese
men consuming a non-purified high-fat, high-fructose diet, acute
fish oil (1 g capsule; 400 mg EPA + 200 mg DHA) supplementation
had no effect on markers of oxidative stress (lipid hydroperoxides,
oxidized-LDL, total antioxidant status) [188]. F2-isoprostanes, the
products of free radical-induced peroxidation of membrane-bound
arachidonic acid, are considered a reliable biomarker of oxidative
stress [189]. In the LIPGENE study in subjects with the metabolic
syndrome, 1.24 g/day of DHA supplementation for 12 weeks did
not alter urinary concentrations of either 8-iso-PGF2a or 15-
keto-dihydro-PGF2a [190]. In patients with normal or slightly ele-
vated total blood cholesterol and TAG concentrations or both, sup-
plementation with krill oil (3.0 g/day, EPA + DHA = 543 mg) or fish
oil (1.8 g/day, EPA + DHA = 864 mg) did not change urinary 8-iso-
PGF2a concentrations after 7 weeks [189].
Although no evidence exists to show definitively that either of
the long chain n3 PUFAs prevents oxidative damage, there is
some evidence to suggest that EPA and DHA at least improve
anti-oxidant enzyme status in humans. In patients on hemodialy-
sis, EPA + DHA (3 g/day) capsule supplementation for 2 months
increased circulating glutathione peroxidase and superoxide dis-
mutase activities in addition to increased ferric reducing antioxi-
dant power and reduced serum malondialdehyde concentrations
[191]. In elderly patients chronically exposed to particulate matter,
fish oil (2 g/day capsule; 52.4% DHA, 25.0% EPA, and 5.8% DPA)
increased superoxide dismutase activity as well as glutathione
plasma concentrations [192].
Few human studies have addressed the role of ALA in oxidative
stress and therefore this role remains poorly understood. In pa-
tients with hypercholesterolemia, 2 months supplementation with
wheat germ oil (8.6% ALA) down-regulated CD40L via an oxidative
stress-mediated mechanism with in vitro experiments showing de-
creased platelet reactive oxygen species production, reduced acti-
vation of NADPH oxidase and phosphorylation of p38 MAP
kinase, a protein implicated in the activation of NADPH oxidase
[193]. However, this study did not account for the high n6 PUFA
or MUFA contents of wheat germ oil.
Down-regulation of the phagocytic and tissue-specific NADPH
oxidase subunits (NOX-4, gp91(phox), p47(phox), p22(phox)) has also
been reported with EPA + DHA administration (0.3 g/kg/day) by
gastric gavage for 12 weeks in Sprague–Dawley rats subjected to
5/6 nephrectomy, a model of chronic renal failure [184]. Parallel
observations in humans with long chain n3 PUFAs are yet to be
made. Male Wistar rats after 30 days of dietary supplementation
with fish oil (0.4 g/kg/day) increased erythrocytic catalase activity
and decreased serum malondialdehyde and NO concentrations,
although no effects on erythrocytic superoxide dismutase and glu-
tathione peroxidase activities were reported [194]. In streptozoto-
cin-induced diabetic rats, treatment with DHA reduced plasma
malondialdehyde and increased glutathione concentrations with
increased glutathione peroxidase activity [195]. In a rat model of
uranyl nitrate-induced nephrotoxicity, dietary fish oil decreased li-
pid peroxidation, superoxide dismutase activity, glutathione per-
oxidase activity, and increased catalase activity [196]. In ApoE/
mice fed on a high fat (non-purified +2% high oleic sunflower
oil), high cholesterol chow diet supplemented with either 2% fish
oil or DHA oil, hepatic soluble epoxide hydrolase concentrations
were lowered by fish oil, but not DHA, compared with high-oleic
acid sunflower seed oil-fed rats [197]. In 1% cholesterol-fed rats,9
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creased plasma and hepatic malondialdehyde concentrations and
improved efficiency of antioxidant enzyme systems [58].
In oligodendroglial OLN-93 cells, DHA, EPA, ALA, LA, AA, oleic or
stearic acids or a-tocopherol were added to the culture media to
study the effects of PUFA supplements on heat shock protein
(HSP) induction, altered cell survival properties and responses to
oxidative stress exerted by hydrogen peroxide [198]. Fatty acid
supplements caused the up-regulation of heme oxygenase-1
(HO-1) depending on the degree of desaturation (DHA having the
highest effect) [198]. However, in Ea.hy 926 endothelial cells,
DHA (50 lM) induced reactive oxygen species production in cells,
aggravated the lysophosphatidylcholine-induced oxidative stress,
and impaired the stimulation of histamine-induced eNOS activa-
tion [199]. EPA (90 lM) diminished the deleterious effect of lyso-
phosphatidylcholine as well as the histamine-stimulated eNOS
activity, although it did not modify the concentrations of reactive
oxygen species produced in the presence or absence of lysophos-
phatidylcholine or basal eNOS activity or the stimulating effect of
histamine on eNOS [199].
Although limited data are available to determine the underlying
anti-oxidative mechanisms of n3 PUFAs, it is most likely a conse-
quence of reduction in AA synthesis by n3 PUFAs as discussed
earlier since AA has been implicated as a major component in
NADPH oxidase activation [200]. Another plausible mechanism is
the prevention of eNOS stimulation over the basal level thereby
reducing the excess production of nitric oxide.
3.5. Inflammation
The n3 PUFA such as ALA, EPA, and DHA compete with AA as
substrates for the formation of pro-inflammatory mediators, such
as leukotrienes, prostaglandins, and cytokines as discussed in Sec-
tion 3.4. Although these pro-inflammatory mediators, in appropri-
ate amounts, are beneficial in response to pathogenic infection,
chronic production can be dangerous and is implicated in causing
some of the pathological responses that occur in sub-clinical
inflammatory conditions [201]. In addition to competitive inhibi-
tion of the n6 fatty acid pathway, n3 PUFAs may also inhibit
production of inflammatory and fibrotic mediators including C-
reactive protein (CRP), interleukins (IL), tumour necrosis factor-a
(TNF-a), matrix metalloproteinases (MMP) 2 and 9, and tissue
inhibitors of metalloproteinase (TIMPs). Although the roles of cyto-
kines in inflammation have been well-documented [202], the exact
role of MMPs in inflammatory conditions is yet to be elucidated
even though MMP up-regulation is the hallmark of many inflam-
matory diseases such as arthritis and atherosclerosis [203].
In exercise-trained men, daily supplementation with 2224 mg
EPA + 2208 mg DHA for 6 months reduced resting CRP and TNF-a
concentrations and the changes were maintained throughout the
exercise [187]. Patients with combined dyslipidemia treated with
EPA and DHA for up to 6 months showed decreased plasminogen
activator inhibitor-1 (PAI-1), fibrinogen, MMP-2, MMP-9, TIMP-1,
TIMP-2, and hsCRP [66]. A study involving randomly selected Jap-
anese employees showed inverse relationships between dietary in-
take of ALA and serum CRP concentrations but no statistically
significant association with either EPA or DHA intake [204]. In
healthy middle-aged men receiving 3.5 g/day fish oil (1.5 g/day to-
tal n3 PUFA), serum concentrations of cytokines, chemokines or
cell adhesion molecules were not affected as compared with pla-
cebo [205]. In subjects with metabolic syndrome, 1 g of fish oil cap-
sule supplementation for 6 months reduced CRP and Hsp27
antibody titres [67]. In a cross-sectional study with 5677 men
and women from the Multi-Ethnic Study of Atherosclerosis (MESA)
cohort, fish intake was inversely associated with plasma concen-
trations of pro-inflammatory IL-6, MMP-3, and CRP [206]. ALA (flaxPageoil, 14 g/day) decreased IL-6 concentrations over 12 weeks with no
other changes in inflammatory cytokines in older adults with ALA
supplementation during a resistance-training program [207].
Decreased concentrations of IL-18, an independent risk factor of
coronary artery diseases, were positively correlated to increases in
serum EPA and DHA concentrations in elderly men at high risk for
atherosclerosis treated with 2.4 g/day of EPA + DHA supplement
[208]. In patients with coronary heart disease, a fatty fish diet de-
creased the ratio of AA to EPA in cholesterol ester and phospholipid
fractions and this effect was strongly correlated with the change in
IL-1 mRNA levels in peripheral blood mononuclear cells [209]. In
healthy Dutch elderly subjects consuming either 1.8 g EPA + D-
HA/day, 0.4 g EPA + DHA/day or 4.0 g high-oleic acid sunflower
oil/day, high EPA + DHA intake changed the expression of 1040
genes in human blood mononuclear cells including those involved
in nuclear transcription factor-B (NF-jB) signaling and eicosanoid
synthesis [210]. Healthy humans placed on fish oil supplement
(775 mg EPA/day) showed reduced expression of PI3Ka and PI3Kc
and the quantity of PI3Ka protein in mononuclear cells in addition
to reduced capacity of stimulated neutrophils to produce LTB4
ex vivo [211]. Furthermore, fish oil supplements (775 mg EPA/
day) reduced the expression of many pro-inflammatory or pleio-
tropic interleukins including IL-1b, IL-5, IL-10, IL-17, and IL-23
[211]. DHA increased the secretion of IL-1 by cystic fibrosis neutro-
phils, but did not affect the secretion of other cytokines or AA in
both cystic fibrosis as well as normal neutrophils [212]. It is there-
fore likely that the genetic effects of fish oil supplements result
from the EPA fraction. However, DHA may affect the anti-inflam-
matory effect by inhibiting the generation of pro-inflammatory
precursors [212].
In Sprague–Dawley rats subjected to 5/6 nephrectomy pro-
duced by surgical resection of the upper and lower thirds of one
kidney and removal of the other kidney, EPA + DHA administration
(0.3 g/kg/day) by gastric gavage for 12 weeks down-regulated
COX-2, PAI-1, transforming growth factor-b (TGF-b), connective
tissue growth factor, a-smooth muscle actin, fibronectin, Smad2,
and monocyte chemoattractant protein-1 (MCP-1), raised Smad7,
and attenuated extracellular signal-regulated kinases (ERK) 1/2
and NF-jB activation [184]. In rats subjected to aortic banding
and dietary supplementation with EPA + DHA or ALA at 0.7%,
2.3%, or 7% of energy intake, ALA supplementation had little effect
on left ventricular remodeling and dysfunction but EPA + DHA
dose-dependently increased EPA and DHA and decreased AA con-
centrations in cardiac membrane phospholipids, and prevented
the increase in left ventricular end-diastolic and -systolic volumes.
EPA + DHA resulted in a dose-dependent increase in the anti-
inflammatory adipokine, adiponectin. Supplementation with
EPA + DHA had anti-aggregatory and anti-inflammatory effects
shown by decreases in urinary thromboxane B2 and serum TNF-a
concentrations [213].
DHA and ALA suppressed apoptotic cell death in pancreatic aci-
nar cells exposed to hydrogen peroxide and inhibited the expres-
sion of inflammatory cytokines, IL-1b and IL-6 [214].
Macrophages treated with EPA and DHA showed reduced expres-
sion of TNF-a, IL-6, and MCP-1 compared to control cells or those
treated with SFA [215]. In addition to its anti-inflammatory effects
by suppressing LTB4 [216], ALA suppressed the synthesis of IL-1b,
IL-6, and TNF-a [217] probably at transcriptional level as both IL-
1 and TNF-a mRNA were reduced with ALA treatment. This effect
may account for the beneficial effects of n3 PUFA in models of
chronic inflammatory disease [218].
Recent advances have highlighted the role of resolvins derived
from n3 PUFA critical to their anti-inflammatory properties
[219]. These include E series resolvins (E1 or RvE1) from EPA, D
series resolvins (D1 or RvD1), and the neuroprotectins/protectins
(PDs) from DHA [219]. The anti-inflammatory effects of resolvins 280
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inflammatory cell recruitment have been shown in in vitro studies
as well as in animal models of inflammation [25,220–223]. Resolv-
ins have been reviewed including their biosynthesis, structures
and effects [25,219]. Most mechanisms linking n3 PUFA with
suppression of inflammation are associated either with their
anti-inflammatory metabolites or the suppression of the n6 fatty
acid pathway.
4. Safety and nutrient-gene/nutrient-drug interactions of n3
PUFAs
The n3 PUFAs may interact with other dietary factors to
modulate the risk factors of metabolic syndrome. n3 Fatty acid
deficiency for 24 weeks with higher dietary protein (30% casein
supplementation) induced hypertension in female rats [139].
Co-treatment of oligodendroglial OLN-93 cells with DHA and
a-tocopherol suppressed HO-1 up-regulation and restored cell
survival whereas treatment with DHA alone induced HO-1
up-regulation [198]. Analysis of the lipid profile demonstrated that
co-treatmentofOLN-93cellswithDHAanda-tocopheroldirectly al-
tered the PUFAprofile of the cellmembranes by increasingn9 fatty
acids such as mead acid at the expense of oleic acid [198].
Leptin modulates insulin action, stimulates glucose uptake and
fatty acid oxidation in addition to increased insulin secretion via
leptin receptors (LepR) present in pancreatic b cells, adipose tissue,
and muscle [224–226]. In individuals with metabolic syndrome,
low plasma n3 and high n6 PUFA status exacerbated the geneticFig. 4. Mechanism of action of n3 PUFA on risk factors for metabolic syndrome. NHE, Na
insulin receptor substrate; JNK, c-jun N-terminal kinase.
Page 28risk conferred by LEPR rs3790433 GG homozygosity to hyperinsu-
linemia and insulin resistance [227]. This study also reported a
negative correlation between LepR polymorphisms and hyperinsu-
linemia and insulin resistance in patients with high n3 and low
n6 PUFA [227].
In transgenic fat-1 mice with enhanced endogenous production
of n3 PUFA infected with virulent H37Rv Mycobacterium tubercu-
losis, higher bacterial loads and less robust inflammatory responses
in lungs increased susceptibility to tuberculosis [228]. Macro-
phages from fat-1 mice had reduced pro-inflammatory cytokine
secretion, impaired oxidative metabolism, and diminished M.
tuberculosis-lysotracker co-localization within phagosomes and
were more readily infected with M. tuberculosis in vitro, compared
with wild-type macrophages [228]. It has been suggested that n3
PUFAs, widely regarded as possessing anti-inflammatory proper-
ties, may also lead to immunosuppression [228].
More studies will be needed to understand interactions of n3
PUFAs with other nutritional factors as well as genetic factors to
make informed dietary recommendations on n3 PUFAs. It will
also be necessary to address any possible safety and toxicological
aspects of n3 PUFAs.
5. Discussion and conclusions
Current evidence strongly suggests that PPARs, JNK, Na+, K+-
ATPase, and Na+–Ca2+ exchangers are early targets for n3 PUFA
to attenuate symptoms of metabolic syndrome (Fig. 4). Although
it is unlikely that these are exclusive targets that elicit the+–H+ exchanger; NCX, Na+–Ca2+ exchanger; CPT, carnitine palmitoyltransferase; IRS,
1
Table 1
Summary of responses and probable target sites of ALA, EPA and DHA.
Physiological responses Probable targets
Risk Factor ALA EPA and DHA ALA EPA and DHA
Adiposity None  Reduces visceral adiposity
 Increases mitochondrial biogenesis and oxidative
metabolism
Unknown Leptin, PPAR-a, PPAR-c, peroxisomal acyl-CoA
oxidase
Dyslipidemia Reduces total
cholesterol,
LDL-cholesterol
and TAG
 Increases HDL-cholesterolReduces TAG
 Increases lipoprotein lipase activity
 Reduces TAG lipase activity
Unknown ApoE up-regulation
Insulin
resistance
 None in humans
 Animal studies show improved glucose tolerance and insulin resis-
tance index
Unknown None in humans. Animal studies suggest PPAR-a and
JNK as the most likely targets. Inconsistency possibly
due to lack of functional peroxisome proliferator
response elements in some PPAR-a regulated genes
in humans
Hypertension Reduces systolic blood pressure  Inhibits renin
secretion
 Reduces the
formation of
thromboxane
A2
 Inhibits ACE
 Structural modification of the blood vessel
 Inhibits Na+/K+–ATPase and Na+/Ca2+ exchange
Oxidative
stress
Data
inconclusive
Does not reduce oxidative damage but improves
serum antioxidant enzymes levels. Animal studies
show reasonable evidence of reducing oxidative
damage but also show pro-oxidant responses to EPA
and DHA at higher doses
Possible NADPH oxidase inhibition/reduced activation
Inflammation Reduces pro-inflammatory cytokines and LOX/COX metabolites of AA Suppression of the n6 fatty acid pathway as well as pro-resolving actions
of resolvins, protectins and maresins derived from EPA and DHA
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sus that the anti-inflammatory effects of n3 fatty acids are mainly
mediated by displacing the pro-inflammatory n6 fatty acid path-
way (Fig. 4). It is also possible that the effects of n3 fatty acids on
one of the risk factors of metabolic syndrome could mitigate the
other risk factors. For example, lipid-lowering effects of n3 fatty
acids could also result in improved glucose handling, reduced
blood pressure and oxidative stress. Serum free fatty acids upreg-
ulate gluconeogenesis in the liver [229], and elevate both insulin
resistance and hypertension by inhibiting aortic NOS activity
through an oxidative mechanism [230,231]. In addition to reduced
NADPH oxidase and iNOS activities due to the anti-inflammatory
effects of n3 fatty acids, metabolic correction by reducing blood
lipids and blood glucose may contribute to the anti-oxidative prop-
erties as well (Fig. 4).
Oxidative stress and inflammation are key and inter-related indi-
cations in obesity andmetabolic syndrome [232,233]. Reactive oxy-
gen species targeted L-type calcium channels on the sarcolemma
and suppressed the Ca2+ current [234] thereby increasing the cyto-
solic Ca2+ concentration through mobilization of intracellular Ca2+
stores and/or through the influx of extracellular Ca2+ [235–237].
Both direct modulation of Ca2+ channels by reactive oxygen species
as well as reactive oxygen species-dependent increases in vascular
intracellular Ca2+ primarily via extracellular Ca2+ influx have been
conclusively demonstrated [237,238]. Therefore, it is plausible that
the reduction in oxidative stress by the n3 fatty acids could also re-
sult in vasorelaxation. The interplay between various risk factors of
metabolic syndrome has to be carefully considered to elucidate the
mechanism of action of n3 fatty acids.
It is clear that studies with ALA are insufficient compared to EPA
andDHA (Table 1). From the limited available data, physiological re-
sponses to ALA differ from EPA and DHA primarily in lipid handling.
While ALA has no effect on adiposity and body weight loss, EPA and
DHA reduce adiposity, and thereby favor bodyweight loss. Also, ALA
reduced LDL-cholesterol whereas EPA and DHA increased HDL-cho-
lesterol concentrations with increased cardiac and hepatic lipopro-
tein/TAG lipases. Most of the responses to all three n3 PUFA
remain comparable, probably with closely associated mechanisms
of action in insulin resistance, hypertension, and inflammationPage(Table 1). Unlike with ALA, the probable targets of EPA and DHA
are seeminglywell studied.However, it is still unclearwhether there
are differentmolecular targets/pathwayswith EPA andDHAasmost
studies employ EPA and DHAmixtures in purified forms as capsules
or oily fish diet/supplements. Since the conversion of EPA to DHA is
even less efficient than the conversion of ALA to EPA [35], EPA and
DHA could, at least in theory, exert their effects through indepen-
dentmediators. More studies need to be implementedwith purified
EPA and DHA to differentiate their effects. Considering the promi-
nence of LOX/COXmetabolites of AA in the risk factors of metabolic
syndrome, we speculate that displacement of AA by EPA contributes
tomost, if not all, effects of oily fish diets/supplements in alleviating
the symptoms of metabolic syndrome, with minimal additional
effects from DHA.
Furthermore, since ALA shows higher affinity towards D6 desat-
urase than LA [35], the physiological responses to ALA could be
mediated through the derived EPA but direct responses to ALA re-
main possible. Evidently, more focused studies with each of the
three n3 fatty acids are required to draw firm conclusions on
the mechanisms of action of the individual fatty acids. Also, in-
ter-species genetic and metabolic variations have to be carefully
considered for animal studies to ensure reliability and reproduc-
ibility of the results in humans.
Conflict of interest
No conflicts of interest.
Acknowledgment
Supported by NHMRC, The Prince Charles Hospital Foundation,
Dr. Red Nutraceuticals.
References
[1] Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al.
Harmonizing the metabolic syndrome: a joint interim statement of the
International Diabetes Federation Task Force on Epidemiology and
Prevention; National Heart, Lung, and Blood Institute; American Heart
Association; World Heart Federation; International Atherosclerosis Society; 282
H. Poudyal et al. / Progress in Lipid Research 50 (2011) 372–387 383and International Association for the Study of Obesity. Circulation
2009;120:1640–5.
[2] Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in
worldwide populations. Endocrinol Metab Clin North Am 2004;33:351–75.
[3] Minich DM, Bland JS. Dietary management of the metabolic syndrome beyond
macronutrients. Nutr Rev 2008;66:429–44.
[4] Iyer A, Panchal S, Poudyal H, Brown L. Potential health benefits of indian
spices in the symptoms of the metabolic syndrome: a review. Indian J
Biochem Biophys 2009;46:467–81.
[5] Yashodhara BM, Umakanth S, Pappachan JM, Bhat SK, Kamath R, Choo BH.
Omega-3 fatty acids: a comprehensive review of their role in health and
disease. Postgrad Med J 2009;85:84–90.
[6] Lee JH, O’Keefe JH, Lavie CJ, Harris WS. Omega-3 fatty acids: cardiovascular
benefits, sources and sustainability. Nat Rev Cardiol 2009;6:753–8.
[7] Saremi A, Arora R. The utility of omega-3 fatty acids in cardiovascular disease.
Am J Ther 2009;16:421–36.
[8] Duda MK, O’Shea KM, Stanley WC. Omega-3 polyunsaturated fatty acid
supplementation for the treatment of heart failure: mechanisms and clinical
potential. Cardiovasc Res 2009;84:33–41.
[9] Anderson BM, Ma DW. Are all n3 polyunsaturated fatty acids created equal?
Lipids Health Dis 2009;8:33.
[10] Bartsch H, Nair J, Owen RW. Dietary polyunsaturated fatty acids and cancers
of the breast and colorectum: emerging evidence for their role as risk
modifiers. Carcinogenesis 1999;20:2209–18.
[11] Ratnayake WM, Galli C. Fat and fatty acid terminology, methods of analysis
and fat digestion and metabolism: a background review paper. Ann Nutr
Metab 2009;55:8–43.
[12] Parker-Barnes JM, Das T, Bobik E, Leonard AE, Thurmond JM, Chaung LT, et al.
Identification and characterization of an enzyme involved in the elongation of
n6 and n3 polyunsaturated fatty acids. Proc Natl Acad Sci USA
2000;97:8284–9.
[13] Stanley JC, Elsom RL, Calder PC, Griffin BA, Harris WS, Jebb SA, et al. UK Food
Standards Agency Workshop Report: the effects of the dietary n6:n3 fatty
acid ratio on cardiovascular health. Br J Nutr 2007;98:1305–10.
[14] Das UN. Essential fatty acids – a review. Curr Pharm Biotechnol
2006;7:467–82.
[15] Russo GL. Dietary n6 and n3 polyunsaturated fatty acids: from
biochemistry to clinical implications in cardiovascular prevention. Biochem
Pharmacol 2009;77:937–46.
[16] Connor WE. Importance of n3 fatty acids in health and disease. Am J Clin
Nutr 2000;71:171S–5S.
[17] Griffin BA. How relevant is the ratio of dietary n6 to n3 polyunsaturated
fatty acids to cardiovascular disease risk? Evidence from the OPTILIP study.
Curr Opin Lipidol 2008;19:57–62.
[18] Fritsche KL. Too much linoleic acid promotes inflammation-doesn’t it?
Prostaglandins Leukot Essent Fatty Acids 2008;79:173–5.
[19] Hu FB, Manson JE, Willett WC. Types of dietary fat and risk of coronary heart
disease: a critical review. J Am Coll Nutr 2001;20:5–19.
[20] Benatti P, Peluso G, Nicolai R, Calvani M. Polyunsaturated fatty acids:
biochemical, nutritional and epigenetic properties. J Am Coll Nutr
2004;23:281–302.
[21] O’Donnell VB, Maskrey B, Taylor GW. Eicosanoids: generation and detection
in mammalian cells. Methods Mol Biol 2009;462:5–23.
[22] Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain
n3 fatty acids for the prevention of cancer: a review of potential
mechanisms. Am J Clin Nutr 2004;79:935–45.
[23] Kapoor R, Huang YS. Gamma linolenic acid: an antiinflammatory omega-6
fatty acid. Curr Pharm Biotechnol 2006;7:531–4.
[24] Horrobin DF. Nutritional and medical importance of gamma-linolenic acid.
Prog Lipid Res 1992;31:163–94.
[25] Serhan CN. Resolution phase of inflammation: novel endogenous anti-
inflammatory and proresolving lipid mediators and pathways. Annu Rev
Immunol 2007;25:101–37.
[26] Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-
inflammatory and pro-resolution lipid mediators. Nat Rev Immunol
2008;8:349–61.
[27] Serhan CN, Gotlinger K, Hong S, Arita M. Resolvins, docosatrienes, and
neuroprotectins, novel omega-3-derived mediators, and their aspirin-
triggered endogenous epimers: an overview of their protective roles in
catabasis. Prostaglandins Other Lipid Mediat 2004;73:155–72.
[28] Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, et al. Maresins:
novel macrophage mediators with potent antiinflammatory and proresolving
actions. J Exp Med 2009;206:15–23.
[29] Crawford MA, Casperd NM, Sinclair AJ. The long chain metabolites of linoleic
avid linolenic acids in liver and brain in herbivores and carnivores. Comp
Biochem Physiol B 1976;54:395–401.
[30] Mohrhauer H, Holman RT. Effect of linolenic acid upon the metabolism of
linoleic acid. J Nutr 1963;81:67–74.
[31] Hassam AG. The influence of alpha-linolenic acid (18:3omega3) on the
metabolism of gamma-linolenic acid (18:3oega6) in the rat. Br J Nutr
1977;38:137–40.
[32] Marshall LA, Johnston PV. Modulation of tissue prostaglandin synthesizing
capacity by increased ratios of dietary alpha-linolenic acid to linoleic acid.
Lipids 1982;17:905–13.
[33] Hwang DH, Carroll AE. Decreased formation of porstaglandins derived from
arachidonic acid by dietary linolenate in rats. Am J Clin Nutr 1980;33:590–7.Page 28[34] Marshall LA, Johnston PV. Alpha-Linolenic and linoleic acids and the immune
response. Prog Lipid Res 1981;20:731–4.
[35] Williams CM, Burdge G. Long-chain n3 PUFA: plant v. marine sources. Proc
Nutr Soc 2006;65:42–50.
[36] Woods J, Ward G, Salem Jr N. Is docosahexaenoic acid necessary in infant
formula? Evaluation of high linolenate diets in the neonatal rat. Pediatr Res
1996;40:687–94.
[37] Abedin L, Lien EL, Vingrys AJ, Sinclair AJ. The effects of dietary alpha-linolenic
acid compared with docosahexaenoic acid on brain, retina, liver, and heart in
the guinea pig. Lipids 1999;34:475–82.
[38] Fu Z, Sinclair AJ. Increased alpha-linolenic acid intake increases tissue alpha-
linolenic acid content and apparent oxidation with little effect on tissue
docosahexaenoic acid in the guinea pig. Lipids 2000;35:395–400.
[39] Burdge GC, Calder PC. Conversion of alpha-linolenic acid to longer-chain
polyunsaturated fatty acids in human adults. Reprod Nutr Dev 2005;
45:581–97.
[40] Brenna JT. Efficiency of conversion of alpha-linolenic acid to long chain n3
fatty acids in man. Curr Opin Clin Nutr Metab Care 2002;5:127–32.
[41] Igarashi M, DeMar Jr JC, Ma K, Chang L, Bell JM, Rapoport SI. Docosahexaenoic
acid synthesis from alpha-linolenic acid by rat brain is unaffected by dietary
n3 PUFA deprivation. J Lipid Res 2007;48:1150–8.
[42] Demar Jr JC, Ma K, Chang L, Bell JM, Rapoport SI. Alpha-Linolenic acid does not
contribute appreciably to docosahexaenoic acid within brain phospholipids
of adult rats fed a diet enriched in docosahexaenoic acid. J Neurochem
2005;94:1063–76.
[43] Igarashi M, Ma K, Chang L, Bell JM, Rapoport SI, DeMar Jr JC. Low
liver conversion rate of alpha-linolenic to docosahexaenoic acid in awake
rats on a high-docosahexaenoate-containing diet. J Lipid Res 2006;
47:1812–22.
[44] Gao F, Kiesewetter D, Chang L, Ma K, Bell JM, Rapoport SI, et al. Whole-body
synthesis-secretion rates of long-chain n3 PUFAs from circulating
unesterified alpha-linolenic acid in unanesthetized rats. J Lipid Res
2009;50:749–58.
[45] Kitson AP, Stroud CK, Stark KD. Elevated production of docosahexaenoic acid
in females: potential molecular mechanisms. Lipids 2010;45:209–24.
[46] Legrand P, Schmitt B, Mourot J, Catheline D, Chesneau G, Mireaux M, et al. The
consumption of food products from linseed-fed animals maintains
erythrocyte omega-3 fatty acids in obese humans. Lipids 2009;45:11–9.
[47] Cunnane SC, Ganguli S, Menard C, Liede AC, Hamadeh MJ, Chen ZY, et al. High
alpha-linolenic acid flaxseed (Linum usitatissimum): some nutritional
properties in humans. Br J Nutr 1993;69:443–53.
[48] Cunnane SC, Hamadeh MJ, Liede AC, Thompson LU, Wolever TM, Jenkins DJ.
Nutritional attributes of traditional flaxseed in healthy young adults. Am J
Clin Nutr 1995;61:62–8.
[49] Clark WF, Parbtani A, Huff MW, Spanner E, de Salis H, Chin-Yee I, et al.
Flaxseed: a potential treatment for lupus nephritis. Kidney Int 1995;
48:475–80.
[50] Jenkins DJ, Kendall CW, Vidgen E, Agarwal S, Rao AV, Rosenberg RS, et al.
Health aspects of partially defatted flaxseed, including effects on serum
lipids, oxidative measures, and ex vivo androgen and progestin activity: a
controlled crossover trial. Am J Clin Nutr 1999;69:395–402.
[51] Mandasescu S, Mocanu V, Dascalita AM, Haliga R, Nestian I, Stitt PA, et al.
Flaxseed supplementation in hyperlipidemic patients. Rev Med Chir Soc Med
Nat Iasi 2005;109:502–6.
[52] Bloedon LT, Balikai S, Chittams J, Cunnane SC, Berlin JA, Rader DJ, et al.
Flaxseed and cardiovascular risk factors: results from a double blind,
randomized, controlled clinical trial. J Am Coll Nutr 2008;27:65–74.
[53] Lucas EA, Wild RD, Hammond LJ, Khalil DA, Juma S, Daggy BP, et al. Flaxseed
improves lipid profile without altering biomarkers of bone metabolism in
postmenopausal women. J Clin Endocrinol Metab 2002;87:1527–32.
[54] Bahram HA, Dilshad AK, Shanil J, Melinda LD, Sreevidya V, Eugenia S,
et al. Whole flaxseed consumption lowers serum LDL-cholesterol
and lipoprotein(a) concentrations in postmenopausal women. 1998;
18:1203–14.
[55] Nieman DC, Cayea EJ, Austin MD, Henson DA, McAnulty SR, Jin F. Chia seed
does not promote weight loss or alter disease risk factors in overweight
adults. Nutr Res 2009;29:414–8.
[56] Dupasquier CM, Weber AM, Ander BP, Rampersad PP, Steigerwald S, Wigle JT,
et al. Effects of dietary flaxseed on vascular contractile function and
atherosclerosis during prolonged hypercholesterolemia in rabbits. Am J
Physiol Heart Circ Physiol 2006;291:H2987–96.
[57] Dupasquier CM, Dibrov E, Kneesh AL, Cheung PK, Lee KG, Alexander HK, et al.
Dietary flaxseed inhibits atherosclerosis in the LDL receptor-deficient mouse
in part through antiproliferative and anti-inflammatory actions. Am J Physiol
Heart Circ Physiol 2007;293:H2394–402.
[58] Makni M, Fetoui H, Gargouri NK, Gargouri M, Jaber H, Makni J, et al.
Hypolipidemic and hepatoprotective effects of flax and pumpkin seed
mixture rich in omega-3 and omega-6 fatty acids in hypercholesterolemic
rats. Food Chem Toxicol 2008;46:3714–20.
[59] Sener A, Zhang Y, Bulur N, Louchami K, Malaisse WJ, Carpentier YA. The
metabolic syndrome of omega3-depleted rats II. Body weight, adipose tissue
mass and glycemic homeostasis. Int J Mol Med 2009;24:125–9.
[60] Valdivielso P, Rioja J, Garcia-Arias C, Sanchez-Chaparro MA, Gonzalez-Santos
P. Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when
added to fluvastatin in patients with type 2 diabetes and mixed
hyperlipidemia: a preliminary report. Cardiovasc Diabetol 2009;8:1.3
384 H. Poudyal et al. / Progress in Lipid Research 50 (2011) 372–387[61] Agren JJ, Hanninen O, Julkunen A, Fogelholm L, Vidgren H, Schwab U, et al.
Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and
postprandial plasma lipid levels. Eur J Clin Nutr 1996;50:765–71.
[62] Link JJ, Rohatgi A, de Lemos JA. HDL cholesterol: physiology, pathophysiology,
and management. Curr Probl Cardiol 2007;32:268–314.
[63] Belalcazar LM, Reboussin DM, Haffner SM, Reeves RS, Schwenke DC,
Hoogeveen RC, et al. Marine omega-3 fatty acid intake: associations with
cardiometabolic risk and response to weight loss intervention in the Look
AHEAD (Action for Health in Diabetes) study. Diabetes Care 2009;33:197–9.
[64] Cussons AJ, Watts GF, Mori TA, Stuckey BG. Omega-3 fatty acid
supplementation decreases liver fat content in polycystic ovary syndrome:
a randomized controlled trial employing proton magnetic resonance
spectroscopy. J Clin Endocrinol Metab 2009;94:3842–8.
[65] Micallef M, Munro I, Phang M, Garg M. Plasma n3 polyunsaturated fatty
acids are negatively associated with obesity. Br J Nutr 2009;102:1370–4.
[66] Derosa G, Maffioli P, D’Angelo A, Salvadeo SA, Ferrari I, Fogari E, et al. Effects
of long chain omega-3 fatty acids on metalloproteinases and their inhibitors
in combined dyslipidemia patients. Expert Opin Pharmacother 2009;
10:1239–47.
[67] Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, Hoseini M, Parizade SM,
Farhoudi F, et al. Omega-3 fatty acid supplements improve the cardiovascular
risk profile of subjects with metabolic syndrome, including markers of
inflammation and auto-immunity. Acta Cardiol 2009;64:321–7.
[68] Ikeda I, Kumamaru J, Nakatani N, Sakono M, Murota I, Imaizumi K. Reduced
hepatic triglyceride secretion in rats fed docosahexaenoic acid-rich
fish oil suppresses postprandial hypertriglyceridemia. J Nutr 2001;
131:1159–64.
[69] Ryan AS, Bailey-Hall E, Nelson EB, Salem Jr N. The hypolipidemic effect of an
ethyl ester of algal-docosahexaenoic acid in rats fed a high-fructose diet.
Lipids 2009;44:817–26.
[70] Kobatake Y, Kuroda K, Jinnouchi H, Nishide E, Innami S. Differential effects of
dietary eicosapentaenoic and docosahexaenoic fatty acids on lowering of
triglyceride and cholesterol levels in the serum of rats on
hypercholesterolemic diet. J Nutr Sci Vitaminol (Tokyo) 1984;30:357–72.
[71] Oarada M, Tsuzuki T, Gonoi T, Igarashi M, Kamei K, Nikawa T, et al. Effects of
dietary fish oil on lipid peroxidation and serum triacylglycerol levels in
psychologically stressed mice. Nutrition 2008;24:67–75.
[72] Batetta B, Griinari M, Carta G, Murru E, Ligresti A, Cordeddu L, et al.
Endocannabinoids may mediate the ability of (n3) fatty acids to reduce
ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr
2009;139:1495–501.
[73] Neschen S, Morino K, Dong J, Wang-Fischer Y, Cline GW, Romanelli AJ, et al.
N3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome
proliferator-activated receptor-alpha-dependent manner. Diabetes
2007;56:1034–41.
[74] Xu Z, Riediger N, Innis S, Moghadasian MH. Fish oil significantly alters fatty
acid profiles in various lipid fractions but not atherogenesis in apo E-KO mice.
Eur J Nutr 2007;46:103–10.
[75] Vanschoonbeek K, Wouters K, van der Meijden PE, van Gorp PJ, Feijge MA,
Herfs M, et al. Anticoagulant effect of dietary fish oil in hyperlipidemia: a
study of hepatic gene expression in APOE2 knock-in mice. Arterioscler
Thromb Vasc Biol 2008;28:2023–9.
[76] Hainault I, Carolotti M, Hajduch E, Guichard C, Lavau M. Fish oil in a high lard
diet prevents obesity, hyperlipemia, and adipocyte insulin resistance in rats.
Ann NY Acad Sci 1993;683:98–101.
[77] Baillie RA, Takada R, Nakamura M, Clarke SD. Coordinate induction of
peroxisomal acyl-CoA oxidase and UCP-3 by dietary fish oil: a mechanism for
decreased body fat deposition. Prostaglandins Leukot Essent Fatty Acids
1999;60:351–6.
[78] Belzung F, Raclot T, Groscolas R. Fish oil n3 fatty acids selectively limit the
hypertrophy of abdominal fat depots in growing rats fed high-fat diets. Am J
Physiol 1993;264:R1111–8.
[79] Parrish CC, Pathy DA, Angel A. Dietary fish oils limit adipose tissue
hypertrophy in rats. Metabolism 1990;39:217–9.
[80] Perez-Matute P, Perez-Echarri N, Martinez JA, Marti A, Moreno-Aliaga MJ.
Eicosapentaenoic acid actions on adiposity and insulin resistance in control
and high-fat-fed rats: role of apoptosis, adiponectin and tumour necrosis
factor-alpha. Br J Nutr 2007;97:389–98.
[81] Takahashi Y, Ide T. Dietary n3 fatty acids affect mRNA level of brown
adipose tissue uncoupling protein 1, and white adipose tissue leptin and
glucose transporter 4 in the rat. Br J Nutr 2000;84:175–84.
[82] Ruzickova J, Rossmeisl M, Prazak T, Flachs P, Sponarova J, Veck M, et al.
Omega-3 PUFA of marine origin limit diet-induced obesity in mice by
reducing cellularity of adipose tissue. Lipids 2004;39:1177–85.
[83] Mascaro C, Acosta E, Ortiz JA, Marrero PF, Hegardt FG, Haro D. Control of
human muscle-type carnitine palmitoyltransferase I gene transcription by
peroxisome proliferator-activated receptor. J Biol Chem 1998;273:8560–3.
[84] Flachs P, Horakova O, Brauner P, Rossmeisl M, Pecina P, Franssen-van Hal N,
et al. Polyunsaturated fatty acids of marine origin upregulate mitochondrial
biogenesis and induce beta-oxidation in white fat. Diabetologia
2005;48:2365–75.
[85] Power GW, Newsholme EA. Dietary fatty acids influence the activity and
metabolic control of mitochondrial carnitine palmitoyltransferase I in rat
heart and skeletal muscle. J Nutr 1997;127:2142–50.
[86] Lorente-Cebrian S, Bustos M, Marti A, Martinez JA, Moreno-Aliaga MJ.
Eicosapentaenoic acid stimulates AMP-activated protein kinase andPageincreases visfatin secretion in cultured murine adipocytes. Clin Sci (Lond)
2009;117:243–9.
[87] Reddy JK, Mannaerts GP. Peroxisomal lipid metabolism. Annu Rev Nutr
1994;14:343–70.
[88] Wanders RJ. Peroxisomes, lipid metabolism, and peroxisomal disorders. Mol
Genet Metab 2004;83:16–27.
[89] Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, Birner-Gruenberger
R, Riederer M, et al. Fat mobilization in adipose tissue is promoted by adipose
triglyceride lipase. Science 2004;306:1383–6.
[90] Auwerx J, Leroy P, Schoonjans K. Lipoprotein lipase: recent contributions
from molecular biology. Crit Rev Clin Lab Sci 1992;29:243–68.
[91] Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-
activated receptor (PPAR) in mediating the effects of fibrates and fatty acids
on gene expression. J Lipid Res 1996;37:907–25.
[92] Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S,
et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific
transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J
1996;15:5336–48.
[93] Krey G, Braissant O, L’Horset F, Kalkhoven E, Perroud M, Parker MG, et al.
Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of
peroxisome proliferator-activated receptors by coactivator-dependent
receptor ligand assay. Mol Endocrinol 1997;11:779–91.
[94] Price PT, Nelson CM, Clarke SD. Omega-3 polyunsaturated fatty acid
regulation of gene expression. Curr Opin Lipidol 2000;11:3–7.
[95] Gani OA. Are fish oil omega-3 long-chain fatty acids and their derivatives
peroxisome proliferator-activated receptor agonists? Cardiovasc Diabetol
2008;7:6.
[96] Gani OA, Sylte I. Molecular recognition of docosahexaenoic acid by
peroxisome proliferator-activated receptors and retinoid-X receptor alpha. J
Mol Graph Model 2008;27:217–24.
[97] Edwards IJ, O’Flaherty JT. Omega-3 Fatty Acids and PPARgamma in Cancer.
PPAR Res 2008;2008:358052.
[98] Varanasi U, Chu R, Huang Q, Castellon R, Yeldandi AV, Reddy JK. Identification
of a peroxisome proliferator-responsive element upstream of the human
peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem
1996;271:2147–55.
[99] Brandt JM, Djouadi F, Kelly DP. Fatty acids activate transcription of the muscle
carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome
proliferator-activated receptor alpha. J Biol Chem 1998;273:23786–92.
[100] Rodriguez JC, Gil-Gomez G, Hegardt FG, Haro D. Peroxisome proliferator-
activated receptor mediates induction of the mitochondrial 3-hydroxy-3-
methylglutaryl-CoA synthase gene by fatty acids. J Biol Chem
1994;269:18767–72.
[101] Schrauwen P, Walder K, Ravussin E. Human uncoupling proteins and obesity.
Obes Res 1999;7:97–105.
[102] Zhou YE, Kubow S, Dewailly E, Julien P, Egeland GM. Decreased activity of
desaturase 5 in association with obesity and insulin resistance aggravates
declining long-chain n3 fatty acid status in Cree undergoing dietary
transition. Br J Nutr 2009;102:888–94.
[103] Mori TA, Bao DQ, Burke V, Puddey IB, Watts GF, Beilin LJ. Dietary fish as a
major component of a weight-loss diet: effect on serum lipids, glucose, and
insulin metabolism in overweight hypertensive subjects. Am J Clin Nutr
1999;70:817–25.
[104] Fasching P, Ratheiser K, Waldhausl W, Rohac M, Osterrode W, Nowotny P,
et al. Metabolic effects of fish-oil supplementation in patients with impaired
glucose tolerance. Diabetes 1991;40:583–9.
[105] Pelikanova T, Kohout M, Valek J, Kazdova L, Base J. Metabolic effects of
omega-3 fatty acids in type 2 (non-insulin-dependent) diabetic patients. Ann
NY Acad Sci 1993;683:272–8.
[106] Griffin MD, Sanders TA, Davies IG, Morgan LM, Millward DJ, Lewis F, et al.
Effects of altering the ratio of dietary n6 to n3 fatty acids on insulin
sensitivity, lipoprotein size, and postprandial lipemia in men and
postmenopausal women aged 45–70 y: the OPTILIP Study. Am J Clin Nutr
2006;84:1290–8.
[107] Giacco R, Cuomo V, Vessby B, Uusitupa M, Hermansen K, Meyer BJ, et al. Fish
oil, insulin sensitivity, insulin secretion and glucose tolerance in healthy
people: is there any effect of fish oil supplementation in relation to the type
of background diet and habitual dietary intake of n6 and n3 fatty acids?
Nutr Metab Cardiovasc Dis 2007;17:572–80.
[108] Fakhrzadeh H, Ghaderpanahi M, Sharifi F, Mirarefin M, Badamchizade Z,
Kamrani AA, et al. The effects of low dose n3 fatty acids on serum lipid
profiles and insulin resistance of the elderly: a randomized controlled clinical
trial. Int J Vitam Nutr Res 2010;80:107–16.
[109] Taylor CG, Noto AD, Stringer DM, Froese S, Malcolmson L. Dietary milled
flaxseed and flaxseed oil improve N3 fatty acid status and do not affect
glycemic control in individuals with well-controlled type 2 diabetes. J Am
Coll Nutr 2010;29:72–80.
[110] Thorseng T, Witte DR, Vistisen D, Borch-Johnsen K, Bjerregaard P, Jorgensen
ME. The association between n3 fatty acids in erythrocyte membranes and
insulin resistance. the Inuit Health in Transition Study. Int J Circumpolar
Health 2009;68:327–36.
[111] Navas-Carretero S, Perez-Granados AM, Schoppen S, Vaquero MP. An oily fish
diet increases insulin sensitivity compared to a red meat diet in young iron-
deficient women. Br J Nutr 2009;102:546–53.
[112] Lankinen M, Schwab U, Erkkila A, Seppanen-Laakso T, Hannila ML, Mussalo H,
et al. PLoS One 2009;4:e5258. 284
H. Poudyal et al. / Progress in Lipid Research 50 (2011) 372–387 385[113] Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS. Fish oil
prevents insulin resistance induced by high-fat feeding in rats. Science
1987;237:885–8.
[114] Jucker BM, Cline GW, Barucci N, Shulman GI. Differential effects of safflower
oil versus fish oil feeding on insulin-stimulated glycogen synthesis,
glycolysis, and pyruvate dehydrogenase flux in skeletal muscle: a 13C
nuclear magnetic resonance study. Diabetes 1999;48:134–40.
[115] Kuda O, Jelenik T, Jilkova Z, Flachs P, Rossmeisl M, Hensler M, et al. N3 fatty
acids and rosiglitazone improve insulin sensitivity through additive
stimulatory effects on muscle glycogen synthesis in mice fed a high-fat
diet. Diabetologia 2009;52:941–51.
[116] Gonzalez-Periz A, Horrillo R, Ferre N, Gronert K, Dong B, Moran-Salvador E,
et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated
by omega-3 fatty acids: a role for resolvins and protectins. FASEB J
2009;23:1946–57.
[117] Andersen G, Harnack K, Erbersdobler HF, Somoza V. Dietary eicosapentaenoic
acid and docosahexaenoic acid are more effective than alpha-linolenic acid in
improving insulin sensitivity in rats. Ann Nutr Metab 2008;52:250–6.
[118] Lombardo YB, Hein G, Chicco A. Metabolic syndrome: effects of n3 PUFAs on
a model of dyslipidemia, insulin resistance and adiposity. Lipids
2007;42:427–37.
[119] Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, et al. Fish
oil regulates adiponectin secretion by a peroxisome proliferator-activated
receptor-gamma-dependent mechanism in mice. Diabetes 2006;55:924–8.
[120] Sanderson LM, de Groot PJ, Hooiveld GJ, Koppen A, Kalkhoven E, Muller M,
et al. PLoS ONE 2008;3:e1681.
[121] Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al. A
central role for JNK in obesity and insulin resistance. Nature 2002;420:333–6.
[122] Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, et al. Beta-amyloid
oligomers induce phosphorylation of tau and inactivation of insulin receptor
substrate via c-Jun Nterminal kinase signaling: suppression by omega-3
fatty acids and curcumin. J Neurosci 2009;29:9078–89.
[123] Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T,
Marzioni M, et al. A model of insulin resistance and nonalcoholic
steatohepatitis in rats: role of peroxisome proliferator-activated receptor-
alpha and n3 polyunsaturated fatty acid treatment on liver injury. Am J
Pathol 2006;169:846–60.
[124] Konig B, Eder K. Differential action of 13-HPODE on PPARalpha downstream
genes in rat Fao and human HepG2 hepatoma cell lines. J Nutr Biochem
2006;17:410–8.
[125] Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, Umbenhauer DR, et al.
Differential gene regulation in human versus rodent hepatocytes by
peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails
to induce peroxisome proliferation-associated genes in human cells
independently of the level of receptor expresson. J Biol Chem
2001;276:31521–7.
[126] Ansorena E, Berasain C, Lopez Zabalza MJ, Avila MA, Garcia-Trevijano ER,
Iraburu MJ. Differential regulation of the JNK/AP-1 pathway by S-
adenosylmethionine and methylthioadenosine in primary rat hepatocytes
versus HuH7 hepatoma cells. Am J Physiol Gastrointest Liver Physiol
2006;290:G1186–93.
[127] Lambe KG, Woodyatt NJ, Macdonald N, Chevalier S, Roberts RA. Species
differences in sequence and activity of the peroxisome proliferator response
element (PPRE) within the acyl CoA oxidase gene promoter. Toxicol Lett
1999;110:119–27.
[128] Woodyatt NJ, Lambe KG, Myers KA, Tugwood JD, Roberts RA. The peroxisome
proliferator (PP) response element upstream of the human acyl CoA oxidase
gene is inactive among a sample human population: significance for species
differences in response to PPs. Carcinogenesis 1999;20:369–72.
[129] Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, et al. The
metabolic syndrome in hypertension: European society of hypertension
position statement. J Hypertens 2008;26:1891–900.
[130] Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-
analysis of controlled trials. Circulation 1993;88:523–33.
[131] Appel LJ, Miller 3rd ER, Seidler AJ, Whelton PK. Does supplementation of diet
with ‘fish oil’ reduce blood pressure? A meta-analysis of controlled clinical
trials. Arch Intern Med 1993;153:1429–38.
[132] Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure
response to fish oil supplementation: metaregression analysis of randomized
trials. J Hypertens 2002;20:1493–9.
[133] Ueshima H, Stamler J, Elliott P, Chan Q, Brown IJ, Carnethon MR, et al. Food
omega-3 fatty acid intake of individuals (total, linolenic acid, long-chain) and
their blood pressure: INTERMAP study. Hypertension 2007;50:313–9.
[134] Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, et al. The effects of
[omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in
chronic kidney disease: a randomized controlled trial. J Hypertens
2009;27:1863–72.
[135] Dodin S, Lemay A, Jacques H, Legare F, Forest JC, Masse B. The effects of
flaxseed dietary supplement on lipid profile, bone mineral density, and
symptoms in menopausal women: a randomized, double-blind, wheat germ
placebo-controlled clinical trial. J Clin Endocrinol Metab 2005;90:1390–7.
[136] Nestel PJ, Pomeroy SE, Sasahara T, Yamashita T, Liang YL, Dart AM, et al.
Arterial compliance in obese subjects is improved with dietary plant n3
fatty acid from flaxseed oil despite increased LDL oxidizability. Arterioscler
Thromb Vasc Biol 1997;17:1163–70.Page 28[137] Paschos GK, Magkos F, Panagiotakos DB, Votteas V, Zampelas A. Dietary
supplementation with flaxseed oil lowers blood pressure in dyslipidaemic
patients. Eur J Clin Nutr 2007;61:1201–6.
[138] Lungershausen YK, Abbey M, Nestel PJ, Howe PR. Reduction of blood pressure
and plasma triglycerides by omega-3 fatty acids in treated hypertensives. J
Hypertens 1994;12:1041–5.
[139] Begg DP, Sinclair AJ, Stahl LA, Garg ML, Jois M, Weisinger RS. Dietary protein
level interacts with omega-3 polyunsaturated fatty acid deficiency to induce
hypertension. Am J Hypertens 2009;23:125–8.
[140] Kenny D, Warltier DC, Pleuss JA, Hoffmann RG, Goodfriend TL, Egan BM. Effect
of omega-3 fatty acids on the vascular response to angiotensin in
normotensive men. Am J Cardiol 1992;70:1347–52.
[141] Chin JP, Gust AP, Nestel PJ, Dart AM. Marine oils dose-dependently inhibit
vasoconstriction of forearm resistance vessels in humans. Hypertension
1993;21:22–8.
[142] Hui R, St-Louis J, Falardeau P. Antihypertensive properties of linoleic acid and
fish oil omega-3 fatty acids independent of the prostaglandin system. Am J
Hypertens 1989;2:610–7.
[143] Armitage JA, Pearce AD, Sinclair AJ, Vingrys AJ, Weisinger RS, Weisinger HS.
Increased blood pressure later in life may be associated with perinatal n3
fatty acid deficiency. Lipids 2003;38:459–64.
[144] Weisinger HS, Armitage JA, Sinclair AJ, Vingrys AJ, Burns PL, Weisinger RS.
Perinatal omega-3 fatty acid deficiency affects blood pressure later in life. Nat
Med 2001;7:258–9.
[145] Codde JP, Croft KD, Barden A, Mathews E, Vandongen R, Beilin LJ. An
inhibitory effect of dietary polyunsaturated fatty acids on renin secretion in
the isolated perfused rat kidney. J Hypertens 1984;2:265–70.
[146] Juan H, Sametz W. Vasoconstriction induced by noradrenaline and
angiotensin II is antagonized by eicosapentaenoic acid independent of
formation of trienoic eicosanoids. Naunyn Schmiedebergs Arch Pharmacol
1986;332:288–92.
[147] Juan H, Sutter D, Sametz W. Influence of eicosapentaenoic acid on
noradrenaline and angiotensin-induced contractions of the rabbit aorta:
mode of action. Prog Clin Biol Res 1987;242:57–62.
[148] Weisinger HS, Vingrys AJ, Bui BV, Sinclair AJ. Effects of dietary n3 fatty acid
deficiency and repletion in the guinea pig retina. Invest Ophthalmol Vis Sci
1999;40:327–38.
[149] Carey RM, Siragy HM. Newly recognized components of the renin-
angiotensin system: potential roles in cardiovascular and renal regulation.
Endocr Rev 2003;24:261–71.
[150] Ogawa A, Suzuki Y, Aoyama T, Takeuchi H. Dietary alpha-linolenic acid
inhibits angiotensin-converting enzyme activity and mRNA expression levels
in the aorta of spontaneously hypertensive rats. J Oleo Sci 2009;58:355–60.
[151] Ogawa A, Suzuki Y, Aoyama T, Takeuchi H. Effect of dietary alpha-linolenic
acid on vascular reactivity in aorta of spontaneously hypertensive rats. J Oleo
Sci 2009;58:221–5.
[152] Kumar KV, Das UN. Effect of cis-unsaturated fatty acids, prostaglandins, and
free radicals on angiotensin-converting enzyme activity in vitro. Proc Soc Exp
Biol Med 1997;214:374–9.
[153] Nestel P, Shige H, Pomeroy S, Cehun M, Abbey M, Raederstorff D. The n3
fatty acids eicosapentaenoic acid and docosahexaenoic acid increase
systemic arterial compliance in humans. Am J Clin Nutr 2002;76:326–30.
[154] Talom RT, Judd SA, McIntosh DD, McNeill JR. High flaxseed (linseed) diet
restores endothelial function in the mesenteric arterial bed of spontaneously
hypertensive rats. Life Sci 1999;64:1415–25.
[155] Engler MB, Engler MM, Ursell PC. Vasorelaxant properties of n3
polyunsaturated fatty acids in aortas from spontaneously hypertensive and
normotensive rats. J Cardiovasc Risk 1994;1:75–80.
[156] Mori TA, Watts GF, Burke V, Hilme E, Puddey IB, Beilin LJ. Differential effects
of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of
the forearm microcirculation in hyperlipidemic, overweight men. Circulation
2000;102:1264–9.
[157] Li Q, Zhang Q, Wang M, Liu F, Zhao S, Ma J, et al. Docosahexaenoic acid affects
endothelial nitric oxide synthase in caveolae. Arch Biochem Biophys
2007;466:250–9.
[158] Engler MB. Effect of omega-3 fatty acids, docosahexaenoic and
eicosapentaenoic, on norepinephrine-induced contractions. Can J Physiol
Pharmacol 1992;70:675–9.
[159] Engler MB. Vascular relaxation to omega-3 fatty acids: comparison to sodium
nitroprusside, nitroglycerin, papaverine, and D600. Cardiovasc Drugs Ther
1992;6:605–10.
[160] Engler MB. Effects of omega-3, omega-6 and omega-9 fatty acids on vascular
smooth muscle tone. Eur J Pharmacol 1992;215:325–8.
[161] De Caterina R, Endres S, Kristensen SD, Schmidt EB. N3 fatty acids and renal
diseases. Am J Kidney Dis 1994;24:397–415.
[162] Chin JPF, Dart AM. How do fish oils affect vascular function? Clin Exp
Pharmacol Physiol 1995;22:71–81.
[163] Engler MB. Vascular effects of omega-3 fatty acids: possible therapeutic
mechanisms in cardiovascular disease. J Cardiovasc Nurs 1994;8:53–67.
[164] Blaustein MP, Hamlyn JM. Pathogenesis of essential hypertension. A link
between dietary salt and high blood pressure. Hypertension 1991;18(3):184–
95.
[165] Taffet GE, Pham TT, Bick DL, Entman ML, Pownall HJ, Bick RJ. The calcium
uptake of the rat heart sarcoplasmic reticulum is altered by dietary lipid. J
Membr Biol 1993;131:35–42.5
386 H. Poudyal et al. / Progress in Lipid Research 50 (2011) 372–387[166] Hallaq H, Smith TW, Leaf A. Modulation of dihydropyridine-sensitive calcium
channels in heart cells by fish oil fatty acids. Proc Natl Acad Sci USA
1992;89:1760–4.
[167] Dlugosova K, Okruhlicova L, Mitasikova M, Sotnikova R, Bernatova I,
Weismann P, et al. Modulation of connexin-43 by omega-3 fatty acids in
the aorta of old spontaneously hypertensive rats. J Physiol Pharmacol
2009;60:63–9.
[168] Dlugosova K, Mitasikova M, Bernatova I, Weismann P, Okruhlicova L. Reduced
connexin-43 expression in the aorta of prehypertensive rats. Physiol Res
2008;57(Suppl 2):S23–9.
[169] Haefliger JA, Meda P, Formenton A, Wiesel P, Zanchi A, Brunner HR, et al.
Aortic connexin43 is decreased during hypertension induced by inhibition of
nitric oxide synthase. Arterioscler Thromb Vasc Biol 1999;19:1615–22.
[170] Kansui Y, Fujii K, Nakamura K, Goto K, Oniki H, Abe I, et al. Angiotensin II
receptor blockade corrects altered expression of gap junctions in vascular
endothelial cells from hypertensive rats. Am J Physiol Heart Circ Physiol
2004;287:H216–24.
[171] Bokkala S, Reis HM, Rubin E, Joseph SK. Effect of angiotensin II and ethanol on
the expression of connexin 43 in WB rat liver epithelial cells. Biochem J
2001;357:769–77.
[172] Dodge SM, Beardslee MA, Darrow BJ, Green KG, Beyer EC, Saffitz JE.
Effects of angiotensin II on expression of the gap junction channel protein
connexin43 in neonatal rat ventricular myocytes. J Am Coll Cardiol
1998;32:800–7.
[173] Haefliger JA, Castillo E, Waeber G, Bergonzelli GE, Aubert JF, Sutter E, et al.
Hypertension increases connexin43 in a tissue-specific manner. Circulation
1997;95:1007–14.
[174] Wang H, Hong T, Wang Y. Altered expression of connexin43 and its possible
role in endothelin-1-induced contraction in rabbit basilar artery. Neurol Res
2009;31:67–73.
[175] Rojas Gomez DM, Schulte JS, Mohr FW, Dhein S. Alpha-1-adrenoceptor
subtype selective regulation of connexin 43 expression in rat
cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 2008;377:77–85.
[176] Salameh A, Krautblatter S, Baessler S, Karl S, Rojas Gomez D, Dhein S, et al.
Signal transduction and transcriptional control of cardiac connexin43 up-
regulation after alpha 1-adrenoceptor stimulation. J Pharmacol Exp Ther
2008;326:315–22.
[177] Sasaki S, Nakamura K, Uchida A, Fujita H, Itoh H, Nakata T, et al. Effects of
gamma-linolenic and eicosapentaenoic acids on blood pressure in SHR. Clin
Exp Pharmacol Physiol Suppl 1995;22:S306–7.
[178] Stanbouly S, Kirshenbaum LA, Jones DL, Karmazyn M. Sodium hydrogen
exchange 1 (NHE-1) regulates connexin 43 expression in cardiomyocytes via
reverse mode sodium calcium exchange and c-Jun NH2-terminal kinase-
dependent pathways. J Pharmacol Exp Ther 2008;327:105–13.
[179] Sotiropoulos KB, Clermont A, Yasuda Y, Rask-Madsen C, Mastumoto M,
Takahashi J, et al. Adipose-specific effect of rosiglitazone on vascular
permeability and protein kinase C activation: novel mechanism for
PPARgamma agonist’s effects on edema and weight gain. FASEB J
2006;20:1203–5.
[180] Gray JP, Burns KA, Leas TL, Perdew GH, Vanden Heuvel JP. Regulation of
peroxisome proliferator-activated receptor alpha by protein kinase C.
Biochemistry 2005;44:10313–21.
[181] Blanquart C, Mansouri R, Paumelle R, Fruchart JC, Staels B, Glineur C. The
protein kinase C signaling pathway regulates a molecular switch between
transactivation and transrepression activity of the peroxisome proliferator-
activated receptor alpha. Mol Endocrinol 2004;18:1906–18.
[182] Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci
2009;84:705–12.
[183] Prasad K. Flaxseed and cardiovascular health. J Cardiovasc Pharmacol
2009;54:369–77.
[184] An WS, Kim HJ, Cho KH, Vaziri ND. Omega-3 fatty acid supplementation
attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in
the remnant kidney. Am J Physiol Renal Physiol 2009;297:F895–903.
[185] McAnulty SR, Nieman DC, Fox-Rabinovich M, Duran V, McAnulty LS, Henson
DA, et al. Effect of n3 fatty acids and antioxidants on oxidative stress after
exercise. Med Sci Sports Exerc 2010;42:1704–11.
[186] Filaire E, Massart A, Portier H, Rouveix M, Rosado F, Bage AS, et al. Effect of 6
Weeks of n3 Fatty-Acid Supplementation on Oxidative Stress in Judo
Athletes. Int J Sport Nutr Exerc Metab 2010;20:496–506.
[187] Bloomer RJ, Larson DE, Fisher-Wellman KH, Galpin AJ, Schilling BK. Effect of
eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced
inflammatory and oxidative stress biomarkers: a randomized, placebo
controlled, cross-over study. Lipids Health Dis 2009;8:36.
[188] Hanwell HE, Kay CD, Lampe JW, Holub BJ, Duncan AM. Acute fish oil and soy
isoflavone supplementation increase postprandial serum (n3)
polyunsaturated fatty acids and isoflavones but do not affect
triacylglycerols or biomarkers of oxidative stress in overweight and obese
hypertriglyceridemic men. J Nutr 2009;139:1128–34.
[189] Ulven S, Kirkhus B, Lamglait A, Basu S, Elind E, Haider T, et al. In healthy
volunteers. Lipids 2010:1–10.
[190] Petersson H, Riserus U, McMonagle J, Gulseth HL, Tierney AC, Morange S,
et al. Effects of dietary fat modification on oxidative stress and inflammatory
markers in the LIPGENE study. Br J Nutr 2010;104:1357–62.
[191] Tayyebi-Khosroshahi H, Houshyar J, Tabrizi A, Vatankhah AM, Razzagi
Zonouz N, Dehghan-Hesari R. Effect of omega-3 Fatty Acid on oxidative
stress in patients on hemodialysis. Iran J Kidney Dis 2010;4:322–6.Page[192] Romieu I, Garcia-Esteban R, Sunyer J, Rios C, Alcaraz-Zubeldia M, Velasco SR,
et al. The effect of supplementation with omega-3 polyunsaturated fatty
acids on markers of oxidative stress in elderly exposed to PM(2.5). Environ
Health Perspect 2008;116:1237–42.
[193] Alessandri C, Pignatelli P, Loffredo L, Lenti L, Del Ben M, Carnevale R, et al.
Alpha-linolenic acid-rich wheat germ oil decreases oxidative stress and CD40
ligand in patients with mild hypercholesterolemia. Arterioscler Thromb Vasc
Biol 2006;26:2577–8.
[194] Iraz M, Erdogan H, Ozyurt B, Ozugurlu F, Ozgocmen S, Fadillioglu E. Brief
communication: omega-3 essential fatty acid supplementation and
erythrocyte oxidant/antioxidant status in rats. Ann Clin Lab Sci
2005;35:169–73.
[195] Arnal E, Miranda M, Johnsen-Soriano S, Alvarez-Nolting R, Diaz-Llopis M,
Araiz J, et al. Beneficial effect of docosahexanoic acid and lutein on retinal
structural, metabolic, and functional abnormalities in diabetic rats. Curr Eye
Res 2009;34:928–38.
[196] Priyamvada S, Khan SA, Khan MW, Khan S, Farooq N, Khan F, et al. Studies on
the protective effect of dietary fish oil on uranyl-nitrate-induced
nephrotoxicity and oxidative damage in rat kidney. Prostaglandins Leukot
Essent Fatty Acids 2009;82:35–44.
[197] Mavrommatis Y, Ross K, Rucklidge G, Reid M, Duncan G, Gordon MJ, et al.
Intervention with fish oil, but not with docosahexaenoic acid, results in lower
levels of hepatic soluble epoxide hydrolase with time in apoE knockout mice.
Br J Nutr 2009;103:16–24.
[198] Brand A, Bauer NG, Hallott A, Goldbaum O, Ghebremeskel K, Reifen R, et al.
Membrane lipid modification by polyunsaturated fatty acids sensitizes
oligodendroglial OLN-93 cells against oxidative stress and promotes up-
regulation of heme oxygenase-1 (HSP32). J Neurochem 2010;113:465–76.
[199] Tardivel S, Gousset-Dupont A, Robert V, Pourci ML, Grynberg A, Lacour B.
Protective effects of EPA and deleterious effects of DHA on eNOS activity in Ea
hy 926 cultured with lysophosphatidylcholine. Lipids 2009;44:225–35.
[200] Vignais PV. The superoxide-generating NADPH oxidase: structural aspects
and activation mechanism. Cell Mol Life Sci 2002;59:1428–59.
[201] Calder PC. N3 polyunsaturated fatty acids, inflammation, and inflammatory
diseases. Am J Clin Nutr 2006;83:1505S–19S.
[202] Curfs JH, Meis JF, Hoogkamp-Korstanje JA. A primer on cytokines: sources,
receptors, effects, and inducers. Clin Microbiol Rev 1997;10:742–80.
[203] Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as
modulators of inflammation and innate immunity. Nat Rev Immunol
2004;4:617–29.
[204] Poudel-Tandukar K, Nanri A, Matsushita Y, Sasaki S, Ohta M, Sato M, et al.
Dietary intakes of alpha-linolenic and linoleic acids are inversely associated
with serum C-reactive protein levels among Japanese men. Nutr Res
2009;29:363–70.
[205] Pot GK, Brouwer IA, Enneman A, Rijkers GT, Kampman E, Geelen A. No effect
of fish oil supplementation on serum inflammatory markers and their
interrelationships: a randomized controlled trial in healthy, middle-aged
individuals. Eur J Clin Nutr 2009;63:1353–9.
[206] He K, Liu K, Daviglus ML, Jenny NS, Mayer-Davis E, Jiang R, et al. Associations
of dietary long-chain n3 polyunsaturated fatty acids and fish with
biomarkers of inflammation and endothelial activation (from the Multi-
Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol 2009;103:1238–43.
[207] Cornish SM, Chilibeck PD. Alpha-linolenic acid supplementation and
resistance training in older adults. Appl Physiol Nutr Metab 2009;34:49–59.
[208] Troseid M, Arnesen H, Hjerkinn EM, Seljeflot I. Serum levels of interleukin-18
are reduced by diet and n3 fatty acid intervention in elderly high-risk men.
Metabolism 2009;58:1543–9.
[209] de Mello VD, Erkkila AT, Schwab US, Pulkkinen L, Kolehmainen M, Atalay M,
et al. The effect of fatty or lean fish intake on inflammatory gene expression
in peripheral blood mononuclear cells of patients with coronary heart
disease. Eur J Nutr 2009;48:447–55.
[210] Bouwens M, van de Rest O, Dellschaft N, Bromhaar MG, de Groot LC, Geleijnse
JM, et al. Fish-oil supplementation induces antiinflammatory gene expression
profiles in human blood mononuclear cells. Am J Clin Nutr 2009;90:415–24.
[211] Weaver KL, Ivester P, Seeds M, Case LD, Arm JP, Chilton FH. Effect of dietary
fatty acids on inflammatory gene expression in healthy humans. J Biol Chem
2009;284:15400–7.
[212] Quattrucci S, Napolitano M, Valentini SB, Giuliani A, Bravo E. Neutrophil
generation of inflammatory precursors is not modulated by docosahexaenoic
acid. Inflamm Res 2009;58:677–85.
[213] Duda MK, O’Shea KM, Tintinu A, Xu W, Khairallah RJ, Barrows BR, et al. Fish
oil, but not flaxseed oil, decreases inflammation and prevents pressure
overload-induced cardiac dysfunction. Cardiovasc Res 2009;81:319–27.
[214] Park KS, Lim JW, Kim H. Inhibitory mechanism of omega-3 fatty acids in
pancreatic inflammation and apoptosis. Ann NY Acad Sci 2009;1171:421–7.
[215] Wang S, Wu D, Lamon-Fava S, Matthan NR, Honda KL, Lichtenstein AH. In
vitro fatty acid enrichment of macrophages alters inflammatory response and
net cholesterol accumulation. Br J Nutr 2009;102:497–501.
[216] Inui K, Fukuta Y, Ikeda A, Kameda H, Kokuba Y, Sato M. The effect of alpha-
linolenic acid-rich emulsion on fatty acid metabolism and leukotriene
generation of the colon in a rat model with inflammatory bowel disease.
Ann Nutr Metab 1996;40:175–82.
[217] Zhao G, Etherton TD, Martin KR, Gillies PJ, West SG, Kris-Etherton PM. Dietary
alpha-linolenic acid inhibits proinflammatory cytokine production by
peripheral blood mononuclear cells in hypercholesterolemic subjects. Am J
Clin Nutr 2007;85:385–91. 286
H. Poudyal et al. / Progress in Lipid Research 50 (2011) 372–387 387[218] Endres S, Lorenz R, Loeschke K. Lipid treatment of inflammatory bowel
disease. Curr Opin Clin Nutr Metab Care 1999;2:117–20.
[219] Serhan CN, Chiang N. Endogenous pro-resolving and anti-inflammatory lipid
mediators: a new pharmacologic genus. Br J Pharmacol 2008;153(Suppl
1):S200–15.
[220] Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan CN. Resolvin E1
receptor activation signals phosphorylation and phagocytosis. J Biol Chem
2009;285:3451–61.
[221] Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel
functional sets of lipid-derived mediators with antiinflammatory actions
generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal
antiinflammatory drugs and transcellular processing. J Exp Med
2000;192:1197–204.
[222] Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, et al.
Increased dietary intake of omega-3-polyunsaturated fatty acids reduces
pathological retinal angiogenesis. Nat Med 2007;13:868–73.
[223] Aoki H, Hisada T, Ishizuka T, Utsugi M, Kawata T, Shimizu Y, et al. Resolvin E1
dampens airway inflammation and hyperresponsiveness in a murine model
of asthma. Biochem Biophys Res Commun 2008;367:509–15.
[224] Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte
hormone to an endocrine mediator. Eur J Endocrinol 2000;143:293–311.
[225] Kieffer TJ, Heller RS, Habener JF. Leptin receptors expressed on pancreatic
beta-cells. Biochem Biophys Res Commun 1996;224:522–7.
[226] Seufert J, Kieffer TJ, Leech CA, Holz GG, Moritz W, Ricordi C, et al. Leptin
suppression of insulin secretion and gene expression in human pancreatic
islets: implications for the development of adipogenic diabetes mellitus. J
Clin Endocrinol Metab 1999;84:670–6.
[227] Phillips CM, Goumidi L, Bertrais S, Field MR, Ordovas JM, Cupples LA, et al.
Leptin receptor polymorphisms interact with polyunsaturated fatty acids to
augment risk of insulin resistance and metabolic syndrome in adults. J Nutr
2009;140:238–44.Page 28[228] Bonilla DL, Fan YY, Chapkin RS, McMurray DN. Transgenic mice enriched in
omega-3 fatty acids are more susceptible to pulmonary tuberculosis:
impaired resistance to tuberculosis in fat-1 mice. J Infect Dis
2010;201:399–408.
[229] Bergman RN. Non-esterified fatty acids and the liver: why is insulin secreted
into the portal vein? Diabetologia 2000;43:946–52.
[230] Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance
reduces arterial prostacyclin synthase and eNOS activities by increasing
endothelial fatty acid oxidation. J Clin Invest 2006;116:1071–80.
[231] Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, et al.
Elevated circulating free fatty acid levels impair endothelium-dependent
vasodilation. J Clin Invest 1997;100:1230–9.
[232] Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with
cardiovascular disease. Nature 2006;444:875–80.
[233] Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, Desouza CA. Influence of
metabolic syndrome on biomarkers of oxidative stress and inflammation in
obese adults. Obesity (Silver Spring) 2006;14:2127–31.
[234] Guerra L, Cerbai E, Gessi S, Borea PA, Mugelli A. The effect of oxygen free
radicals on calcium current and dihydropyridine binding sites in guinea-pig
ventricular myocytes. Br J Pharmacol 1996;118:1278–84.
[235] Yang ZW, Zheng T, Wang J, Zhang A, Altura BT, Altura BM. Hydrogen peroxide
induces contraction and raises [Ca2+]i in canine cerebral arterial smooth
muscle: participation of cellular signaling pathways. Naunyn Schmiedebergs
Arch Pharmacol 1999;360:646–53.
[236] Yang ZW, Zheng T, Zhang A, Altura BT, Altura BM. Mechanisms of hydrogen
peroxide-induced contraction of rat aorta. Eur J Pharmacol 1998;344:169–81.
[237] Tabet F, Savoia C, Schiffrin EL, Touyz RM. Differential calcium regulation by
hydrogen peroxide and superoxide in vascular smooth muscle cells from
spontaneously hypertensive rats. J Cardiovasc Pharmacol 2004;44:200–8.
[238] Ermak G, Davies KJ. Calcium and oxidative stress: from cell signaling to cell
death. Mol Immunol 2002;38:713–21.7
Chronic high-carbohydrate, high-fat feeding in rats induces reversible
metabolic, cardiovascular, and liver changes
Hemant Poudyal,1 Sunil K. Panchal,2 Leigh C. Ward,3 Jennifer Waanders,4 and Lindsay Brown2
1School of Biomedical Sciences, University of Queensland, Brisbane, Australia; 2Department of Biological and Physical
Sciences, University of Southern Queensland, Toowoomba, Australia; 3School of Chemistry and Molecular Biosciences,
University of Queensland, Brisbane, Australia; 4School of Agriculture and Food Sciences, University of Queensland,
Brisbane, Australia
Submitted 27 February 2012; accepted in final form 19 March 2012
Poudyal H, Panchal SK, Ward LC, Waanders J, Brown L.
Chronic high-carbohydrate, high-fat feeding in rats induces reversible
metabolic, cardiovascular, and liver changes. Am J Physiol Endocri-
nol Metab 302: E000–E000, 2012. First published March 20, 2012;
doi:10.1152/ajpendo.00102.2012.—Age-related physiological changes
develop at the same time as the increase in metabolic syndrome in
humans after young adulthood. There is a paucity of data in models
mimicking chronic diet-induced changes in human middle age and
interventions to reverse these changes. This study measured the
changes during chronic consumption of a high-carbohydrate (as corn-
starch), low-fat (C) diet and a high-carbohydrate (as fructose and
sucrose), high-fat (H) diet in rats for 32 wk. C diet feeding induced
changes without metabolic syndrome, such as disproportionate in-
creases in total body lean and fat mass, reduced bone mineral content,
cardiovascular remodeling with increased systolic blood pressure, left
ventricular and arterial stiffness, and increased plasma markers of
liver injury. H diet feeding induced visceral adiposity with reduced
lean mass, increased lipid infiltration in the skeletal muscle, impaired
glucose and insulin tolerance, cardiovascular remodeling, hepatic
steatosis, and increased infiltration of inflammatory cells in the heart
and the liver. Chia seed supplementation for 24 wk attenuated most
structural and functional modifications induced by age or H diet,
including increased whole body lean mass and lipid redistribution
from the abdominal area, and normalized the chronic low-grade
inflammation induced by H diet feeding; these effects may be medi-
ated by increased metabolism of anti-inflammatory n-3 fatty acids
from chia seed. These results suggest that chronic H diet feeding for
32 wk mimics the diet-induced cardiovascular and metabolic changes
in middle age and that chia seed may serve as an alternative dietary
strategy in the management of these changes.
obesity; chia seed; omega-3 fatty acids; metabolic syndrome
METABOLIC SYNDROME is defined as a cluster of risk factors,
including type 2 diabetes mellitus, hypertension, dyslipidemia,
and central obesity, leading to cardiovascular diseases (3). The
worldwide pandemic of metabolic syndrome and, particularly,
central obesity has been attributed to increased consumption of
lipogenic sugars, such as fructose, together with saturated fats
(1, 37). The Western diet, characterized by excessive intake of
saturated and trans fatty acids and a low n-3-to-n-6 polyunsat-
urated fatty acid (PUFA) ratio, has been associated with
chronic diseases such as metabolic syndrome, renal diseases,
and arthritis (2, 12, 24, 36).
Early onset of obesity is a key predictor of type 2 diabetes,
dyslipidemia, hypertension, and obesity in young adulthood
and middle age (9, 13, 19, 20). Childhood or adolescent obesity
is a direct cause of cardiovascular disease in young, middle-
aged, and elderly populations and increased all-cause mortality
(25). The progression from childhood through middle age to
old age is associated with major changes in body composition,
including loss of skeletal muscle mass, disproportionate de-
cline in muscle strength, and increased abdominal fat accumu-
lation (18). These effects are accompanied by markedly re-
duced resting metabolic rate and physical activity and de-
creased insulin sensitivity, with a shift toward preferential
oxidation of carbohydrate over fat (18). This may lead to a
sharper decline in skeletal muscle mass and characteristic lipid
redistribution, with loss of subcutaneous fat and increased
infiltration into lean mass, in the elderly (4, 18).
The high global prevalence of obesity and metabolic syn-
drome in the 40-yr age group (14, 22, 23, 35), coupled with
age-related physiological changes, produces an intricate patho-
physiology for the management of metabolic syndrome in
old-age groups. Although the etiology and pathophysiology of
metabolic syndrome induced by high-carbohydrate, high-fat, or
a combination of both have been widely studied in animal
models mimicking the young adult human condition (27), there
is a paucity of data on physiological adaptations in models
mimicking the human middle age started on a high-carbohy-
drate, high-fat diet during adolescence or young adulthood.
Understandably, such data from human studies are sparse
because of the need to monitor the subjects over four decades
or more.
We previously reported that the chronic changes following a
high-carbohydrate (mainly fructose), high-fat (beef tallow) (H)
diet for 16 wk in young male Wistar rats mimic the changes in
humans, including abdominal obesity, increased total body fat
mass, elevated plasma lipids and blood pressure, impaired
glucose tolerance and insulin sensitivity, hepatic steatosis, and
cardiovascular remodeling, compared with those following a
high-carbohydrate (cornstarch), low-fat (C) diet (28). Our pre-
vious studies showed that chia seed as a source of dietary
-linolenic acid (C18:3n-3) for 8 wk attenuated most risk
factors of metabolic syndrome in young H diet-fed rats (32).
Chia seed supplementation induced lipid redistribution, with
lipid trafficking away from the abdominal area, with increased
bone mineral content, feed conversion efficiency, and total
fat-free mass (32). In this study, we have investigated the
changes in body composition, fatty acid profiles of major
tissues, cardiovascular remodeling, and hepatic structure and
function following the administration of a C or H diet for 32
wk and the effects of chronic chia seed supplementation for the
final 24 wk of either diet. These rats were10 mo of age at the
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end of the protocol and, therefore, could be defined as middle-
aged. Male Wistar rats live to 27–30 mo of age (11), and
most animal houses retire male Wistar rats as breeders at
10–12 mo of age.
MATERIALS AND METHODS
Rats and diets. The experimental groups consisted of 48 male
Wistar rats (9–10 wk old) supplied by the University of Queensland
Biological Resources unit and individually housed at the University of
Southern Queensland Animal House. All experimentation was ap-
proved by the Animal Experimentation Ethics Committee of the
University of Southern Queensland under the guidelines of the Na-
tional Health and Medical Research Council of Australia. The rats
were randomly divided into four separate groups (n  12 each) and
fed the C diet (335  1 g), the C diet  chia seed (CC; 338  1 g),
the H diet (336  2 g), or the H diet  chia seed (HC; 333  2 g).
All experimental groups were housed in a temperature-controlled,
12:12-h light-dark cycle environment with ad libitum access to water
and the group-specific rat diet. Body weight and food and water
intakes were measured daily to monitor the day-to-day health of the
rats. Feed efficiency (%) was calculated as follows: [mean body
weight gain (g)/daily energy intake (kJ)]  100 (26).
The preparation and macronutrient composition of all four diets,
including the fatty acid profiles, are described elsewhere (28, 30, 32).
Briefly, the H diet consisted of 175 g of fructose, 395 g of sweetened
condensed milk, 200 g of beef tallow, 155 g of powdered rat food, 25
g of Hubble, Mendel-and-Wakeman salt mixture, and 50 g of water
per kilogram of diet. In the C diet, fructose and sweetened condensed
milk were replaced by the equivalent amount of cornstarch (570 g)
and the beef tallow was replaced by equivalent amounts of water (200 g)
per kilogram of diet. The chia seed-supplemented diets were prepared
by addition of 5% (wt/wt) of the seed replacing an equivalent amount
of water in the diet. Chia seed-supplemented diets were administered
for 24 wk starting 8 wk after commencement of C or H diet feeding.
Drinking water of the H and HC groups was augmented with 25%
fructose for the duration of the study.
Cardiovascular measurements. Systolic blood pressure was mea-
sured at 0, 8, 16, 24, and 32 wk under light sedation following
intraperitoneal injection of Zoletil [tiletamine (15 mg/kg)  zolaz-
epam (15 mg/kg); Virbac, Peakhurst, NSW, Australia] using a piezo-
electric pulse transducer (model MLT1010) and inflatable tail cuff
Table 1. Dietary intake, body composition, anthropometrics, organ wet weights, tissue fatty acid composition, and plasma
biochemistry in C, CC, H, and HC groups
n
Group P Value
C CC H HC Diet Treatment Interaction
Food intake, g/day 10 39.4  0.6* 38.9  0.5* 28.6  1.0† 25.9  0.7‡ 0.0001 0.0337 0.14
Water intake, ml/day 10 24.1  1.4† 36.6  2.9* 23.5  1.1† 30.7  0.9* 0.07 0.0001 0.14
Chia seed intake, g/day 10 0.0  0.0† 1.9  0.1* 0.0  0.0† 1.3  0.1* 0.0001 0.0001 0.0001
Energy intake, kJ/day 10 442.2  6.4* 475.3  6.5* 593.6  23.3† 583.8  12.2† 0.0001 0.41 0.13
Feed efficiency, % 10 2.5  0.3‡ 6.0  0.4† 6.0  0.8† 7.2  0.6* 0.0002 0.0002 0.047
Body wt gain (8–16 wk), % 23.6  2.0‡ 48.7  2.7* 37.0  4.3† 47.3  3.8* 0.08 0.0001 0.0324
Visceral adiposity index, % 10 6.9  0.8† 6.6  0.4† 11.2  0.8* 7.0  0.4† 0.0007 0.0011 0.0039
Bone mineral content, g 8–10 15.8  0.5† 19.5  0.8* 19.1  0.5* 19.1  0.5* 0.0188 0.0034 0.0034
Total body lean mass, g 8–10 277.1  9.5† 334.6  12.7* 240.8  7.4‡ 336.5  7.0* 0.08 0.0001 0.05
Total body fat mass, g 8–10 185.9  23.5† 260.5  29.0*† 334.7  24.4* 261.9  15.8*† 0.0031 0.97 0.0036
Body fat, % 8–10 37.9  3.4† 41.7  3.2† 55.6  2.1* 42.2  1.8† 0.0025 0.09 0.004
Tissue wet wt, mg/mm tibial length 10
Retroperitoneal fat 291.5  51.2† 376.2  26.3† 673.4  68.3* 425.2  40.4† 0.0001 0.1 0.0017
Epididymal fat 227.7  46.7† 249.6  22.1*† 342.4  27.0* 286.5  19.6*† 0.0186 0.58 0.21
Omental fat 171.5  19.9† 194.6  18.1† 327.2  35.7* 152.5  11.3† 0.0187 0.0023 0.0001
Liver 234.6  11.2‡ 292.0  5.1† 319.4  11.3*† 337.8  13.8* 0.0001 0.0013 0.08
Heart 22.2  1.0† 27.1  1.1‡ 27.6  1.2‡ 28.8  1.5‡ 0.006 0.0167 0.14
Tissue lipid content, mg/g 6
Retroperitoneal fat 767.7  40.9* 690.7  35.9† 726.1  16.2* 662.4  27.1† 0.28 0.0369 0.83
Liver 59.1  10.1 54.7  7.7 74.3  7.1 57.7  2.9 0.22 0.21 0.39
Skeletal muscle 67.5  3.9† 15.8  2.0‡ 176.1  23.4* 28.1  5.2‡ 0.0001 0.0001 0.0008
Heart 23.9  0.8† 32.2  6.2* 23.4  3.2† 45.6  9.5* 0.31 0.0238 0.28
Plasma total cholesterol, mmol/l 10 1.6  0.2*† 1.1  0.05† 1.9  0.2* 1.6  0.1*† 0.0114 0.0114 0.51
Plasma triglyceride, mmol/l 10 0.6  0.1† 1.0  0.1† 0.7  0.1† 1.4  0.2* 0.07 0.0002 0.26
Plasma NEFA, mmol/l 10 2.2  0.3 2.7  0.3 2.5  0.3 3.1  0.3 0.25 0.08 0.87
Plasma fatty acid, g/100 g total fatty acid
content
6
C16:0 52.06  1.36 51.32  2.64 47.76  2.34 42.86  2.74 0.0128 0.24 0.38
C16:1n-7 0.00  0.00 0.00  0.00 0.00  0.00 0.00  0.00 1 1 1
C18:0 15.07  0.60 14.97  1.16 15.87  0.35 15.51  0.88 0.42 0.78 0.87
C18:1n-9 13.25  0.90† 11.84  1.14† 20.86  1.65* 26.14  3.23* 0.0001 0.33 0.1
C18:2n-6 6.27  0.50‡ 12.98  1.20* 7.08  0.49‡ 9.34  0.31† 0.06 0.0001 0.0053
C18:3n-3 0.00  0.00† 3.66  1.47* 0.00  0.00† 2.16  0.30* 0.33 0.0009 0.33
C20:4n-6 13.35  1.12* 5.23  0.46‡ 8.44  0.86† 3.99  0.40‡ 0.0007 0.0001 0.027
Total SFA 67.12  1.24 66.29  3.05 63.62  2.50 58.37  3.36 0.0445 0.27 0.42
Total MUFA 13.25  0.90† 11.84  1.14† 20.86  1.65* 26.14  3.23* 0.0001 0.33 0.1
Total PUFA 19.62  1.01*† 21.87  2.18* 15.52  1.16† 15.49  0.40† 0.0009 0.42 0.41
n-3-to-n-6 ratio 0.00  0.00† 0.21  0.08* 0.00  0.00† 0.16  0.02* 0.55 0.0002 0.55
Values are means  SE; n, number of repetitive experiments. C, high-carbohydrate, low-fat; CC, C diet  chia seed; H, high-carbohydrate, high-fat; HC, H
diet chia seed; NEFA, nonesterified fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid. Means within
a row with different symbols (*, †, ‡) are significantly different (P  0.05).
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connected to a physiological pressure transducer (model MLT844)
using a PowerLab data acquisition unit (ADInstruments, Sydney,
Australia), as previously described (32).
At 32 wk, rats were anesthetized using intraperitoneal Zoletil, as
previously described (6, 30), and echocardiographic examination
(Hewlett Packard Sonos 5500, 12-MHz transducer) was performed, in
accordance with the guidelines of the American Society of Echocar-
diography, using the leading-edge method (34).
Terminal anesthesia was induced via injection of pentobarbitone
sodium (Lethabarb, 100 mg/kg ip). Heparin (200 IU; Sigma-Aldrich
Australia, Sydney, Australia) was administered through the right
femoral vein, and blood (5 ml) was collected from the abdominal
aorta. After blood withdrawal, the rate of pressure increase (dP/dt)
and decrease (	dP/dt) and the diastolic stiffness constant were as-
sessed using the Langendorff isolated heart preparation, as previously
described (5, 30, 32), and a latex balloon catheter connected to a
Capto SP844 MLT844 physiological pressure transducer and Chart
software on a Maclab system (ADInstruments Australia and Pacific
Islands, Bella Vista, NSW, Australia).
Thoracic aortic rings (4 mm long) were suspended in an organ
bath chamber with a resting tension of 10 mN. Cumulative concen-
tration-response (contraction) curves were measured for norepineph-
rine (Sigma-Aldrich Australia); concentration-response (relaxation)
curves were measured for acetylcholine (Sigma-Aldrich Australia)
and sodium nitroprusside (Sigma-Aldrich Australia) in the presence of
a submaximal (70%) contraction to norepinephrine (30).
Oral glucose tolerance and insulin tolerance tests. The oral glucose
tolerance test (OGTT) and the insulin tolerance test (ITT) were
performed 2 days apart at 32 wk. For the OGTT, basal blood glucose
concentrations were measured in blood taken from the tail vein using
a Medisense Precision QID glucose meter (Abbott Laboratories,
Bedford, MA) after 10–12 h of overnight food deprivation. The rats
were given glucose (2 g/kg body wt) as a 40% solution via oral
gavage. Tail vein blood samples were taken at 0, 30, 60, 90, and 120
min following glucose administration.
For the ITT, basal blood glucose concentrations were measured
after 4–5 h of food deprivation, as described above. The rats were
injected with insulin-R (0.75 IU/kg ip; Eli Lilly, West Ryde, NSW,
Australia), and tail vein blood samples were taken at 0, 30, 60, 90, and
120 min. Rats were withdrawn from the test if the blood glucose
concentrations dropped below 1.1 mmol/l, and 4 g/kg glucose solution
was immediately administered by oral gavage to prevent hypoglyce-
mia. For the OGTT and ITT, fructose-supplemented drinking water in
the H and HC groups was replaced with normal water for the
food-deprivation period.
Body composition measurements. A dual-energy X-ray absorpti-
ometer (DXA; model XR36, Norland) was used for DXA measure-
ments on the rats after 32 wk of feeding, 2 days before rats were
euthanized for pathophysiological assessments. DXA scans were
analyzed using the manufacturer’s recommended software for use in
laboratory animals (Small Subject Analysis Software, version 2.5.3/
1.3.1, Norland), as previously described (38). The precision error
Fig. 1. Changes in body weight (A), abdominal circumference (B), and systolic blood pressure (C) at 32 wk in rats fed the cornstarch-rich (C) diet, the C diet  chia
seed (CC), the high-carbohydrate, high-fat (H) diet, and the H diet chia seed (HC). Values are means SE; n  10 per group. End-point means without a common
lower-case letter (a–d) in each data set are significantly different.
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of lean mass for replicate measurements with repositioning was
3.2%. Visceral adiposity index (%) was calculated as follows:
{[retroperitoneal fat (g)  omental fat (g)  epididymal fat
(g)]/body weight (g)}  100 (17).
Organ weights. The right ventricle and left ventricle (LV, with
septum) were separated after perfusion experiments and weighed.
Liver, retroperitoneal fat, epididymal fat, and omental fat were re-
moved following heart removal and blotted dry for weighing. Organ
weights were normalized relative to the tibial length at the time of
their removal (in mg/mm). Immediately after they were weighed, LV,
liver, skeletal muscle, and retroperitoneal fat were stored at 	20°C in
50-ml polypropylene centrifuge tubes for fatty acid analysis.
Fatty acid analysis. Tissue and dietary lipids were extracted by
manual solvent extraction using a 2:1 chloroform-methanol mixture
with 0.1% butylated hydroxytoluene as an antioxidant, as described in
previous studies (16).
Approximately 15–20 mg of extracted lipid samples, with 1 mg of
heptadecanoic acid (C17:0) added as an internal standard, were
methylated in a clean 10-ml test tube. Saponified lipids were extracted
with 2 ml of heptane and then transferred to an autosampler vial for
gas chromatography. Fatty acid methyl esters were analyzed on an
Agilent J&W DB-23 column (60 m  0.25 mm  0.25 
m; Agilent
Technologies) by a gas chromatograph (model GC-17A, Shimadzu)
equipped with a flame ionization detector. A multiacid standard
mixture was used to check the performance of the gas chromatograph
and as a recovery test for the sample preparation procedure. Quanti-
tation of the fatty acids in all samples was based on a linear calibration
equation obtained from the C17:0 standard. For identification pur-
poses, standard containing a mixture of 28 fatty acid methyl esters
(Nu-Check Prep) was used for retention time calibration. A plot of
carbon number vs. logarithm of retention time for the saturated series,
one degree of unsaturation, and two degrees of unsaturation allowed
a relationship to be developed for identification purposes. All fatty
acids are expressed as grams per 100 g of total recovered fatty acids.
The n-3-to-n-6 ratio was derived using the following formula: (C18:
3n-3 C20:3n-3 C20:5n-3 C22:5n-3 C22:6n-3)/(C18:2n-6
C18:3n-6  C20:2n-6  C20:3n-6  C20:4n-6  C22:2n-6 
C22:4n-6).
Histology. Two rats per group were used exclusively for histolog-
ical analysis. Two slides were prepared per tissue specimen; two
random, nonoverlapping fields per slide were taken to avoid biased
analysis. Organs were also collected from rats used for ex vivo
studies. Immediately after removal, heart and liver tissues were fixed
in 10% neutral buffered formalin for 3 days and then dehydrated and
embedded in paraffin wax, as previously described (30). Thin (7-
m)
sections of LV and liver were cut and stained with hematoxylin-eosin
for determination of inflammatory cell infiltration. Collagen distribu-
tion in LV was determined using picrosirius red stain. The extent of
collagen deposition in selected tissue sections was determined by laser
confocal microscopy (Zeiss LSM 510 upright confocal microscope),
with color intensity quantitatively analyzed using ImageJ software
(National Institutes of Health) (30).
Plasma biochemistry. Briefly, blood was centrifuged at 5,000 g for
15 min within 30 min of collection into heparinized tubes. Plasma was
separated and transferred to Eppendorf tubes for storage at 	20°C
before analysis. Activities of plasma enzymes and analyte concen-
trations were determined using an Olympus analyzer (model AU
400) and kits and controls supplied by Olympus, as previously
described (30).
Statistical analysis. Values are means  SE. Results were tested
for variance using Bartlett’s test, and variables that were not normally
distributed were transformed (using log10 function) prior to statistical
analyses. Data from C, CC, H, and HC groups were tested by two-way
ANOVA. When interaction and/or the main effects were significant,
means were compared using Newman-Keuls multiple-comparison
post hoc test. Where transformations did not result in normality or
constant variance, a Kruskal-Wallis nonparametric test was per-
formed. P  0.05 was considered statistically significant. All statis-
tical analyses were performed using Prism version 5.00 for Windows
(GraphPad, San Diego, CA).
RESULTS
Dietary intake, body parameters, and plasma biochemistry.
H rats consumed less food than C rats but equivalent volumes
of water throughout the 32 wk (Table 1). Despite the lower
food intake, the mean energy intake, feed efficiency, and,
therefore, increases in body weight were higher in H than C
rats throughout the 32-wk feeding period because of the higher
energy density of the H diet (Table 1, Fig. 1A). Consequently,
chronic H diet feeding increased measures of whole body and
abdominal adiposity, such as total body fat mass, abdominal
circumference, abdominal fat (retroperitoneal, epididymal, and
omental), and visceral adiposity index (Table 1, Fig. 1B). The
increase in body weight was the combination of an increase in
Fig. 2. Glucose (2 g/kg; A) and insulin (0.75 IU/kg; B) tolerance in C, CC, H, and HC groups. Values are means  SE; n  8–10 per group. End-point means
without a common lower-case letter in each data set are significantly different.
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total body fat mass and a decrease in total body lean mass
induced by 32 wk of H diet feeding (Table 1). The bone
mineral content was higher in H than C rats (Table 1).
Chia seed supplementation for 24 wk, starting at 8 wk of the
feeding period, increased and maintained a higher water intake
in the CC and HC rats but lowered food intake only in the HC
rats compared with their respective controls throughout the
feeding period (Table 1). Despite the added dietary energy
from chia seed supplementation, the energy intake remained
unchanged in CC and HC rats compared with C and H rats,
respectively (Table 1). However, chia seed-supplemented
rats showed increased feed efficiency and, therefore, in-
creased body weight compared with C rats (Table 1, Fig.
1A). These effects were accompanied by increased lean
mass in CC and HC rats but increased bone mineral content
only in CC rats (Table 1). Chia seed supplementation did not
change whole body adiposity but decreased the visceral
adiposity index, abdominal fat, and abdominal circumfer-
ence (Table 1, Fig. 1B).
Although H diet feeding for 32 wk did not alter plasma total
cholesterol, triglyceride, or nonesterified fatty acid concentra-
tions, chia seed supplementation decreased plasma total cho-
lesterol in CC rats and increased plasma triglycerides in HC
rats (Table 1). H diet feeding increased the lipid content of
skeletal muscle, but not heart, liver, or retroperitoneal fat
(Table 1). Chia seed supplementation decreased the lipid con-
tent in retroperitoneal fat and increased it in the heart of CC
and HC rats, whereas chia seed supplementation decreased the
lipid content in skeletal muscle of HC rats (Table 1). H diet
feeding also decreased the tolerance to exogenous glucose and
insulin, and these effects were attenuated by chia seed supple-
mentation (Fig. 2).
The fatty acid profile of the plasma shows that H diet feeding
increased the total plasma monounsaturated fatty acids (MUFA;
Table 2. Changes in cardiovascular structure, function, and fatty acid composition in C, CC, H, and HC groups
n
Group P Value
C CC H HC Diet Treatment Interaction
Heart rate, beats/min 316  16 275  16 305  19 266  26 0.61 0.0495 0.96
IVSd, mm 10 1.99  0.05 2.01  0.07 1.99  0.09 1.99  0.05 0.88 0.88 0.88
LVIDd, mm 10 7.34  0.19† 7.82 0.28† 8.77  0.28* 7.84 0.14† 0.0033 0.34 0.0042
LVPWd, mm 10 1.98  0.05 1.97  0.05 2.00  0.05 2.00  0.04 0.6 0.92 0.92
IVSs, mm 10 3.34  0.10 3.14  0.10 3.42  0.14 3.18  0.11 0.6 0.06 0.86
LVIDs, mm 10 3.48  0.24 4.13  0.25 3.98  0.31 3.95  0.21 0.53 0.23 0.19
LVPWs, mm 10 3.39  0.07 3.07  0.12 3.34  0.10 3.25  0.15 0.57 0.08 0.32
Fractional shortening, % 10 52.8  2.4 47.5  1.6 52.3  3.3 49.7  1.9 0.72 0.11 0.58
Vmax, m/s
Ascending aorta 10 1.01 0.04† 0.82 0.03‡ 1.22  0.06* 0.83 0.05‡ 0.0231 0.0001 0.0378
Descending aorta 10 0.84 0.03† 0.81 0.03† 1.10  0.04* 0.82 0.03† 0.0002 0.0001 0.0005
Ejection time, ms 10 80.6 3.5 83.7  3.5 87.1  3.3 90.1  3.1 0.06 0.37 0.99
Diastolic volume, 
l 10 422.4  32.1† 519.1 56.2† 724.0 61.5* 507.5 27.3† 0.0037 0.21 0.0019
Systolic volume, 
l 10 49.8  10.7 81.0  14.5 76.8  18.4 69.0  11.1 0.6 0.41 0.17
Stroke volume, 
l 10 372.6  25.8† 438.1 44.4† 647.3 63.9* 438.5 19.1† 0.0024 0.1 0.0024
Estimated LV mass, g 10 1.02 0.05† 1.12 0.06† 1.31  0.07* 1.12 0.03† 0.0116 0.41 0.0116
Cardiac output, ml 10 116.6 8.6† 120.3 14.0† 201.7 26.3* 114.7 9.0† 0.0187 0.0141 0.008
Ejection fraction, % 10 88.8 1.8 85.2  1.4 88.9  3.1 86.8  1.5 0.68 0.18 0.72
Relative wall thickness 10 0.54 0.02 0.52  0.03 0.46  0.02 0.51  0.01 0.0408 0.48 0.11
Systolic blood pressure, mmHg 10 135.4 1.1† 126.7 1.7‡ 167.6 3.5* 134.3 2.2† 0.0001 0.0001 0.0001
Systolic wall stress, mmHg 10 70.7 6.5† 86.9  6.9† 101.7  10.2* 83.9 7.0† 0.08 0.92 0.0358
LV developed pressure, mmHg 10 55.9 2.6* 47.6  2.9*† 39.5  1.9† 54.8  5.0* 0.001 0.2971 0.1729
dP/dt, mmHg/s 10 990.3  49.4* 893.2 46.5*† 716.9 32.1† 1016.6 118.7* 0.0077 0.1578 0.2926
	dP/dt, mmHg/s 10 	575.0  33.3* 	409.9  26.1*† 	362.3  18.9† 	568.0  61.7* 0.0001 0.602 0.4838
Diastolic stiffness 10 27.8  0.9† 27.8  0.9† 35.9  1.7* 29.4  1.6† 0.0216 0.0216 0.001
LV  septum wet wt, mg/mm 10 18.8  0.8† 21.5  0.9*† 22.7  1.2* 23.3  0.9* 0.0061 0.1 0.28
RV wet wt, mg/mm 10 3.4  0.3 5.5  0.4 4.9  1.1 5.6  0.6 0.25 0.0485 0.3
Fatty acid, g/100 g of total fatty acid content 6
C16:0 27.80  1.04* 22.31 0.79† 23.76 1.52† 19.22 0.61‡ 0.0028 0.0001 0.66
C16:1n-7 1.74  0.10* 0.00 0.00† 0.63  0.07* 0.00 0.00† 0.0001 0.0001 0.0001
C18:0 18.83  0.50‡ 22.70 0.41† 21.63 0.75† 24.90 0.20* 0.0001 0.0001 0.56
C18:1n-9 10.62  0.69† 8.05 0.84† 14.18 0.68* 10.42 0.70† 0.0006 0.0003 0.42
C18:1trans-7 4.21  0.06* 4.08 0.15* 2.50  0.08† 2.97 0.10† 0.0001 0.11 0.0087
C18:2n-6 11.01  0.91† 18.21 0.32* 9.04 0.38‡ 11.97 0.31† 0.0001 0.0001 0.0008
C20:4n-6 16.96  0.33* 12.83 0.35§ 15.81 0.49† 14.42 0.29‡ 0.56 0.0001 0.0015
C22:5n-3 0.78  0.20† 3.63 0.18* 1.92  0.16† 3.77 0.24* 0.0041 0.0001 0.0197
C22:6n-3 7.45  0.33§ 8.19 0.40‡ 10.53 0.50† 12.33 0.53* 0.0001 0.0101 0.25
Total SFA 47.24  0.50* 45.01 0.63*† 45.38 0.84*† 44.12 0.46† 0.0398 0.0113 0.45
Total MUFA 16.57  0.75* 12.13 0.88† 17.31 0.73* 13.39 0.73† 0.21 0.0001 0.74
Total PUFA 36.19  1.14† 42.86 0.56* 37.31 1.02† 42.49 0.79* 0.68 0.0001 0.42
n-3-to-n-6 ratio 0.30  0.02§ 0.38 0.02‡ 0.50  0.03† 0.61 0.02* 0.0001 0.0005 0.52
Stearoyl-CoA desaturase index 0.06  0.00* 0.00 0.00† 0.03  0.00* 0.00 0.00† 0.0001 0.0001 0.0001
Values are means  SE; n, number of repetitive experiments. Left ventricular (LV)  septum and right ventricular (RV) wet weights were normalized against
tibial length at the time of removal. IVSd and IVSs, interventricular septal wall thickness at end diastole and end systole; LVIDd and LVIDs, LV internal diameter
in diastole and systole; LVPWd and LVPWs, LV posterior wall dimension in diastole and systole; Vmax, aortic pulse wave velocity; dP/dt, rate of pressure
increase; 	dP/dt, rate of pressure decrease. Means within a row with different symbols (*, †, ‡, §) are significantly different (P  0.05).
E5CHRONIC MODEL OF DIET-INDUCED OBESITY
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00102.2012 • www.ajpendo.org
F2
tapraid4/zh1-aend/zh1-aend/zh101112/zh16552d12z xppws S1 4/26/12 8:57 MS: E-00102-2012 Ini: 06/kl/dlh
Page 292
mainly C18:1n-9) without changing the total saturated fatty
acids (SFA) and PUFA compared with the C rats (Table 1).
Chia seed supplementation increased C18:2n-6 and C18:3n-3
and decreased the proinflammatory C20:4n-6 in the plasma
(Table 1).
Cardiovascular structure, function, and fatty acid composition.
Compared with C rats, the H diet induced eccentric hypertro-
phy, characteristic of increased preload, defined as increased
LV internal diameter in diastole, without changes in relative
wall thickness or end-systolic dimensions (Table 2). Conse-
quently, H rats showed impaired systolic function with in-
creased wall stress, increased diastolic stiffness, decreased
developed pressure, and decreased dP/dt compared with C rats
(Table 2). However, fractional shortening, ejection time, and
ejection fraction were not affected (Table 2). Additionally,
diastolic and stroke volumes and, consequently, cardiac output
were elevated in H rats compared with C rats, but heart rate
was not affected (Table 2). The ascending and descending
aortic pulse wave velocities (Vmax) increased in H rats com-
pared with C rats, suggesting arterial stiffening (Table 2).
These changes were accompanied by increased estimated LV
mass and LV wet weight. H diet feeding also increased systolic
blood pressure throughout the 32-wk protocol (Fig. 1C).
CC and HC rats showed normalized LV volumes and ec-
centric hypertrophy and, hence, the consequent abnormalities
induced by H diet feeding (Table 2). CC and HC rats showed
Fig. 3. A–D: hematoxylin-eosin-stained sections of left ventricle showing inflammatory cells (in) as dark spots outside the myocytes in C (A), CC (B), H (C),
and HC (D) groups. Magnification 20. E–H: picrosirius red-stained sections of left ventricle showing interstitial collagen deposition (cd) in C (E), CC (F), H
(G), and HC (H) groups. Magnification 40. hy, Hypertrophied cardiomyocytes.
Table 3. Changes in hepatic structure, function, and fatty acid composition in C, CC, H, and HC groups
n
Group P Value
C CC H HC Diet Treatment Interaction
Plasma ALT, U/l 10 24.8  1.0† 19.2  1.6§ 34.8  2.7* 29.8  1.0† 0.0001 0.004 0.86
Plasma AST, U/l 10 109.5  9.3* 67.0  2.3† 78.2  4.9† 75.9  3.9† 0.06 0.0004 0.0012
Plasma LDH, U/l 10 497.2  82.4 317.7  27.3 328.5  46.2 345.1  39.2 0.17 0.12 0.06
Plasma ALP, U/l 10 114.6  6.0* 111.8  5.5* 153.0  16.5† 183.6  1.8‡ 0.0001 0.14 0.08
Bilirubin, 
mol/l 10 2.3  0.2* 1.7  0.1† 2.1  0.1* 1.8  0.2† 0.75 0.0073 0.35
Fatty acid, g/100 g total fatty acid content 6
C16:0 26.08  0.86* 22.71  0.63† 25.80  0.45* 22.89  0.67† 0.94 0.0001 0.73
C16:1n-7 5.11  0.81* 4.82  0.80* 1.66  0.25† 1.64  0.18† 0.0001 0.8 0.82
C18:0 10.83  1.42 8.92  1.34 8.50  1.05 10.95  0.39 0.9 0.81 0.07
C18:1n-9 31.31  2.02‡ 21.56  1.07§ 50.08  2.84* 39.03  1.05† 0.0001 0.0001 0.74
C18:1trans-7 4.19  0.12* 3.81  0.32* 1.58  0.22† 1.87  0.10† 0.0001 0.83 0.13
C18:2n-6 7.91  0.62† 13.06  0.74* 4.44  0.38‡ 7.64  0.47† 0.0001 0.0001 0.1
C18:3n-3 0.00  0.00‡ 8.73  0.93* 0.00  0.00‡ 1.66  0.10† 0.0001 0.0001 0.0001
C20:4n-6 10.67  1.43* 4.83  0.45† 4.86  1.13† 5.05  0.37† 0.0084 0.0079 0.005
C20:5n-3 0.00  0.00‡ 3.29  0.13* 0.00  0.00‡ 1.65  0.14† 0.0001 0.0001 0.0001
C22:5n-3 0.00  0.00‡ 3.35  0.23* 0.00  0.00‡ 1.41  0.12† 0.0001 0.0001 0.0001
C22:6n-3 3.09  0.41† 4.76  0.42* 1.69  0.77‡ 4.55  0.27* 0.12 0.0002 0.25
Total SFA 37.73  1.16* 31.81  1.82† 35.68  0.74*† 34.78  0.95*† 0.71 0.0121 0.06
Total MUFA 40.61  2.76† 30.18  1.95‡ 53.32  2.83* 42.53  1.06† 0.0001 0.0001 0.94
Total PUFA 21.67  2.21† 38.01  1.39* 10.99  2.17‡ 22.69  1.08† 0.0001 0.0001 0.21
n-3-to-n-6 ratio 0.16  0.01‡ 1.14  0.06* 0.15  0.06‡ 0.70  0.02† 0.0001 0.0001 0.0001
Stearoyl-CoA desaturase index 0.19  0.03* 0.21  0.04* 0.07  0.01† 0.07  0.01† 0.0002 0.73 0.73
Values are means  SE; n, number of repetitive experiments. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase;
LDH, lactate dehydrogenase. Means within a row with different symbols are significantly different (P  0.05).
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normalized diastolic stiffness and systolic wall stress. Chia
seed supplementation normalized systolic blood pressure after
12 wk of treatment (Fig. 1C) compared with H rats and
decreased Vmax measured at the end of the protocol (Table 2).
After 32 wk, H rats showed greater infiltration of inflamma-
tory cells into the LV (Fig. 3C), as well as increased interstitial
collagen deposition (Fig. 3G), compared with C rats (Fig. 3, A
and E). Chia seed supplementation normalized inflammatory
state (Fig. 3D) and markedly reduced collagen deposition in
HC rats (Fig. 3H). Minimal changes were seen in CC rats (Fig.
3, B and F). The reduction in LV fibrosis and inflammation was
consistent with the reduced diastolic stiffness in HC rats (Fig.
3, D and H, Table 3).
Furthermore, H diet feeding diminished endothelium-depen-
dent relaxation to acetylcholine (Fig. 4C) but did not affect the
endothelium-independent relaxation to sodium nitroprusside
(Fig. 4B) or the 1-adrenoceptor-mediated vascular contraction
to norepinephrine in isolated thoracic aortic rings compared
with C rats (Fig. 4A). Although chia seed supplementation did
not change 1-adrenoceptor responses, it improved endothelium-
dependent and -independent relaxation in isolated thoracic
aortic rings (Fig. 4). This effect may contribute to the blood
pressure-lowering response to chia seeds.
Similar to the plasma fatty acid profile, H rats showed
increases in the proportion of total MUFA compared with C
rats but maintained the proportions of SFA and PUFA in the
heart (Table 2). Chia seed supplementation decreased C16:0,
C16:1n-7, and C18:1n-9 but increased C18:0 (Table 2). CC and
HC rats accumulated C18:2n-6 and depleted its elongation
product, C20:4n-6, and increased elongation products of C18:
3n-3 (C20:5n-3 and C22:6n-3). These results strongly suggest
the preferential metabolism of the n-3 PUFA by 6- and
5-desaturases, thereby inhibiting the proinflammatory n-6
metabolism pathway.
Hepatic structure, function, and fatty acid composition. H
rats showed elevated plasma alanine transaminase and alkaline
phosphatase activities compared with C rats (Table 3). How-
ever, aspartate transaminase activity was elevated in the C rats,
and plasma lactate dehydrogenase activity and total bilirubin
concentration remained unchanged (Table 3). Chia seed sup-
plementation normalized plasma activities of alanine transam-
inase, aspartate transaminase, and lactate dehydrogenase, while
alkaline phosphatase activity was increased in HC rats, and CC
and HC rats showed reduced plasma bilirubin concentrations
(Table 3). Additionally, H rats showed increased inflammatory
cell infiltration (Fig. 5C) and lipid deposition (Fig. 5G) com-
Fig. 4. Cumulative concentration-response curves for norepinephrine (A), sodium nitroprusside (B), and acetylcholine (C) in thoracic aortic rings from C, CC,
H, and HC groups. Values are means  SE; n  8–10/group. End-point means without a common lower-case letter in each data set are significantly different.
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pared with C rats (Fig. 5, A and E). CC (Fig. 5, B and F) and
HC (Fig. 5, D and H) rats showed normalized macrovesicular
steatosis and portal inflammation.
H diet feeding increased the total MUFA (mainly C18:1n-9)
content and decreased the total PUFA (C18:2n-6 and C20:
4n-6) content in liver compared with C rats (Table 3). Chia
seed supplementation decreased the MUFA content and in-
creased C18:2n-6, C18:3n-3, C20:5n-3, C22:5n-3, and C22:
6n-3, consequently increasing the n-3-to-n-6 ratio (Table 3).
C20:4n-6 decreased only in the CC rats (Table 3).
Adipose tissue and skeletal muscle fatty acid composition.
Similar to the fatty acid profile in liver and heart, H diet
feeding increased C18:0 and C18:1n-9 and decreased C16:1n-7
and C18:2n-6 content in adipose tissue compared with C rats
(Table 4). Chia seed supplementation decreased C16:0 and
C18:0 in HC rats and C16:1n-7 and C18:1n-9 in CC rats. These
effects were accompanied by increased proportions of C18:
2n-6 and C18:3n-3 in adipose tissue (Table 4).
Similarly, the skeletal muscle of H rats had increased pro-
portions of C18:1n-9 and decreased proportions of C18:2n-6
(Table 5). Chia seed supplementation increased SFA (C16:0
and C18:0) and n-6 fatty acids (C18:2n-6 and C20:4n-6) and
decreased C18:1n-9 in skeletal muscle. C18:3n-3, C22:5n-3,
and C22:6n-3 were increased in the chia seed-supplemented
groups (Table 5).
DISCUSSION
We have shown that long-term C or H diet feeding in male
Wistar rats closely mimics the changes in normal middle-aged
humans and the pathophysiology of middle-aged humans with
metabolic syndrome, respectively. Compared with our previ-
ous studies of young rats fed a C diet for 16 wk (28, 32),
chronic C diet feeding for 32 wk induced age-dependent
physiological changes without metabolic syndrome, such as
disproportionate increases in total body lean and fat mass,
reduced bone mineral content, cardiovascular remodeling with
increases in systolic blood pressure, LV, and arterial stiffness,
and increased plasma markers of liver injury. Compared with C
diet feeding, H diet feeding for 32 wk induced increases in
visceral adiposity with reduced lean mass, impaired glucose
tolerance and insulin sensitivity, and increased LV and arterial
Fig. 5. Hematoxylin-eosin staining of hepatocytes showing inflammatory cells (in) around the portal region in C (A), CC (B), H (C), and HC (D) groups and
hepatocytes with enlarged fat vacuole (fv) in C (E), CC (F), H (G), and HC (H) groups. Magnification 20.
Table 4. Fatty acid profiles of retroperitoneal adipose tissue and desaturase index in C, CC, H, and HC groups
Group P Value
C CC H HC Diet Treatment Interaction
C14:0 1.56  0.04‡ 1.36  0.08§ 2.20  0.02* 1.95  0.06† 0.0001 0.0005 0.65
C14:1n5 0.15  0.00* 0.00  0.00† 0.14  0.03* 0.00  0.00† 0.74 0.0001 0.74
C16:0 24.57  0.46* 23.71  0.73* 21.01  0.24† 18.67  0.22‡ 0.0001 0.0024 0.12
C16:1n-7 9.37  0.43* 5.77  1.10† 2.18  0.15‡ 2.23  0.15‡ 0.0001 0.0078 0.0064
C18:0 2.29  0.11‡ 2.56  0.08‡ 7.07  0.32* 5.96  0.30† 0.0001 0.08 0.007
C18:1n-9 46.92  0.40† 33.98  0.54‡ 63.04  0.44* 62.91  0.72* 0.0001 0.0001 0.0001
C18:1trans-7 5.41  0.14* 4.15  0.10† 0.86  0.28‡ 0.60  0.29‡ 0.0001 0.0024 0.0336
C18:2n-6 9.23  0.40* 16.54  0.59* 3.00  0.11§ 5.50  0.14‡ 0.0001 0.0001 0.0001
C18:3n-3 0.44  0.03‡ 11.94  0.29* 0.00  0.00§ 2.19  0.05† 0.0001 0.0001 0.0001
Total SFA 28.42  0.55† 27.63  0.84† 30.78  0.50* 26.57  0.49† 0.3 0.0006 0.0112
Total MUFA 61.85  0.29† 43.90  0.75‡ 66.22  0.49* 65.73  0.59* 0.0001 0.0001 0.0001
Total PUFA 9.73  0.46* 28.47  0.70* 3.00  0.11§ 7.69  0.13‡ 0.0001 0.0001 0.0001
n-3-to-n-6 ratio 0.05  0.00‡ 0.73  0.03* 0.00  0.00‡ 0.40  0.02† 0.0001 0.0001 0.0001
Stearoyl-CoA desaturase index 0.39 0.02* 0.25  0.06† 0.10  0.01‡ 0.12  0.01‡ 0.0001 0.08 0.0227
Values are means  SE. Means within a row with different symbols are significantly different (P  0.05).
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stiffening, cardiac fibrosis, hypertension, and hepatic steatosis.
These results are consistent with the effects of 16 wk of H diet
feeding (28), except 32 wk of H diet feeding additionally
induced arterial stiffening and loss of lean mass and increased
fat storage typical of the aging process (18).
The cardiovascular remodeling with the H diet aggravates
the typical characteristics of a middle-aged human heart. Age-
dependent structural deterioration of the heart includes LV, as
well as cardiomyocyte, hypertrophy, increased collagen depo-
sition, and stiffening of the ventricular wall (15). The func-
tional manifestation of these changes includes impaired dia-
stolic function without alterations of systolic function, with
preserved fractional shortening, ejection fraction, stroke vol-
ume, cardiac output, and resting heart rate (15). In addition to
these changes, H diet feeding increased diastolic and stroke
volume while maintaining resting heart rate and systolic vol-
ume, thereby increasing cardiac output. These increases in
diastolic volume and stroke volume are due to the increased
preload and consequent eccentric hypertrophy characteristic of
H diet feeding (28).
The shift from young adulthood to middle age is associated
with changes in arterial function, such as impaired distensibil-
ity with increased Vmax, a noninvasive clinical measure of
aortic stiffness (10, 15). Age and blood pressure are indepen-
dently associated with increased Vmax (10). However, in-
creased arterial stiffness is not exclusively the result of age-
dependent deterioration of arterial structure but may also be
affected by the endothelial regulation of vascular smooth
muscle tone. Aging arteries have increased endothelial perme-
ability and reduced endothelium-dependent relaxation re-
sponses to acetylcholine (15, 21). Consistent with the litera-
ture, H diet feeding increased Vmax, elevated systolic blood
pressure, and reduced vasodilator response to acetylcholine in
isolated thoracic aorta. However, neither 1-adrenoceptor-me-
diated vascular contraction to norepinephrine nor endothelium-
independent relaxation response to sodium nitroprusside was
affected. This suggests that the H diet selectively reduced
production or availability of nitric oxide from the endothelium
while preserving the contractility of vascular smooth muscle
and nitric oxide-mediated vasodilation pathways.
In the absence of the traditional cardiovascular risk factors,
obesity and type 2 diabetes are associated with increased
arterial stiffness (10, 33). H diet feeding produced increased
whole body and visceral adiposity, with the loss of lean mass
and increased accumulation of fat in the skeletal muscle. These
effects may have been mediated by reduced skeletal muscle
mitochondrial function and generalized decline in muscle pro-
tein synthesis with aging (18).
The loss of muscle mass is coupled with gradual loss of
subcutaneous fat after young adulthood (7). This is where
dietary supplementation with chia seed may be an important
strategy in improving the quality of life in an aging population.
Consistent with our previous report (32), 24 wk of chia seed
supplementation attenuated and maintained most structural and
functional modifications induced by age or the H diet. More
importantly, chia seed supplementation increased whole body
lean mass and reduced abdominal fat, but not whole body fat,
therefore suggesting lipid redistribution away from the abdom-
inal area. As the total lipid content in major tissues, such as
skeletal muscle and liver, decreased or remained unchanged, it
is plausible that most of the fat from the viscera was redistrib-
uted as subcutaneous fat. Additionally, chia seed supplemen-
tation normalized the chronic low-grade inflammation induced
by H diet feeding. This effect is most likely caused by the
decrease in the proinflammatory n-6 fatty acid metabolism seen
as increased precursor (C18:2n-6) and decreased or unchanged
product (C20:4n-6), together with increases in the anti-inflam-
matory fatty acids of the n-3 series (C18:3n-3, C20:5n-3,
C22:5n-3, and C22:6n-3) in all tissues. The n-3 series fatty
acids have been well studied for their role in maintaining
cardiovascular structure and function, as well as reducing the
risk factors of metabolic syndrome (31). Although the high
-linolenic acid content may play an important role in miti-
gating the responses to chronic chia seed supplementation, chia
seed is also a rich source of proteins [25% (wt/wt)] and
minerals (mainly calcium and phosphorus) (8), which may also
contribute to some of the observed effects, especially on body
composition. More importantly, the response to chia seed
supplementation was maintained from our previously reported
16-wk study, and no major adverse effects were observed (32).
Table 5. Fatty acid profiles of skeletal muscle and desaturase index in C, CC, H, and HC groups
Group P Value
C CC H HC Diet Treatment Interaction
C14:0 1.73  0.06† 1.41  0.10‡ 2.43  0.10* 1.95  0.06† 0.0001 0.0001 0.34
C14:1n-5 0.00  0.00† 0.00  0.00† 0.20  0.02* 0.00  0.00† 0.0001 0.0001 0.0001
C16:0 25.44  0.35*† 27.33  0.33* 21.74  0.84‡ 24.04  1.05† 0.0001 0.0082 0.78
C16:1n-7 8.73  0.69* 6.60  0.80† 2.91  0.30‡ 2.50  0.22‡ 0.0001 0.0346 0.14
C18:0 3.32  0.21‡ 8.38  0.67† 7.13  0.66† 10.26  0.62* 0.0001 0.0001 0.11
C18:1n-9 44.42  0.28† 22.97  0.83‡ 57.99  2.07* 42.14  2.79† 0.0001 0.0001 0.13
C18:1trans-7 5.50  0.09* 3.88  0.07† 1.23  0.33§ 2.17  0.04‡ 0.0001 0.07 0.0001
C18:2n-6 9.65  0.35† 14.28  0.62* 4.01  0.37§ 8.19  0.38‡ 0.0001 0.0001 0.62
C18:3n-3 0.00  0.00‡ 5.48  0.29* 0.28  0.03‡ 1.91  0.14† 0.0001 0.0001 0.0001
C20:4n-6 1.22  0.14† 2.81  0.38* 0.82  0.42† 2.32  0.37* 0.21 0.0002 0.9
C22:5n-3 0.00  0.00‡ 2.18  0.19* 0.00  0.00‡ 1.24  0.17† 0.0015 0.0001 0.0015
C22:6n-3 0.00  0.00† 4.12  0.37* 0.00  0.00† 3.27  0.60* 0.24 0.0001 0.24
Total SFA 30.48  0.38† 37.12  0.39* 31.80  1.43† 36.26  1.52* 0.83 0.0001 0.32
Total MUFA 58.64  0.53* 33.45  1.58‡ 63.09  2.15* 46.80  2.84† 0.0002 0.0001 0.0349
Total PUFA 10.88  0.46‡ 29.43  1.25* 5.11  0.73§ 16.94  1.39† 0.0001 0.0001 0.0039
n-3-to-n-6 ratio 0.00  0.00§ 0.73  0.03* 0.07  0.01‡ 0.60  0.03† 0.18 0.0001 0.0002
Stearoyl-CoA desaturase index 0.34  0.03* 0.24  0.03† 0.14  0.02‡ 0.11  0.01‡ 0.0001 0.0135 0.16
Values are means  SE. Means within a row with different symbols are significantly different (P  0.05).
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In addition, while 8 wk of chia seed supplementation failed to
attenuate increased blood pressure as a result of H diet feeding
for 16 wk (32), blood pressure was normalized with chronic
chia seed supplementation.
However, there are striking differences in the handling of
SFA, MUFA, and trans fatty acids with both H diet and chia
seed supplementation compared with our 16-wk study (32).
We found that 32 wk of C or H diet feeding decreased the net
proportion of trans fats, as well as the desaturation index,
therefore decreasing MUFA and increasing SFA content com-
pared with our previous study (32). Also, H diet feeding for 32
wk induced preferential storage of C18:1n-9 over C16:1n-7 as
the primary MUFA compared with the C rats. Because of this
change in fatty acid content, the stearoyl-CoA desaturase index
was normalized with 32 wk of H diet feeding, as the index is
calculated as a ratio of C16:0 to C16:1n-7. In contrast to the
16-wk study (32), chia seed supplementation in this study only
affected the n-6 and n-3 PUFA metabolism, and not SFA,
MUFA, or trans fatty acids. Since mammals can produce fatty
acids up to C18:1 in situ following a series of elongation and
desaturation reactions (29), these results strongly suggest a
transition in fatty acid metabolism with age toward increased
lipogenesis, as the complete pathway would result in the
formation of C18:1n-9 or C16:1n-7 as the final products
irrespective of the starting substrate (29). In heart, liver, and
skeletal muscle, the proportions of C18:1n-9 were reduced in
rats supplemented with chia seed compared with H rats and
remained comparable to or lower than proportions of C18:1n-9
in C rats, suggesting a possible inhibitory role of chia seed in
lipogenesis.
These results validate our hypothesis that long-term con-
sumption of the C diet mimics the process of aging, while H
diet feeding exacerbates this process, with cardiovascular re-
modeling, obesity, loss of lean mass, and liver injury. Chia
seeds may serve as a complementary dietary strategy to man-
age age-related morbidity due to the unique lipid redistribution,
increased lean mass, and other cardiovascular and hepatic
protective responses.
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Appendix E: Conference presentations during the 
candidature 
1. Oral presentation on “Ibuprofen attenuates metabolic and 
cardiovascular symptoms in rats fed a high carbohydrate/high fat 
(HCHF) diet” in International Conference of Australian Health and 
Medical Research Congress on November 20, 2008 at Brisbane 
Convention and Exhibition Centre, Brisbane, Australia. 
2. Oral presentation on “Does a high carbohydrate/high fat (HCHF) diet 
in rats induce oxidative stress-related metabolic and cardiovascular 
symptoms? in International Conference of Society for Free Radical 
Research (Australia) on November 30, 2008 at Bio21, The University 
of Melbourne, Melbourne, Australia. 
3. Poster presentation on “Rutin attenuates symptoms of metabolic 
syndrome” in International Conference of Society for Free Radical 
Research (Malaysia/Asia) on Chemoprevention and Translational 
Research held during July 9 to 12, 2009 at Langkawi, Malaysia. 
4. Poster presentation on “Attenuation of non-alcoholic steatohepatitis by 
rutin” in International Conference on Polyphenols held during August 
24 to 27, 2010 at Montpellier, France. 
5. Oral presentation on “Rutin attenuates non-alcoholic steatohepatitis in 
high-carbohydrate, high-fat diet-fed rats” in International Liver 
Congress organised by The European Association for the Study of the 
Liver held during March 30 to April 3, 2011 at Berlin, Germany. 
6. Oral presentation on “Differential effects of rutin and quercetin in diet-
induced metabolic syndrome in rats” in National level conference on 
Natural Products in Healthcare organised by Gurunanak College of 
Pharmacy, Nagpur, India held during November 24 to 26, 2011 at 
Nagpur, India. 
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